Koninklijke Philips (PHG) 20-F 20 Feb 24 2023 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2023 € / shares shares
Document And Entity Information [Line Items]
Entity Central Index Key	0000313216
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Document Type	20-F
Document Period End Date	Dec. 31, 2023
Entity File Number	001-05146-01
Entity Registrant Name	KONINKLIJKE PHILIPS NV
Entity Incorporation, State or Country Code	P7
Entity Address, Address Line One	Philips Center
Entity Address, Address Line Two	Amstelplein 2
Entity Address, Postal Zip Code	1096 BC
Entity Address, City or Town	Amsterdam
Entity Address, Country	NL
Entity Common Stock, Shares Outstanding | shares	906,403,156
Entity Listing, Par Value Per Share | € / shares	€ 0.2
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Auditor Name	Ernst & Young Accountants LLP
Auditor Firm ID	1396
Auditor Location	Amsterdam, the Netherlands
Business Contact [Member]
Document And Entity Information [Line Items]
Entity Address, Address Line One	Philips Center
Entity Address, Address Line Two	Amstelplein 2
Entity Address, Postal Zip Code	1096 BC
Entity Address, City or Town	Amsterdam
Entity Address, Country	NL
Contact Personnel Name	Marnix van Ginneken
City Area Code	+31 20
Local Phone Number	59 77232
Contact Personnel Email Address	marnix.van.ginneken@philips.com

Consolidated statements of inco

Consolidated statements of income - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Consolidated statements of income [Abstract]
Sales		€ 18,169		€ 17,827		€ 17,156
Cost of sales		10,721		10,633		9,988
Gross margin		7,448		7,194		7,168
Selling expenses		4,524		4,621		4,258
General and administrative expenses		608		671		599
Research and development expenses		1,890		2,091		1,806
Impairment of goodwill	[1]	8		1,357		15
Other business income		112		127		186
Other business expenses		645		109		123
Income from operations		(115)		(1,529)		553
Financial income		63		58		149
Financial expenses		376		258		188
Investments in associates, net of income taxes		(98)		(2)		(4)
Income before taxes		(526)		(1,731)		509
Income tax (expense) benefit		(73)		(113)		(103)
Income from continuing operations		(454)	[2]	(1,618)	[1]	612	[1]
Discontinued operations, net of income taxes		(10)	[1]	13	[1]	2,711	[2]
Net income		(463)	[2]	(1,605)	[1]	3,323	[1]
Net income attributable to shareholders of Koninklijke Philips N.V	[2]	(466)		(1,608)		3,319
Net income attributable to non-controlling interests	[2]	€ 2		€ 3		€ 4
Basic earnings per common share attributable to shareholders of Koninklijke Philips N.V. - Income from continuing operations	[3]	€ (0.5)		€ (1.76)		€ 0.64
Basic earnings per common share attributable to shareholders of Koninklijke Philips N.V. - Net income	[2],[3]	(0.51)		(1.75)		3.52
Diluted earnings per common share attributable to shareholders of Koninklijke Philips N.V. - Income from continuing operations	[3]	(0.5)		(1.76)		0.64
Diluted earnings per common share attributable to shareholders of Koninklijke Philips N.V. - Net income	[2],[3],[4]	€ (0.51)		€ (1.75)		€ 3.5
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. The dilutive potential common shares are not taken into account in the periods for which there is a loss, as the effect would be antidilutive

Consolidated statements of comp

Consolidated statements of comprehensive income - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Consolidated statements of comprehensive income [Abstract]
Net income for the period	€ (463)	[1]	€ (1,605)	[2]	€ 3,323	[2]
Pensions and other-post employment plans: Remeasurement, before tax	(26)		101		134
Pensions and other-post employment plans: Income tax effect on remeasurements	(3)		20		21
Financial assets fair value through OCI: Net current-period change, before tax	(20)		(32)		(39)
Financial assets fair value through OCI: Income tax effect on net current-period change	(3)		(1)		(1)
Total of items that will not be reclassified to Income Statement	(40)		49		74
Currency translation differences: Net current period change, before tax	(579)		748		1,078
Currency translation differences: Income tax effect on net current-period change	0		(2)		5
Currency translation differences: Reclassification adjustment for (gain) loss realized	26		0		(36)
Currency translation differences: Reclassification adjustment for (gain) loss realized, in discontinued operations					(69)
Cash flow hedges: Net current-period change, before tax	29		(29)		(52)
Cash flow hedges: Income tax effect on net current-period change	2		10		(18)
Cash flow hedges: Reclassification adjustment for (gain) loss realized	19		(63)		14
Total of items that are or may be reclassified to Income Statement	(597)		774		1,129
Other comprehensive income for the period	(637)		823		1,203
Total comprehensive income for the period	(1,100)		(782)		4,527
Total comprehensive income (loss) attributable to: Shareholders of Koninklijke Philips N.V	(1,101)		(786)		4,520
Total comprehensive income (loss) attributable to: Non-controlling interests	€ 1		€ 4		€ 7
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Consolidated balance sheets

Consolidated balance sheets - EUR (€) € in Millions	Dec. 31, 2023		Dec. 31, 2022
Consolidated balance sheets [Abstract]
Property, plant and equipment	€ 2,483		€ 2,638
Goodwill	9,876		10,238
Intangible assets excluding goodwill	3,190		3,526
Non-current receivables	193		279
Investments in associates	381		537
Other non-current financial assets	619		660
Non-current derivative financial assets	3		4
Deferred tax assets	2,627		2,449
Other non-current assets	93		98
Total non-current assets	19,466		20,429
Inventories	3,491		4,049
Other current financial assets	3		11
Other current assets	500		490
Current derivative financial assets	45		123
Income tax receivable	220		222
Current receivables	3,733		4,115
Assets classified as held for sale	79		77
Cash and cash equivalents	1,869		1,172
Total current assets	9,940		10,259
Total assets	29,406		30,688
Shareholders' equity	12,028		13,249
Equity - Common shares	183		178
Equity - Capital in excess of par value	5,827		5,025
Equity - Reserves	879		1,488
Equity - Other	5,139		6,558
Non-controlling interests	33		34
Group equity	12,061		13,283
Long-term debt	7,035		7,270
Non-current derivative financial liabilities	3		4
Long-term provisions	1,035		1,097
Deferred tax liabilities	71		91
Non-current contract liabilities	469		515
Non-current tax liabilities	390		435
Other non-current liabilities	54		60
Total non-current liabilities	9,058		9,471
Short-term debt	654		931
Current derivative financial liabilities	40		207
Income tax payable	83		40
Accounts payable	1,917	[1],[2]	1,968
Accrued liabilities	1,887		1,626
Current contract liabilities	1,809		1,696
Short-term provisions	1,463		1,018
Dividend payable	11		0
Liabilities directly associated with assets held for sale	9		0
Other current liabilities	414		448
Total current liabilities	8,287		7,934
Total liabilities and group equity	€ 29,406		€ 30,688
[1] Amounts in this table are undiscounted This table excludes post-employment benefit plan contribution commitments and income tax liabilities in respect of tax risks because it is not possible to make a reasonably reliable estimate of the actual period of cash settlement.

Consolidated statements of cash

Consolidated statements of cash flows - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Consolidated statements of cash flows [Abstract]
Profit (loss)	€ (463)	[1]	€ (1,605)	[2]	€ 3,323	[2]
Cash flows from operating activities - Results of discontinued operations, net of income tax	(10)	[2]	13	[2]	2,711	[1]
Cash flows from operating activities - Depreciation, amortization, and impairment of assets	1,261		1,602		1,323
Cash flows from operating activities - Impairment of goodwill	8		1,357		15
Cash flows from operating activities - Share-based compensation	88		95		108
Cash flows from operating activities - Net loss (gain) on sale of assets	(71)		(115)		55
Cash flows from operating activities - Interest income	46		25		18
Cash flows from operating activities - Interest expense on debt, borrowings, and other liabilities	255		226		152
Cash flows from operating activities - Investments in associates, net of income taxes	(107)		(112)		(4)
Cash flows from operating activities - Income taxes	(71)		(113)		(103)
Cash flows from operating activities - Decrease (increase) in working capital	(913)		862		401
Cash flows from operating activities - Decrease (increase) in receivables and other current assets	298		(342)		(39)
Cash flows from operating activities - Decrease (Increase) in inventories	257		(572)		(581)
Cash flows from operating activities - Increase (decrease) in accounts payable, accrued and other current liabilities	358		52		219
Cash flows from operating activities - Decrease (increase) in non-current receivables and other assets	33		(1)		46
Cash flows from operating activities - Increase (decrease) in other liabilities	(38)		(84)		33
Cash flows from operating activities - Increase (decrease) in provisions	422		(199)		427
Cash flows from operating activities - Other items	129		(39)		(164)
Cash flows from operating activities - Interest received	53		15		17
Cash flows from operating activities - Interest paid	250		205		151
Cash flows from operating activities - Dividends received from investments in associates	13		12		14
Cash flows from operating activities - Income taxes paid	152		333		249
Net cash provided by (used for) operating activities	2,136		(173)		1,629
Cash flows from investing activities - Net capital expenditures	554		788		729
Cash flows from investing activities - Purchase of intangible assets	96		105		107
Cash flows from investing activities - Expenditures on development assets	203		257		259
Cash flows from investing activities - Capital expenditures on property, plant and equipment	345		444		397
Cash flows from investing activities - Proceeds from sales of property, plant and equipment	90		18		33
Cash flows from investing activities - Net proceeds from (cash used for) derivatives and current financial assets	(46)		(72)		48
Cash flows from investing activities - Purchase of other non-current financial assets	92		116		124
Cash flows from investing activities - Proceeds from other non-current financial assets	48		78		124
Cash flows from investing activities - Purchase of businesses, net of cash acquired	73		712		3,098
Cash flows from investing activities - Net proceeds from sale of interests in businesses, net of cash disposed	80		124		107
Net cash provided by (used for) for investing activities	(636)		(1,487)		(3,672)
Cash flows from financing activities - Proceeds from issuance (payments on) short-term debt	29		47		(25)
Cash flows from financing activities - Principal payments on current portion of long-term debt	754		1,472		302
Cash flows from financing activities - Proceeds from issuance of long-term debt	544		2,516		76
Cash flows from financing activities - Re-issuance of treasury shares			12		23
Cash flows from financing activities - Purchase of treasury shares	662		187		1,636
Cash flows from financing activities - Dividends paid to shareholders of Koninklijke Philips N.V	2		412		482
Cash flows from financing activities - Dividends paid to shareholders of non-controlling interests	3		6		2
Net cash provided by (used for) financing activities	(848)		500		(2,347)
Net cash provided by (used for) continuing operations	652		(1,160)		(4,390)
Net cash provided by (used for) discontinued operations	123		(12)		3,403
Net cash provided by (used for) continuing and discontinued operations	776		(1,172)		(986)
Effect of changes in exchange rates on cash and cash equivalents	(79)		41		65
Cash and cash equivalents at the beginning of the period	1,172		2,303		3,226
Cash and cash equivalents at the end of the period	€ 1,869		€ 1,172		€ 2,303
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Consolidated statements of chan

Consolidated statements of changes in equity - EUR (€) € in Millions	Total	Issued capital [member]	Share premium [member]	Reserve of gains and losses on financial assets measured at fair value through other comprehensive income [member]	Reserve of cash flow hedges [member]	Reserve of exchange differences on translation [member]	Retained earnings [member]	Treasury shares [member]	Equity attributable to owners of parent [member]	Non-controlling interests [member]
Balance as of January 1 at Dec. 31, 2020	€ 11,901	€ 182	€ 4,400	€ (305)	€ 23	€ (58)	€ 7,828	€ (199)	€ 11,870	€ 31
Total comprehensive income (loss)	4,527			(39)	(48)	1,175	3,432		4,520	7
Dividend distributed	484	(1)	(290)				773		482	2
Minority Buy-out	0									0
Transfer of result on disposal of equity investments at FVTOCI to retained earnings	0						0		0
Purchase of treasury shares	757						0	758	757
Re-issuance of treasury shares	11	0	(150)				18	143	11
Forward contracts	(821)						48	(869)	(821)
Share call options	(9)						12	(21)	(9)
Cancellation of treasury shares		(7)					(1,221)	1,228
Share-based compensation plans	110		110						110
Income tax share-based compensation plans	4		4						4
Balance as of December 31 at Dec. 31, 2021	14,475	177	4,646	(344)	(25)	1,117	9,344	(476)	14,438	36
Total comprehensive income (loss)	(782)			(32)	23	749	(1,527)		(786)	4
Dividend distributed	418	(3)	(326)				741		412	6
Minority Buy-out	0									0
Transfer of result on disposal of equity investments at FVTOCI to retained earnings	0			(1)			1		0
Purchase of treasury shares	24						0	24	24
Re-issuance of treasury shares	7		(43)				(28)	77	7
Forward contracts	(64)						76	(140)	(64)
Share call options	(6)						5	(12)	(6)
Cancellation of treasury shares		(2)					(298)	299
Share-based compensation plans	95		95						95
Income tax share-based compensation plans	(1)		(1)						(1)
Balance as of December 31 at Dec. 31, 2022	13,283	178	5,025	(376)	(2)	1,866	6,832	(275)	13,249	34
Total comprehensive income (loss)	(1,100)			(17)	8	(604)	(488)		(1,101)	1
Dividend distributed	70	(8)	(741)				816		68	3
Transfer of result on disposal of equity investments at FVTOCI to retained earnings	0			4			(4)		0
Purchase of treasury shares	0						0		0
Re-issuance of treasury shares	0		(29)				(24)	54	0
Forward contracts	(143)						465	(608)	(143)
Share call options	0								0
Cancellation of treasury shares	566	(3)					(563)	566
Share-based compensation plans	88		88						88
Income tax share-based compensation plans	(2)		(2)						(2)
Balance as of December 31 at Dec. 31, 2023	€ 12,061	€ 183	€ 5,827	€ (390)	€ 6	€ 1,263	€ 5,402	€ (262)	€ 12,028	€ 33

General information to the Cons

General information to the Consolidated financial statements	12 Months Ended
	Dec. 31, 2023
General information to the Consolidated financial statements [Abstract]
General information to the Consolidated financial statements [Text Block]	1 Reporting entity and its operations Koninklijke Philips N.V. (‘Royal Philips’), incorporated and domiciled in the Netherlands, is a public limited liability company organized under Dutch Law. Philips is headquartered in Amsterdam, the Netherlands and has its registered address at High Tech Campus 52, 5656 AG Eindhoven, the Netherlands. The consolidated financial statements of Royal Philips as of December 31, 2023 comprise Royal Philips and its subsidiaries (together referred to as the 'company’ or ‘Philips’ or the 'Group’). Philips is a leading health technology company primarily involved in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Basis of preparation The Consolidated financial statements are: prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union (EU) and comply with the statutory provisions of Part 9, Book 2 of the Dutch Civil Code. All standards and interpretations issued by the International Accounting Standards Board (IASB) and the IFRS Interpretations Committee effective 2023 have been endorsed by the EU; consequently, the accounting policies applied by Philips also comply with IFRS as issued by the IASB. These accounting policies have been applied by group entities; authorized for issue by the Board of Management of Royal Philips on February 19, 2024; prepared under the historical cost convention, unless otherwise indicated; prepared on a going concern basis; presented in euro, which is the presentation currency; rounded to the nearest million euro unless stated otherwise; subject to rounding, whereby amounts may not add up precisely to the totals provided. Accounting estimates and judgments The preparation of financial statements requires management to make a number of estimates and judgments that affect the application of accounting policies and the reporting amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Amounts recognized are based on factors that are by default associated with uncertainty. Actual results may therefore differ from estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to estimates are recognized prospectively. Where applicable, the estimates and judgments of specific financial statement items are described in the respective note to the consolidated financial statements. The areas involving a higher degree of judgment and complexity in applying accounting principles and for which changes in the assumptions and estimates could result in significantly different results than those recorded in the consolidated financial statements are the following: Assessment of control (below paragraph Basis of consolidation and Interests in entities Revenue recognition ( Income from operations For acquisitions, the identification and valuation of acquired assets and liabilities including contingent considerations provisions ( Acquisitions and divestments Provisions Determination of deferred tax assets for losses carried forward and uncertain tax positions ( Income taxes Assumptions used for impairment testing ( Goodwill Intangible assets excluding goodwill Assessments of exposure to credit risk of financial instruments ( Other financial assets Receivables Debt Fair value of financial assets and liabilities Details of treasury and other financial risks Assumptions used to determine the net realizable value of inventories ( Inventories Actuarial assumptions of future events that are used in calculating post-employment benefit expenses and liabilities ( Post-employment benefits Estimates and assumptions regarding the timing and the amount of outflow of resources, as well as estimating the likelihood of a potential outflow of resources and the ability to make a reliable estimate of the obligation relating to provisions and contingent liabilities ( Provisions Contingencies The company regularly updates its significant assumptions and estimates to support the reported amounts of assets, liabilities, income and expenses. In preparing the consolidated financial statements management has considered the impact of climate change, specifically the financial impact of Philips meeting its internal and external climate related aims, the potential impact of climate related risks and the costs incurred to pro-actively manage such risks. These considerations did not have a material impact on the financial reporting judgments, estimates or assumptions. The specific financial impacts considered include, for example: specific climate mitigation measures, such as the use of lower carbon energy sources, the costs of developing more sustainable product offerings and expenses incurred to mitigate against the impact of extreme weather conditions. Philips uses 100% electricity from renewable sources, mainly through long-term Power Purchase Agreements thereby mitigating the impact of carbon taxes. The development of more sustainable products are covered through our EcoDesign program and already included in our R&D expenses. The physical risk related to climate change on our sites resulting from our TCFD-assessment is currently considered limited. Material accounting policies The material accounting policies as generally applied throughout the financial statements are described below. Material accounting policies relating to specific financial statement items are included in the respective notes to the financial statements. Basis of consolidation The Consolidated financial statements comprise the financial statements of Koninklijke Philips N.V. and all subsidiaries that the company controls on a consolidated basis. Control exists when the company is exposed or has rights to variable returns from its involvement with the investee and the company has the ability to affect those returns through its power over the investee. Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and in cases where Philips has less than a majority of the voting or similar rights of an investee, Philips considers all relevant facts and circumstances in assessing whether it has power over an investee, including the contractual arrangement(s) with the other vote holders of the investee, rights arising from other contractual arrangements and the company’s voting rights and potential voting rights. Subsidiaries are fully consolidated from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated in the Consolidated financial statements. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment. Foreign currency transactions The financial statements of all group entities are measured using the currency of the primary economic environment in which the entity operates (functional currency). The euro (EUR) is the functional currency of the company and the presentation currency of the consolidated financial statements. Foreign currency transactions are converted into the functional currency using the exchange rates prevailing at transaction date or the valuation date in cases where items are remeasured. Gains and losses resulting from the settlement of foreign currency transactions and those resulting from the conversion of foreign currency denominated monetary assets and liabilities at period-end exchange rates are recognized in the Consolidated statements of income, except for qualifying cash flow hedges, qualifying net investment hedges and equity investments measured at fair value through OCI which are recognized in other comprehensive income. All foreign exchange differences are presented as part of Cost of sales, apart from tax items and financial income and expense, which are recognized in the same line item as they relate to in the Consolidated statements of income. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency using the exchange rate at the date the fair value was determined. Non-monetary items in a foreign currency that are measured based on historical cost are translated using the exchange rate at the transaction date. Foreign operations The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated to euros at the exchange rates prevailing at the reporting date. The income and expenses of foreign operations are translated to euros at the exchange rates prevailing at the dates of the transactions. Foreign currency differences arising upon translation of foreign operations into euros are recognized in Other comprehensive income and presented as part of Currency translation differences in Equity. However, if the operation is not a wholly-owned subsidiary, the proportionate share of the translation difference is allocated to Non-controlling interests. When a foreign operation is disposed of such that control, significant influence or joint control is lost, the cumulative amount in the Currency translation differences related to the foreign operation is reclassified to the Consolidated statements of income as part of the gain or loss on disposal. When the company disposes of only part of its interest in a subsidiary that includes a foreign operation while retaining control, the respective proportion of the cumulative amount is reattributed to Non-controlling interests. When the company disposes of only part of its investment in an associate or joint venture that includes a foreign operation while retaining significant influence or joint control, the relevant proportion of the cumulative amount is reclassified to the Consolidated statements of income. New accounting policies effective in 2023 No new IFRS accounting standards or amendments to existing standards, effective in 2023, had a significant impact on the consolidated financial statements. The company has not early adopted any standards or amendments to existing standards. Consistent with the IAS 12 amendment regarding Pillar Two taxation as issued by the IASB and adopted by the EU, Philips does not recognize and disclose deferred taxes arising from tax laws that implement Pillar Two model rules published by the Organisation for Economic Co-operation and Development. Furthermore, Philips will recognize and disclose the impact (if any) from Pillar Two income taxes on current tax effective from 2024 . New accounting policies effective after 2023 The IASB has issued several IFRS accounting standards, or amendments to standards, with an effective date after 2023. The company does not anticipate that the application of these standards, or amendments to standards, will have a significant effect on the consolidated financial statements upon adoption. Changes in presentation from the prior year Accounting policies have been applied consistently for all periods presented in these consolidated financial statements. Certain prior-year amounts have been reclassified to conform to the current year presentation due to immaterial organizational changes. Philips has realigned the composition of its reporting segments effective from April 1, 2023. The most notable change is the shift of the previous Enterprise Diagnostic Informatics business from the Diagnosis & Treatment segment to the Connected Care segment. This business, together with other informatics solutions in the Connected Care segment, now forms the Enterprise Informatics business. Accordingly, the comparative figures for the affected segments have been restated in the consolidated financial statements.

Information by segment and main

Information by segment and main country	12 Months Ended
	Dec. 31, 2023
Information by segment and main country [Abstract]
Information by segment and main country [Text Block]	2 Accounting policies Segment accounting policies are the same as the accounting policies applied by the company. Operating segments are components of the company’s business activities about which separate financial information is available that is evaluated regularly by the Chief Operating Decision-Maker (the Board of Management of the company). The Board of Management decides how to allocate resources and assesses performance. Reportable segments comprise the operating segments Diagnosis & Treatment, Connected Care and Personal Health. Additionally, besides these reportable segments, segment Other contains the items Innovation & Strategy, IP Royalties, Central costs, and other small items. Accounting estimates and judgments Determining reportable segments requires significant judgment and involves evaluating the information which is reviewed by the Chief Operating Decision-Maker (the Board of Management) to assess performance and allocate resources, in accordance with IFRS 8 'Operating Segments'. The Philips business segments are Diagnosis & Treatment, Connected Care and Personal Health, each being responsible for the management of its business worldwide. As of the first quarter of 2021 the Domestic Appliances business was presented as a discontinued operation and therefore no longer part of the Personal Health segment. The comparative results prior to that were restated to reflect the treatment of the Domestic Appliances business as a discontinued operation. Refer to Discontinued operations and assets classified as held for sale Philips focuses on improving people’s lives through meaningful innovation. The Diagnosis & Treatment segment unites the businesses related to the goal of precision diagnosis and disease pathway selection, and the businesses related to image-guided, minimally invasive treatment. The Connected Care segment focuses on patient care solutions, advanced informatics and analytics, and patient and workflow optimization inside and outside the hospital, and aims to unlock synergies from integrating and optimizing patient care pathways, and leveraging provider-payer-patient business models. The Personal Health segment focuses on healthy living and preventative care. Philips has realigned the composition of its business segments effective from April 1, 2023. The most notable change is the shift of the previous Enterprise Diagnostic Informatics business from the Diagnosis & Treatment segment to the Connected Care segment. This business, together with other informatics solutions in the Connected Care segment, now forms the Enterprise Informatics business. Accordingly, the comparative figures for the affected segments have been restated. The realignment did not impact the presentation of the business segments or the key segmental performance measure, which continues to be Adjusted EBITA. Philips Group Information on income statements in millions of EUR sales sales including intercompany depreciation and amortization 1 ) Adjusted EBITA 2023 Diagnosis & Treatment 8,818 9,253 (306) 1,026 Connected Care 5,138 5,149 (445) 369 Personal Health 3,602 3,685 (115) 597 Other 612 428 (394) (71) Inter-segment eliminations (346) Philips Group 18,169 18,169 (1,261) 1,921 2022 Diagnosis & Treatment 8,290 8,576 (417) 788 Connected Care 5,268 5,280 (646) 111 Personal Health 3,626 3,684 (132) 538 Other 643 736 (407) (119) Inter-segment eliminations (449) Philips Group 17,827 17,827 (1,602) 1,318 2021 Diagnosis & Treatment 7,825 8,023 (363) 1,028 Connected Care 5,371 5,388 (472) 553 Personal Health 3,429 3,462 (131) 590 Other 530 636 (357) (117) Inter-segment eliminations (353) Philips Group 17,156 17,156 (1,323) 2,054 1 ) Includes impairments (excluding goodwill impairment); for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill The term Adjusted EBITA is used to evaluate the performance of Philips and its segments. Adjusted EBITA represents Income from operations excluding amortization and impairment of acquired intangible assets and impairment of goodwill (EBITA) and excluding gains or losses from restructuring costs, acquisition-related charges and other items. Adjusted EBITA is not a recognized measure of financial performance under IFRS. Presented in the following table is a reconciliation of Adjusted EBITA to the most directly comparable IFRS measure, Net income, for the years indicated. Net income is not allocated to segments as certain income and expense line items are monitored on a centralized basis, resulting in them being shown on a Philips Group level only. Philips Group Reconciliation from net income to Adjusted EBITA In millions of EUR Philips Group Diagnosis & Treatment Connected Care Personal Health Other 2023 Net Income (463) Discontinued operations, net of income taxes 10 Income taxes (73) Investments in associates, net of income taxes 98 Financial expenses 376 Financial income (63) Income from operations (115) 720 (1,199) 552 (188) Amortization and impairment of acquired intangible assets 290 89 178 14 9 Impairment of goodwill 8 8 - EBITA 183 816 (1,020) 567 (179) Restructuring and acquisition-related charges 381 118 115 9 140 Other items: 1,358 92 1,275 22 (32) Respironics litigation provision 575 575 Respironics field-action connected to the proposed consent decree 363 363 Respironics field-action running remediation costs 224 224 Quality remediation actions 175 81 94 Provision for a legal matter 31 31 Investment re-measurement loss 23 23 Gain on divestment of business (35) (35) Remaining items 2 11 (12) (1) 3 Adjusted EBITA 1,921 1,026 369 597 (71) Philips Group Reconciliation from net income to Adjusted EBITA In millions of EUR Philips Group Diagnosis & Treatment Connected Care Personal Health Other 2022 Net Income (1,605) Discontinued operations, net of income taxes (13) Income taxes (113) Investments in associates, net of income taxes 2 Financial expenses 258 Financial income (58) Income from operations (1,529) 538 (2,347) 515 (235) Amortization and impairment of acquired intangible assets 363 115 226 15 8 Impairment of goodwill 1,357 1,357 EBITA 192 652 (764) 531 (227) Restructuring and acquisition-related charges 202 3 125 11 62 Other items: 925 133 750 (4) 46 Respironics field-action connected to the proposed consent decree 250 250 Respironics field-action running remediation costs 210 210 R&D project impairments 134 73 59 3 Portfolio realignment charges 109 109 Provision for public investigations tender irregularities 60 60 Quality remediation actions 59 59 Impairments of assets in S&RC 39 39 Remaining items 63 - 24 (6) 46 Adjusted EBITA 1,318 788 111 538 (119) Philips Group Reconciliation from net income to Adjusted EBITA In millions of EUR Philips Group Diagnosis & Treatment Connected Care Personal Health Other 2021 Net Income 3,323 Discontinued operations, net of income taxes (2,711) Income taxes (103) Investments in associates, net of income taxes 4 Financial expenses 188 Financial income (149) Income from operations 553 948 (716) 576 (255) Amortization and impairment of acquired intangible assets 322 142 158 15 6 Impairment of goodwill 15 2 13 EBITA 890 1,092 (545) 591 (248) Restructuring and acquisition-related charges 95 (30) 130 (1) (5) Other items: 1,069 (35) 968 - 136 Respironics field-action connected to the proposed consent decree 719 719 Respironics field-action running remediation costs 94 94 Quality remediation actions 94 94 Loss on divestment of business 76 76 Remaining items 87 (35) 61 - 61 Adjusted EBITA 2,054 1,028 553 590 (117) Transactions between the segments are mainly related to components and parts included in the product portfolio of the other segments. The pricing of such transactions was at cost or determined on an arm’s length basis. Philips has no single external customer that represents 10% or more of sales. Philips Group Main countries in millions of EUR sales 1 ) tangible and intangible assets 2 ) 2023 Netherlands 2,390 1,624 United States 7,178 11,410 China 1,408 234 Japan 941 407 Germany 573 348 Other countries 5,679 1,527 Total main countries 18,169 15,550 2022 Netherlands 2,021 1,746 United States 7,226 12,087 China 1,239 260 Japan 1,011 436 Germany 642 323 Other countries 5,688 1,550 Total main countries 17,827 16,402 2021 Netherlands 1,860 1,934 United States 6,403 12,615 China 1,400 258 Japan 1,068 480 Germany 970 305 France 446 49 India 431 85 United Kingdom 426 567 Other countries 4,150 693 Total main countries 17,156 16,986 1 ) To better align with the Country Activity and Tax reporting, the allocation of country-level sales was revised from country of destination to country of origin. Comparative information in this table has been restated to be consistent with the current-period presentation. 2 ) Consists of Property plant and equipment, Intangible assets excluding goodwill and Goodwill

Discontinued operations and ass

Discontinued operations and assets classified as held for sale	12 Months Ended
	Dec. 31, 2023
Discontinued operations and assets classified as held for sale [Abstract]
Discontinued operations and assets classified as held for sale [Text Block]	3 Accounting policies Assets classified as held-for-sale Non-current assets (or disposal groups) are classified as held-for-sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use. Non-current assets (or disposal groups) classified as held-for-sale are measured at the lower of their carrying amount or the fair value less costs of disposal. Depreciation or amortization of an asset ceases when it is classified as held-for-sale. When non-current assets (or disposal groups) are classified as held-for-sale, comparative balances prior to such date are not represented in the Consolidated balance sheets. Discontinued operations A discontinued operation is a component of the company that has either been disposed of or is classified as held-for-sale and represents a separate major line of business or geographical area of operations or is a part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations. Any gain or loss from disposal, together with the results of these operations until the date of disposal, are reported separately as discontinued operations in the Consolidated statements of income. The financial information of discontinued operations is excluded from the respective captions in the Consolidated financial statements and related notes for all periods presented. Comparatives are re-presented for presentation of discontinued operations in the Consolidated statements of income and Consolidated statements of cash flows. Accounting estimates and judgments The determination of the fair value less costs of disposal involves the use of estimates and assumptions that tend to be uncertain. Circumstances to which these adjustments may relate include resolution of uncertainties that arise from the terms of the disposal transaction, such as the resolution of purchase price adjustments and indemnifications, resolution of uncertainties that arise from and are directly related to the operations of the component before its disposal, such as environmental and assurance-type product warranty obligations retained by the company, and the settlement of employee benefit plan obligations provided that the settlement is directly related to the disposal transaction. In 2023 and 2022 discontinued operations consist of certain costs related to other divestments, which were previously reported as discontinued operations. In 2021 discontinued operations consist primarily of the Domestic Appliances business. The following table summarizes the results of discontinued operations, net of income taxes, reported in the consolidated statements of income. Philips Group Discontinued operations, net of income taxes in millions of EUR 2021 2022 2023 Domestic Appliances 2,698 3 (2) Other 13 10 (7) Discontinued operations, net of income taxes 2,711 13 (10) Discontinued operations: Domestic Appliances On March 25, 2021, Philips signed an agreement to sell its Domestic Appliances business to global investment firm Hillhouse Investment. Since the first quarter of 2021, the Domestic Appliances business is presented as a discontinued operation, and comparative results have been restated to reflect the treatment of the Domestic Appliances business as a discontinued operation, because the sale of the Domestic Appliances business constitutes the discontinuance of a major line of business from the Personal Health segment. The following table summarizes the results of Domestic Appliances included in the consolidated statements of income as a discontinued operation. Philips Group Results of Domestic Appliances in millions of EUR 2021 2022 2023 Sales 1,516 6 - Costs and expenses (1,322) (2) (2) Income from operations 194 4 (2) Result on the sale of discontinued operations 3,241 1 (1) Income before tax 3,435 5 (3) Income tax benefit (expense) 1 ) 6 (2) 1 Income tax related the sale of discontinued operations (743) Results from discontinued operations 2,698 3 (2) 1 ) The income tax of discontinued operations is calculated based on the separate return method, as if Domestic Appliances was filing its own separate tax returns. Costs of EUR 64 million incurred in relation to the separation of the Domestic Appliances business in 2021 have been accounted for in continuing operations, because these costs reflect expenses incurred by Royal Philips in the divestment process and are not considered representative of the core business results of the Domestic Appliances business. On September 1, 2021, the company completed the sale of the Domestic Appliances business and recognized a transaction gain before tax of EUR 3,241 million. Philips received consideration of EUR 4,041 million, which is based on an enterprise value of EUR 3,850 million, increased by an amount of EUR 191 million for closing adjustments related to working capital and net indebtedness. The transaction gain before tax is the net effect of (i) the EUR 4,041 million consideration (ii) less the derecognition of net assets employed of EUR 715 million (iii) less transaction related costs of EUR 16 million, (iv) less the release of cumulative translation losses of EUR 69 million included in Other comprehensive income. The income tax charges related to the divestment process was EUR 743 million, resulting in an after-tax transaction gain of EUR 2,499 million. The income tax charge represents the consolidated tax expense resulting from asset transactions completed as part of the disentanglement of the business in anticipation of its sale, a significant portion of which relates to taxes payable in the Netherlands. In addition, Philips and the buyer entered into a 15-year brand license agreement with future annual payments that represents an estimated net present value of approximately EUR 0.7 billion, which will be received and recognized over time. Discontinued operations: Other Certain costs related to other divestments, which were previously reported as discontinued operations, resulted in a net loss of EUR (7) million in 2023, a net gain of EUR 10 million in 2022 and a net gain of EUR 13 million in 2021. Discontinued operations cash flows The following table presents the net cash provided by (used for) discontinued operations reported in the Consolidated statements of cash flows. Net cash provided by (used for) discontinued operations in millions of EUR 2021 2022 2023 Net cash provided by (used for) operating activities 85 (27) 123 Net cash provided by (used for) investing activities 3,319 15 Net cash provided by (used for) discontinued operations 3,403 (12) 123 In 2023, net cash provided by discontinued operations was EUR 123 million and consisted primarily of a refund received of one-off advance tax payments related to a previously divested business. In 2022, net cash used for discontinued operations was EUR (12) million and consisted primarily of cash flows related to the tax claims from a previously divested business. In 2021, net cash provided for discontinued operations was EUR 3,403 million and consisted primarily of the net cash inflow of EUR 3,319 million from the sale of the Domestic Appliances business on September 1, 2021. Assets classified as held for sale As of December 31, 2023, assets held for sale primarily consisted of assets and liabilities directly associated with a business held for sale. As of December 31, 2022, assets held for sale consists of property, plant and equipment mainly related to the APAC Center Singapore building. The sale was finalized in January 2023.

Acquisitions and divestments

Acquisitions and divestments	12 Months Ended
	Dec. 31, 2023
Acquisitions and divestments [Abstract]
Acquisitions and divestments [Text Block]	4 Accounting policies Acquisitions The company accounts for business combinations using the acquisition method when control is transferred to the group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired and the liabilities assumed. Transaction costs are expensed as incurred. Any contingent consideration is measured at fair value at the acquisition date and is initially presented in Long-term provisions. When the timing and amount of the consideration become more certain, it is reclassified to Accrued liabilities. If the contingent consideration that meets the definition of a financial instrument is classified as equity, it is not remeasured and settlement is accounted for within equity. Otherwise, subsequent changes in the fair value of the contingent consideration are recognized in the Consolidated statements of income. Changes to the initial fair value of the acquired assets and liabilities, based on new information about the circumstances at the acquisition date, can be made up to twelve months after the acquisition date. Divestments Upon loss of control, the company derecognizes the assets and liabilities of the subsidiary, any non-controlling interests and the other components of equity related to the subsidiary. Any surplus or deficit arising from the loss of control is recognized in the Consolidated statements of income. If the company retains any interest in the previous subsidiary, such interest is measured at fair value at the date the control is lost. Subsequently it is accounted for as either an equity-accounted investee (associate) or as a financial asset, depending on the level of influence retained. Further information on loss of control can be found in Discontinued operations and assets classified as held for sale Accounting estimates and judgments Intangible assets acquired in a business acquisition and the financial liability related to non-controlling interest are measured at fair value at the date of the acquisition. To determine the fair value of intangible assets at the acquisition date, estimates and assumptions are required. The valuation of the identifiable intangible assets involves estimates of expected sales, earnings and/or future cash flows and require use of key assumptions such as discount rate, royalty rate and growth rates. Estimates are also applied when determining the fair value of legal cases and tax positions in the acquired entity. The fair value is based on estimates of the likelihood, the expected timing and the amount of the potential cash outflow. Provisions for legal cases and non-income tax positions are recognized at fair value even if it is not probable that an outflow will be required to settle the obligation. After initial recognition and until the liability is settled, cancelled or expired, the liability is measured at the higher of the amount that would be recognized in accordance with IAS 37 'Provisions, contingent liabilities and contingent assets' and the initial liability amount. For income tax positions, the company applies IAS 12 'Income Taxes', which requires recognition of provisions only when the likelihood of cash outflow is considered probable. 2023 Acquisitions On May 5, 2023, Philips completed one acquisition within Ultrasound business unit to accelerate the growth of its Diagnosis & Treatment segment. The total equity purchase price and the settlement of debt, net of acquired cash, involved an amount of EUR 53 million and a contingent consideration of EUR 6 million at fair value, the latter recognized as a Long-term provision. Upon acquisition, the company recognized Goodwill of EUR 24 million, Other intangible assets of EUR 40 million and deferred tax asset and liability of EUR 5 million and EUR 2 million, respectively. The acquisition is subject to final purchase price allocation procedures, which is expected to be finalized in the second quarter of 2024. The primary provisional accounts subject to change are related to acquired intangible assets and goodwill. Since the acquisition date through December 31, 2023, the contribution to sales to third parties and net income of the acquiree was not material. The sales and net income would not differ materially if the acquisition date had been January 1, 2023. Acquisition-related costs were recognized in General and administrative expenses and were not material. Divestments During 2023 Philips completed six divestments for net cash consideration of EUR 80 million and a gain of EUR 50 million 2022 Acquisitions In 2022 Philips completed three acquisitions. The acquisitions involved aggregated net cash outflow of EUR 359 million. Including final purchase price adjustments processed in the course of 2023, the company recognized contingent consideration of EUR 96 million measured at fair value, aggregated Goodwill of EUR 307 million, Other intangible assets of EUR 179 million, Deferred tax assets of EUR 20 million and Deferred tax liabilities generated from the intangible assets of EUR 43 million. Vesper Medical Inc. (Vesper) was the most notable acquisition and is discussed below. The remaining two acquisitions involved aggregated net cash outflow of EUR 139 million. Including final purchase price adjustments processed in the course of 2023, the company recognized contingent consideration of EUR 61 million measured at fair value, aggregated Goodwill of EUR 130 million, Other intangible assets of EUR 95 million and Deferred tax liabilities of EUR 23 million. Since the respective acquisition dates through December 31, 2022, the contribution to sales to third parties and net income of the three acquired entities was not material. The sales and net income of the combined entities would not differ materially from these amounts if the acquisition date had been January 1, 2022. Acquisition-related costs were not material. Vesper On January 11, 2022, Philips acquired all shares of Vesper for an amount of EUR 227 million in cash and EUR 34 million contingent consideration at fair value. Vesper, headquartered in Wayne, Pennsylvania, US, is a medical technology company that develops minimally-invasive peripheral vascular devices. The company is developing the Vesper DUO Venous Stent System®, commercialization of which is estimated to start after approval by the US Food and Drug Administration (FDA), expected in 2024. The Vesper DUO Venous Stent System® consists of venous stents intended to treat deep venous obstruction. It provides physicians with a modular portfolio to customize therapy, restore venous flow, and resolve the painful symptoms of deep venous disease for the broad range of patients suffering from chronic venous insufficiency. As of the acquisition date, Vesper forms part of the Image-Guided Therapy business portfolio of the Diagnosis & Treatment segment. The condensed opening balance sheet of Vesper was as follows: Opening balance sheet in millions of EUR At acquisition date Vesper Medical Inc, Assets Intangible assets excluding goodwill 84 Deferred tax assets 15 Cash 7 Total Assets 106 Liabilities Accounts payable and other payables (1) Deferred tax liabilities (20) Total Liabilities (21) Total identifiable net assets at fair value 85 Goodwill arising on acquisition 177 Total purchase consideration 262 Of which: Purchase consideration transferred 227 Contingent consideration 34 Goodwill recognized in the amount of EUR 177 million mainly represents revenue synergies expected from the combination of Philips’ peripheral vascular portfolio and Vesper's venous stenting solution to address the root cause of chronic deep venous disease (DVD). Strong clinical synergies between Vesper’s innovative stenting solution and Philips' existing peripheral vascular offering will help to better support clinicians to decide, guide, treat and confirm during the procedure, thereby enhancing patient care. Vesper goodwill is not tax-deductible. The majority of the intangible assets balance relates to capitalized development costs capitalized development costs apitalized development costs The contingent consideration arrangement requires Philips to pay the former owners of Vesper up to a maximum undiscounted amount of EUR 44 million contingent upon FDA approval of the Vesper DUO Venous Stent System. The fair value of the contingent consideration arrangement of EUR 34 million has been estimated by calculating the present value of the future expected cash flows. The estimate is based on a discount rate of 12% and assumed probability adjusted likelihood of FDA approval at a certain point in time. During 2022 Philips completed two divestments that were not material.

Interests in entities

Interests in entities	12 Months Ended
	Dec. 31, 2023
Interests in entities [Abstract]
Interests in entities [Text Block]	5 Accounting policies Associates are all entities over which the company has significant influence, but not control or joint control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting and are initially recognized at cost. The carrying amount of an investment in associate includes the carrying amount of goodwill identified on acquisition. An impairment loss on such investment is allocated to the investment as a whole. The company’s share of the net income of these associates is included in Investments in associates, net of income taxes, in the Consolidated statements of income, after adjustments to align the accounting policies with those of the company. Dilution gains and losses arising from investments in associates are recognized in the Consolidated statements of income as part of Investments in associates, net of income taxes. Impairment losses and gains or losses on sale of investments are recorded in the Consolidated statements of income, more specifically on the line item ’Investments in associates, net of income taxes’. When the company’s share of losses exceeds its interest in an associate, the carrying amount of that interest is reduced to zero and recognition of further losses is discontinued except to the extent that the company has an obligation or made payments on behalf of the associate. The nature of the company’s interests in its consolidated entities and associates, and the effects of those interests on the company’s financial position and financial performance are discussed below. Group companies Below is a list of material subsidiaries as of December 31, 2023 representing greater than 5% of either the consolidated group Sales, Income from operations or Income from continuing operations (before any intra-group eliminations) of Group legal entities. All of the entities are fully consolidated in the Group financial statements. Philips Group Interests in group companies in alphabetical order by country 2023 Legal entity name Principal country of business Philips (China) Investment Company, Ltd. China Philips Medizin Systeme Böblingen GmbH Germany 1 ) Philips Japan, Ltd. Japan Philips Consumer Lifestyle B.V. Netherlands Philips Medical Systems (Cleveland), Inc. United States ATL International LLC United States Philips North America LLC United States Philips RS North America LLC United States 1 ) Application of Sec. 264 (3) and Sec. 264b HGB (German Commercial Code) for fully consolidated legal entities: Philips GmbH, Hamburg; Philips Medical Systems DMC GmbH, Hamburg; Respironics Deutschland GmbH & Co. KG, München; Philips Medizin Systeme Hofheim-Wallau GmbH, Hamburg; Philips Medizin Systeme Böblingen GmbH, Böblingen; TomTec Imaging Systems GmbH, Unterschleißheim; Forecare GmbH, Ratingen. Information related to non-controlling interests As of December 31, 2023, four consolidated subsidiaries are not wholly owned by Philips (December 31, 2022: four). In 2023, Sales to third parties and Net income for these subsidiaries in aggregate are EUR 492 million (December 31, 2022: EUR 472 million) and EUR 27 million (December 31, 2022: EUR 28 million), respectively. Investments in associates Philips has investments in a number of associates. During 2023, Philips made two investments in associates for a total amount of EUR 3 million. Due to the loss of significant influence in Candid Care during 2023, Philips reclassified the investment to Other non-current financial asset at FVTOCI (Level 3). On reclassification Philips recorded a loss of EUR 23 million in Ot Other financial assets Fair value of financial assets and liabilities In 2023, Philips recorded its share in negative results of associates of EUR 51 million and impairment of EUR 58 million. The impairment losses mainly related to HALO Dx (EUR 33 million) and were recorded within the Investments in associates, net of income taxes line item. Cumulative translation adjustments related to investments in associates were EUR (21) million as of December 31, 2023 (2022: EUR (22) million). Involvement with unconsolidated structured entities Philips founded three Philips Medical Capital (PMC) entities, in the US, France and Germany, in which Philips holds a minority interest. Philips Medical Capital, LLC in the US is the most significant entity. PMC entities provide healthcare equipment financing and leasing services to Philips customers for diagnostic imaging equipment, patient monitoring equipment, and clinical IT systems. The company concluded that it does not control, and therefore should not consolidate the PMC entities. In the US, PMC operates as a subsidiary of De Lage Landen Financial Services, Inc. The same structure and treatment is applied to the PMC entities in the other countries, with other majority shareholders. Operating agreements are in place for all PMC entities, whereby acceptance of sales and financing transactions resides with the respective majority shareholder. After acceptance of a transaction by PMC, Philips transfers control and does not retain any obligations towards PMC or its customers, from the sales contracts. As of December 31, 2023, Philips’ shareholding in Philips Medical Capital, LLC had a carrying value of EUR 27 million (December 31, 2022: EUR 29 million). The company does not have any material exposures to losses from interests in unconsolidated structured entities other than the invested amounts.

Income from operations

Income from operations	12 Months Ended
	Dec. 31, 2023
Income from operations [Abstract]
Income from operations [Text Block]	6 Accounting policies Revenue recognition The company recognizes revenue when it transfers control over a good or service to a customer, in an amount that reflects the consideration (i.e., transaction price) to which the company expects to be entitled to in exchange for the good or service. The consideration expected by the company may include fixed and/or variable amounts which can be impacted by sales returns, trade discounts and volume rebates. The company adjusts the consideration for the time value of money if the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds six months. Transfer of control varies depending on the individual terms of the contract of sale. For consumer-type products in the Personal Health segment, control is transferred when the product is shipped and delivered to the customer and title and risk have passed to the customer (depending on the delivery conditions) and acceptance of the product has been obtained. Revenues from transactions relating to distinct goods or services are accounted for separately based on their relative stand-alone selling prices. The stand-alone selling price is the price that would be charged for the goods or service in a separate transaction under similar conditions to similar customers. The transaction price is determined (considering variable considerations) and allocated to performance obligations based on their relative stand-alone selling prices. These transactions mainly occur in the segments Diagnosis & Treatment and Connected Care and include arrangements that require subsequent installation and training activities to make distinct goods operable for the customer. As such, the related installation and training activities are part of equipment sales rather than separate performance obligations. Revenue is recognized when the performance obligation is satisfied, i.e., when the installation has been completed and the equipment is ready to be used by the customer in the way contractually agreed. Variable consideration is included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur once associated uncertainties are resolved. Such assessment is performed on each reporting date to check whether it is constrained. For products for which a right of return exists during a defined period, revenue recognition is determined based on the historical pattern of actual returns, or in cases where such information is not available, revenue recognition is postponed until the return period has lapsed. Return policies are typically based on customary return arrangements in local markets. A provision is recognized for assurance-type product warranty at the time of revenue recognition and reflects the estimated costs of replacement and free-of-charge services that will be incurred by the company with respect to the products sold. For certain products, the customer has the option to purchase the warranty separately, which is considered a separate performance obligation on top of the assurance-type product warranty. For such warranties which provide distinct service, revenue recognition occurs on a straight-line basis over the extended warranty contract period. Occasionally, the company may offer a full or partial refund of consideration previously paid, for example as part of the resolution to warranty related matters. In such instances, a provision is recognized for the amounts expected to be refunded to customers, and remeasured at each reporting date to reflect changes in the estimated refunds, with a corresponding adjustment to revenue. In the case of loss under a sales agreement, the loss is recognized immediately. Sale of goods Revenues are recognized at a point in time when control of the goods passes to the buyer, based on the allocation of the transaction price to the performance obligation. Revenue from services Revenues are recognized over time as the company transfers control of the services to the customer which is demonstrated by the customer simultaneously receiving and consuming the benefits provided by the company. The amount of revenues is measured by reference to the progress made towards complete satisfaction of the performance obligation, which in general is evenly over time. Service revenue related to repair and maintenance activities for goods sold is recognized ratably over the service period or as services are rendered. Income from royalties Royalty income from brand license arrangements and from intellectual property rights, such as technology licenses or patents, is recognized on an accrual basis in accordance with the substance of the relevant agreement. Shipping and handling Expenses incurred for shipping and handling are mainly recorded as cost of sales. When shipping and handling are part of a project and billed to the customer, then the related expenses are recorded as cost of sales. Shipping and handling related to sales to third parties are partly recorded as selling expenses. When shipping and handling billed to customers are considered a distinct and separate performance obligation, the fees are recognized as revenue and costs included in cost of sales. Other business income (expenses) Other business income (expenses) includes gains and losses on the sale of property, plant and equipment, gains and losses on the sale of businesses as well as other gains and losses not related to the company’s operating activities. Government grants Grants from governments are recognized at their fair value when there is a reasonable assurance that the grant will be received and the company will comply with the conditions. Grants related to costs are deferred in the consolidated balance sheet and recognized in the consolidated statement of income as a reduction of the related costs that they are intended to compensate. Grants related to assets are deducted from the cost of the asset and presented net in the consolidated balance sheets. Accounting estimates and judgments Sales-related accruals The company has sales promotions-related agreements with distributors and retailers designed to promote the sale of products. Among the programs are arrangements under which rebates and discounts can be earned by the distributors and retailers by attaining agreed upon sales levels, or for participating in specific marketing programs. Management estimates the sales-related accruals associated with these arrangements based on a combination of historical patterns and future expectations regarding which promotional targets are expected to be met by distributors and retailers. Accrued customer rebates are presented as other current liabilities, unless there is a right to offset against the respective accounts receivable. A breakdown by nature of the income (loss) from operations is as follows: Philips Group Sales and costs by nature in millions of EUR 2021 2022 2023 Sales 17,156 17,827 18,169 Costs of materials used (4,142) (4,320) (4,626) Employee benefit expenses (6,246) (6,952) (6,903) Depreciation and amortization 1 ) (1,323) (1,602) (1,261) Impairment of goodwill (15) (1,357) (8) Shipping and handling (645) (756) (668) Advertising and promotion (752) (739) (700) Lease expenses (19) (39) (51) Other operational costs (3,524) (3,609) (3,535) Other business income (expenses) 63 18 (533) Income from operations 553 (1,529) (115) 1 ) Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill Sales composition and disaggregation For information related to sales on a segment and geographical basis, refer to Information by segment and main country Philips Group Sales composition in millions of EUR 2021 2022 2023 Goods 11,981 12,139 12,419 Services 4,374 4,878 4,926 Royalties 383 419 434 Total sales from contracts with customers 16,738 17,435 17,779 Sales from other sources 418 391 390 Total sales 17,156 17,827 18,169 Sales of goods include provisions of EUR 174 million that were recognized as a reduction of sales, primarily for (partial) refunds to customers in connection with the proposed Respironics consent decree. Refer to Provisions Total sales from other sources mainly relates to operating leases EUR 234 million (2022: EUR 258 million 2021: EUR 293 million). Sales represent revenue from external customers. As of December 31, 2023, the aggregate amount of the transaction price allocated to remaining performance obligations from a sale of goods and services was EUR 15,571 million. The company expects to recognize approximately 47% of the remaining performance obligations within 1 year. Revenue expected to be recognized beyond 1 year is mostly related to longer term customer service and software contracts. Sales over time represent services and Other also includes royalties over time (2023: EUR 283 million 2022: EUR 292 million 2021: EUR 220 million). Philips Group Disaggregation of Sales per segment in millions of EUR 2023 Sales at a Sales Total sales from Sales from Total Diagnosis & Treatment 5,762 2,978 8,742 76 8,818 Connected Care 2,970 1,854 4,824 314 5,138 Personal Health 3,586 16 3,602 3,602 Other 251 361 612 - 612 Philips Group 12,569 5,210 17,779 390 18,169 Philips Group Disaggregation of Sales per segment in millions of EUR 2022 Sales at a Sales Total sales from Sales from Total Diagnosis & Treatment 5,285 2,950 8,234 55 8,290 Connected Care 3,079 1,853 4,932 336 5,268 Personal Health 3,615 11 3,626 3,626 Other 284 357 643 - 643 Philips Group 12,263 5,172 17,435 391 17,827 Philips Group Disaggregation of Sales per segment in millions of EUR 2021 Sales at a Sales Total sales from Sales from Total Diagnosis & Treatment 5,120 2,656 7,776 50 7,825 Connected Care 3,399 1,604 5,002 369 5,371 Personal Health 3,423 6 3,429 3,429 Other 200 330 530 - 530 Philips Group 12,142 4,596 16,738 418 17,156 Philips Group Disaggregation of Sales per geographic area in millions of EUR 2023 Sales at a Sales Total sales from Sales from Total Western Europe 2,552 1,221 3,770 49 3,819 North America 4,859 2,608 7,470 92 7,562 Other mature geographies 980 398 1,378 248 1,626 Mature geographies 8,392 4,227 12,618 389 13,007 Growth geographies 4,177 984 5,161 1 5,162 Sales 12,569 5,210 17,779 390 18,169 Philips Group Disaggregation of Sales per geographic area in millions of EUR 2022 Sales at a Sales Total sales from Sales from Total Western Europe 2,387 1,183 3,572 31 3,603 North America 4,889 2,612 7,502 86 7,588 Other mature geographies 972 399 1,369 274 1,643 Mature geographies 8,248 4,194 12,443 390 12,833 Growth geographies 4,015 978 4,992 1 4,993 Sales 12,263 5,172 17,435 391 17,827 Philips Group Disaggregation of Sales per geographic area in millions of EUR 2021 Sales at a Sales Total sales from Sales from Total Western Europe 2,537 1,087 3,624 21 3,645 North America 4,427 2,268 6,695 86 6,781 Other mature geographies 1,000 386 1,386 309 1,694 Mature geographies 7,964 3,741 11,705 415 12,120 Growth geographies 4,178 856 5,033 3 5,036 Sales 12,142 4,596 16,738 418 17,156 Costs of materials used Cost of materials used represents the inventory recognized in cost of sales. Employee benefit expenses Philips Group Employee benefit expenses in millions of EUR 2021 2022 2023 Salaries and wages excluding share-based compensation 5,014 5,594 5,635 Share-based compensation 115 104 97 Post-employment benefit costs 396 439 402 Other social security and similar charges: Required by law 529 590 567 Voluntary 192 225 202 Employee benefit expenses 6,246 6,952 6,903 The employee benefit expenses relate to employees who are working on the payroll of Philips, both with permanent and temporary contracts. For further information on post-employment benefit costs, refer to Post-employment benefits For details on the remuneration of the members of the Board of Management and the Supervisory Board, refer to Information on remuneration Employees The average number (full-time equivalents, or FTEs) of employees by category is summarized as follows: Philips Group Employees by category in FTEs 2021 2022 2023 Production 38,618 39,742 35,281 Research & development 10,751 11,690 10,833 Other 22,543 23,019 23,001 Employees 71,912 74,451 69,115 Third party workers 4,533 4,086 3,149 Philips Group 76,445 78,538 72,264 Employees consist of those persons working on the payroll of Philips and whose costs are reflected in employee benefit expenses. Other consists of employees in commercial, general and administrative functions. Third party workers consist of personnel hired on a per-period basis, via external companies. Philips Group Employees by geographical location in FTEs 2021 2022 2023 Netherlands 11,142 11,180 9,794 Other countries 65,303 67,357 62,471 Philips Group 76,445 78,538 72,264 Depreciation and amortization Depreciation of property, plant and equipment and amortization of intangible assets, including impairments, are as follows: Philips Group Depreciation and amortization 1 ) in millions of EUR 2021 2022 2023 Depreciation of property, plant and equipment 630 711 689 Amortization of software 88 117 98 Amortization of other intangible assets 322 363 290 Amortization of development costs 284 411 184 Depreciation and amortization 1,323 1,602 1,261 1 ) Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill Depreciation of property, plant and equipment is mainly included in cost of sales. Amortization of software is mainly included in general and administration expenses. Amortization of other intangible assets is included in selling expenses for brand names and customer relationships and is included in cost of sales for technology based and other intangible assets. Amortization of development costs is included in research and development expenses. Impairment of goodwill In 2023 a goodwill charge of EUR 8 million was recorded for the partial impairment of goodwill allocated to a business that was classified as held-for-sale as of December 31, 2023. of goodwill impairment charges were recorded in the Sleep & Respiratory Care business, due to revisions to the expected future cash flows. In addition, a EUR 27 million goodwill impairment was recognized in the Precision Diagnosis Solutions business. Goodwill Shipping and handling Shipping and handling costs are included in cost of sales and selling expenses in the Consolidated statements of income Advertising and promotion Advertising and promotion costs are included in selling expenses in the Consolidated statements of income Lease expense Lease expense relates to short-term and low value leases. Other operational costs Other operational costs contain items which are dissimilar in nature and individually insignificant in amount to disclose separately. These costs contain among others expenses for outsourcing services, mainly in Information Technology and Human Resources, third party workers, consultants, warranty, patents, costs for travelling and external legal service. Government grants of EUR 95 million were recognized as cost reduction in 2023 (2022: EUR 103 million 2021: EUR 104 million). The grants mainly relate to research and development activities and business development. Audit and audit-related fees The following table shows the fees attributable to the fiscal years 2021, 2022 and 2023 for services rendered by the external auditors. Philips Group Audit and audit-related fees in millions of EUR 2021 2022 2023 EY NL 1 ) EY Network Total EY NL 1 ) EY Network Total EY NL 1 ) EY Network Total Audit fees 10.3 5.4 15.7 9.5 5.6 15.2 9.7 5.1 14.7 consolidated financial statements 10.3 2.7 13.0 9.5 3.1 12.6 9.7 2.6 12.3 statutory financial statements 2.7 2.7 2.5 2.5 2.5 2.5 Audit-related fees 2 ) 0.6 0.3 0.9 0.8 0.2 1.0 0.9 0.2 1.0 divestment sustainability assurance 0.5 0.5 0.6 0.6 0.8 0.8 other 0.1 0.3 0.4 0.1 0.2 0.3 0.1 0.2 0.3 Tax fees - - All other fees Fees 10.9 5.7 16.6 10.3 5.8 16.2 10.6 5.2 15.8 1 ) Ernst & Young Accountants LLP 2 ) Also known as Assurance fees Other business income (expenses) Other business income (expenses) consists of the following: Philips Group Other business income (expenses) in millions of EUR 2021 2022 2023 Result on disposal of businesses: income - 4 50 expenses (75) - - Result on disposal of fixed assets: income 24 3 12 expenses (5) (1) (1) Result on other remaining businesses: income 161 121 49 expenses (43) (109) (643) Other business income (expenses) 63 18 (533) Total other business income 186 127 112 Total other business expenses (123) (109) (645) The result on disposal of businesses mainly relates to divestment of non-strategic businesses. For more information refer to Acquisitions and divestments The result on disposal of fixed assets mainly relates to the sale of real estate assets. The result on other remaining businesses mainly relates to the revaluation of contingent consideration and various legal matters. In 2023 Philips Respironics recorded a EUR 575 million provision in connection with the anticipated resolution of the economic loss class action. For more information on contingent consideration, refer to Provisions Interests in entities

Financial income and expenses

Financial income and expenses	12 Months Ended
	Dec. 31, 2023
Financial income and expenses [Abstract]
Financial income and expenses [Text Block]	7 Accounting policies Financial income and expenses are recognized on the accrual basis in the consolidated statements of income. Interest income and expense are measured using the effective interest method. Dividend income is recognized in the consolidated statements of income on the date that the company’s right to receive payment is established, which in the case of quoted securities is normally the ex-dividend date. Philips Group Financial income and expenses in millions of EUR 2021 2022 2023 Interest income 18 25 46 Interest income from loans and receivables 7 7 13 Interest income from cash and cash equivalents 11 18 33 Dividend income from financial assets 2 3 2 Net gains from disposal of financial assets - - - Net change in fair value of financial assets through profit or loss 95 9 Other financial income 33 20 15 Financial income 149 58 63 Interest expense (159) (235) (277) Interest expense on debt and borrowings (126) (200) (229) Finance charges under lease contract (25) (25) (27) Interest expense on pensions (8) (10) (21) Provision-related accretion expenses (5) (9) (29) Net foreign exchange gains (losses) - 9 (23) Net change in fair value of financial assets through profit or loss (26) Other financial expenses (24) (24) (21) Financial expenses (188) (258) (376) Financial income and expenses, net (39) (200) (314) In 2023, financial income and expenses, net increased by EUR 114 million year-on-year, mainly due to fair value losses and net foreign exchange losses in 2023, compared to gains in 2022. The fair value losses mainly relate to power purchase agreements for renewable energy, limited-life funds (mainly Gilde Healthcare) and other investments recognized at fair value through profit and loss. Furthermore, provision-related accretion expenses and net interest expense were higher in 2023 compared to 2022. Net interest expense in 2023 was EUR 21 million higher than in 2022, mainly due the issuance of new debt in 2022 and 2023 and the impact of increasing interest rates. In 2022, Financial income and expenses increased by EUR 161 million year-on-year, mainly due to higher interest expense and lower fair value gains. The lower fair value gains compared to 2021 are mainly from investments in limited-life funds (mainly Gilde Healthcare) and other investments recognized at fair value through profit or loss. Net interest expense in 2022 was EUR 69 million higher than in 2021, mainly due to the financial charges related to early redemption of EUR and USD bonds and the issuance of new EUR bonds in 2022. The decrease in 2022 compared to 2021 in other financial income is mainly due to higher interest income on tax in 2021.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2023
Income taxes [Abstract]
Income taxes [Text Block]	8 Accounting policies Income taxes comprise of current, non-current and deferred tax. Income tax is recognized in the Consolidated statements of income except to the extent that it relates to items recognized directly within equity or in other comprehensive income. Current tax is the expected taxes payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. In cases where it is concluded it is not probable that tax authorities will accept a tax treatment, the effect of the uncertainty is reflected in the recognition and measurement of tax assets and liabilities or, alternatively, a provision is made for the amount that is expected to be settled, where this can be reasonably estimated. This assessment relies on estimates and assumptions and may involve a series of judgments about future events. New information may become available that causes the company to change its judgment regarding the adequacy of existing tax assets and liabilities. Such changes to tax assets and liabilities will impact the income tax expense in the period during which such a determination is made. Deferred tax assets and liabilities are recognized, using the consolidated balance sheet method, for the expected tax consequences of temporary differences between the carrying amounts of assets and liabilities and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: (a) the initial recognition of goodwill; or (b) the initial recognition of an asset or liability in a transaction which: (i) is not a business combination, (ii) at the time of transaction, affects neither accounting profit nor taxable profit (tax loss), (iii) at the time of the transaction, does not give rise to equal amounts of taxable and deductible differences; or (c) differences relating to investments in subsidiaries, joint ventures and associates where the reversal of the respective temporary difference can be controlled by the company and it is probable that it will not reverse in the foreseeable future. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity or on different taxable entities, but the company intends to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences to the extent that it is probable that there will be future taxable profits against which they can be utilized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Deferred tax liabilities for withholding taxes are recognized for subsidiaries in situations where the income is to be paid out as dividend in the foreseeable future and for undistributed earnings of unconsolidated companies to the extent that these withholding taxes are not expected to be refundable or deductible. Changes in tax rates and tax laws are reflected in the period when the change was enacted or substantively enacted by the reporting date. Any subsequent adjustment to a tax asset or liability that originated in discontinued operations and for which no specific arrangements were made at the time of divestment, due to a change in the tax base or its measurement, is allocated to discontinued operations (i.e. backwards tracing). Examples are a tax rate change or change in retained assets or liabilities directly relating to the discontinued operation. Any subsequent change to the recognition of deferred tax assets is allocated to the component in which the taxable gain is or will be recognized. The above principles are applied to the extent the ‘discontinued operations’ are sufficiently separable from continuing operations. Consistent with the IAS 12 amendment regarding Pillar Two taxation as issued by the IASB and adopted by the EU, Philips does not recognize and disclose deferred taxes arising from tax laws that implement Pillar Two model rules published by the Organisation for Economic Co-operation and Development. Furthermore, Philips will recognize and disclose the impact (if any) from Pillar Two income taxes on current tax effective from 2024 . Accounting estimates and judgments Deferred tax recoverability Deferred tax assets are recognized to the extent that it is probable that there will be future taxable profits against which these can be utilized. Significant judgment is involved in determining whether such profits are probable. Management determines this on the basis of expected taxable profits arising from the reversal of recognized deferred tax liabilities, appropriate tax planning opportunities to support business goals and on the basis of forecasts. Uncertain tax positions Uncertain tax positions are recognized as liabilities if and to the extent it is probable that additional tax will be due and the amount can be reliably measured. Significant judgment is involved in determining these positions. The income tax benefit of continuing operations amounts to EUR 73 million (2022: EUR 113 million tax benefit, 2021: EUR 103 million tax benefit). The components of income before taxes and income tax expense are as follows: Philips Group Income tax expense in millions of EUR 2021 2022 2023 Income before taxes 509 (1,731) (526) Investments in associates, net of income taxes (4) (2) (98) Income before taxes and Investment in associates 513 (1,729) (429) Current tax (expense) benefit (298) (97) (201) Deferred tax (expense) benefit 401 210 274 Income tax (expense) benefit of continuing operations 103 113 73 Income tax benefit of continuing operations excludes the tax benefit of the discontinued operations of EUR 9 million (2022: EUR 18 million benefit, 2021: EUR 737 million expense), mainly related to the release of provisions. The components of income tax expense of continuing operations are as follows: Philips Group Current income tax expense in millions of EUR 2021 2022 2023 Current year tax (expense) benefit (291) (111) (211) Prior year tax (expense) benefit (7) 14 10 Current tax (expense) benefit (298) (97) (201) Philips Group Deferred income tax expense In millions of EUR 2021 2022 2023 Recognition of previously unrecognized tax loss and credit carryforwards 138 2 72 Unrecognized tax loss and credit carryforwards (10) (13) (41) Changes to recognition of temporary differences (1) (4) (112) Prior year tax (expense) benefit 20 (1) (2) Tax rate changes 10 (18) 4 Origination and reversal of temporary differences, tax losses and tax credits 245 244 353 Deferred tax (expense) benefit 401 210 274 Philips’ operations are subject to income taxes in various foreign jurisdictions. The statutory income tax rate varies per country, which results in a difference between the weighted average statutory income tax rate and the Netherlands’ statutory income tax rate of 25.8% (2022: 25.8% 2021: 25.0%). A reconciliation of the weighted average statutory income tax rate to the effective income tax rate of continuing operations is as follows: Philips Group Effective income tax rate in % 2021 2022 2023 Weighted average statutory income tax rate in % 22.7 23.6 22.0 Recognition of previously unrecognized tax loss and credit carryforwards (26.9) 0.1 16.8 Unrecognized tax loss and credit carryforwards 1.9 (0.7) (9.6) Changes to recognition of temporary differences 0.3 (0.2) (26.2) Non-taxable income and tax incentives (40.6) 5.8 22.8 Non-deductible expenses 19.3 (22.9) (10.7) Withholding and other taxes 7.2 (1.4) (5.1) Tax rate changes (1.9) (1.0) 0.9 Prior year tax (2.4) 0.7 1.9 Tax expense (benefit) due to change in uncertain tax treatments 4.4 2.8 2.3 Others, net (4.0) (0.2) 1.9 Effective income tax rate (20.0) 6.5 17.0 The effective income tax rate is lower than the weighted average statutory income tax rate in 2023 mainly due to the recognition of previously unrecognized tax loss and credit carryforwards, which is mainly related to a one-off recognition of tax credits and non-taxable income and tax incentives which includes recurring favorable tax incentives related to R&D investments, the innovation box regime in the Netherlands and export activities. This is partly offset by the changes to recognition of temporary differences, which mostly represents deferred tax assets not fully recognized in United States. Due to the loss position in 2023, items such as non-deductible expense lead to a decrease of the effective income tax rate and items such as tax incentives lead to an increase in the effective income tax rate. Global minimum tax (Pillar Two) In December 2021, the OECD released model rules to introduce a global minimum corporate income tax rate of 15% applicable to multinational enterprise groups with global revenue over EUR 750 million (“Pillar Two”). The formal adoption of Directive (EU) 2022/2523 in December 2022 aims to achieve a coordinated implementation of Pillar Two in the EU Member States. The Dutch implementation of Pillar Two, the so-called Minimum Tax Rate Act 2024 (the “MTR Act”), was enacted in December 2023 and will apply to Philips from the financial year ending December 31, 2024 and onwards. Under this legislation, Philips may be required to pay top-up taxes on profits if the related Pillar Two jurisdictional effective tax rate is less than 15%. Philips will be affected by the “MTR Act” as well as the implementation of Pillar Two per local law in other jurisdictions and has performed an assessment of the Group’s potential exposure to the Pillar Two legislation. This assessment indicates potential exposure from the constituent entities in Hong Kong and the United Arab Emirates, where the Pillar Two effective tax rate is below 15%. This would potentially have resulted in top-up taxes had Pillar Two legislation been effective in 2023. The assessment of the potential exposure to top-up taxes is based on the profits and tax expenses determined as part of the preparation of Philips’ consolidated financial statement, most recent tax fillings and country-by-country reporting. The Pillar Two effective tax rate is lower in these jurisdictions due to exempted income and domestic tax rates either below or close to 15%. The group effective tax rate, had Pillar Two legislation been effective from 2023, would have been 16.4% which is 0.6% lower than the reported effective tax rate of 17% under IFRS. The decrease in the effective tax rate can be attributed to the reduction in the income tax benefit of continuing operations resulting from the inclusion of potential top-up tax exposure (expense). Deferred tax assets and liabilities Deferred tax assets are recognized for temporary differences, unused tax losses, and unused tax credits to the extent that realization of the related tax benefits is probable. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Net deferred tax assets relate to the following underlying assets and liabilities and tax loss carryforwards (including tax credit carryforwards) and their movements during the years 2023 and 2022 respectively are presented in the following tables. The net deferred tax assets of EUR 2,556 million (2022: EUR 2,358 million) consist of deferred tax assets of EUR 2,627 million (2022: EUR 2,449 million) and deferred tax liabilities of EUR 71 million (2022: EUR 91 million). Of the total deferred tax assets of EUR 2,627 million as of December 31, 2023 (2022: EUR 2,449 million), EUR 1,676 million (2022: EUR 1,453 million) is recognized in respect of entities in various countries where there have been tax losses in the current or preceding period, primarily the United States (US). The increase is mainly related to the US where there has been a tax loss in 2023, among others due to the Philips Respironics’ business operations. Philips assessed the recoverability of the tax losses and recognized the related deferred tax asset only to the extent future tax profits are considered probable. For the recoverability assessment, the income projections were determined using similar methodology as used for goodwill impairment testing (for more information please refer to note Goodwill As of December 31, 2023 the temporary differences associated with investments, including potential income tax consequences on dividends, for which no deferred tax liabilities are recognized, aggregate to EUR 444 million (2022: EUR 355 million). Philips Group Deferred tax assets and liabilities in millions of EUR Balance as of January 1, 2023 recognized in income statement other 1 ) Balance as of December 31, 2023 Assets Liabilities Intangible assets 630 61 (12) 679 826 (147) Property, plant and equipment (2) 18 (103) (88) 44 (132) Inventories 464 (26) (78) 360 363 (2) Other assets 44 20 120 184 233 (48) Pensions and other employee benefits 153 69 (29) 193 204 (11) Other liabilities 483 (56) 69 496 521 (25) Deferred tax assets on tax loss carryforwards 586 188 (44) 730 730 Set-off deferred tax positions (294) 294 Net deferred tax assets 2,358 274 (77) 2,556 2,627 (71) 1 ) Other includes the movements of assets and liabilities recognized in equity and OCI, which includes foreign currency translation differences, acquisitions and divestments. Philips Group Deferred tax assets and liabilities in millions of EUR Balance as of January 1, 2022 recognized in income statement other 1 ) Balance as of December 31, 2022 Assets Liabilities Intangible assets 587 63 (20) 630 783 (152) Property, plant and equipment 29 (33) 2 (2) 49 (52) Inventories 372 75 17 464 473 (8) Other assets 68 (16) (8) 44 98 (55) Pensions and other employee benefits 180 6 (32) 153 175 (22) Other liabilities 499 (34) 17 483 560 (77) Deferred tax assets on tax loss carryforwards 398 149 38 586 586 Set-off deferred tax positions (275) 275 Net deferred tax assets 2,134 210 14 2,358 2,449 (91) 1 ) Other includes the movements of assets and liabilities recognized in equity and OCI, which includes foreign currency translation differences, acquisitions and divestments. The company has available tax loss and credit carryforwards, which expire as follows: Philips Group Expiry years of net operating loss and credit carryforwards in millions of EUR Total Unrecognized Total Unrecognized Within 1 year 4 3 17 15 1 to 2 years 10 5 20 16 2 to 3 years 9 3 7 2 3 to 4 years 13 4 9 5 4 to 5 years 38 3 38 16 Later 812 93 808 81 Unlimited 2,301 920 2,997 1,231 Total 3,187 1,032 3,896 1,366 The increase in the unrecognized balance as of December 31, 2023 is mainly explained by the US. As of December 31, 2023, the amount of deductible temporary differences for which no deferred tax asset has been recognized in the balance sheet was EUR 125 million (2022: EUR 45 million). Tax risks Philips is exposed to tax risks and uncertainty over tax treatments. For particular tax treatments that are not expected to be accepted by tax authorities, Philips either recognizes a liability or reflects the uncertainty in the recognition and measurement of its current and deferred tax assets and tax attributes. For the measurement of the uncertainty, Philips uses the most likely amount or the expected value of the tax treatment. The expected liabilities resulting from the uncertain tax treatments are included in non-current tax liabilities (2023: EUR 390 million, 2022: EUR 435 million, decrease due to release of liabilities, in combination with higher tax losses or similar tax carryforwards that can be used if uncertain tax treatments were settled for the presumed amount at balance sheet date). The positions include, among others, the following: Transfer pricing risks Philips has issued transfer pricing directives, which are in accordance with international guidelines such as those of the Organization of Economic Co-operation and Development. In order to reduce the transfer pricing uncertainties, monitoring procedures are carried out by Group Tax to safeguard the correct implementation of the transfer pricing directives. However, tax disputes can arise due to inconsistent transfer pricing regimes and different views on "at arm's length" pricing. Tax risks on general and specific service agreements and licensing agreements Due to the centralization of certain activities (such as research and development, IT and group functions), costs are also centralized. As a consequence, these costs and/or revenues must be allocated to the beneficiaries, i.e. the various Philips entities. For that purpose, service contracts such as intra-group service agreements and licensing agreements are signed with a large number of group entities. Tax authorities review these intra-group service and licensing agreements, and may reject the implemented intra-group charges. Furthermore, buy in/out situations in the case of (de)mergers could affect the cost allocation resulting from the intragroup service agreements between countries. The same applies to the specific service agreements. Tax risks due to disentanglements and acquisitions When a subsidiary of Philips is disentangled, or a new company is acquired, tax risks may arise. Philips creates merger and acquisition (M&A) teams for these disentanglements or acquisitions. In addition to representatives from the involved business, these teams consist of specialists from various group functions and are formed, among other things, to identify tax risks and to reduce potential tax claims. Tax risks due to permanent establishments A permanent establishment may arise when a Philips entity has activities in another country, tax claims could arise in both countries on the same income.

Earnings per share

Earnings per share	12 Months Ended
	Dec. 31, 2023
Earnings per share [Abstract]
Earnings per share [Text Block]	9 Accounting policies The company presents basic and diluted earnings per share (EPS) data for its common shares. Basic EPS is calculated by dividing the Net income (loss) attributable to shareholders by the weighted average number of common shares outstanding (after deduction of treasury shares) during the period. Diluted EPS is determined by adjusting the Net income (loss) attributable to shareholders and the weighted average number of common shares outstanding (after deduction of treasury shares) during the period, for the effects of all dilutive potential common shares, which comprise performance shares, restricted shares and share options granted under share-based compensation plans as well as forward contracts to repurchase shares. Philips Group Earnings per share in millions of EUR unless otherwise stated 1 ) 2021 2022 2023 Income from continuing operations 612 (1,618) (454) Income from continuing operations attributable to shareholders 608 (1,622) (456) Income from continuing operations attributable to non-controlling interests 4 3 2 Income from discontinued operations 2,711 13 (10) Income from discontinued operations attributable to shareholders 2,711 13 (10) Net income 3,323 (1,605) (463) Net income attributable to shareholders 3,319 (1,608) (466) Net income attributable to non-controlling interests 4 3 2 Weighted average number of common shares outstanding (after deduction of treasury shares) during the period 943,606,613 920,950,800 917,440,090 Plus incremental shares from assumed conversions of: Share options 387,125 25,506 Performance shares 2,548,891 1,147,790 2,623,097 Restricted shares 2,376,736 1,986,538 2,574,738 Forward contracts to repurchase shares 70,329 17,611,920 15,511,844 Dilutive potential common shares 2 ) 5,383,080 20,771,753 20,709,680 Diluted weighted average number of shares outstanding (after deduction of treasury shares) during the period 948,989,692 920,950,800 917,440,090 Basic earnings per common share in EUR Income from continuing operations attributable to shareholders 0.64 (1.76) (0.50) Income from discontinued operations attributable to shareholders 2.87 0.01 (0.01) Net income attributable to shareholders 3.52 (1.75) (0.51) Diluted earnings per common share in EUR 2 ) Income from continuing operations attributable to shareholders 0.64 (1.76) (0.50) Income from discontinued operations attributable to shareholders 2.86 0.01 (0.01) Net income attributable to shareholders 3.50 (1.75) (0.51) Dividend distributed per common share in EUR 0.85 0.85 0.85 1 ) Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. 2 ) The dilutive potential common shares are not taken into account in the periods for which there is a loss, as the effect would be antidilutive Per-share calculations adjusted for share dividend On May 9, 2023, the General Meeting of Shareholders approved a dividend of EUR 0.85 per common share, in shares only. The dividend was settled in May through the issuance of 39,334,938 new common share. In accordance with IAS 33 Earnings Per Share, per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2023
Property, plant and equipment [Abstract]
Property, plant and equipment [Text Block]	10 Accounting policies Owned assets The cost of property, plant and equipment comprise all directly attributable costs (including the cost of material and direct labor). Depreciation is generally calculated using the straight-line method over the useful life of the asset. Land and assets under construction are not depreciated. When assets under construction are ready for their intended use, they are transferred to the relevant asset category and depreciation starts. All other property, plant and equipment items are depreciated over their estimated useful lives to their estimated residual values. The estimated useful lives of property, plant and equipment are as follows: Philips Group Useful lives of property, plant and equipment Buildings from 5 to 50 years Machinery and installations from 3 to 20 years Other equipment from 1 to 10 years Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the assets concerned may not be recoverable. An impairment loss is recognized for the amount by which the asset's book value exceeds their recoverable amount. Impairments are reversed if and to the extent that the impairment no longer exists. The recoverable amount is defined as the higher of the asset’s fair value less costs of disposal and its value in use. Gains and losses on the sale of property, plant and equipment are included in other business income. Costs related to repair and maintenance activities are expensed in the period in which they are incurred unless they extend the asset's original lifetime or capacity. Right-of-use assets The company leases various items of real estate, vehicles and other equipment. The company determines whether an arrangement constitutes or contains a lease based on the substance of the arrangement at the lease inception. The arrangement constitutes or contains a lease if fulfillment is dependent on the use of a specific asset and the arrangement conveys a right to use the asset, even if that asset is not explicitly specified in the arrangement. Company as a lessee The company recognizes right-of-use assets and lease liabilities for leases with a term of more than twelve months if the underlying asset is not of low value. Payments for short-term and low-value leases are expensed over the lease term. Extension options are included in the lease term if their exercise is reasonably certain. Right-of-use assets are measured at cost less accumulated depreciation and impairment losses, adjusted for any remeasurements. Right-of-use assets are depreciated using the straight-line method over the shorter of the lease term and the useful life of the underlying assets. Company as a lessor When the company acts as a lessor, it determines at lease inception whether a lease is a finance lease or an operating lease. Leases in which the company does not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating leases. The company recognizes lease payments received under operating leases as income on a straight-line basis over the lease term in the Consolidated statement of income. Accounting estimates and judgments Impairment of owned and right-of-use assets Judgments are required, not only to determine whether there is an indication that an asset may be impaired, but also whether indications exist that impairment losses previously recognized may no longer exist or may have decreased (impairment reversal). After indications of impairment have been identified, estimates and assumptions are used in the determination of the recoverable amount of a fixed asset. These involve estimates of expected future cash flows (based on future growth rates and remaining useful life) and residual value assumptions, as well as discount rates to calculate the present value of the future cash flows. Owned assets Estimates are required to determine the (remaining) useful lives of fixed assets. Useful lives are determined based on an asset's age, the frequency of its use, repair and maintenance policy, technology changes in production and expected restructuring. The company estimates the expected residual value per asset item. The residual value is the higher of the asset's expected sales price (based on recent market transactions of similar sold items) and its material scrap value. Right-of-use assets Judgment is required to determine the lease term. The assessment of whether the company is reasonably certain to exercise extension options impacts the lease term, which could affect the amount of lease liabilities and right-of-use assets recognized. Property, plant and equipment are fixed assets that are owned or right-of-use assets under a lease agreement. Owned and right-of-use assets are held for use in Philips' operating activities. Philips Group Property, plant and equipment in millions of EUR 2022 2023 Owned assets 1,718 1,565 Right-of-use assets 919 919 Total 2,638 2,483 Philips Group Property, plant and equipment - owned assets in millions of EUR Land and Machinery and installations Other Assets under construction Total Balance as of Cost 1,135 1,779 1,454 309 4,676 Accumulated depreciation (621) (1,291) (1,046) (2,958) Book value 514 488 408 309 1,718 Additions 1 115 77 239 433 Assets available for use 20 90 144 (262) (8) Depreciation (56) (196) (167) (420) Impairments (5) (23) (17) - (45) Transfer (to) from AHFS (1) (1) (45) (46) Reclassifications 15 2 (17) (5) (6) Translation differences and other (14) (22) (19) (7) (62) Total change (39) (35) (45) (35) (154) Balance as of Cost 1,114 1,731 1,404 274 4,521 Accumulated depreciation (638) (1,278) (1,041) (2,957) Book value 476 453 363 274 1,565 Philips Group Property, plant and equipment - right-of-use assets in millions of EUR Land and Other Total Balance as of January 1, 2023 Cost 1,365 206 1,571 Accumulated depreciation (543) (108) (651) Book value 822 98 919 Additions 175 62 236 Assets available for use 2 6 8 Depreciation (150) (51) (201) Impairments (23) - (23) Transfer (to) from AHFS (2) (2) Reclassifications - 4 4 Translation differences and other (18) (5) (23) Total change (16) 15 (1) Balance as of December 31, 2023 Cost 1,425 216 1,641 Accumulated depreciation (619) (104) (722) Book value 806 112 919 Philips Group Property, plant and equipment - owned assets in millions of EUR Land and Machinery and installations Other Assets under construction Total Balance as of Cost 1,097 1,585 1,382 208 4,273 Accumulated depreciation (591) (1,074) (967) (2,632) Book value 506 511 415 208 1,641 Additions 1 102 77 314 494 Assets available for use 34 69 111 (220) (6) Depreciation (56) (215) (176) - (447) Impairments (3) (20) (18) (1) (42) Transfer (to) from AHFS (3) - (3) Reclassifications 18 14 (5) 2 29 Translation differences and other 16 26 2 5 50 Total change 8 (23) (8) 100 78 Balance as of Cost 1,135 1,779 1,454 309 4,676 Accumulated depreciation (621) (1,291) (1,046) (2,958) Book value 514 488 408 309 1,718 Philips Group Property, plant and equipment - right-of-use assets in millions of EUR Land and Machinery and Other Total Balance as of January 1, 2022 Cost 1,332 176 216 1,724 Accumulated depreciation (418) (139) (109) (666) Book value 914 37 107 1,058 Additions 52 - 54 106 Assets available for use 5 1 6 Depreciation (155) (2) (58) (214) Impairments (8) - - (9) Transfer (to) from AHFS 3 3 Reclassifications (19) (13) - (32) Translation differences and other 31 (23) (6) 1 Total change (92) (37) (9) (139) Balance as of December 31, 2022 Cost 1,365 - 206 1,571 Accumulated depreciation (543) (108) (651) Book value 822 - 98 919 Lease related notes Below are the references with respect to year-end disclosures as lessee: Short-term and low-value leases, are disclosed in Income from operations Disclosures regarding interest expenses on lease liabilities, are disclosed in Financial income and expenses For disclosure on leasing related cash outflow and the split between interest and principal payments, refer to Cash flow statement supplementary information For disclosure on sale and leaseback transactions, refer to Details of treasury and other financial risks For disclosure on lease liabilities and maturity analysis, refer to Debt Other qualitative and quantitative disclosures regarding the nature of lessee’s leasing activities and future lease obligations, refer to Debt Below are the references with respect to year-end disclosures as lessor: For disclosures on lease income and sublease income, refer to Details of treasury and other financial risks Other qualitative disclosures regarding the nature of lessors leasing activities and risk management, refer to Details of treasury and other financial risks

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2023
Goodwill [Abstract]
Goodwill [Text Block]	11 Accounting policies The measurement of goodwill at initial recognition is described in the Acquisitions and divestments note. Goodwill is subsequently measured at cost less accumulated impairment losses. Goodwill is not amortized but is instead tested for impairment annually in the fourth quarter, or more frequently if indicators of potential impairment exist. Internal and external sources of information are considered to assess if there are indicators that an asset or groups of cash-generating units (CGUs) may be impaired. Goodwill is allocated to groups of CGUs and tested for impairment at the business level (one level below segment), as this represents the lowest level at which goodwill is monitored for internal management purposes. An impairment loss is recognized in the Consolidated statements of income whenever and to the extent that the carrying amount of a group of CGUs exceeds the recoverable amount for the group of CGUs, whichever is the greater, its value in use or its fair value less cost of disposal. Value in use is measured as the present value of future cash flows expected to be generated by the asset. Fair value less cost of disposal is measured as the amount obtained from the sale of an asset in an arm’s length transaction, less costs of disposal. Accounting estimates and judgments The cash flow projections used in the value in use calculations for goodwill impairment testing contain various judgments and estimations as described in the ‘key assumptions’ section. The changes in 2022 and 2023 were as follows: Philips Group Goodwill in millions of EUR 2022 2023 Balance as of January 1 Cost 11,793 12,747 Impairments (1,156) (2,509) Book value 10,637 10,238 Acquisitions 1 ) 317 24 Impairments (1,357) (8) Divestments and transfers to assets classified as held for sale 2 ) (8) Translation differences and other 641 (370) Total change (399) (362) Balance as of December 31 Cost 12,747 12,133 Impairments (2,509) (2,256) Book value 10,238 9,876 1 ) Refer to Acquisitions and divestments 2 ) Refer to Discontinued operations and assets classified as held for sale Effective from April 1, 2023, Philips implemented a simplified operating model (refer to relevant sections of General information to the Consolidated financial statements Goodwill impairment testing For impairment testing, goodwill is allocated to groups of CGUs and tested for impairment at the business level (one level below segment level), which represents the lowest level at which the goodwill is monitored internally for management purposes. Goodwill is tested for impairment annually in the fourth quarter, or more frequently if indicators of potential impairment exist. An impairment trigger assessment is performed on a quarterly basis to determine whether there is an indication based on either internal or external sources of information, that a group of CGUs may be impaired. During 2023, interim impairment tests were completed for the Sleep & Respiratory Care (S&RC) business mainly following revisions to the expected future cashflow assumptions regarding the estimated impact of the proposed Respironics consent decree, along with updates to expected business performance and changes to the pre-tax discount rate. The interim goodwill impairment tests did not result in an impairment. Goodwill allocated to the businesses (groups of cash-generating units) as of December 31, 2023, is presented in the following table: Philips Group Goodwill by business in millions of EUR 2022 2023 Monitoring 1 ) 4,110 3,964 Image-Guided Therapy 3,154 3,044 Precision Diagnosis 1,429 1,363 Sleep & Respiratory Care 731 687 Personal Health 488 483 Enterprise Informatics 327 336 Book value 10,238 9,876 1 ) Monitoring includes the goodwill previously allocated to Hospital Patient Monitoring and Ambulatory Monitoring & Diagnostics as disclosed in the Annual Report 2022. The carrying amount of each group of CGUs is compared to the recoverable amount of the group of CGUs. Unless otherwise noted, the recoverable amount for each group of CGUs is based on value in use calculations. Value in use is measured as the present value of future cash flows expected to be generated from the continuing use of the assets. In the 2023 annual goodwill impairment test, these cash flow projections were determined using Royal Philips managements’ internal forecasts that cover an initial forecast period from 2024 to 2026. Projections were extrapolated using the growth rates disclosed in the following table for an extrapolation period of 4 years (2027-2030), after which a terminal value was calculated per 2031. For the terminal value calculation, growth rates were capped at a historical long-term average growth rate. The company uses scenarios in the business forecasting process and the most reasonable and supportable assumptions which represent management’s best estimate are used as the basis for the value in use calculations. Key assumptions Key assumptions used in the value in use calculations were compound sales growth rates, EBITA * ) The compound sales growth rate is the annualized steady nominal growth rate over the forecast period calculated with reference to the latest full year of actual sales as the base for the growth. The compound sales growth rate used to calculate terminal value is only applied to the first year after the extrapolation period, after which no further growth is assumed for the terminal value calculation. The compound sales growth rates and EBITA * ) * ) The rates used for discounting the projected cash flows in goodwill impairment testing is based on a weighted cost of capital (WACC), which in turn is based on business-specific inputs along with other inputs as mentioned below. The WACC is based on post-tax cost of equity and cost of debt, and is further calculated based on market data and inputs to accurately capture changes to the time value of money, such as the risk-free interest rate, the beta factor and country risk premium. In order to properly reflect the different risk-profiles of different businesses, a WACC is determined for each business. As such, the beta factor is determined based on a selection of peer companies, which can differ per business. Different businesses have different geographical footprints, resulting in business-specific inputs for variables like country risk. Philips performs the value in use calculations using post-tax cashflows and discount rate, the implicit pre-tax rate discount rate is derived from an iterative calculation for disclosure purposes. The values assigned to the key assumptions used for the value in use calculations were as follows: Philips Group Key assumptions 2023 compound sales growth rate initial forecast period extrapolation period used to calculate terminal value pre-tax discount rates Monitoring 8.2% 5.5% 2.5% 9.5% Image-Guided Therapy 7.9% 5.2% 2.5% 10.7% Precision Diagnosis 3.8% 3.4% 2.5% 10.4% Sleep & Respiratory Care 9.5% 9.3% 2.5% 10.8% Personal Health 5.0% 4.6% 2.5% 10.3% Enterprise Informatics 5.3% 5.8% 2.5% 9.0% The assumptions used for the 2022 value in use calculations for cash-generating units to which a significant amount of goodwill was allocated were as follows: Philips Group Key assumptions 2022 compound sales growth rate initial forecast period extrapolation period used to calculate terminal value pre-tax discount rates Ambulatory Monitoring & Diagnostics 1 ) 15.4% 9.5% 2.5% 8.5% Hospital Patient Monitoring 1 ) 4.8% 3.4% 2.5% 8.5% Image-Guided Therapy 8.7% 5.0% 2.5% 10.6% Sleep & Respiratory Care 10.0% 5.0% 2.5% 9.9% 1 ) Effective April 1, 2023, the Hospital Patient Monitoring and Ambulatory Monitoring & Diagnostics CGUs are included in the group of CGUs that comprise the Monitoring business. The S&RC compound sales growth rate during the extrapolation period increased from 5.0% in 2022 to 9.3% in 2023. The growth rate percentage is calculated with reference to the last year of the initial forecast period. Although the absolute forecasted sales during the extrapolation period used in 2023 decreased compared to that used in 2022, the larger decline in the forecasted sales of the respective reference year results in a higher calculated growth rate percentage compared to 2022. Impairment losses Goodwill impairment charges for the years ended December 31, 2023 and 2022, were EUR 8 million and EUR 1,357 million, respectively. The 2023 charge relates to the partial impairment of goodwill allocated to a business that was classified as held-for-sale as of December 31, 2023. At the time of classification as held-for-sale, goodwill totaling EUR 16 million was allocated from the Precision Diagnosis business to the held-for-sale business, of which EUR 8 million was subsequently impaired. For further information refer to Discontinued operations and assets classified as held for sale The 2022 charges relate to the impairment charge of EUR 1,331 million in the S&RC CGU within the Connected Care segment and a charge of EUR 27 million recognized in relation to the Precision Diagnosis Solutions CGU, which was formerly part of the Diagnosis & Treatment segment but is now included in the Enterprise Informatics business within the Connected Care segment. Sensitivity to changes in assumptions In performing the value-in-use calculations for the S&RC CGU, it was necessary for management to make assumptions regarding the estimated impact on the business of the proposed Respironics consent decree. These assumptions include, amongst others, the expected financial impact of the scope of products, geography, and duration of the proposed consent decree, as well as expected additional costs. These assumptions were determined by management based on the proposed Respironics consent decree and other available sources of information. The value-in-use of the S&RC CGU remains sensitive to the assumptions set out above. This means that there is a higher risk that deviations in the mentioned key assumptions could cause the recoverable amount to fall below the level of its carrying value. There continues to be uncertainty associated with the initiated voluntary recall notification in the US and field safety notice outside the US for certain sleep and respiratory care products and the impact on the business of the proposed Respironics consent decree. Based on the annual impairment test, the estimated recoverable amount of the S&RC CGU exceeds the carrying value by EUR 326 million. It was noted that an increase of 190 basis points in the pre-tax discount rate, a 690 basis points decline in the compound sales growth rate during the extrapolation period or a 27% decrease in terminal value would, individually, cause its recoverable amount to fall to the level of its carrying value. Additionally, any significant adverse changes to the assumptions related to the expected financial impact of the proposed Respironics consent decree could cause the recoverable amount of the CGU to fall below its carrying value, resulting in impairment. The results of the annual impairment tests of Monitoring, Image-Guided Therapy, Precision Diagnosis, Personal Health and Enterprise Informatics indicate that a reasonably possible change in key assumptions would not cause the value in use to fall to the level of the carrying value. * ) The definition of this non-IFRS measure and a reconciliation to the IFRS measure is included in Information by segment and main country

Intangible assets excluding goo

Intangible assets excluding goodwill	12 Months Ended
	Dec. 31, 2023
Intangible assets excluding goodwill [Abstract]
Intangible assets excluding goodwill [Text Block]	12 Accounting policies Acquired finite-lived intangible assets are amortized using the straight-line method over their estimated useful life. The useful lives are evaluated annually. Intangible assets are initially capitalized at cost, with the exception of intangible assets acquired as part of a business combination, which are capitalized at their acquisition date fair value. The company expenses all research costs as incurred. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized as an intangible asset if the product or process is technically and commercially feasible, the company has sufficient resources and the intention to complete development and can measure the attributable expenditure reliably. The capitalized development expenditure comprises of all directly attributable costs (including the cost of materials and direct labor). Other development expenditures and expenditures on research activities are recognized in the Consolidated statements of income. Capitalized development expenditure is stated at cost less accumulated amortization and impairment losses. Amortization of capitalized development expenditure is charged to the Consolidated statements of income on a straight-line basis over the estimated useful lives of the intangible assets. The expected useful lives of the intangible assets excluding goodwill are as follows: Philips Group Expected useful lives of intangible assets excluding goodwill in years Brand names 2-20 Customer relationships 2-25 Technology 3-20 Other 1-10 Software 1-10 Product development 3-10 The weighted average expected remaining life of brand names, customer relationships, technology and other intangible assets is 9.3 years as of December 31, 2023 (2022: 9.4 years). Impairment of intangible assets not yet ready for use Intangible assets not yet ready for use are not amortized but are tested for impairment annually and whenever impairment indicators require. In the case of intangible assets not yet ready for use, either internal or external sources of information are considered to assess if there are indicators that an asset or a CGU may be impaired. Impairment of non-financial assets other than goodwill, intangible assets not yet ready for use, inventories and deferred tax assets Non-financial assets other than goodwill, intangible assets not yet ready for use, inventories and deferred tax assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is assessed by a comparison of the carrying amount of an asset with the greater of its value in use and fair value less cost of disposal. Value in use is measured as the present value of future cash flows expected to be generated by the asset. Fair value less cost of disposal is measured as the amount obtained from a sale of an asset in an arm’s length transaction, less costs of disposal. If the carrying amount of an asset is deemed not recoverable, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the recoverable amount. The review for impairment is carried out at the level where cash flows occur that are independent of other cash flows. Impairment losses recognized in prior periods for Intangible assets other than goodwill are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if and to the extent that there has been a change in the estimates used to determine the recoverable amount. The loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Reversals of impairment are recognized in the Consolidated statements of income. Accounting estimates and judgments The cash flow projections used in the value in use calculations for intangible assets excluding goodwill contain various judgments and estimations. For intangible assets excluding goodwill, estimates are required to determine the (remaining) useful lives. Philips Group Intangible assets excluding goodwill in millions of EUR brand names customer relationships technology product development product development construction in progress software other total Balance as of January 1, 2023 Cost 647 2,735 2,947 2,605 648 869 152 10,602 Amortization / impairments (507) (1,665) (1,845) (2,212) (146) (589) (113) (7,077) Book value 140 1,070 1,102 393 502 280 39 3,526 Additions 33 - 214 70 - 317 Assets available for use 157 (157) Acquisitions 40 - - 40 Amortization (20) (137) (131) (169) (97) (1) (556) Impairments - - - (7) (7) (1) - (16) Transfers to assets classified as held for sale (1) (20) (8) (2) (32) Translation differences and other (1) (37) (30) (38) 1 18 - (87) Total change (22) (195) (89) (57) 42 (13) (1) (335) Balance as of December 31, 2023 Cost 629 2,593 2,908 2,432 635 929 139 10,265 Amortization / impairments (511) (1,718) (1,895) (2,096) (91) (662) (101) (7,075) Book Value 118 875 1,013 336 544 267 38 3,190 Philips Group Intangible assets excluding goodwill in millions of EUR brand names customer relationships technology product development product development construction in progress software other total Balance as of January 1, 2022 Cost 644 2,590 2,605 2,701 505 754 146 9,944 Amortization / impairments (481) (1,447) (1,605) (2,102) (91) (467) (101) (6,294) Book value 162 1,143 1,000 599 414 287 44 3,650 Additions (3) - 51 - 257 109 1 416 Assets available for use 118 (118) - - - Acquisitions 1 3 177 - - - 180 Amortization (24) (141) (140) (206) (1) (100) (3) (614) Impairments - (6) (46) (123) (81) (17) (2) (276) Translation differences and other 4 71 59 5 31 1 (2) 169 Total change (22) (74) 102 (206) 88 (7) (6) (125) Balance as of December 31, 2022 Cost 647 2,735 2,947 2,605 648 869 152 10,602 Amortization / impairments (507) (1,665) (1,845) (2,212) (146) (589) (113) (7,077) Book Value 140 1,070 1,102 393 502 280 39 3,526 Acquisitions in 2023 involved intangible assets of EUR 40 million in aggregate (2022: EUR 180 million). For more information, refer to Acquisitions and divestments Impairments in 2023 were EUR 16 million (2022: EUR 276 million) and mainly relate to product development construction in progress and product development. The company uses scenarios in the business forecasting process and the most reasonable and supportable assumptions which represent management’s best estimate are used as the basis for the value-in-use calculations. The amortization and impairment of intangible assets is further specified in Income from operations The most notable intangible assets as of December 31, 2023 relate to the BioTelemetry customer relationships and technology with a carrying value of EUR 327 million and EUR 123 million and a remaining amortization period of 13 years and 9 years, respectively and Spectranetics customer relationships and technology with a carrying value of EUR 261 million and EUR 175 million and a remaining amortization period of 14 years and 9 years, respectively. The most notable intangible assets as of December 31, 2022 relate to the BioTelemetry customer relationships and technology with value of EUR 385 million and EUR 150 million and a remaining amortization period of 14 years and 10 years, respectively and Spectranetics customer relationships and technology with a carrying value of EUR 291 million and EUR 203 million and a remaining amortization period of 15 years and 10 years, respectively.

Other financial assets

Other financial assets	12 Months Ended
	Dec. 31, 2023
Other financial assets [Abstract]
Other financial assets [Text Block]	13 Accounting policies Classification and measurement of financial assets The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the company’s business model for managing them. The company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. For the purposes of subsequent measurement, financial assets are classified into four categories: Financial assets at amortized cost (debt instruments). Financial assets at fair value through other comprehensive income (OCI) with recycling of cumulative gains and losses (debt instruments). Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments). Financial assets at fair value through profit or loss (debt instruments and equity instruments). Impairment of financial assets The company recognizes a loss allowance for expected credit losses for trade receivables, contract assets, lease receivables, debt investments carried at amortized cost and fair value through other comprehensive income (FVTOCI). At each balance sheet date, the company assesses whether there is objective evidence that a financial asset or a group of financial assets is impaired and recognizes a loss allowance for expected credit losses for financial assets measured at either amortized costs or at fair value through other comprehensive income. If, at the reporting date, the credit risk on a financial instrument has not increased significantly since initial recognition, the company measures the loss allowance for the financial instrument at an amount equal to 12 months of expected credit losses. If, at the reporting date, the credit risk on a financial instrument has increased significantly since initial recognition, the company measures the loss allowance for the financial instrument at an amount equal to the lifetime-expected credit losses. For all trade receivables, contract assets and lease receivables the company measures the loss allowance at an amount equal to lifetime-expected credit losses. Accounting estimates and judgments The determination of fair value is subject to estimates for investments that are not publicly traded. Refer to Fair value of financial assets and liabilities Financial assets classified at amortized cost and at fair value through OCI are subject to impairment assessment. The calculation of expected credit losses requires the company to apply significant judgment and make estimates and assumptions that involve significant uncertainty at the time they are made. Changes to these estimates and assumptions can result in significant changes to the timing and amount of expected credit losses to be recognized. Other current financial assets In 2023, Other current financial assets decreased from EUR 11 million to EUR 3 million (2022: increased from EUR Other non-current financial assets The company’s investments in Other non-current financial assets mainly consist of investments in common shares of companies in various industries and investments in limited life funds. The changes during 2023 and 2022 were as follows: Philips Group Other non-current financial assets in millions of EUR Non-current financial assets at FVTP&L Non-current financial assets at FVTOCI Non-current financial assets at Amortized cost Total Balance as of January 1, 2023 322 284 54 660 Changes: Acquisitions/additions 71 14 20 105 Sales/redemptions/reductions (33) (14) (11) (58) Impairments Value adjustment through OCI - (17) (17) Value adjustment through P&L (39) - (39) Translation differences and other (29) (14) (1) (44) Reclassifications (8) 5 15 12 Balance as of December 31, 2023 284 258 77 619 Philips Group Other non-current financial assets in millions of EUR Non-current financial assets at FVTP&L Non-current financial assets at FVTOCI Non-current financial assets at Amortized cost Total Balance as of January 1, 2022 283 300 47 630 Changes: Acquisitions/additions 114 18 18 150 Sales/redemptions/reductions (75) (3) (8) (86) Impairments (3) (1) (5) Value adjustment through OCI - (35) (35) Value adjustment through P&L 5 - 5 Translation differences and other (2) 5 (1) 2 Reclassifications 1 (2) (1) (2) Balance as of December 31, 2022 322 284 54 660 As of December 31, 2023, equity investments of EUR 231 million (2022: EUR 259 million) are accounted under the FVTOCI category based on the company's election at initial recognition mainly because such investments are neither held for trading purposes nor primarily for their increase in value and the elected presentation is considered to reflect the nature and purpose of the investment.

Other assets

Other assets	12 Months Ended
	Dec. 31, 2023
Other assets [Abstract]
Other assets [Text Block]	14 Accounting policies The company recognizes contract assets for revenue earned from installation services because the receipt of consideration is conditional on successful completion of the installation. Upon completion of the installation and acceptance by the customer, the amount recognized as contract assets is reclassified to trade receivables. Other assets are measured at amortized cost minus any impairment losses. Other non-current assets Other non-current assets as of December 31, 2023 were EUR 93 million (2022: EUR 98 million). These are mainly related to prepaid expenses. Other current assets Other current assets as of December 31, 2023 of EUR 500 million (2022: EUR 490 million) included contract assets of EUR 297 million (2022: EUR 292 million), accrued income of EUR 6 million (2022: EUR 24 million) and prepaid expenses of EUR 197 million (2022: EUR 174 million) mainly related to Diagnosis & Treatment businesses and Connected Care businesses.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
Inventories [Text Block]	15 Accounting policies Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. The costs of conversion of inventories include direct labor and fixed and variable production overheads, considering the stage of completion and the normal capacity of production facilities. Costs of idle facility and abnormal waste are expensed. The cost of inventories is determined using the first-in, first-out (FIFO) method. The write-down of inventories to net realizable value is included in cost of sales. Accounting estimates and judgments Inventory is reduced for the estimated losses due to obsolescence. This reduction is determined for groups of products based on sales in the recent past and/or expected future demand. Inventories are summarized as follows: Philips Group Inventories in millions of EUR 2022 2023 Raw materials and supplies 1,541 1,309 Work in process 648 552 Finished goods 1,860 1,629 Inventories 4,049 3,491 In 2023, overall global inventories have operationally decreased in all categories due to the deployment of strategic management of aging and unhealthy inventory accompanied by a more optimized tracking in both production and commercial inventories. The write-down of inventories to net realizable value was EUR 339 million in 2023 (2022: EUR 215 million), including EUR 82 million related to the proposed Respironics consent decree (refer to Provisions

Receivables

Receivables	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Receivables [Text Block]	16 Accounting policies Receivables are held by the company to collect the related cash flows. These receivables are measured at fair value and subsequently measured at amortized cost minus any impairment losses. Receivables are derecognized when the company has transferred substantially all risks and rewards, which includes transactions in which the company enters into factoring transactions, or if the company does not retain control over the receivables. Accounting estimates Receivables are subject to impairment assessment, which involves estimating expected credit losses. Refer to Other financial assets Non-current receivables Non-current receivables are associated mainly with customer financing in the Diagnosis & Treatment businesses amounting to EUR 102 million (2022: EUR 69 million), for Signify indemnification amounting to EUR 4 million (2022: EUR 26 million), an income tax receivable amounting to EUR 12 million (which includes an interest receivable of EUR 3 million) for which Philips expects to get a refund (2022: EUR 126 million) and insurance receivables in the US amounting to EUR 33 million (2022: EUR 30 million). Current receivables Current receivables of EUR 3,733 million (2022: EUR 4,115 million) as of December 31, 2023 included trade accounts receivable (net of allowance) of EUR 3,546 million (2022: EUR 3,832 million), accounts receivable other of EUR 170 million (2022: EUR 228 million) and accounts receivable from investments in associates of EUR 18 million (2022: EUR 55 million). The trade accounts receivable, net, per segment are as follows: Philips Group Trade accounts receivable, net in millions of EUR 2022 2023 Diagnosis & Treatment 1,795 1,688 Connected Care 1,332 1,105 Personal Health 479 576 Other 226 177 Trade accounts receivable, net 3,832 3,546 The aging analysis of trade accounts receivable, net, representing current and overdue but not fully impaired receivables, is as follows: Philips Group Aging analysis in millions of EUR 2022 2023 Current 3,280 3,132 Overdue 1-30 days 169 117 Overdue 31-180 days 282 234 Overdue more than 180 days 101 63 Trade accounts receivable, net 3,832 3,546 The changes in the allowance for doubtful accounts receivable are as follows: Philips Group Allowance for accounts receivable in millions of EUR 2022 2023 Balance as of January 1 190 226 Additions charged to expense 66 27 Deductions from allowance 1 ) (51) (26) Transfer to assets held for sale (1) Other movements 21 (10) Balance as of December 31 226 216 1 ) Write-offs for which an allowance was previously provided. The allowance for doubtful accounts receivable has been primarily established for receivables that are past due. The allowance presented also includes the allowance for Non-current customer finance receivables of EUR 8 million (2022: EUR 7 million). Other movements in the current period are mainly related to foreign currency valuations. Included in the above balances as of December 31, 2023 are allowances for individually impaired receivables of EUR 210 million (2022: EUR 222 million).

Equity

Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Equity [Text Block]	17 Accounting policies Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from equity. Where the company repurchases the company’s equity share capital (treasury shares), the consideration paid, including any directly attributable incremental transaction costs (net of income taxes), is deducted from shareholders’ equity until such treasury shares are cancelled or reissued. Where such treasury shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in shareholders’ equity. Call options on own shares are treated as equity instruments. Dividends are recognized as a liability in the period in which they are declared and approved by shareholders. The income tax consequences of dividends are recognized when a liability to pay the dividend is recognized. Common shares As of December 31, 2023, authorized common shares consist of 2 billion shares (December 31, 2022: 2 billion; December 31, 2021: 2 billion) and the issued and fully paid share capital consists of 913,515,966 common shares, each share having a par value of EUR 0.20 (December 31, 2022: 889,315,082; December 31, 2021: 883,898,969). Preference shares As a means to protect the company against (an attempt at) an unsolicited takeover or other attempt to exert (de facto) control of the company, the ‘Stichting Preferente Aandelen Philips’ has been granted the right to acquire preference shares in the company. As of December 31, 2023, no such right has been exercised and no preference shares have been issued. Authorized preference shares consist of 2 billion shares as of December 31, 2023 (December 31, 2022: 2 billion; December 31, 2021: 2 billion). Options, restricted and performance shares Under its share-based compensation plans, the company granted stock options on its common shares and other conditional rights to receive common shares in the future such as restricted shares and performance shares (refer to Share-based compensation Treasury shares In connection with the company’s share repurchase programs, shares which have been repurchased and are held in Treasury for the purpose of (i) delivery under share-based compensation plans upon exercise of options, or vesting of restricted or performance shares, and (ii) capital reduction, are accounted for as a reduction of shareholders’ equity. Treasury shares are recorded at cost, representing the market price on the acquisition date. When treasury shares are delivered by the company under its share-based compensation plans, such shares are removed from treasury shares on a first-in, first-out (FIFO) basis. When treasury shares are delivered by the company upon exercise of options, the difference between the cost and the cash received is recorded in retained earnings. When treasury shares are delivered by the company upon vesting of restricted shares or performance shares (granted under the company’s share-based compensation plans), the difference between the market price of the shares and the cost is recorded in retained earnings, and the market price is recorded in capital in excess of par value. The following table shows the movements in the outstanding number of shares over the last three years: Philips Group Outstanding number of shares 2021 2022 2023 Balance as of January 1 905,128,293 870,182,445 881,480,527 Dividend distributed 6,345,968 14,174,568 39,334,938 Purchase of treasury shares (45,486,392) (5,080,693) (15,964,445) Delivery of treasury shares 4,194,577 2,204,207 1,552,136 Balance as of December 31 870,182,445 881,480,527 906,403,156 The following table reflects transactions that took place in relation to former and current share-based compensation plans: Philips Group Transactions related to share-based compensation plans 2021 2022 2023 Shares acquired 3,996,576 2,142,445 3,000,000 Average market price EUR 36.15 EUR 31.76 EUR 41.59 Amount paid EUR 144 million EUR 68 million EUR 125 million Shares delivered 4,194,577 2,204,207 1,552,136 Average price (FIFO) EUR 34.14 EUR 35.16 EUR 34.59 Cost of delivered shares EUR 143 million EUR 77 million EUR 54 million Total shares in treasury at year-end 5,726,708 5,664,946 7,112,810 Total cost EUR 201 million EUR 191 million EUR 262 million The following transactions took place for capital reduction purposes: Philips Group Transactions related to capital reduction 2021 2022 2023 Shares acquired 41,489,816 2,938,248 12,964,445 Average market price EUR 36.22 EUR 36.61 EUR 37.25 Amount paid EUR 1,503 million EUR 108 million EUR 483 million Cancellation of treasury shares (shares) 33,500,000 8,758,455 15,134,054 Cancellation of treasury shares (EUR) EUR 1,216 million EUR 299 million EUR 566 million Total shares in treasury at year-end 7,989,816 2,169,609 Total cost EUR 287 million EUR 83 million Share purchase transactions related to employee option and share plans, as well as transactions related to the reduction of share capital, involved a cash outflow of EUR 662 million in 2023. In 2023, the settlement of forward contracts resulted in a withholding tax liability for an amount of EUR 66 million relating to the dividend distribution. As of December 31, 2023, the remaining liability to be settled amounted to EUR 11 million. Share repurchase methods for share-based remuneration plans and capital reduction purposes Philips uses different methods to repurchase shares in its own capital: (i) share buyback repurchases in the open market via an intermediary; (ii) repurchase of shares via forward contracts for future delivery of shares; and (iii) the unwinding of call options on own shares. During 2023, Philips used method (ii) to repurchase shares for capital reduction purposes and share-based compensation plans. Forward contracts to repurchase shares For share-based compensation plans On June 14, 2023, Royal Philips announced that it will repurchase up to 7.1 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchases plans. Under this program, Philips entered into one forward contract for an amount of EUR 138 million to acquire 7.1 million shares with settlement dates varying between November 2024 and November 2025 and a weighted average forward price of EUR 19.43. On June 13, 2022, Royal Philips announced that it will repurchase up to 3.2 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchases plans. Under this program, Philips entered into one forward contract for an amount of EUR 63 million to acquire 3.2 million shares with settlement dates in November 2024 and December 2024 and a weighted average forward price of EUR 19.75. On May 19, 2021, Royal Philips announced that it will repurchase up to 2 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchase plans. Under this program, Philips entered into one forward contract for an amount of EUR 90 million to acquire 2 million shares with settlement dates in October 2023 and November 2023 and a weighted average forward price of EUR 44.85. As of December 31, 2023, all shares under this program were acquired (settled in the fourth quarter of 2023). This resulted in a EUR 90 million increase in retained earnings against treasury shares. On January 29, 2020, Philips announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchase plans. Under this program, Philips entered into three forward contracts to acquire in total 5 million for an amount of EUR 174 million to acquire with settlement dates varying between October 2021 and November 2022 and a weighted average forward price of EUR 34.85. On October 26, 2022, the original settlement date of two tranches entered into under this program (in total 1.75 million shares) has been extended from November 23, 2022 to November 2023, and November 2024, respectively. As of December 31, 2023, a total of 4.3 million shares (December 31, 2022: 3.3 million shares) under this program were acquired (settled in the fourth quarter of 2021, 2022, and 2023). This resulted in a EUR 35 million (2022: EUR 57 million) increase in retained earnings against treasury shares. As of December 31, 2023, the remaining forward contracts to cover obligations under share-based compensation plans related to 11.1 million shares (December 31, 2022: 7.0 million shares) and amounted to EUR 224 million (December 31, 2022: EUR 211 million). For capital reduction On July 26, 2021, Philips announced a share buyback program for share cancellation purposes for an amount of up to EUR 1.5 billion. Consequently, in the third quarter of 2021 Philips entered into three forward contracts for an amount of EUR 731 million to acquire 20 million shares with settlement dates in 2022, 2023 and 2024 and a weighted average forward price of EUR 37.36. Philips executed the remainder of the program through open market purchases by an intermediary in the fourth quarter of 2021 (acquiring 21 million shares) and January 2022 (acquiring 0.8 million shares). This resulted in a EUR 781 million increase in retained earnings against treasury shares. As of December 31, 2023, a total of 15.1 million (December 31, 2022: 2.2 million) shares under this program were acquired (in the fourth quarter of 2022 and third and fourth quarters of 2023). This resulted in EUR 483 million (including dividend adjustment) increase in retained earnings against treasury shares (2022: EUR 83 million). As of December 31, 2023, the remaining forward contracts entered into for capital reduction purposes relate to 4.4 million shares (December 31, 2022: 17.4 million shares) and amounted to EUR 167 million (December 31, 2022: EUR 648 million). Share call options In 2016, Philips purchased EUR-denominated and USD-denominated call options on its own shares to hedge options granted to employees up to 2013. On December 31, 2022, there were 55,750 EUR-denominated call options outstanding. As of December 31, 2023, all outstanding EUR-denominated call options have expired. Shares cancellation In December 2023, Philips completed the cancellation of 15.1 million of its common shares (with a cost price of EUR 566 million). The cancelled shares were acquired as part of Philips’ EUR 1.5 billion share repurchase program announced on July 26, 2021. Dividend distribution 2023 In May 2023, Philips distributed a dividend of EUR 0.85 per common share, representing a total value of EUR 749 million (including costs). The dividend was distributed in the form of shares only, resulting in the issuance of 39,334,938 new common shares. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Further reference is made to Earnings per share A proposal will be submitted to the 2024 Annual General Meeting of Shareholders to pay a dividend of EUR 0.85 per common share, in common shares only, against retained earnings for 2023. 2022 In May 2022, Philips distributed a dividend of EUR 0.85 per common share, representing a total value of EUR 741 million (including costs). Shareholders could elect for a cash dividend or a share dividend. Approximately 45% of the shareholders elected for a share dividend, resulting in the issuance of 14,174,568 new common shares. The settlement of the cash dividend involved an amount of EUR 411 million (including costs). 2021 In June 2021, Philips distributed a dividend of EUR 0.85 per common share, representing a total value of EUR 773 million (including costs). Shareholders could elect for a cash dividend or a share dividend. Approximately 38% of the shareholders elected for a share dividend, resulting in the issuance of 6,345,968 new common shares. The settlement of the cash dividend involved an amount of EUR 482 million (including costs). Limitations in the distribution of shareholders’ equity As of December 31, 2023, pursuant to Dutch law, certain limitations exist relating to the distribution of shareholders’ equity of EUR 2,435 million. Such limitations relate to common shares of EUR 183 million, as well as to legal reserves required by Dutch law included under retained earnings of EUR 990 million and unrealized currency translation differences of EUR 1,263 million. The unrealized gain related to cash flow hedges of EUR 6 million and unrealized loss related to fair value through OCI financial assets of EUR 390 million qualify as revaluation reserves and reduce the distributable amount due to the fact that these reserves are negative. The legal reserves required by Dutch law of EUR 990 million included under retained earnings relates to any legal or economic restrictions on the ability of affiliated companies to transfer funds to the parent company in the form of dividends. As of December 31, 2022, these limitations in distributable amounts were EUR 3,054 million and related to common shares of EUR 178 million, as well as to legal reserves required by Dutch law included under retained earnings of EUR 1,010 million and unrealized currency translation differences of EUR 1,866 million. The unrealized losses related to fair value through OCI financial assets of EUR 376 million and unrealized loss related to cash flow hedges of EUR 2 million qualify as a revaluation reserve and reduce the distributable amount due to the fact that this reserve is negative. Non-controlling interests Non-controlling interests relate to minority stakes held by third parties in consolidated group companies. Capital management Philips manages capital based upon the IFRS measures, net cash provided by operating activities and net cash used for investing activities as well as the non-IFRS measure net debt. The definition of this non-IFRS measure and a reconciliation to the IFRS measure is included below. Net debt is defined as the sum of long and short-term debt minus cash and cash equivalents. Group equity is defined as the sum of shareholders’ equity and non-controlling interests. This measure is used by Philips Treasury management and investment analysts to evaluate financial strength and funding requirements. The Philips net debt position is managed with the intention of retaining the current strong investment grade credit rating. Furthermore, Philips’ aim when managing the net debt position is dividend stability and a pay-out ratio of 40% to 50% of Adjusted income from continuing operations attributable to shareholders (reconciliation to the most directly comparable IFRS measure, Net income, is provided at the end of this note). Philips Group Composition of net debt and group equity in millions of EUR unless otherwise stated 2021 2022 2023 Long-term debt 6,473 7,270 7,035 Short-term debt 506 931 654 Total debt 6,980 8,201 7,689 Cash and cash equivalents 2,303 1,172 1,869 Net debt 4,676 7,028 5,820 Shareholders' equity 14,438 13,249 12,028 Non-controlling interests 36 34 33 Group equity 14,475 13,283 12,061 Net debt and group equity ratio 24:76 35:65 33:67 Adjusted income from continuing operations attributable to shareholders is not a recognized measure of financial performance under IFRS. The reconciliation of Adjusted income from continuing operations attributable to shareholders to the most directly comparable IFRS measure, Net income for 2023 is included in the following table. Philips Group Adjusted income from continuing operations attributable to shareholders 1 ) 2021 2022 2023 Net income 3,323 (1,605) (463) Discontinued operations, net of income taxes (2,711) (13) 10 Income from continuing operations 612 (1,618) (454) Income from continuing operations attributable to non-controlling interests (4) (3) (2) Income from continuing operations attributable to shareholders 1 ) 608 (1,622) (456) Adjustments for: Amortization and impairment of acquired intangible assets 322 363 290 Impairment of goodwill 15 1,357 8 Restructuring costs and acquisition-related charges 95 202 381 Other items: 1,069 925 1,358 Respironics litigation provision 575 Respironics field-action connected to the proposed consent decree 719 250 363 Respironics field-action running remediation cost 94 210 224 Quality remediation actions 94 59 175 R&D project impairments 134 Portfolio realignment charges 109 Impairment of assets in S&RC 39 Provision for public investigations tender irregularities 60 Provision for a legal matter 31 Investment re-measurement loss 23 Loss (gain) on divestment of business 76 (35) Remaining items 87 63 2 Net finance income/expenses (84) (4) 18 Tax impact of adjusted items and tax only adjusting items (527) (376) (450) Adjusted Income from continuing operations attributable to shareholders 1 ) 1,497 845 1,148 1 ) Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt [Abstract]
Debt [Text Block]	18 Accounting policies Debt Debt is initially measured at fair value net of directly attributable transaction costs. Subsequently, debt is measured at amortized cost using the effective interest rate method. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Lease liabilities Lease liabilities are measured at the present value of the lease payments due over the lease term, generally discounted using the incremental borrowing rate. Lease liabilities are subsequently measured at amortized cost using the effective interest method. Lease liabilities are remeasured in case of modifications or reassessments of the lease. Philips has a USD 2.5 billion Commercial Paper Program and a EUR 1 billion committed standby revolving credit facility that can be used for general group purposes, such as a backstop of its Commercial Paper Program. As of December 31, 2023, Philips did not have any loans outstanding under either facility. These facilities do not have a material adverse change clause, have no financial covenants and no credit-rating-related acceleration possibilities. Philips established a Euro Medium-Term Note (EMTN) program, a framework that facilitates the issuance of notes for a total amount up to EUR 10 billion. As of December 31, 2023, Philips has EUR 3.3 billion outstanding under this program of which EUR 500 million fixed rate notes were issued in August 2023 with a maturity date in 2031. The provisions applicable to all USD-denominated corporate bonds issued by the company in March 2008 and March 2012 (due 2038 and 2042) contain a ‘Change of Control Triggering Event’. If the company would experience such an event with respect to a series of corporate bonds the company might be required to offer to purchase the bonds that are still outstanding at a purchase price equal to 101% In 2023, Philips issued EUR 500 million of fixed rate notes under the company’s EMTN program that mature in 2031 and used the proceeds for general corporate purposes, including the repayment of EUR 500 million that was outstanding under the credit facility entered into in the fourth quarter of 2022. In 2023, Philips entered into a total amount of EUR 138 million forward contracts relating to the company’s long-term incentive plans. These forwards mature in the fourth quarters of 2024 (EUR 61m) and 2025 (EUR 77m). In addition, a total of EUR 125 million forward contracts relating to the long-term incentive and employee stock purchase plans and EUR 481 million of forwards related to the share buyback program announced in 2021 matured throughout 2023. In 2022, Philips announced a series of Liability Management transactions to optimize its debt maturity profile. The transactions included the issuance of three series of Notes under its EMTN program for a total of EUR 2 billion with maturities in 2027, 2029 and 2033. Part of the proceeds were used to tender certain of Philips’ outstanding US Dollar denominated bonds due 2025 and 2026 and Euro-denominated bonds due 2023, 2024 and 2025, as well as make-whole and fully redeem the Euro-denominated bonds due 2023 and 2024 that were not purchased as part of the Euro tender offer. Philips issued Commercial Paper of EUR 200 million in September 2022 and EUR 101 million in October 2022. These tranches were repaid throughout the fourth quarter of 2022. In addition, in October 2022 Philips entered into a EUR 1 billion credit facility that could be used for general corporate purposes. The credit facility matured in October 2023 and had a 12-month extension option at Philips discretion. Per year-end 2022, EUR 500 million was utilized and outstanding under the credit facility. In 2022, Philips entered into a total amount of EUR 63 million forward contracts relating to the company’s long-term incentive and employee stock purchase plans. A total of EUR 57 million forward contracts relating to the long-term incentive and employee stock purchase plans and EUR 83 million of forwards related to the share buyback program announced in 2021 matured throughout 2022. Long-term debt The following tables present information about the long-term debt outstanding, its maturity and average interest rates in 2023 and 2022. Philips Group Long-term debt in millions of EUR unless otherwise stated 2023 amount outstanding Current portion Non-current portion Between amount due after 5 years average remaining term (in years) average rate of interest USD bonds 1,325 1,325 240 1,085 13.3 6.3% EUR bonds 4,569 4,569 2,335 2,234 5.1 2.0% Forward contracts 396 321 76 76 0.8 1.4% Lease liabilities 1,074 211 864 505 358 3.9 3.1% Bank borrowings 203 1 201 201 1.2 4.2% Other long-term debt - - - - - 7.4 1.2% Long-term debt 7,568 532 7,035 3,357 3,678 6.0 2.9% Philips Group Long-term debt in millions of EUR unless otherwise stated 2022 amount outstanding Current portion Non-current portion Between amount due after 5 years average remaining term (in years) average rate of interest USD bonds 1,378 1,378 250 1,128 14.3 6.3% EUR bonds 4,061 4,061 1,836 2,225 5.7 1.7% Forward contracts 858 606 252 252 1.0 Lease liabilities 1,082 230 852 504 348 3.9 2.4% Bank borrowings 705 2 702 702 1.9 1.7% Other long-term debt 28 4 24 17 6 8.9 2.9% Long-term debt 8,111 842 7,270 3,562 3,706 6.1 2.4% Bonds The following table presents the amount outstanding and effective rate of bonds. Philips Group Unsecured Bonds in millions of EUR unless otherwise stated effective rate 2022 2023 Unsecured EUR Bonds Due 30/03/2025; 1 3/8% 1.509% 346 346 Due 22/05/2026; 1/2% 0.608% 750 750 Due 05/05/2027; 1 7/8% 2.049% 750 750 Due 02/05/2028; 1 3/8% 1.523% 500 500 Due 05/11/2029; 2 1/8% 2.441% 650 650 Due 30/03/2030; 2% 2.128% 500 500 Due 08/09/2031; 4 2/8% 4.330% 500 Due 05/05/2033; 2 5/8% 2.710% 600 600 Unsecured USD Bonds Due 15/05/2025; 7 3/4% 7.429% 51 49 Due 15/05/2025; 7 1/8% 6.794% 78 75 Due 01/06/2026; 7 1/5% 6.885% 119 114 Due 03/11/2038; 6 7/8% 7.210% 683 657 Due 15/03/2042; 5% 5.273% 470 452 Adjustments 1 ) (57) (47) Unsecured Bonds 5,439 5,894 1 ) Adjustments related to both EUR and USD bonds and concern bond discounts, premium and transaction costs. Leases The following table presents a reconciliation between the total of future minimum lease payments and their present value. Philips Group Lease liabilities in millions of EUR 2022 2023 future minimum lease payments interest present value of minimum lease payments future minimum lease payments interest present value of minimum lease payments Less than one year 251 21 230 239 28 211 Between one and five years 554 49 505 572 67 505 More than five years 376 28 348 388 30 358 Lease liabilities 1,180 98 1,082 1,200 125 1,074 Short-term debt Philips Group Short-term debt in millions of EUR 2022 2023 Short-term bank borrowings 89 122 Current portion of long-term debt 842 532 Short-term debt 931 654 During 2023, the weighted average interest rate on the bank borrowings was 8.6% (2022: 5.7%

Provisions

Provisions	12 Months Ended
	Dec. 31, 2023
Provisions [Abstract]
Provisions [Text Block]	19 Accounting policies A provision is a liability of uncertain timing or amount. Provisions are recognized if, as a result of a past event, the company has a present legal or constructive obligation, it is probable that an outflow of economic benefits will be required to settle the obligation and the amount can be estimated reliably. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax discount rate that reflects current market assessments of the time value of money. The increase in the provision due to passage of time (accretion) is recognized as interest expense. Restructuring-related provisions Provisions for severance and termination benefits are recognized for those costs only when the company has a detailed formal plan for the restructuring and has raised a valid expectation with those affected that it will carry out the restructuring by starting to implement that plan or announcing its main features to those affected by it. Before a provision is established, the company recognizes any impairment loss on the assets associated with the restructuring. Accounting estimates and judgments By their nature, the recognition of provisions requires estimates and assumptions regarding the timing and the amount of outflow of resources. The main estimates include: Respironics field-action provision Product warranty provisions Environmental provisions Legal provisions . Contingent consideration provisions Philips Group Provisions in millions of EUR Post-employment Respironics Product Environmental Restructuring- Legal Contingent Other Total Current 366 287 20 134 74 23 112 1,018 Non-current 546 23 57 83 6 14 89 279 1,097 Balance as of December 31, 2022 546 390 344 104 140 89 113 390 2,115 Additions 112 240 313 18 263 644 24 223 1,836 Utilizations (91) (285) (268) (14) (219) (235) (20) (134) (1,266) Releases (10) (20) (2) (67) (10) (7) (45) (159) Accretion 5 23 1 (3) 25 Acquisitions 6 6 Changes in discount rate (6) (6) Translation differences and other - (10) (12) (3) (2) (23) (2) (1) (53) Total change 12 (55) 13 (2) (24) 399 2 39 383 Current 331 293 22 102 477 57 181 1,463 Non-current 558 3 64 80 14 10 58 248 1,035 Balance as of December 31, 2023 558 334 357 102 116 487 115 429 2,498 Philips Group Provisions in millions of EUR Post-employment Respironics Product Environmental Restructuring Legal Contingent Other Total Current 525 207 26 58 39 52 92 998 Non-current 659 52 32 99 8 53 156 257 1,315 Balance as of December 31, 2021 659 577 238 124 66 91 208 349 2,313 Additions 61 250 320 15 154 89 160 1,049 Utilizations (185) (486) (224) (17) (61) (100) (105) (95) (1,274) Releases (1) (2) (18) (3) (35) (59) Accretion 4 - (3) 2 Acquisitions 4 96 99 Changes in discount rate (27) (27) Fair value changes (86) (86) Translation differences and other 12 49 9 7 (1) 7 14 97 Total change (113) (187) 105 (21) 74 (3) (95) 41 (198) Current 366 287 20 134 74 23 112 1,018 Non-current 546 23 57 83 6 14 89 279 1,097 Balance as of December 31, 2022 546 390 344 104 140 89 113 390 2,115 Respironics field action provision On June 14, 2021, Philips’ subsidiary, Philips Respironics initiated a voluntary recall notification in the United States and field safety notice outside the US for certain sleep and respiratory care products related to the polyester-based polyurethane (PE-PUR) sound abatement foam in these devices. The remediation is progressing globally. As of December 31, 2023, the production required for the delivery of replacement devices to patients has been substantially completed and the total number of units expected to be remediated remained stable during the year at 5.6 million devices (specific CPAP, BiPAP and mechanical ventilator devices), excluding certain end-of-life-devices which are expected to be retired. Philips has recognized a provision based on Philips’ best estimate of the costs to repair, replace or refund devices, subject to the Respironics field action. The provision is related to the cost to repair, replace or refund affected devices and includes, amongst others, the costs for the remaining production, the cost of intensified communication with physicians and patients, material costs, labor cost and logistics, as well as costs relating to the (partial) refunds provided to customers under the field action. The provision does not include any product liability costs or other claims. The additions for the year primarily reflect the impact of the revised remediation approach in relation to the mechanical ventilator devices subject to the recall, following the agreed terms of the proposed consent decree (see below). The revised approach, which includes a revised repair program and assumes (partial) refunds to customers (refer to Income from operations The completion of the field action continues to be subject to uncertainty, which requires management to make estimates and assumptions about items such as quantities and the portion to be replaced, repaired and refunded. An increase in the assumption for the refund portion by 10 percentage points, could have the effect of increasing the provision by an estimated EUR 19 million. Actual outcomes in future periods may differ from these estimates and affect the company’s results of operations, financial position and cash flows. Further to the above, running remediation costs of EUR 224 million (2022: EUR 210 million) related to the remediation, such as testing, external advisory and regulatory response and additional right-of-return and warranty provisions, have been incurred. Following the US Food and Drug Administration (FDA) inspection of certain of Philips Respironics' facilities in the US in 2021 and the subsequent inspectional observations, the US Department of Justice, acting on behalf of the FDA, in July 2022 started discussions with Philips regarding the terms of a consent decree to resolve the identified issues, which Philips has now agreed. As a consequence of addressing the consent decree, the company recorded charges of EUR 363 million in December 2023, mainly consisting of EUR 240 million addition to the Respironics field action provision, EUR 82 million inventory write-down (refer to Inventories In addition to the above, Philips and its affiliates are defendants in a number of consumer class action lawsuits from users of the affected devices and a number of individual personal injury and other compensation claims. For legal matters including claims refer to the legal provisions section of this note as well as Contingencies Product warranty provisions The field action provision in connection with the Philips Respironics voluntary recall notification is shown separately above. Additions in 2023 The company expects the provisions to be utilized mainly within the next year. Environmental provisions The environmental provisions include accrued costs recorded with respect to environmental remediation in various countries. In the US, subsidiaries of the company have been named as potentially responsible parties in state and federal proceedings for the clean-up of certain sites. The additions and the releases of the provisions originate from additional insights in relation to factors like the estimated cost of remediation, changes in regulatory requirements and efficiencies in completion of various site work phases. Approximately EUR 63 million of the long-term provision is expected to be utilized after one to five years, with the remainder after five years. For more details on the environmental remediation refer to Contingencies Restructuring-related provisions Philips Group Restructuring-related provisions in millions of EUR December 31, 2022 December 31, 2023 Diagnosis & Treatment 42 36 Connected Care 42 18 Personal Health 10 7 Other 47 56 Philips Group 140 116 Further to the workforce reduction in 2022, measures were announced on January 30, 2023 that primarily focus on the reduction of 6,000 positions by 2025. In 2023, the restructuring costs, net of releases, for these measures were EUR 140 million. In addition, restructuring projects were executed during the year, of which the most significant impacted Connected Care and Other and mainly took place in the US and Netherlands. The restructuring mainly comprised product portfolio rationalization and the reorganization of global support functions. The company expects the provisions to be utilized mainly within the next year. In 2022, Philips initiated general productivity actions aimed at simplifying the organization to streamline the way of working and reduce operating expenses. This includes an immediate reduction of around 4,000 positions globally across the organization, with severance and termination-related costs of EUR 80 million recorded in 2022. Legal provisions The company and certain of its group companies and former group companies are involved as a party in legal proceedings, including regulatory and other governmental proceedings. Additions mainly relate to a EUR 575 million in connection with the anticipated resolution of the economic loss class action in the US. The final cost of the settlement may vary based on, among other things, how many patients and other settlement class members participate in the settlement. Utilizations mainly relate to the settlement the company reached with the US Securities and Exchange Commission (SEC) to resolve the SEC inquiry regarding alleged tender irregularities in the medical device industry in China, for which the company had recorded a provision of approximately EUR 60 million in 2022. The settlement reached was in line with the amount provided for and EUR 58 million was subsequently paid in 2023. In addition the company funded an amount of USD 155 million (EUR 141 million) into the Qualified Settlement Fund in relation to the economic loss class action settlement announced on September 7, 2023. For details of other legal matters, including regulatory and other governmental proceedings, refer to Contingencies The company expects the provisions to be utilized mainly within the next three years. Contingent consideration provisions In 2023, the addition of EUR 24 million is largely offset by utilizations of EUR 20 million. The acquisition of a business within Ultrasound resulted in a EUR 6 million increase. Approximately EUR 28 million of the long-term provision is expected to be utilized within the next three years, with the remainder after four years. Other provisions The main elements of other provisions are: Philips Group Other provisions in millions of EUR unless otherwise stated 2022 2023 Employee jubilee funds 83 77 Self-insurance 57 63 Non-income taxes / social security 46 51 Rights of return 36 39 Decommissioning costs 33 34 Onerous contracts 38 76 Remaining 97 89 Balance as of December 31 390 429 Onerous contracts reflect non-cancellable commitments on supplies for which no future demand or alternative usage has been identified, including EUR 31 million in connection with the proposed Respironics consent decree as of December 31, 2023. Remaining provisions relate to a variety of positions, for example provision for disability of employees and provision for royalty obligations. Releases in 2022 and 2023 are due to the reassessment of the positions in other provisions throughout the year. The company expects the other provisions to be utilized mainly within the next five years.

Post-employment benefits

Post-employment benefits	12 Months Ended
	Dec. 31, 2023
Post-employment benefits [Abstract]
Post-employment benefits [Text Block]	20 Accounting policies Defined contribution plans A defined contribution plan is a post-employment benefit plan for which the company pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an employee benefit expense in the Consolidated statements of income in the periods during which services are rendered by employees. Defined benefit plans A defined benefit plan is a post-employment benefit plan that is not a defined contribution plan. Defined benefit plans define an amount of pension benefit that an employee will receive after retirement. That pension benefit typically depends on several factors such as years of service, age and salary. The net pension asset or liability recognized in the Consolidated balance sheets in respect of defined benefit plans is the fair value of plan assets less the present value of the projected defined benefit obligation at the balance sheet date. The defined benefit obligation is calculated annually by qualified actuaries using the projected unit credit method. Recognized assets are limited to the present value of any reductions in future contributions or any future refunds. The net pension liability is presented as a long-term provision; no distinction is made for the short-term portion. For the company’s major plans, a full discount rate curve of high-quality corporate bonds is used to determine the defined benefit obligation, where available. The curves are based on the Mercer Yield Curve methodology, which uses data of corporate bonds rated AA or equivalent. For the other plans the Mercer Yield Curve/Mercer Methodology has also been used taking into account the cash flows as much as possible in case there is a deep market in corporate bonds. For plans in countries without a deep corporate bond market, the discount rate is based on government bonds and the plan’s maturity. Pension costs in respect of defined benefit plans primarily represent the increase of the actuarial present value of the obligation for post-employment benefits based on employee service during the year and the interest on the net recognized asset or liability in respect of employee service in previous years. Remeasurements of the net defined benefit asset or liability comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (excluding interest). The company recognizes all remeasurements in Other comprehensive income. Past service costs arising from the introduction of a change to the benefit payable under a plan or a significant reduction of the number of employees covered by a plan (curtailment) are recognized in full in the Consolidated statements of income. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. The company recognizes a liability and an expense for bonuses and incentives based on a formula that takes into consideration the profit attributable to the company’s shareholders after certain adjustments. The company’s net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods, such as jubilee entitlements. That benefit is discounted to determine its present value. Remeasurements are recognized in the Consolidated statements of income in the period in which they arise. Further information on other employee benefits can be found in Provisions Accounting estimates and judgments To make the actuarial calculations for the valuation of defined benefit obligations, assumptions are needed for interest rates, healthcare cost increases, future pension increases, life expectancy and employee turnover rates. The actuarial calculations are made by external actuaries based on inputs from observable market data, such as corporate bond returns and yield curves to determine the discount rates to apply, mortality tables to determine life expectancy and inflation rates to determine future salary and pension growth assumptions. Employee post-employment benefit plans have been established in many countries in accordance with the legal requirements, customs and the local practice in the countries involved. The larger part of post-employment benefits are company pension plans, of which some are funded and some are unfunded. All funded post-employment benefit plans are considered to be related parties. Most employees that take part in a company pension plan are covered by defined contribution (DC) pension plans. The main DC plans are in the Netherlands and the United States. The company also sponsors a number of defined benefit (DB) pension plans. The benefits provided by these plans are based on employees’ years of service and compensation levels. The company also sponsors a limited number of DB retiree medical plans. The benefits provided by these plans typically cover a part of the healthcare costs after retirement. None of these plans are individually significant to the company and are therefore not further separately disclosed. The larger funded DB and DC plans are governed by independent Trustees who have a legal obligation to protect the interests of all plan members and operate under the local regulatory framework. The DB plans in Germany and the US make up most of the defined benefit obligation (DBO) and the net position. The company also has DB plans in the rest of the world; however these are individually not significant to the company and do not have a significantly different risk profile that would warrant separate disclosure. The adjacent table provides a break-down of the present value of the funded and unfunded DBO, the fair value of plan assets and the net position in Germany, the US and in Other Countries. The table also provides the value of reimbursement rights. Philips Group Post-employment benefits in millions of EUR Germany United States Other Countries Total 2022 2023 2022 2023 2022 2023 2022 2023 Present value of funded DBO (489) (511) (440) (404) (179) (182) (1,108) (1,097) Present value of unfunded DBO (249) (253) (128) (118) (136) (137) (513) (508) Total present value of DBO (738) (764) (568) (522) (315) (319) (1,621) (1,605) Fair value of plan assets 477 481 474 442 171 166 1,122 1,089 Net position (261) (283) (94) (80) (144) (153) (499) (516) Value of reimbursement rights 6 8 6 8 The classification of the net position is as follows: Philips Group Classification net position in millions of EUR Germany United States Other Countries Total 2022 2023 2022 2023 2022 2023 2022 2023 Total asset for plans in a surplus 9 - 34 39 4 2 46 41 Total liability for plans in a deficit (270) (283) (128) (118) (148) (156) (546) (558) Provisions for post-employment benefit plans under AHFS Net position (261) (283) (94) (80) (144) (153) (499) (516) Germany The company has several DB plans in Germany, which are partially unfunded, meaning that after retirement the company is responsible for the benefit payments to retirees. Due to the relatively high level of social security in Germany, the company’s pension plans mainly provide benefits for the higher earners. The plans are open for future pension accrual. Indexation is mandatory due to legal requirements. Some of the German plans have a DC design, but are accounted for as DB plans due to a legal minimum return requirement. Company pension commitments in Germany are partly protected against employer bankruptcy via the “Pensions-Sicherungs-Verein” which charges a fee to all German companies providing pension promises. Philips is one of the sponsors of Philips Pensionskasse VVaG in Germany, which is a multi-employer plan. The plan is classified and accounted for as a DC plan. United States The US DB pension plans are closed plans without future pension accrual. For the funding of any deficit in the US plan the Group adheres to the minimum funding requirements of the US Pension Protection Act. The assets of the US funded pension plans are in Trusts governed by fiduciaries. The non-qualified pension plans that cover accrual above the maximum salary of the funded qualified plan are unfunded. The company’s qualified pension commitments in the US are covered via the Pension Benefit Guaranty Corporation which charges a fee to US companies providing DB pension plans. The fee is also dependent on the amount of unfunded vested liabilities. Risks related to DB plans DB plans expose the company to various demographic and economic risks such as longevity risk, investment risks, currency and interest rate risk and in some cases inflation risk. The latter plays a role in the assumed wage increase but more importantly in some countries where indexation of pensions is mandatory. The company has an active de-risking strategy in which it constantly looks for opportunities to reduce the risks associated with its DB plans. Liability-driven investment strategies, lump sum cash-out options, buy-ins, buy-outs and a change to DC are examples of the strategy. Investment policy in the largest pension plans Pension fund trustees are responsible for and have full discretion over the investment strategy of the plan assets. The plan assets of the Philips pension plans are invested in well diversified portfolios. The interest rate sensitivity of the fixed income portfolio is closely aligned to that of the plan’s pension liabilities for most of the plans. Any contributions from the sponsoring company are used to further increase the fixed income part of the assets. As part of the investment strategy, any improvement in the funded ratio over time is used to further decrease the interest rate mismatch between the plan assets and the pension liabilities. Summary of pre-tax costs for post-employment benefits and reconciliations The adjacent table contains the total of current and past service costs, administration costs and settlement results as included in Income from operations and the interest cost as included in Financial expenses. Philips Group Pre-tax costs for post-employment benefits in millions of EUR 2021 2022 2023 Defined benefit plans 36 50 47 - included in income from operations 28 39 25 - included in financial expense 8 10 21 - included in Discontinued operations 1 Defined contribution plans 375 400 376 - included in income from operations 368 400 376 - included in Discontinued operations 7 Post-employment benefits costs 411 449 423 Summary of the reconciliations for the DBO and plan assets The adjacent tables contain the reconciliations for the DBO and plan assets. Philips Group Defined benefit obligations in millions of EUR 2022 2023 Balance as of January 1 1,970 1,621 Service cost 32 32 Interest cost 36 71 Employee contributions 4 3 Actuarial (gains) / losses - demographic assumptions 2 - financial assumptions (366) 48 - experience adjustment 12 2 (Negative) past service cost 16 (9) Settlements - 2 Benefits paid from plan (95) (104) Benefits paid directly by employer (41) (39) Translation differences and other 52 (22) Balance as of December 31 1,621 1,605 Philips Group Plan assets in millions of EUR 2022 2023 Balance as of January 1 1,380 1,122 Interest income on plan assets 26 49 Admin expenses paid (1) (1) Return on plan assets excluding interest income (254) 23 Employee contributions 4 3 Employer contributions 17 14 Settlements Benefits paid from plan (95) (104) Translation differences and other 45 (17) Balance as of December 31 1,122 1,089 The past service cost in 2023 and 2022 mainly relate to the retiree medical plans in Brazil. Plan assets allocation The asset allocation in the company’s DB plans as of December 31, was as follows: Philips Group Plan assets allocation in millions of EUR 2022 2023 Assets quoted in active markets - Debt securities 560 513 - Equity securities - Other 203 182 Assets not quoted in active markets - Debt securities - Equity securities 101 31 - Other 258 363 Total assets 1,122 1,089 The plan assets in 2023 contain 36% (2022: 32%) unquoted plan assets. Plan assets in 2023 do not include property occupied by or financial instruments issued by the company. Assumptions The mortality tables used for the company’s largest DB plans are: Germany: Heubeck-Richttafeln 2018 Generational, assuming 93% of mortality rates for male retirees between age 60 and 85 The weighted averages of the assumptions used to calculate the DBO as of December 31, were as follows: Philips Group Assumptions used for defined benefit obligations in % Germany United States Other Countries Total 2022 2023 2022 2023 2022 2023 2022 2023 Discount rate 4.1% 3.7% 5.2% 5.0% 4.9% 4.9% 4.7% 4.3% Inflation rate 2.0% 2.0% 2.3% 2.3% 2.6% 2.5% 2.2% 2.2% Salary increase 2.8% 2.8% 0.0% 0.0% 3.3% 4.3% 2.9% 3.0% Sensitivity analysis The following table illustrates the approximate impact on the DBO from movements in key assumptions. The DBO was recalculated using a change in the assumptions of 1% which overall is considered a reasonably possible change. The impact on the DBO because of changes in discount rate is normally accompanied by offsetting movements in plan assets, especially when using matching strategies. The average duration in years of the DBO of the DB plans is 10 (Germany: 11, United States: 8, and Other countries: 10) as of December 31, 2023 (2022: 8). Philips Group Sensitivity of key assumptions in millions of EUR 2022 2023 Increase Discount rate (1% movement) (122) (123) Pension increase (1% movement) 57 60 Salary increase (1% movement) 12 12 Longevity 1 ) 32 32 Decrease Discount rate (1% movement) 145 147 Pension increase (1% movement) (49) (52) Salary increase (1% movement) (11) (11) 1 ) The mortality table (i.e. longevity) also impacts the DBO. The above sensitivity table illustrates the impact on the DBO of a further 10% decrease in the assumed rates of mortality for the company’s major plans. A 10% decrease in assumed mortality rates equals improvement of life expectancy by 0.5 - 1 year. Cash flows and costs in 2024 Cash outflows in relation to post-employment benefits are estimated to amount to EUR 434 million in 2024, consisting of: EUR 17 million employer contributions to DB plans (Germany: EUR 8 million, US: EUR 0 million, Other Countries: EUR 9 million); EUR 42 million cash outflows in relation to DB plans (Germany: EUR 20 million, US: EUR 10 million, Other Countries: EUR 12 million); and EUR 375 million employer contributions to DC plans (Netherlands: EUR 174 million, US: EUR 136 million, Other Countries: EUR 65 million). The service and administration cost for 2024 is expected to amount to EUR 30 million for DB plans. The net interest cost for 2024 for the DB plans is expected to amount to EUR 21 million. The cost for DC pension plans in 2024 is equal to the expected DC cash flow.

Accrued liabilities

Accrued liabilities	12 Months Ended
	Dec. 31, 2023
Accrued liabilities [Abstract]
Accrued liabilities [Text Block]	21 Accounting policies Accrued liabilities are initially measured at fair value and subsequently at amortized cost and are derecognized when the obligation under the liability is discharged, cancelled or has expired. Accrued liabilities are summarized as follows: Philips Group Accrued liabilities in millions of EUR 2022 2023 Personnel-related costs: - Salaries and wages 490 791 - Accrued holiday entitlements 97 96 - Other personnel-related costs 101 93 Fixed-asset-related costs: - Gas, water, electricity, rent and other 46 43 Communication and IT costs 64 61 Distribution costs 110 99 Sales-related costs: - Commission payable 8 12 - Advertising and marketing-related costs 127 133 - Other sales-related costs 20 20 Material-related costs 132 138 Interest-related accruals 71 76 Other accrued liabilities 361 324 Accrued liabilities 1,626 1,887

Other liabilities

Other liabilities	12 Months Ended
	Dec. 31, 2023
Other liabilities [Abstract]
Other liabilities [Text Block]	22 Accounting policies Other liabilities are initially measured at fair value and subsequently at amortized cost and are derecognized when the obligation under the liability is discharged, cancelled or has expired. The company recognizes contract liabilities if a payment is received or a payment is due (whichever is earlier) from a customer before the company transfers the related goods or services. Contract liabilities are recognized as revenue when the company performs under the contract (i.e., transfers control of the related goods or services to the customer). Other non-current liabilities Non-current liabilities were EUR 54 million as of December 31, 2023 (December 31, 2022: EUR 60 million). Non-current liabilities are associated mainly with indemnification and non-current accruals. Other current liabilities Other current liabilities are summarized as follows: Philips Group Other current liabilities in millions of EUR 2022 2023 Accrued customer rebates 213 186 Other taxes including social security premiums 115 129 Other liabilities 120 98 Other current liabilities 448 414 Contract liabilities Non-current contract liabilities were EUR 469 million as of December 31, 2023 (December 31, 2022: EUR 515 million) and current contract liabilities were EUR 1,809 million as of December 31, 2023 (December 31, 2022: EUR 1,696 million). The current contract liabilities increased by EUR 113 million, which is mainly driven by an increase in deferred balances for customer service contracts. The current contract liabilities as of December 31, 2022 resulted in revenue recognized of EUR 1,696 million in 2023.

Cash flow statement supplementa

Cash flow statement supplementary information	12 Months Ended
	Dec. 31, 2023
Cash flow statement supplementary information [Abstract]
Cash flow statement supplementary information [Text Block]	23 Accounting policies Cash and cash equivalents Cash and cash equivalents include all cash balances, certain money market funds and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. Bank overdrafts are included in borrowings in current liabilities. Cash flow statements The cash flow statement is prepared using the indirect method. Cash flows related to interest and tax are included in operating activities. Assets and liabilities acquired as part of a business combination are included in investing activities (net of cash acquired). Dividends paid to shareholders are included in financing activities. Dividends received are included in operating activities. Cash flows arising from transactions in a foreign currency are translated into the company’s functional currency using the exchange rate at the date of the cash flow. Cash flows from derivative instruments that are accounted for as cash flow hedges are classified in the same category as the cash flows from the hedged items. Cash flows from other derivative instruments are classified as investing cash flows. Income taxes Income taxes in 2023 include EUR 2 million of interest related to uncertain tax positions. Cash paid for leases In 2023, gross lease payments of EUR 271 million (2022: EUR 316 million; 2021: EUR 308 million) included interest of EUR 27 million (2022: EUR 25 million; 2021: EUR 25 million). Net cash used for derivatives and current financial assets In 2023, a total of EUR 46 million cash was paid with respect to foreign exchange derivative contracts related to activities for liquidity management (2022: EUR 72 million outflow; 2021: EUR 48 million inflow). Purchase and proceeds from non-current financial assets In 2023, the net cash outflow is EUR 44 million. In 2022, the net cash outflow is EUR 38 million. In 2021, the net cash flow is EUR 0 million. Reconciliation of liabilities arising from financing activities Certain items in the statements of cash flows do not correspond to the differences between the balance sheet amounts for the respective items, principally because of the effects of translation differences and consolidation changes. Philips Group Reconciliation of liabilities arising from financing activities in millions of EUR Balance as of Cash flow Currency effects and Other 1 ) Balance as of December 31, 2023 Long term debt 2 ) 8,111 (210) (96) (238) 7,567 EUR bonds 4,061 497 11 4,569 USD bonds 1,378 (53) 1,325 Leases 1,082 (200) (42) 235 1,074 Forward contracts 3 ) 858 (462) 396 Bank borrowings 705 (502) 203 Other long-term debt 28 (5) (1) (22) Short term debt 2 ) 89 29 3 122 Short-term bank borrowings 89 46 (14) 122 Other short-term loans (17) 17 Equity (1,133) (666) 1,143 (656) Dividend payable (4) 4 Forward contracts 3 ) (858) 465 (394) Treasury shares 4 ) (275) (662) 675 (262) Total (848) 1 ) Besides non-cash, other includes interest paid on leases, which is part of cash flows from operating activities 2 ) In this table, current portion of long-term debt is included in long-term debt (and excluded from short-term debt). 3 ) The forward contracts are related to the share buyback program and LTI plans 4 ) Cash flow in 2023 includes withholding tax for share buyback amounting to EUR 55 million. Philips Group Reconciliation of liabilities arising from financing activities in millions of EUR Balance as of Cash flow Currency effects and consolidation changes Other 1 ) Balance as of Long term debt 2 ) 6,933 1,045 107 27 8,111 EUR bonds 3,233 827 4,061 USD bonds 1,313 (20) 85 1,378 Leases 1,220 (260) 17 105 1,082 Forward contracts 3 ) 934 (76) 858 Bank borrowings 203 498 4 705 Other long-term debt 30 (1) 1 (1) 28 Short term debt 2 ) 47 47 (6) 1 89 Short-term bank borrowings 47 47 (6) 1 89 Other short-term loans Equity (1,410) (593) 869 (1,133) Dividend payable (418) 418 Forward contracts 3 ) (934) 76 (858) Treasury shares (476) (174) 375 (275) Total 500 1 ) Besides non-cash, other includes interest paid on finance leases, which is part of cash flows from operating activities 2 ) In this table, current portion of long-term debt is included in long-term debt (and excluded from short-term debt). 3 ) The forward contracts are related to the share buyback program and LTI plans

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2023
Contingencies [Abstract]
Contingencies [Text Block]	24 Accounting policies Contingent liabilities A contingent liability is a liability of uncertain timing and amount. Contingencies are not recognized in the balance sheet because they are dependent on the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company or because the risk of loss is estimated to be possible but not probable or because the amount cannot be measured reliably. Pursuant to IAS 37, Provisions, Contingent Liabilities and Contingent Assets, certain information is not disclosed for legal proceedings for which the company concludes that disclosure can be expected to seriously prejudice the outcome of the matter. Contingent assets Contingent assets are disclosed if the inflow of economic benefits is probable, but not virtually certain. If the inflow of economic benefits becomes virtually certain, the asset would be considered no longer contingent and its recognition appropriate. Contingent assets are assessed continually and require management to apply judgment, especially to estimate the likelihood of the inflow of economic benefits. Financial guarantees Philips’ policy is to provide guarantees and other letters of support only in writing. Philips does not stand by other forms of support. The company recognizes a liability at the fair value of the obligation at the inception of a financial guarantee contract. The guarantee is subsequently measured at the higher of the best estimate of the obligation or the amount initially recognized less, when appropriate, cumulative amortization. Accounting estimates and judgments Significant judgment is required to determine the likelihood of a potential outflow of resources. In addition, judgment is involved in determining whether the amount of an obligation can be measured with sufficient reliability. Contingencies involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties, governmental actions, tax and environmental remediation. Guarantees The total fair value of guarantees recognized on the balance sheet amounts to EUR nil Environmental remediation The company and its subsidiaries are subject to environmental laws and regulations. Under these laws, the company and/or its subsidiaries may be required to remediate the effects of certain manufacturing activities on the environment. Legal proceedings The company and certain of its group companies and former group companies are involved as a party in legal proceedings, regulatory and other governmental proceedings, including discussions on potential remedial actions, relating to such matters as competition issues, commercial transactions, product liability, participations, and environmental pollution. While it is not feasible to predict or determine the outcome of all pending or threatened legal proceedings, regulatory and governmental proceedings, the company is of the opinion that the cases described below may have, or have had in the recent past, a significant impact on the company’s consolidated financial position, results of operations and cash flows. Public Investigations In May 2023, the company reached a settlement with the US Securities and Exchange Commission (SEC) to resolve the SEC inquiry regarding alleged tender irregularities in the medical device industry in China, for which the company had recorded a provision of approximately EUR 60 million in 2022. The settlement reached was in line with the amount provided for. In addition, the previously disclosed SEC inquiry regarding alleged similar conduct in Brazil and Bulgaria has been discontinued. The US Department of Justice (DOJ) has closed its parallel inquiry into these matters. In February 2023, the company received a statement of objections from the French Competition Authority (FCA) initiating a formal investigation to verify whether the company and certain other manufacturers of small domestic appliances breached antitrust rules in France in the period 2009-2014 through the alleged exchange of commercially sensitive information. The company filed its response to the statement of objections denying such allegations in May 2023 and is continuing to defend itself. The FCA is expected to organize a hearing and issue its decision in 2024. It is the company’s assessment that it is possible but not probable that this matter could lead to an outflow of economic resources. Given the uncertain outcome of the investigation and subsequent proceedings, the company is not able to reliably estimate the financial impact, if any, and no provision has been recognized as of December 31, 2023. Respironics field action On June 14, 2021, Philips’ subsidiary Philips RS North America LLC (Philips Respironics) issued a voluntary recall notification in the United States and field safety notice outside the United States for specific Philips Respironics CPAP, Bi-Level PAP, and mechanical ventilator devices (the “Recalled Devices”). Consent decree On August 26, 2021, the US Food and Drug Administration (FDA) commenced an inspection of the Philips Respironics manufacturing facility in Murrysville, Pennsylvania and provided Philips Respironics with its preliminary inspectional observations on November 9, 2021. Philips Respironics responded to the FDA's inspectional observations in December 2021, which described the actions already taken by the company, as well as additional planned actions. Philips Respironics is also providing periodic updates to the FDA on its progress for the planned actions. In July 2022, Philips started discussions with the DOJ, acting on behalf of the FDA on a consent decree that would, among other things, address compliance requirements for future sales, the resolution of the inspectional findings and the completion of the recall. On January 29, 2024, Philips announced that it agrees on the terms of a consent decree with the DOJ, representing the FDA. For further details please see Subsequent events DOJ investigation On April 8, 2022, Philips Respironics and certain of Philips' subsidiaries in the US received a subpoena from the DOJ to provide information related to events leading to the Respironics recall. The relevant subsidiaries are cooperating with the investigation. The criminal and civil investigation is being conducted by the DOJ's Consumer Protection Branch and Civil Fraud Section, and the US Attorney’s Office for the Eastern District of Pennsylvania. Given the early stages of the investigation, the company is not able to reliably estimate the financial impact, if any. Product liability claims Following the voluntary recall notification, a number of civil complaints have been filed in several jurisdictions against Philips Respironics and certain of its affiliates (including the company) generally alleging economic loss, personal injury and/or the potential for personal injury allegedly caused by the Recalled Devices. In the United States, consumer and commercial class action lawsuits have been filed alleging economic loss and medical monitoring claims. Individual personal injury lawsuits have also been filed. On October 8, 2021, a Multi-District Litigation (MDL) in the US District Court for the Western District of Pennsylvania was formed, and most of these class action and personal injury lawsuits have been consolidated in the MDL for pre-trial proceedings. As of December 31, 2023, plaintiffs have filed a consolidated economic loss class action complaint on behalf of device users, hospitals, and insurers and other third-party payers, a consolidated medical monitoring class action complaint on behalf of device users, and over 600 individual personal injury complaints. The company anticipates that the number of individual personal injury complaints will continue to increase in 2024. On September 7, 2023, Philips Respironics reached agreement on a class action settlement in relation to the economic loss class action complaint, for which the company recorded a EUR 575 million provision in the first quarter of 2023. Under the agreement, which was preliminarily approved by the US District Court for the Western District of Pennsylvania on October 10, 2023, the Philips defendants will provide predefined cash awards to all eligible participants in the US depending on the type of device, extended warranties on all remediated devices provided as part of Respironics’ recall program, and an additional cash award if they return the Recalled Device to Philips Respironics. The settlement also provides for compensation for individuals who acquired replacement devices in the market after the recall and prior to the announcement of the settlement. The settlement also provides for compensation to private insurers and other third-party payers. The final cost of the settlement may vary based on, among other things, how many patients and other settlement class members participate in the settlement. The final approval hearing is scheduled for April 11, 2024. In September 2022, the MDL court established a voluntary, court-approved census registry, and associated tolling, for potential claimants who have not filed claims, but may file claims in the future, relating to the Recalled Devices. The census registry replaced the private tolling agreement that had been in effect before the establishment of the census registry. At the time of termination, approximately 60,000 individuals had entered into the private tolling agreement. In the event these individuals wish to pursue or preserve their claims, they will need to file a lawsuit or register on the census registry. By December 31, 2023, approximately 57,000 individuals had joined the census registry. The company anticipates that the number of individuals on the census registry will increase in 2024. To better assess the claimed injuries and their relation, if any, to use of the Recalled Devices, Philips Respironics is working to require census registrants to supplement the information they are required to submit in the census registry established by the MDL court. In Australia, a consumer class action lawsuit alleging personal injury was filed against the company’s subsidiary Philips Electronics Australia Ltd on October 4, 2021. In the course of 2022, the plaintiff in the case sought leave of the court to discontinue the class action citing that there is insufficient evidence to warrant the continuation of the class action and that since the issue of proceedings, Philips Respironics has been repairing, replacing, or (partially) refunding the devices which are the subject of the recall, meaning that any compensation relating to financial loss would be relatively confined. During the process for withdrawal of the case, a new lead plaintiff came forward in the second half of 2023 and is now continuing the class action. Philips Respironics and certain of its affiliates (including the company) are also defendants in consumer class action lawsuits in Canada and Israel and collective actions in Chile, France and the Netherlands alleging economic loss and/or personal injury. In Canada, where various class actions had been filed, the court issued a decision on a carriage motion in April 2023, deciding that a class action filed in British Columbia may continue as a nationwide class action while defendants are seeking for all other class actions to be stayed. While the company believes it is probable that these lawsuits will in the aggregate lead to an outflow of economic resources for Philips Respironics or other Philips entities, given the significant uncertainty regarding the nature of the relevant events and potential obligations, the company is not currently able to reliably estimate the amount of the obligation associated with these various lawsuits. The final outcome of the lawsuits and the cost to resolve them cannot currently be determined due to a number of variables, including uncertainty regarding the ultimate number of claimants and their allegations. Moreover, Philips Respironics has not yet completed its test and research program, including the additional testing requested by the FDA, for the Recalled Devices. For the United States specifically, the lack of clarity around the nature of the specific injury each census registrant is claiming and its relation, if any, to use of the Recalled Devices contribute to the uncertainty. In addition, the MDL court has not yet decided several significant motions, and plaintiffs have not yet filed their motion for class certification in the medical monitoring action. Further, while document discovery has progressed, expert discovery has not yet begun, and the Court has not yet been asked to decide the question of whether any of the claimed injuries could have been caused by use of the Recalled Devices. An adverse outcome with respect to any or all of these lawsuits and/or any future claims could have a material impact on the company’s consolidated financial position, results of operations and cash flows. The company has product liability insurance in place that it expects to partially cover product liability-related cash outflows. Based on ongoing discussions with certain insurance carriers that took place during 2023, management of the company concluded that the likelihood of cash inflows changed to probable, but (consistent with prior periods) not virtually certain. Given the uncertainties associated with the cash outflows of the above claims and the applicable conditions of insurance coverage, no reliable estimate can be made or disclosed in relation to the expected insurance recovery. Securities claims On August 16, 2021, a securities class action complaint was filed against the company, its former CEO and its CFO in the US District Court for the Eastern District of New York alleging violations of the Securities Exchange Act of 1934 causing damage to investors. On January 3, 2022, the lead plaintiff in the case filed its amended complaint seeking to represent individuals that purchased Philips shares between February 23, 2016, through November 12, 2021. Following the filing and briefing of the company’s motion to dismiss in the first half of 2022, plaintiff filed a second amended complaint on November 30, 2022, naming an additional defendant and expanding the alleged damage period to include certain share price declines that were allegedly based on disclosures made in 2022. The second amended complaint now focuses on share price declines that allegedly occurred as a result of various disclosures starting on April 26, 2021 through October 2022. The company's motion to dismiss the second amended complaint was filed in the first quarter of 2023. As of December 31, 2023, that motion is still pending with the Court. In the Netherlands, in addition to the September 2022 letter from shareholders representative organization European Investors-VEB, holding the company and its directors liable for an alleged failure to make timely disclosures in relation to the Respironics recall, the company received letters from two other parties with similar allegations. As of December 31, 2023, no formal claims have been filed in this respect. It is the company’s assessment that it is possible but not probable that these cases could lead to a certain outflow of economic resources. The company is not able to reliably estimate the financial impact, if any. An adverse outcome of these cases could have a material impact on the company’s consolidated financial position, results of operations and cash flows. Other claims On October 12, 2021, SoClean, a company offering ozone-based cleaning products for sleep devices, filed a lawsuit against the company and certain of its affiliates alleging that the defendants’ statements about the potential adverse effect ozone cleaning may have on the Recalled Devices has significantly damaged its business. Philips believes that the claim is without merit and will vigorously defend itself. In November 2023, the Court ruled on one of the motions to dismiss filed by defendants and partially dismissed some of SoClean’s claims. On January 4, 2024, Philips and its affiliates filed their answer and counterclaims against SoClean and one of its affiliates. In addition, some of Philips Respironics’ business partners such as distributors and durable medical equipment providers have filed or threatened to file claims alleging economic losses suffered as a consequence of the voluntary recall. Philips Respironics is engaging with certain of its business partners on the level of compensation they allege to be entitled to under Philips Respironics’ replacement program of the Recalled Devices. It is the company’s assessment that it is possible but not probable that these cases could lead to a certain outflow of economic resources. The company is not able to reliably estimate the financial impact, if any. In the event of an adverse outcome, these matters could have a material impact on the company’s consolidated financial position, results of operations and cash flows. To date , Other In the second half of 2023, Electro Medical Systems S.A., a manufacturer of among others medical devices for dental prophylaxis, filed a lawsuit against the company alleging that the company materially breached its duties under a cooperation agreement entered into between the parties in 2016, claiming damages in excess of EUR 300 million, alleging loss of profit and lost increase in brand value. Philips disagrees with the allegations and will vigorously defend itself. Miscellaneous For details on other contractual obligations, please refer to liquidity risk in Details of treasury and other financial risks

Related-party transactions

Related-party transactions	12 Months Ended
	Dec. 31, 2023
Related-party transactions [Abstract]
Related-party transactions [Text Block]	25 In the normal course of business, Philips purchases and sells goods and services from/to various related parties in which Philips typically holds between 20% and 50% equity interest and has significant influence. These transactions are generally conducted with terms comparable to transactions with third parties. Philips Group Related-party transactions in millions of EUR 2021 2022 2023 Sales of goods and services 116 111 106 Purchases of goods and services 41 46 42 Receivables from related parties 40 55 18 Payables to related parties 2 2 2 The above table includes sales transactions between Philips and PMC of EUR 87 million in 2023 (2022: EUR 101 million; 2021: EUR 106 million), under which PMC has leased the equipment to the ultimate customer. In addition, as part of its S&RC operations in the US, Philips Medical Capital LLC funded durable medical equipment (DMEs) providers, through loans and leases. PMC-funded transactions these DMEs entered into with Philips amount to EUR 117 million in 2023 (2022: EUR 117 million; 2021: EUR 162 million). The associated costs of these funding transactions are borne by the ultimate customer and settled directly with Philips Medical Capital LLC. Philips Medical Capital LLC, a Pennsylvania limited liability company, is owned 60% by De Lage Landen Financial Services, Inc. (DLL) and 40% by Philips Electronics North America Corporation (Philips). On August 14, 2023, it was announced that Exor N.V. acquired a 15% minority stake in Philips’ shares and entered into a relationship agreement with the company. This relationship agreement includes Exor’s right to propose one member to the Supervisory Board. It is expected that the Supervisory Board will, upon Exor’s exercise of its right, submit a proposal for the appointment of the relevant nominee at the upcoming 2024 Annual General Meeting of Shareholders. Upon such appointment, Exor will be considered a related party for reporting purposes. In light of the composition of the Executive Committee, the company considers the members of the Executive Committee and the Supervisory Board to be the key management personnel as defined in IAS 24 Related Party Disclosures. For remuneration details of the Executive Committee, the Board of Management and the Supervisory Board see Information on remuneration For Post-employment benefit plans see Post-employment benefits

Share-based compensation

Share-based compensation	12 Months Ended
	Dec. 31, 2023
Share-based compensation [Abstract]
Share-based compensation [Text Block]	26 Accounting policies Philips share-based compensation is an equity-settled plan comprising restricted and performance shares. The restricted shares are subject to a three-year service condition and the performance shares include both market and non-market-based performance conditions, in addition to a three-year service condition. These shares are awarded to the Executive Committee and Senior Management. The grant date fair value of market-based performance shares is determined through a Monte Carlo valuation model. The grant date fair value of non-market-based performance shares and restricted shares is determined as the share price at the grant date as participants receive notional dividends throughout the vesting period. The costs of share-based compensation plans are revised for expected performance (non-market-based performance shares) and forfeiture and are spread evenly over the service period. In 2023, an additional non-recurring retention option grant was issued for certain key employees. This grant has an exercise price that was 15% higher than the share price at grant and will vest in two years and expires ten years after the grant date. The grant date fair value was calculated using the Black-Scholes-Merton option valuation model. Share-based compensation is recognized over the service period as personnel expense in the consolidated statement of income, with a corresponding increase to equity. Accounting estimates and judgments The use of a valuation model to determine market-based performance share fair value requires estimates for the expected volatility of the Philips share price and correlation among input variables. At each reporting date, Philips calculates the expected realization the of non-market-based performance targets and revises the expected share-based compensation expense. The cumulative effect is recorded in the consolidated statement of income with a corresponding adjustment in equity. No expense is recognized for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. The purpose of the share-based compensation plans is to align the interests of management with those of shareholders by providing incentives to improve the company’s performance on a long-term basis, thereby increasing shareholder value. The company has the following plans: performance shares: rights to receive common shares in the future based on performance and service conditions; restricted shares: rights to receive common shares in the future based on a service condition; and options on its common shares, including the 2013 Accelerate! grant. Since 2013 the Board of Management and other members of the Executive Committee are only granted performance shares * ) Under the terms of employee stock purchase plans established by the company in various countries, employees are eligible to purchase a limited number of Philips shares at discounted prices through payroll withholdings. Share-based compensation costs were EUR 97 million (2022: EUR 104 million; 2021: EUR 115 million). This includes the employee stock purchase plan of EUR 9 million, which is not a share-based compensation that affects equity. In the Consolidated statements of changes in equity EUR 88 million is recognized in 2023 and represent the costs of the share-based compensation plans. The amount recognized as an expense is adjusted for forfeiture. USD-denominated performance shares, restricted shares and options are granted to employees in the United States only. Performance shares The performance is measured over a three-year performance period. The performance shares have three performance conditions, relative Total Shareholders’ Return ('TSR') compared to a peer group of 20 companies including Philips (2022: 20 companies; 2021: 20 companies, 2020: 20 companies), adjusted Earnings Per Share growth ** ) Environment, Social and Governance The performance shares vest three years after the grant date. The number of performance shares that will vest is dependent on achieving the performance conditions provided that the grantee is still employed with the company. The amount recognized as an expense is adjusted for actual performance of adjusted EPS growth ** ) The fair value of the performance shares is measured based on Monte-Carlo simulation, which takes into account dividend payments between the grant date and the vesting date by including reinvested dividends as well as the market conditions expected to impact relative Total Shareholders’ Return performance in relation to selected peers. The following weighted-average assumptions were used for the 2023 grants: Risk-free rate: 2.55% Expected share price volatility: 36% The assumptions were used for these calculations only and do not necessarily represent an indication of Management’s expectation of future developments for other purposes. The company has based its volatility assumptions on historical experience measured over a ten-year period. A summary of the status of the company’s performance share plans as of December 31, 2023 and changes during the year are presented in the following table: Philips Group Performance shares 2022 2023 shares weighted average shares weighted average EUR-denominated Outstanding as of January 1 3,097,713 45.28 4,385,837 33.13 Granted 2,323,435 20.55 2,299,280 23.65 Notional dividends 1 ) 155,067 33.91 240,977 27.15 Vested/Issued (434,329) 40.90 (154,987) 44.08 Forfeited (233,556) 38.67 (489,295) 27.05 Adjusted quantity 2 ) (522,493) 40.48 (889,777) 44.27 Outstanding as of December 31 4,385,837 33.13 5,392,035 27.22 USD-denominated Outstanding as of January 1 2,005,000 51.48 2,749,983 36.66 Granted 1,530,585 21.93 1,667,812 25.96 Notional dividends 1 ) 98,883 37.15 152,750 29.78 Vested/Issued (248,848) 45.23 (121,760) 48.33 Forfeited (309,570) 44.04 (596,846) 28.95 Adjusted quantity 2 ) (326,066) 45.26 (590,890) 48.28 Outstanding as of December 31 2,749,983 36.66 3,261,048 29.73 1 ) Dividend declared in 2023 on outstanding shares. 2 ) Adjusted quantity includes the adjustments made to Performance shares outstanding due to updates on the actual TSR, EPS, and SDG. As of December 31, 2023, a total of EUR 102 million of unrecognized compensation costs relate to non-vested performance shares (as of December 31, 2022 EUR 103 million; as of December 31, 2021 EUR 110 million). These costs are expected to be recognized over a weighted-average period of 1.98 years. Restricted shares The fair value of restricted shares is equal to the share price at grant date. The company issues restricted shares that, in general, have a 3 year cliff-vesting period provided that the grantee is still employed with the company. A summary of the status of the company’s restricted shares as of December 31, 2023 and changes during the year are presented in the following table: Philips Group Restricted shares 2022 2023 shares weighted average shares weighted average EUR-denominated Outstanding as of January 1 1,618,488 39.93 2,321,250 30.73 Granted 1,349,003 22.03 1,471,975 16.35 Notional dividends 1 ) 81,500 35.67 135,791 27.98 Vested/Issued (540,930) 35.82 (595,796) 35.07 Forfeited (186,811) 35.06 (337,968) 24.46 Outstanding as of December 31 2,321,250 30.73 2,995,252 23.39 USD-denominated Outstanding as of January 1 1,611,021 46.26 2,345,263 33.87 Granted 1,463,855 23.60 1,284,761 17.72 Notional dividends 1 ) 83,151 39.37 126,498 31.12 Vested/Issued (541,336) 41.48 (679,430) 37.83 Forfeited (271,427) 38.51 (422,899) 26.79 Outstanding as of December 31 2,345,263 33.87 2,654,193 26.04 1 ) Dividend declared in 2023 on outstanding shares. As of December 31, 2023, a total of EUR 63 million of unrecognized compensation costs relate to non-vested restricted shares (as of December 31, 2022 EUR 72 million; as of December 31, 2021 EUR 66 million). These costs are expected to be recognized over a weighted-average period of 1.80 years. Option plans Option plans including Accelerate! option plan In previous years, the company granted options that expire after ten years. These options vest after three years, provided that the grantee is still employed with the company. All outstanding options have vested under this option plan and as of December 31, 2022, there were 55,000 Accelerate! EUR-denominated options with weighted average exercise price of EUR 22.43, 750 EUR-denominated options with weighted average exercise price of EUR 22.43, and 1,950 USD-denominated options with weighted average exercise price of USD 30.27 exercisable. All outstanding options under this plan have expired as of December 31, 2023. Since all the outstanding options have expired in 2023, there were no cash received from exercises under the company's previous option plans including Accelerate! options (2022: EUR 7 million, 2021: EUR 10 million) and no actual tax deductions realized as a result of options exercises including Accelerate! options (2022: EUR 0.7 million, 2021: EUR 1 million). Retention option plan In April 2023, the Company granted non-recurring retention options that expire after ten years. These options vest after two years, provided that the grantee is still employed with the company. The fair value of the options under this plan is measured based on Black-Scholes-Merton option pricing model. The following table list the inputs to the model used for the options granted: Philips Group Black-Scholes-Merton option pricing model inputs EUR-denominated USD-denominated Share price at grant date EUR 18.24 USD 21.12 Exercise price EUR 22.16 USD 24.42 Risk-free interest rate 2.37% 3.5% Expected dividend yield 4.45% 4.45% Expected option life 6 years 6 years Expected share price volatility 30.47% 32.31% The fair value of a EUR-denominated option was EUR 2.61 and the fair value of a USD-denominated option was USD 3.89. The assumptions were used for these calculations only and do not necessarily represent an indication of Management’s expectation of future developments for other purposes. The Company has based its volatility assumptions on historical experience for a period equal to the expected life of the options. The expected life of the options is calculated as the average between vesting period (2 years) and the total contractual life (10 years). The following tables summarize information about the company’s options as of December 31, 2023 and changes during the year: Philips Group Options on EUR-denominated listed share options weighted average Granted on April 28, 2023 3,831,000 22.16 Forfeited (171,000) 22.16 Outstanding as of December 31, 2023 3,660,000 22.16 There were no exercisable EUR-denominated options as of December 31, 2023. The weighted average remaining contractual term for options outstanding and options exercisable as of December 31, 2023, was 9.3 years. Philips Group Options on USD-denominated listed share options weighted average Granted on April 28, 2023 2,179,500 24.42 Forfeited (250,500) 24.42 Outstanding as of December 31, 2023 1,929,000 24.42 There were no exercisable USD-denominated options as of December 31, 2023. The weighted average remaining contractual term for options outstanding and options exercisable as of December 31, 2023, was 9.3 years. As of December 31, 2023, a total of EUR 11 million of unrecognized compensation costs relate to outstanding options. These costs are expected to be recognized over a weighted-average period of 1.3 years. Philips Group Outstanding options in millions of EUR unless otherwise stated number of intrinsic value weighted average EUR-denominated 20-25 3,660,000 0 9.3 Outstanding options 3,660,000 0 9.3 USD-denominated 20-25 1,929,000 0 9.3 Outstanding options 1,929,000 0 9.3 * ) Executive Committee members can receive restricted share rights as a sign-on LTI awards upon hiring. ** ) The definition of this non-IFRS measure and a reconciliation to the IFRS measure is included in Equity

Information on remuneration

Information on remuneration	12 Months Ended
	Dec. 31, 2023
Information on remuneration [Abstract]
Information on remuneration [Text Block]	27 Remuneration of the Executive Committee In 2023, the total remuneration costs relating to the members of the Executive Committee (consisting of 16 members throughout the year, including the members of the Board of Management) amounted to EUR 32.8 million (2022: EUR 25.6 million; 2021: EUR 33.4 million) consisting of the elements in the following table. Philips Group Remuneration costs of the Executive Committee 1 ) in EUR 2021 2022 2023 Base salary/Base compensation 9,598,588 9,528,279 8,729,458 Annual incentive 2 ) 5,250,408 208,370 11,405,130 Performance shares 3 ) 12,610,073 11,242,581 7,272,815 Stock options 13,358 Restricted share rights 3 ) 1,380,644 1,191,529 1,907,511 Pension allowances 4 ) 2,107,953 1,949,204 1,346,937 Pension scheme costs 306,694 288,179 260,554 Other compensation 5 ) 2,104,044 1,216,163 1,900,224 Total 33,358,405 25,624,305 32,835,987 1 ) The Executive Committee consisted of 13 members as per December 31, 2023 (2022: 13 members; 2021: 13 members) 2 ) The annual incentives are related to the performance in the year reported which are paid out in the subsequent year. 3 ) Costs of performance shares and restricted share rights are based on accounting standards (IFRS) and do not reflect the value of performance shares at the vesting/release date 4 ) Pension allowances are gross taxable allowances paid to the Executive Committee members in the Netherlands. These allowances are part of the pension arrangement 5 ) The stated amounts mainly concern (share of) allowances to members of the Executive Committee that can be considered as remuneration. In a situation where such a share of an allowance can be considered as (indirect) remuneration (for example, private use of the company car), then the share is both valued and accounted for here. The method employed by the fiscal authorities is the starting point for the value stated As of December 31, 2023, the members of the Executive Committee (including the members of the Board of Management) held 0 stock options (2022: 0; 2021: 184,900). Remuneration of the Board of Management In 2023, the total remuneration costs relating to the members of the Board of Management amounted to EUR 9.9 million (2022: EUR 8.4 million; 2021: EUR 10.3 million), see the following table. Philips Group Remuneration costs of individual members of the Board of Management in EUR base compen­sation/salary annual incentive 1 ) perfor­mance shares 2 ) restricted share rights 2 ) pension allowances 3 ) pension scheme costs other compen­sation total costs 2023 R. Jakobs 1,200,000 2,004,480 968,922 267,798 31,891 109,256 4,582,347 A. Bhattacharya 810,000 1,075,939 793,429 197,133 31,891 94,516 3,002,907 M.J. van Ginneken 630,000 846,922 614,840 125,298 31,891 53,446 2,302,397 2,640,000 3,927,341 2,377,191 590,228 95,673 257,218 9,887,650 2022 R. Jakobs 4 ) 256,438 112,737 57,973 6,012 11,507 444,667 F.A. van Houten 4 ) 1,041,849 208,370 2,930,068 444,051 22,121 42,533 4,688,992 A. Bhattacharya 806,250 763,140 237,250 28,133 61,308 1,896,081 M.J. van Ginneken 626,250 585,490 141,622 28,133 35,343 1,416,837 2,730,788 208,370 4,391,434 880,896 84,398 150,691 8,446,577 2021 F.A. van Houten 1,325,000 850,915 2,626,295 565,403 27,462 57,224 5,452,299 A. Bhattacharya 790,000 360,103 1,172,533 233,857 27,462 68,908 2,652,864 M.J. van Ginneken 605,000 317,192 886,035 150,755 27,462 42,610 2,029,054 2,720,000 1,528,211 4,684,863 950,014 82,387 168,742 10,134,217 1 ) The annual incentives are related to the performance in the year reported which are paid out in the subsequent year. 2 ) Costs of performance shares and restricted share rights are based on accounting standards (IFRS) and do not reflect the value of performance shares at the vesting/release date 3 ) The stated amounts mainly concern (share of) allowances to members of the Board of Management that can be considered as remuneration. In a situation where such a share of an allowance can be considered as (indirect) remuneration (for example, private use of the company car), then the share is both valued and accounted for here. The method employed by the fiscal authorities is the starting point for the value stated. 4 ) As per October 15, 2022, Roy Jakobs was appointed as CEO of the company. The table includes actual costs incurred in respect of the remuneration received by Mr Van Houten and Mr Jakobs, respectively, as CEO. The accumulated annual pension entitlements and the pension costs of individual members of the Board of Management are as follows: Philips Group Accumulated annual pension entitlements and pension-related costs in EUR unless otherwise stated age at December 31, 2023 accumulated annual pension as of December 31, 2023 total pension related costs R. Jakobs 49 56,383 299,689 A. Bhattacharya 62 40,324 229,024 M.J. van Ginneken 50 53,769 157,189 Pension costs 685,901 When pension rights are granted to members of the Board of Management, necessary payments (if insured) and all necessary provisions are made in accordance with the applicable accounting principles. In 2023, no (additional) pension benefits were granted to former members of the Board of Management. Remuneration of the Supervisory Board The remuneration of the members of the Supervisory Board amounted to EUR 1.5 million (2022: EUR 1.5 million; 2021: EUR 1.3 million). Former members received no remuneration. The members of the Supervisory Board do not receive any share-based remuneration. Therefore, as of December 31, 2023 the members of the Supervisory Board held no stock options, performance shares or restricted shares. The individual members of the Supervisory Board received, by virtue of the positions they held, the following remuneration: Philips Group Remuneration of the Supervisory Board in EUR membership committees other compensation 1 ) total 2023 F. Sijbesma 155,000 35,000 16,345 206,345 P.A.M. Stoffels 115,000 35,000 22,269 172,269 D.E.I. Pyott 100,000 35,000 19,769 154,769 A.M. Harrison 100,000 14,000 19,769 133,769 M.E. Doherty 100,000 27,000 27,269 154,269 P. Löscher 100,000 32,000 17,269 149,269 I. Nooyi 100,000 14,000 17,269 131,269 S.K. Chua 100,000 18,000 22,269 140,269 H. Verhagen 100,000 14,000 7,269 121,269 S. Poonen 100,000 18,000 19,769 137,769 1,070,000 242,000 189,266 1,501,266 2022 F. Sijbesma 155,000 35,000 16,345 206,345 P.A.M. Stoffels 115,000 35,000 27,269 177,269 N. Dhawan 35,616 6,411 5,808 47,836 D.E.I. Pyott 100,000 35,000 17,269 152,269 A.M. Harrison 100,000 14,000 12,269 126,269 M.E. Doherty 100,000 27,000 24,769 151,769 P. Löscher 100,000 32,000 24,769 156,769 I. Nooyi 100,000 14,000 17,269 131,269 S.K. Chua 100,000 18,000 22,269 140,269 H. Verhagen 100,000 14,000 7,269.0 121,269 S. Poonen 100,000 18,000 17,269 135,269 1,105,616 248,411 192,574 1,546,602 2021 J. van der Veer 53,507 12,082 3,916 69,505 C.A. Poon 39,699 16,915 783 57,397 N. Dhawan 100,000 18,000 2,269 120,269 O. Gadiesh 34,521 4,833 783 40,137 D.E.I. Pyott 100,000 36,370 2,269 138,639 P.A.M. Stoffels 109,863 27,808 4,769 142,440 A.M. Harrison 100,000 14,000 2,269 116,269 M.E. Doherty 100,000 27,000 4,769 131,769 P. Löscher 100,000 32,000 4,769 136,769 F. Sijbesma 141,301 27,808 8,237 177,346 I. Nooyi 100,000 14,000 2,269 116,269 S.K. Chua 65,753 11,836 1,492 79,081 1,044,644 242,652 38,595 1,325,891 1 ) The amounts mentioned under other compensation relate to the fee for intercontinental travel, inter-European travel, the entitlement of EUR 2,000 under the Philips product arrangement and the annual fixed net expense allowance. Supervisory Board members’ and Board of Management members’ interests in Philips shares Members of the Supervisory Board and of the Board of Management are prohibited from writing call and put options or similar derivatives of Philips securities. Philips Group Shares held by Board members 1 ) 2 ) in number of shares December 31, 2022 December 31, 2023 R. Jakobs 109,422 126,809 A. Bhattacharya 169,517 177,088 M.J. van Ginneken 123,914 129,447 P. Stoffels 17,000 17,759 S. Poonen 3,000 3,133 I. Nooyi 3,100 3,238 D. Pyott 19,000 19,848 S.K. Chua 2,000 2,089 F. Sijbesma 12,500 25,000 M. Harrison 1,500 1,567 P. Löscher 20,732 21,658 1 ) Reference date for board membership is December 31, 2023. 2 ) The total shares held by the members of the Board of Management is less than 1% of the company's issued share capital.

Fair value of financial assets

Fair value of financial assets and liabilities	12 Months Ended
	Dec. 31, 2023
Fair value of financial assets and liabilities [Abstract]
Fair value of financial assets and liabilities [Text Block]	28 Accounting policies Fair value hierarchy For financial reporting purposes, financial instruments are categorized into Level 1, 2 or 3, based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are as follows: Level 1 – inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets that the company can access at the measurement date. Level 2 – all significant inputs (other than quoted prices included within Level 1) are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices). Level 3 – one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, for the asset or liability. Transfers between levels of the fair value hierarchy are recognized at the end of the reporting period during which the change has occurred. Offsetting and master netting agreements Financial assets and liabilities are offset and the net amount is reported in the balance sheet when, and only when, the company has currently a legally enforceable right to set-off the amounts and the group intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Accounting estimates and judgments Determining the fair value of financial instruments requires the use of estimates according to the method applied for each type of financial asset of liability. The estimated fair value of financial instruments has been determined by the company using available market information and appropriate valuation methods. The estimates presented are not necessarily indicative of the amounts that will ultimately be realized by the company upon maturity or disposal. The use of different market assumptions and/or estimation methods may have a material effect on the estimated fair value amounts. Specific valuation techniques used to value financial instruments include: Level 1 Instruments included in level 1 are comprised primarily of listed equity investments classified as financial assets carried at fair value through profit or loss or carried at fair value through other comprehensive income. The fair value of financial instruments traded in active markets is based on quoted market prices at the balance sheet date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm’s length basis. Level 2 The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives or convertible bond instruments) is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are based on observable market data, the instrument is included in level 2. The fair value of derivatives is calculated as the present value of the estimated future cash flows based on observable interest yield curves, basis spread and foreign exchange rates. The valuation of convertible bond instruments uses observable market quoted data for the options and present value calculations using observable yield curves for the fair value of the bonds. The fair value of debt is estimated on the basis of the quoted market prices for certain issuances, or on the basis of discounted cash flow analysis using market rates plus Philips’ spread for the particular tenors of the borrowing arrangement. Accrued interest is not included within the carrying amount or estimated fair value of debt. Level 3 If one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, the instrument is included in level 3. The fair value of contingent consideration is dependent on the terms of the respective acquisition agreement that may require Philips to pay additional consideration to former shareholders if specified future events occur or conditions are met, such as the achievement of certain regulatory milestones or the achievement of certain commercial milestones. The fair value of the contingent consideration provision is generally determined using a probability-weighted and a risk-adjusted approach to estimate the achievement of future regulatory and commercial milestones, respectively. The discount rates used in the risk adjusted approach reflect the inherent risk related to achieving the commercial milestones. Both regulatory and commercial milestones are discounted for the time value of money at risk-free rates. The fair value measurement is based on management’s estimates and assumptions and hence classified as Level 3 in the fair value hierarchy. The following tables show the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. Fair value information for financial assets and financial liabilities not carried at fair value is not included if the carrying amount is a reasonable approximation of fair value. Philips Group Fair value of financial assets and liabilities in millions of EUR carrying amount estimated fair value 1 ) Level 1 Level 2 Level 3 December 31, 2023 Financial assets Carried at fair value: Debt instruments 226 226 226 Equity instruments 2 2 2 Other financial assets 56 56 34 22 Financial assets carried at FVTP&L 284 284 34 250 Debt instruments 27 27 26 Equity instruments 231 231 14 217 Current financial assets 3 3 3 Receivables - current 32 32 32 Financial assets carried at FVTOCI 293 293 14 26 253 Derivative financial instruments 48 48 48 Financial assets carried at fair value 624 624 14 108 503 Carried at (amortized) cost: Cash and cash equivalents 1,869 Loans and receivables: Current loans receivables - Other non-current loans and receivables 77 Receivables - current 3,701 Receivables - non-current 193 Financial assets carried at (amortized) cost 5,840 Total financial assets 6,465 Financial liabilities Carried at fair value: Contingent consideration (115) (115) (115) Financial liabilities carried at FVTP&L (115) (115) (115) Derivative financial instruments (43) (43) (43) Financial liabilities carried at fair value (158) (158) (43) (115) Carried at (amortized) cost: Accounts payable (1,917) Interest accrual (76) Debt (Corporate bonds and leases) (6,969) (6,798) (5,724) (1,074) Debt (excluding corporate bonds and leases) (721) Financial liabilities carried at (amortized) cost (9,682) Total financial liabilities (9,840) 1 ) For Cash and cash equivalents, Loans and receivables, Accounts payable, interest accrual and Debt (excluding corporate bonds and leases), the carrying amounts approximate fair value because of the nature of these instruments (including maturity and interest conditions) and therefore fair value information is not included in the table above. Philips Group Fair value of financial assets and liabilities in millions of EUR carrying amount estimated fair value 1 ) Level 1 Level 2 Level 3 December 31, 2022 Financial assets Carried at fair value: Debt instruments 232 232 232 Equity instruments 4 4 1 2 Other financial assets 86 86 35 51 Financial assets carried at FVTP&L 322 322 1 35 285 Debt instruments 25 25 25 Equity instruments 259 259 30 229 Current financial assets 9 9 9 Receivables - current 26 26 26 Financial assets carried at FVTOCI 319 319 30 25 264 Derivative financial instruments 127 127 127 Financial assets carried at fair value 768 768 32 187 549 Carried at (amortized) cost: Cash and cash equivalents 1,172 Loans and receivables: Current loans receivables 2 Other non-current loans and receivables 54 Receivables - current 4,088 Receivables - non-current 279 Financial assets carried at (amortized) cost 5,596 Total financial assets 6,364 Financial liabilities Carried at fair value: Contingent consideration (113) (113) (113) Financial liabilities carried at FVTP&L (113) (113) (113) Derivative financial instruments (211) (211) (211) Financial liabilities carried at fair value (324) (324) (211) (113) Carried at (amortized) cost: Accounts payable (1,968) Interest accrual (71) Debt (Corporate bonds and leases) (6,520) (6,083) (5,001) (1,082) Debt (excluding corporate bonds and leases) (1,680) Financial liabilities carried at (amortized) cost (10,240) Total financial liabilities (10,564) 1 ) For Cash and cash equivalents, Loans and receivables, Accounts payable, interest accrual and Debt (excluding corporate bonds and leases), the carrying amounts approximate fair value because of the nature of these instruments (including maturity and interest conditions) and therefore fair value information is not included in the table above. The following table shows the reconciliation from the beginning balance to the end balance for Level 3 fair value measurements. Philips Group Reconciliation of Level 3 fair value measurements in millions of EUR Financial assets Financial liabilities Balance as of January 1, 2023 549 113 Acquisitions 6 Purchase 85 Sales (56) Utilizations (20) Recognized in profit and loss: other business income 16 financial income and expenses 1 ) (43) 1 Recognized in other comprehensive income 2 ) (40) (2) Receivables held to collect and sell 6 Reclassification 1 Balance as of December 31, 2023 503 115 1 ) Refer to Financial income and expenses 2 ) Includes translation differences Philips Group Reconciliation of Level 3 fair value measurements in millions of EUR Financial assets Financial liabilities Balance as of January 1, 2022 523 208 Acquisitions 96 Purchase 131 Sales (76) Utilizations (105) Recognized in profit and loss: other business income (85) financial income and expenses 7 (8) Recognized in other comprehensive income 1 ) 8 Receivables held to collect and sell (41) Reclassification from associates 5 Balance as of December 31, 2022 549 113 1 ) Includes translation differences Offsetting and master netting agreements Transactions in derivatives are subject to master netting and set-off agreements. In the case of certain termination events, under the terms of the master agreement, Philips can terminate the outstanding transactions and aggregate their positive and negative values to arrive at a single net termination sum (or close-out amount). This contractual right is subject to the following: The right may be limited by local law if the counterparty is subject to bankruptcy proceedings. The right applies on a bilateral basis. Philips Group Financial assets subject to offsetting, enforceable master netting arrangements or similar agreements in millions of EUR 2022 2023 Derivatives Gross amounts of recognized financial assets 127 48 Gross amounts of recognized financial liabilities offset in the balance sheet Net amounts of financial assets presented in the balance sheet 127 48 Related amounts not offset in the balance sheet Financial instruments (54) (34) Net amount 73 13 Philips Group Financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in millions of EUR 2022 2023 Derivatives Gross amounts of recognized financial liabilities (211) (43) Gross amounts of recognized financial assets offset in the balance sheet Net amounts of financial liabilities presented in the balance sheet (211) (43) Related amounts not offset in the balance sheet Financial instruments 54 34 Net amount (157) (9)

Details of treasury and other f

Details of treasury and other financial risks	12 Months Ended
	Dec. 31, 2023
Details of treasury and other financial risks [Abstract]
Details of treasury and other financial risks [Text Block]	29 Accounting policies Derivative financial instruments, including hedge accounting The company uses derivative financial instruments principally to manage its foreign currency risks and, to a more limited extent, interest rate and commodity price risks. All derivative financial instruments are accounted for at the trade date and classified as current or non-current assets or liabilities based on the maturity date or the early termination date. The company measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivatives are recognized in the Consolidated statements of income, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of foreign exchange forward contracts attributable to forward points and changes in the time value of the option contracts are deferred in the cash flow hedges reserve within equity. The deferred amounts are recognized in the Consolidated statements of income against the related hedged transaction when it occurs. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated statements of income are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognized in the Consolidated statements of income. The company formally assesses, both at the hedge’s inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the company discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the company continues to carry the derivative on the Consolidated balance sheets at its fair value, and gains and losses that were accumulated in OCI are recognized immediately in the same line item as they relate to in the Consolidated statements of income. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognized directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognized in the Consolidated statements of income. Accounting estimates and judgments Financial assets are subject to impairment assessment, which involves estimating expected credit losses. Refer to Other financial assets Philips is exposed to several types of financial risks which are further analyzed below. Philips does not purchase or hold derivative financial instruments for speculative purposes. Information regarding financial instruments is included in Fair value of financial assets and liabilities Liquidity risk Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. Liquidity risk for the group is monitored through the Treasury liquidity committee, which tracks the development of the actual cash flow position for the group and uses input from a number of sources in order to forecast the overall liquidity position on both short and longer term basis. Philips invests surplus cash in short-term deposits with appropriate maturities to ensure sufficient liquidity is available to meet liabilities when due and in money market funds. The rating of the company’s debt by major rating agencies may improve or deteriorate. As a result, Philips’ future borrowing capacity may be influenced and its financing costs may fluctuate. Philips has various sources to mitigate the liquidity risk for the group. As of December 31, 2023, Philips had EUR 1,869 million in cash and cash equivalents (2022: EUR 1,172 million), within which short-term deposits of EUR 1,399 million (2022: EUR 482 million). Cash and cash equivalents include all cash balances, money market funds and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. Philips pools cash from subsidiaries to the extent legally and economically feasible; cash not pooled remains available for the company’s operational or investment needs. Philips faces cross-border foreign exchange controls and/or other legal restrictions in a few countries that could limit its ability to make these balances available on short notice for general use by the group. Philips has a USD 2.5 billion Commercial Paper Program and a EUR 1 billion committed standby revolving credit facility that can be used for general group purposes, such as a backstop for its Commercial Paper Program. As of December 31, 2023, Philips did not have any loans outstanding under either facility. These facilities do not have a material adverse change clause, have no financial covenants and no credit-rating-related acceleration possibilities. As per March 9, 2020, Philips established a Euro Medium-Term Note (EMTN) program, a framework that facilitates the issuance of notes for a total amount up to EUR 10 billion. As of December 31, 2023, Philips has EUR 3.3 billion outstanding under this program of which EUR 500 million fixed rates notes were issued in August 2023 with maturity date in 2031. For a description of Philips’ credit facilities, refer to Debt In addition to cash and cash equivalents, as of December 31, 2023, Philips also held EUR 14 million of listed (level 1) equity investments at fair value (classified as other non-current financial assets). The following table presents a summary of the Group’s fixed contractual cash obligations and commitments as of December 31, 2023. These amounts are an estimate of future payments which could change as a result of various factors such as a change in interest rates, foreign exchange, contractual provisions, as well as changes in business strategy and needs. Therefore, the actual payments made in future periods may vary from those presented in the following table: Philips Group Contractual cash obligations 1 ) 2 ) in millions of EUR payments due by period total less than 1 year 1-3 years 3-5 years after 5 years Long-term debt 7,615 533 1,934 1,431 3,717 Short-term debt 122 122 Interest on debt 1,704 180 328 285 911 Derivative liabilities 39 38 1 Purchase obligations 3 ) 668 355 286 27 Trade and other payables 1,917 1,917 Contractual cash obligations 12,065 3,145 2,549 1,716 4,655 1 ) Amounts in this table are undiscounted 2 ) This table excludes post-employment benefit plan contribution commitments and income tax liabilities in respect of tax risks because it is not possible to make a reasonably reliable estimate of the actual period of cash settlement. 3 ) Purchase obligations are agreements to purchase goods or services that are enforceable and legally binding for the Group. They specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions and the approximate timing of the transaction. They do not include open purchase orders or other commitments which do not specify all significant terms. Philips has contracts with investment funds where it committed itself to make, under certain conditions, capital contributions to these funds of an aggregated remaining amount of EUR 153 million (2022: EUR 127 million). As of December 31, 2023 capital contributions already made to these investment funds are recorded as non-current financial assets. Philips offers voluntary supply chain finance programs with third parties which provide participating suppliers the opportunity to factor their trade receivables at the sole discretion of both the suppliers and the third parties. Philips continues to recognize these liabilities as trade payables and settles them accordingly on the invoice maturity date based on the terms and conditions of those arrangements. As of December 31, 2023 approximately EUR 114 million (2022: EUR 151 million) of the Philips account payable were transferred under these arrangements. With respect to the Respironics field action, please refer to Contingencies Leasing activities The company leases various items of real estate, vehicles and other equipment where it acts as a lessee. The company has multiple extension and termination options in a number of lease contracts. These are used to maximize operational flexibility in terms of managing the assets used in the company's operations. The options considered reasonably certain are part of lease liabilities. In addition, the company is committed to leases not yet commenced to EUR 128 million. The company's lease contracts do not contain financial covenants. The company enters into sale-and-leaseback transactions primarily for its Sleep & Respiratory Care businesses. These transactions are accounted for at market value. The payments for these leases are considered in determining lease liabilities. Principal repayments are part of cash flows used for financing activities and interest payments are part of cash flows used for operating activities. The cash inflows arising from the sales transactions are part of cash flows provided by financing activities. Lease payments under sale-and-leaseback arrangements for 2023 were EUR 55 million (2022: EUR 72 million). The remaining minimum payment under sale-and-leaseback arrangements included in lease obligations above are as follows: Philips Group Remaining minimum payments under sale-and-leaseback arrangements in millions of EUR 2024 43 2025 30 2026 21 2027 12 2028 5 Thereafter 26 Philips has leasing activities where it acts as lessor. In such arrangements, Philips provides the customer with a right to use of medical equipment in exchange for a series of payments. Residual values of assets under lease form an insignificant part of the carrying amount of those assets. Residual values are influenced by asset market prices and are therefore subject to management estimation. Residual values are at least reassessed on an annual basis, or more often when necessary. Reassessments are based on a combination of realization of assets sold, expert knowledge and judgment of local markets. For lease receivables, the value of unguaranteed residual values as of December 31, 2023 was EUR 0.0 million (2022: EUR 0.6 million). In order to reduce residual value risk exposures there may be residual value guarantees or purchase options embedded in the customer contract. Credit risk for lease receivables is reviewed regularly and mitigated, for example, by retaining a security interest in the leased asset. Currency risk Currency risk is the risk that reported financial performance or the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Philips operates in many countries and currencies and therefore currency fluctuations may impact Philips’ financial results. Philips is exposed to currency risk in the following areas: Transaction exposures, related to anticipated sales and purchases and on-balance-sheet receivables/payables resulting from such transactions Translation exposure of foreign-currency intercompany and external debt and deposits Translation exposure of net income in foreign entities Translation exposure of foreign-currency-denominated equity invested in consolidated companies Translation exposure to equity interests in non-functional-currency investments in associates and other non-current financial assets. It is Philips’ policy to reduce the potential year-on-year volatility caused by foreign-currency movements on its net earnings by hedging the anticipated net exposure of foreign currencies resulting from foreign-currency sales and purchases. In general, net anticipated exposures for the Group are hedged during a period of 15 months in layers of 20% up to a maximum hedge of 80%. Philips’ policy requires significant committed foreign currency exposures to be fully hedged, generally using forwards. However, not every foreign currency can or shall be hedged as there may be regulatory barriers or prohibitive hedging cost preventing Philips from effectively and/or efficiently hedging its currency exposures. As a result, hedging activities cannot and will not eliminate all currency risks for anticipated and committed transaction exposures. The following table outlines the estimated nominal value in millions of EUR for committed and anticipated transaction exposure and related hedges for Philips’ most significant currency exposures consolidated as of December 31, 2023: Philips Group Estimated transaction exposure and related hedges in millions of EUR Sales/Receivables Purchases/Payable exposure hedges exposure hedges Balance as of December 31, 2023 Exposure currency USD 1,793 (1,449) (888) 805 JPY 547 (319) (14) 14 GBP 312 (196) (12) 12 CNY 439 (304) (98) 95 CAD 249 (161) (1) 1 PLN 91 (103) AUD 226 (137) CHF 103 (63) (1) 1 CZK 63 (70) SEK 33 (18) (3) 3 EUR 233 (232) (114) 113 Others 198 (134) (216) 130 Total 2023 4,287 (3,185) (1,346) 1,173 Total 2022 3,779 (2,920) (1,468) 1,326 Philips uses foreign exchange spot and forward contracts, as well as zero cost collars in hedging the exposure. The derivatives related to transactions are, for hedge accounting purposes, split into hedges of on-balance-sheet accounts receivable/ payable and forecasted sales and purchases. Changes in the value of on-balance-sheet foreign-currency accounts receivable/payable, as well as the changes in the fair value of the hedges related to these exposures, are reported in the income statement under costs of sales. Hedges related to forecasted transactions, where hedge accounting is applied, are accounted for as cash flow hedges. The results from such hedges are deferred in other comprehensive income within equity to the extent that the hedge is effective. As of December 31, 2023, a gain of EUR 6 million was deferred in equity as a result of these hedges (2022: EUR 2 million loss). The result deferred in equity will be released to earnings mostly during 2024 at the time when the related hedged transactions affect the income statement. During 2023, nil The total net fair value of hedges related to transaction exposure as of December 31, 2023, was an unrealized gain of EUR 10 million. The estimated impact of a 10% increase of value of the EUR is estimated to be EUR 116 million. The following table contains an overview of the instantaneous 10% increase in the value of EUR against major currencies. Philips Group Estimated impact of 10% increase of value of the EUR on the fair value of hedges in millions of EUR 2022 2023 USD 68 64 JPY 15 15 GBP 16 16 CHF 4 5 PLN 2 1 RUB - The EUR 116 million increase includes a gain of EUR 40 million that would impact the income statement, which would largely offset the opposite revaluation effect on the underlying accounts receivable and payable, and the remaining gain of EUR 77 million would be recognized in equity to the extent that the cash flow hedges were effective. Foreign exchange exposure also arises as a result of inter-company loans and deposits. Where the company enters into such arrangements, the financing is generally provided in the functional currency of the subsidiary entity. The currency of the company’s external funding and liquid assets is matched with the required financing of subsidiaries, either directly through external foreign currency loans and deposits, or synthetically by using foreign exchange derivatives, including cross currency interest rate swaps and foreign exchange forward contracts. In certain cases where group companies may also have external foreign currency debt or liquid assets, these exposures are also hedged through the use of foreign exchange derivatives. Changes in the fair value of hedges related to this exposure are recognized within financial income and expenses in the statements of income. When such loans would be considered part of the net investment in the subsidiary, net investment hedging would be applied. Translation exposure of foreign-currency equity invested in consolidated entities is generally not hedged. If a hedge is entered into, it is accounted for as a net investment hedge. Net current-period change, before tax, of the currency translation reserve of negative EUR 579 million mainly relates to the development of the USD versus the EUR. As of December 31, 2023, a weakening of USD by 10% versus the EUR would result in a decrease in the currency translation reserve in equity of approximately EUR 1,146 million, while a strengthening of USD by 10% versus the EUR would result in an increase in the currency translation reserve in equity of approximately EUR 1,400 million. Refer to the country risk paragraph for countries with significant foreign currency denominated equity invested. As of December 31, 2023, external bond funding for a nominal value of USD 1,474 million (liability at book value: EUR 1,325 million) was designated as a net investment hedge of financing investments in foreign operations for an equal amount. During 2023 a total loss of EUR 2 million was recognized in the income statement as ineffectiveness on net investment hedges, arising from counterparty and own credit risk. An instantaneous 10% increase in the value of the EUR against all currencies would lead to an decrease of EUR 52 million in the value of the derivatives, including a EUR 11 million increase related to the USD. As of December 31, 2022, cross-currency interest rate swaps for a nominal value of USD 500 million (liability at fair value: EUR 147 million) and external bond funding for a nominal value of USD 1,490 million (liability at book value: EUR 1,378 million) were designated as a net investment hedge of financing investments in foreign operations for an equal amount. During 2022 a total gain of EUR 1.1 million was recognized in the income statement as ineffectiveness on net investment hedges, arising from counterparty and own credit risk. The total net fair value of financing derivatives as of December 31, 2022, was a liability of EUR 147 million. An instantaneous 10% increase in the value of the EUR against all currencies would lead to an increase of EUR 192 million in the value of the derivatives, including a EUR 191 million increase related to the USD. Philips does not currently hedge the foreign exchange exposure arising from equity interests in non-functional-currency investments in associates and other non-current financial assets. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As of December 31, 2023, Philips had outstanding debt of EUR 7,689 million (2022: EUR 8,201 million), which constitutes an inherent interest rate risk with potential negative impact on financial results. As of December 31, 2023, Philips held EUR 1,869 million in cash and cash equivalents (2022: EUR 1,172 million), and had total long-term debt of EUR 7,035 million (2022: EUR 7,270 million) and total short-term debt of EUR 654 million (2022: EUR 931 million). As of December 31, 2023, Philips had a ratio of fixed-rate long-term debt to total outstanding debt of approximately 89% compared to 80% one year earlier. Philips debt has a long maturity profile with an average tenor of long-term debt of 6.0 years with maturities up to 2042. The following table provides the impact of a 1% increase/decrease of interest rates on the fair value of the debt and the annualized net interest expenses. Philips Group Net debt 1 ) in millions of EUR 2022 2023 Impact 1% interest increase on the fair value of the fixed-rate long-term debt 2 ) 3 ) (274) (283) Impact 1% interest decrease on the fair value of the fixed-rate long-term debt 2 ) 3 ) 274 284 Impact 1% interest increase on the annualized net interest expense 4 ) 4 15 1 ) The definition of this non-IFRS measure and a reconciliation to the IFRS measure is included in Equity 2 ) The sensitivity analysis conducted shows that if long-term interest rates were to increase/decrease instantaneously by 1% from their level of December 31, 2023, with all other variables (including foreign exchange rates) held constant. 3 ) Fixed-rate long-term debt is excluding forward contracts. 4 ) The impact is based on the outstanding net floating-rate position as of December 31, 2023. Equity price risk Equity price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in equity prices. Philips is a shareholder in some publicly listed companies and as a result is exposed to potential financial loss through movements in their share prices. The aggregate equity price exposure in such financial assets amounted to approximately EUR 14 million as of December 31, 2023 (2022: EUR 32 million). Philips does not hold derivatives in the above-mentioned listed companies. Philips also has shareholdings in several privately-owned companies amounting to EUR 219 million, mainly consisting of minority stakes in companies in various industries. As a result, Philips is exposed to potential value adjustments. Commodity price risk Commodity price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in commodity prices. Philips is a purchaser of certain base metals, precious metals and energy. Philips may hedge certain commodity price risks using derivative instruments to minimize significant, unanticipated earnings fluctuations caused by commodity price volatility. As of December 31, 2023 and 2022, respectively, Philips did not have any significant outstanding financial commodity derivatives. Credit risk Credit risk represents the loss that would be recognized at the reporting date, if counterparties failed completely to perform their payment obligations as contracted. Credit risk is present within Philips trade receivables and contract assets. To have better insights into the credit exposures, Philips performs ongoing evaluations of the financial and non-financial condition of its customers and adjusts credit limits when appropriate. In instances where the creditworthiness of a customer is determined not to be sufficient to grant the credit limit required, there are a number of mitigation tools that can be utilized to close the gap, including reducing payment terms, cash on delivery, pre-payments and pledges on assets. Philips invests available cash and cash equivalents with various financial institutions and is exposed to credit risk with these counterparties. Philips is also exposed to credit risks in the event of non-performance by financial institutions with respect to financial derivative instruments. Philips actively manages concentration risk and on a daily basis measures the potential loss under certain stress scenarios, should a financial institution default. These worst-case scenario losses are monitored and limited by the company. The company does not enter into any financial derivative instruments to protect against default by financial institutions. However, where possible the company requires all financial institutions with which it deals in derivative transactions to complete legally enforceable netting agreements under an International Swap Dealers Association master agreement or otherwise prior to trading, and whenever possible, to have a strong credit rating. Philips also regularly monitors the development of the credit risk of its financial counterparties. Wherever possible, cash is invested and financial transactions are concluded with financial institutions with strong credit ratings or with governments or government-backed institutions. The following table shows the number of financial institutions with credit rating A- and above with which Philips has cash at hand and short-term deposits above EUR 10 million as of December 31, 2023. Philips Group Credit risk with number of counterparties for deposits above EUR 10 million 10-100 million 100-500 million 500 million and above AAA rated bank counterparties 4 AA- rated bank counterparties 1 A+ rated bank counterparties 2 3 A rated bank counterparties 2 1 A- rated bank counterparties 1 6 8 For an overview of the overall maximum credit exposure related to debt instruments, derivatives and loans and receivables, refer to Fair value of financial assets and liabilities Country risk Country risk is the risk that political, legal, or economic developments in a single country could adversely impact performance. The country risk per country is defined as the sum of the equity of all subsidiaries and associated companies in country cross-border transactions, such as intercompany loans, accounts receivable from third parties and intercompany accounts receivable. The country risk is monitored on a regular basis. As of December 31, 2023, the company had country risk exposure of EUR 13.3 billion in the United States, EUR 1.4 billion in the Netherlands, EUR 1.3 billion in China (including Hong Kong). Other countries higher than EUR 500 million are Germany EUR 786 million, United Kingdom EUR 731 million, and Japan The impact of hyperinflation is also routinely assessed and was not material for the periods presented. Other insurable risks Philips is insured for a broad range of losses by global insurance policies in the areas of property damage/business interruption, general and product liability, transport, directors’ and officers’ liability, employment practice liability, crime and cybersecurity. The counterparty risk related to the insurance companies participating in the above-mentioned global insurance policies is actively managed. As a rule, Philips only selects insurance companies with a financial strength of at least A-. Throughout the year the counterparty risk is monitored on a regular basis. To lower exposures and to avoid potential losses, Philips has a global Risk Engineering program in place. The main focus of this program is on property damage and business interruption risks including company interdependencies. Regular on-site assessments take place at Philips locations and business-critical suppliers by risk engineers of the insurer in order to provide an accurate assessment of the potential loss and its impact. The results of these assessments are shared across the company’s stakeholders. On-site assessments are carried out against the predefined Risk Engineering standards, which are agreed between Philips and the insurers. Recommendations are made in a Risk Improvement report and are monitored centrally. This is the basis for decision-making by the local management of the business as to which recommendations will be implemented. For all policies, deductibles are in place, which vary from EUR 0 million to EUR 10 million per occurrence and this variance is designed to differentiate between the existing risk categories within Philips. Above a first layer of working deductibles, Philips operates its own re-insurance captive, which during 2023 retained EUR 25 million per claim and EUR 50 million in the annual aggregate for general, product, professional liability, and marine cargo claims and EUR 15 million aggregate for cyber. New contracts were signed effective December 31, 2023, for the coming year, whereby the re-insurance captive retentions remained the same.

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2023
Subsequent events [Abstract]
Subsequent events [Text Block]	30 Philips Respironics consent decree On January 29, 2024, Philips announced that it has agreed on the terms of a consent decree with the US Department of Justice (DOJ), representing the US Food and Drug Administration (FDA). The proposed consent decree primarily focuses on Philips Respironics’ business operations in the US. The proposed consent decree is being finalized and will be submitted to the relevant US court for approval. The decree will provide Philips Respironics with a roadmap of defined actions, milestones, and deliverables to demonstrate compliance with regulatory requirements and to restore the business. In the US, Philips Respironics will continue to service sleep and respiratory care devices already with healthcare providers and patients, and supply accessories (including patient interfaces), consumables (including patient circuits), and replacement parts (including repair kits). Until the relevant requirements of the proposed consent decree are met, Philips Respironics will not sell new CPAP or BiPAP sleep therapy devices or other respiratory care devices in the US. Outside the US, Philips Respironics will continue to provide new sleep and respiratory care devices, accessories (including patient interfaces), consumables (including patient circuits), replacement parts (including repair kits) and services, subject to certain requirements. As a consequence of addressing this proposed consent decree, which is a multi-year plan, Philips recorded charges of EUR 363 million in December 2023 that relate to remediation activities, inventory write-downs and onerous contract provisions. Refer to Provisions

Material accounting policies (P

Material accounting policies (Policies)	12 Months Ended
	Dec. 31, 2023
Material Accounting Policies [Abstract]
Disclosure of basis of preparation of financial statements [text block]	Basis of preparation The Consolidated financial statements are: prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union (EU) and comply with the statutory provisions of Part 9, Book 2 of the Dutch Civil Code. All standards and interpretations issued by the International Accounting Standards Board (IASB) and the IFRS Interpretations Committee effective 2023 have been endorsed by the EU; consequently, the accounting policies applied by Philips also comply with IFRS as issued by the IASB. These accounting policies have been applied by group entities; authorized for issue by the Board of Management of Royal Philips on February 19, 2024; prepared under the historical cost convention, unless otherwise indicated; prepared on a going concern basis; presented in euro, which is the presentation currency; rounded to the nearest million euro unless stated otherwise; subject to rounding, whereby amounts may not add up precisely to the totals provided.
Disclosure of accounting judgements and estimates [text block]	Accounting estimates and judgments The preparation of financial statements requires management to make a number of estimates and judgments that affect the application of accounting policies and the reporting amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Amounts recognized are based on factors that are by default associated with uncertainty. Actual results may therefore differ from estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to estimates are recognized prospectively. Where applicable, the estimates and judgments of specific financial statement items are described in the respective note to the consolidated financial statements. The areas involving a higher degree of judgment and complexity in applying accounting principles and for which changes in the assumptions and estimates could result in significantly different results than those recorded in the consolidated financial statements are the following: Assessment of control (below paragraph Basis of consolidation and Interests in entities Revenue recognition ( Income from operations For acquisitions, the identification and valuation of acquired assets and liabilities including contingent considerations provisions ( Acquisitions and divestments Provisions Determination of deferred tax assets for losses carried forward and uncertain tax positions ( Income taxes Assumptions used for impairment testing ( Goodwill Intangible assets excluding goodwill Assessments of exposure to credit risk of financial instruments ( Other financial assets Receivables Debt Fair value of financial assets and liabilities Details of treasury and other financial risks Assumptions used to determine the net realizable value of inventories ( Inventories Actuarial assumptions of future events that are used in calculating post-employment benefit expenses and liabilities ( Post-employment benefits Estimates and assumptions regarding the timing and the amount of outflow of resources, as well as estimating the likelihood of a potential outflow of resources and the ability to make a reliable estimate of the obligation relating to provisions and contingent liabilities ( Provisions Contingencies The company regularly updates its significant assumptions and estimates to support the reported amounts of assets, liabilities, income and expenses. In preparing the consolidated financial statements management has considered the impact of climate change, specifically the financial impact of Philips meeting its internal and external climate related aims, the potential impact of climate related risks and the costs incurred to pro-actively manage such risks. These considerations did not have a material impact on the financial reporting judgments, estimates or assumptions. The specific financial impacts considered include, for example: specific climate mitigation measures, such as the use of lower carbon energy sources, the costs of developing more sustainable product offerings and expenses incurred to mitigate against the impact of extreme weather conditions. Philips uses 100% electricity from renewable sources, mainly through long-term Power Purchase Agreements thereby mitigating the impact of carbon taxes. The development of more sustainable products are covered through our EcoDesign program and already included in our R&D expenses. The physical risk related to climate change on our sites resulting from our TCFD-assessment is currently considered limited.
Disclosure of material accounting policy information [text block]	Material accounting policies The material accounting policies as generally applied throughout the financial statements are described below. Material accounting policies relating to specific financial statement items are included in the respective notes to the financial statements.
Disclosure of basis of consolidation [text block]	Basis of consolidation The Consolidated financial statements comprise the financial statements of Koninklijke Philips N.V. and all subsidiaries that the company controls on a consolidated basis. Control exists when the company is exposed or has rights to variable returns from its involvement with the investee and the company has the ability to affect those returns through its power over the investee. Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and in cases where Philips has less than a majority of the voting or similar rights of an investee, Philips considers all relevant facts and circumstances in assessing whether it has power over an investee, including the contractual arrangement(s) with the other vote holders of the investee, rights arising from other contractual arrangements and the company’s voting rights and potential voting rights. Subsidiaries are fully consolidated from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated in the Consolidated financial statements. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.
Description of accounting policy for foreign currency translation [text block]	Foreign currency transactions The financial statements of all group entities are measured using the currency of the primary economic environment in which the entity operates (functional currency). The euro (EUR) is the functional currency of the company and the presentation currency of the consolidated financial statements. Foreign currency transactions are converted into the functional currency using the exchange rates prevailing at transaction date or the valuation date in cases where items are remeasured. Gains and losses resulting from the settlement of foreign currency transactions and those resulting from the conversion of foreign currency denominated monetary assets and liabilities at period-end exchange rates are recognized in the Consolidated statements of income, except for qualifying cash flow hedges, qualifying net investment hedges and equity investments measured at fair value through OCI which are recognized in other comprehensive income. All foreign exchange differences are presented as part of Cost of sales, apart from tax items and financial income and expense, which are recognized in the same line item as they relate to in the Consolidated statements of income. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency using the exchange rate at the date the fair value was determined. Non-monetary items in a foreign currency that are measured based on historical cost are translated using the exchange rate at the transaction date. Foreign operations The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated to euros at the exchange rates prevailing at the reporting date. The income and expenses of foreign operations are translated to euros at the exchange rates prevailing at the dates of the transactions. Foreign currency differences arising upon translation of foreign operations into euros are recognized in Other comprehensive income and presented as part of Currency translation differences in Equity. However, if the operation is not a wholly-owned subsidiary, the proportionate share of the translation difference is allocated to Non-controlling interests. When a foreign operation is disposed of such that control, significant influence or joint control is lost, the cumulative amount in the Currency translation differences related to the foreign operation is reclassified to the Consolidated statements of income as part of the gain or loss on disposal. When the company disposes of only part of its interest in a subsidiary that includes a foreign operation while retaining control, the respective proportion of the cumulative amount is reattributed to Non-controlling interests. When the company disposes of only part of its investment in an associate or joint venture that includes a foreign operation while retaining significant influence or joint control, the relevant proportion of the cumulative amount is reclassified to the Consolidated statements of income.
Disclosure of changes in accounting policies [text block]	New accounting policies effective in 2023 No new IFRS accounting standards or amendments to existing standards, effective in 2023, had a significant impact on the consolidated financial statements. The company has not early adopted any standards or amendments to existing standards. Consistent with the IAS 12 amendment regarding Pillar Two taxation as issued by the IASB and adopted by the EU, Philips does not recognize and disclose deferred taxes arising from tax laws that implement Pillar Two model rules published by the Organisation for Economic Co-operation and Development. Furthermore, Philips will recognize and disclose the impact (if any) from Pillar Two income taxes on current tax effective from 2024 . New accounting policies effective after 2023 The IASB has issued several IFRS accounting standards, or amendments to standards, with an effective date after 2023. The company does not anticipate that the application of these standards, or amendments to standards, will have a significant effect on the consolidated financial statements upon adoption. Changes in presentation from the prior year Accounting policies have been applied consistently for all periods presented in these consolidated financial statements. Certain prior-year amounts have been reclassified to conform to the current year presentation due to immaterial organizational changes. Philips has realigned the composition of its reporting segments effective from April 1, 2023. The most notable change is the shift of the previous Enterprise Diagnostic Informatics business from the Diagnosis & Treatment segment to the Connected Care segment. This business, together with other informatics solutions in the Connected Care segment, now forms the Enterprise Informatics business. Accordingly, the comparative figures for the affected segments have been restated in the consolidated financial statements.
Description of accounting policy for segment reporting [text block]	2 Accounting policies Segment accounting policies are the same as the accounting policies applied by the company. Operating segments are components of the company’s business activities about which separate financial information is available that is evaluated regularly by the Chief Operating Decision-Maker (the Board of Management of the company). The Board of Management decides how to allocate resources and assesses performance. Reportable segments comprise the operating segments Diagnosis & Treatment, Connected Care and Personal Health. Additionally, besides these reportable segments, segment Other contains the items Innovation & Strategy, IP Royalties, Central costs, and other small items. Accounting estimates and judgments Determining reportable segments requires significant judgment and involves evaluating the information which is reviewed by the Chief Operating Decision-Maker (the Board of Management) to assess performance and allocate resources, in accordance with IFRS 8 'Operating Segments'.
Description of accounting policy for discontinued operations [text block]	3 Accounting policies Assets classified as held-for-sale Non-current assets (or disposal groups) are classified as held-for-sale if their carrying amounts are expected to be recovered through a sale transaction rather than through continuing use. Non-current assets (or disposal groups) classified as held-for-sale are measured at the lower of their carrying amount or the fair value less costs of disposal. Depreciation or amortization of an asset ceases when it is classified as held-for-sale. When non-current assets (or disposal groups) are classified as held-for-sale, comparative balances prior to such date are not represented in the Consolidated balance sheets. Discontinued operations A discontinued operation is a component of the company that has either been disposed of or is classified as held-for-sale and represents a separate major line of business or geographical area of operations or is a part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations. Any gain or loss from disposal, together with the results of these operations until the date of disposal, are reported separately as discontinued operations in the Consolidated statements of income. The financial information of discontinued operations is excluded from the respective captions in the Consolidated financial statements and related notes for all periods presented. Comparatives are re-presented for presentation of discontinued operations in the Consolidated statements of income and Consolidated statements of cash flows. Accounting estimates and judgments The determination of the fair value less costs of disposal involves the use of estimates and assumptions that tend to be uncertain. Circumstances to which these adjustments may relate include resolution of uncertainties that arise from the terms of the disposal transaction, such as the resolution of purchase price adjustments and indemnifications, resolution of uncertainties that arise from and are directly related to the operations of the component before its disposal, such as environmental and assurance-type product warranty obligations retained by the company, and the settlement of employee benefit plan obligations provided that the settlement is directly related to the disposal transaction.
Description of accounting policy for business combinations [text block]	4 Accounting policies Acquisitions The company accounts for business combinations using the acquisition method when control is transferred to the group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired and the liabilities assumed. Transaction costs are expensed as incurred. Any contingent consideration is measured at fair value at the acquisition date and is initially presented in Long-term provisions. When the timing and amount of the consideration become more certain, it is reclassified to Accrued liabilities. If the contingent consideration that meets the definition of a financial instrument is classified as equity, it is not remeasured and settlement is accounted for within equity. Otherwise, subsequent changes in the fair value of the contingent consideration are recognized in the Consolidated statements of income. Changes to the initial fair value of the acquired assets and liabilities, based on new information about the circumstances at the acquisition date, can be made up to twelve months after the acquisition date. Divestments Upon loss of control, the company derecognizes the assets and liabilities of the subsidiary, any non-controlling interests and the other components of equity related to the subsidiary. Any surplus or deficit arising from the loss of control is recognized in the Consolidated statements of income. If the company retains any interest in the previous subsidiary, such interest is measured at fair value at the date the control is lost. Subsequently it is accounted for as either an equity-accounted investee (associate) or as a financial asset, depending on the level of influence retained. Further information on loss of control can be found in Discontinued operations and assets classified as held for sale Accounting estimates and judgments Intangible assets acquired in a business acquisition and the financial liability related to non-controlling interest are measured at fair value at the date of the acquisition. To determine the fair value of intangible assets at the acquisition date, estimates and assumptions are required. The valuation of the identifiable intangible assets involves estimates of expected sales, earnings and/or future cash flows and require use of key assumptions such as discount rate, royalty rate and growth rates. Estimates are also applied when determining the fair value of legal cases and tax positions in the acquired entity. The fair value is based on estimates of the likelihood, the expected timing and the amount of the potential cash outflow. Provisions for legal cases and non-income tax positions are recognized at fair value even if it is not probable that an outflow will be required to settle the obligation. After initial recognition and until the liability is settled, cancelled or expired, the liability is measured at the higher of the amount that would be recognized in accordance with IAS 37 'Provisions, contingent liabilities and contingent assets' and the initial liability amount. For income tax positions, the company applies IAS 12 'Income Taxes', which requires recognition of provisions only when the likelihood of cash outflow is considered probable.
Description of accounting policy for investment in associates [text block]	5 Accounting policies Associates are all entities over which the company has significant influence, but not control or joint control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting and are initially recognized at cost. The carrying amount of an investment in associate includes the carrying amount of goodwill identified on acquisition. An impairment loss on such investment is allocated to the investment as a whole. The company’s share of the net income of these associates is included in Investments in associates, net of income taxes, in the Consolidated statements of income, after adjustments to align the accounting policies with those of the company. Dilution gains and losses arising from investments in associates are recognized in the Consolidated statements of income as part of Investments in associates, net of income taxes. Impairment losses and gains or losses on sale of investments are recorded in the Consolidated statements of income, more specifically on the line item ’Investments in associates, net of income taxes’. When the company’s share of losses exceeds its interest in an associate, the carrying amount of that interest is reduced to zero and recognition of further losses is discontinued except to the extent that the company has an obligation or made payments on behalf of the associate.
Description of accounting policy for recognition of revenue [text block]	6 Accounting policies Revenue recognition The company recognizes revenue when it transfers control over a good or service to a customer, in an amount that reflects the consideration (i.e., transaction price) to which the company expects to be entitled to in exchange for the good or service. The consideration expected by the company may include fixed and/or variable amounts which can be impacted by sales returns, trade discounts and volume rebates. The company adjusts the consideration for the time value of money if the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds six months. Transfer of control varies depending on the individual terms of the contract of sale. For consumer-type products in the Personal Health segment, control is transferred when the product is shipped and delivered to the customer and title and risk have passed to the customer (depending on the delivery conditions) and acceptance of the product has been obtained. Revenues from transactions relating to distinct goods or services are accounted for separately based on their relative stand-alone selling prices. The stand-alone selling price is the price that would be charged for the goods or service in a separate transaction under similar conditions to similar customers. The transaction price is determined (considering variable considerations) and allocated to performance obligations based on their relative stand-alone selling prices. These transactions mainly occur in the segments Diagnosis & Treatment and Connected Care and include arrangements that require subsequent installation and training activities to make distinct goods operable for the customer. As such, the related installation and training activities are part of equipment sales rather than separate performance obligations. Revenue is recognized when the performance obligation is satisfied, i.e., when the installation has been completed and the equipment is ready to be used by the customer in the way contractually agreed. Variable consideration is included in the transaction price to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur once associated uncertainties are resolved. Such assessment is performed on each reporting date to check whether it is constrained. For products for which a right of return exists during a defined period, revenue recognition is determined based on the historical pattern of actual returns, or in cases where such information is not available, revenue recognition is postponed until the return period has lapsed. Return policies are typically based on customary return arrangements in local markets. A provision is recognized for assurance-type product warranty at the time of revenue recognition and reflects the estimated costs of replacement and free-of-charge services that will be incurred by the company with respect to the products sold. For certain products, the customer has the option to purchase the warranty separately, which is considered a separate performance obligation on top of the assurance-type product warranty. For such warranties which provide distinct service, revenue recognition occurs on a straight-line basis over the extended warranty contract period. Occasionally, the company may offer a full or partial refund of consideration previously paid, for example as part of the resolution to warranty related matters. In such instances, a provision is recognized for the amounts expected to be refunded to customers, and remeasured at each reporting date to reflect changes in the estimated refunds, with a corresponding adjustment to revenue. In the case of loss under a sales agreement, the loss is recognized immediately. Sale of goods Revenues are recognized at a point in time when control of the goods passes to the buyer, based on the allocation of the transaction price to the performance obligation. Revenue from services Revenues are recognized over time as the company transfers control of the services to the customer which is demonstrated by the customer simultaneously receiving and consuming the benefits provided by the company. The amount of revenues is measured by reference to the progress made towards complete satisfaction of the performance obligation, which in general is evenly over time. Service revenue related to repair and maintenance activities for goods sold is recognized ratably over the service period or as services are rendered. Income from royalties Royalty income from brand license arrangements and from intellectual property rights, such as technology licenses or patents, is recognized on an accrual basis in accordance with the substance of the relevant agreement. Shipping and handling Expenses incurred for shipping and handling are mainly recorded as cost of sales. When shipping and handling are part of a project and billed to the customer, then the related expenses are recorded as cost of sales. Shipping and handling related to sales to third parties are partly recorded as selling expenses. When shipping and handling billed to customers are considered a distinct and separate performance obligation, the fees are recognized as revenue and costs included in cost of sales. Other business income (expenses) Other business income (expenses) includes gains and losses on the sale of property, plant and equipment, gains and losses on the sale of businesses as well as other gains and losses not related to the company’s operating activities. Government grants Grants from governments are recognized at their fair value when there is a reasonable assurance that the grant will be received and the company will comply with the conditions. Grants related to costs are deferred in the consolidated balance sheet and recognized in the consolidated statement of income as a reduction of the related costs that they are intended to compensate. Grants related to assets are deducted from the cost of the asset and presented net in the consolidated balance sheets. Accounting estimates and judgments Sales-related accruals The company has sales promotions-related agreements with distributors and retailers designed to promote the sale of products. Among the programs are arrangements under which rebates and discounts can be earned by the distributors and retailers by attaining agreed upon sales levels, or for participating in specific marketing programs. Management estimates the sales-related accruals associated with these arrangements based on a combination of historical patterns and future expectations regarding which promotional targets are expected to be met by distributors and retailers. Accrued customer rebates are presented as other current liabilities, unless there is a right to offset against the respective accounts receivable.
Description of accounting policy for finance income and costs [text block]	7 Accounting policies Financial income and expenses are recognized on the accrual basis in the consolidated statements of income. Interest income and expense are measured using the effective interest method. Dividend income is recognized in the consolidated statements of income on the date that the company’s right to receive payment is established, which in the case of quoted securities is normally the ex-dividend date.
Description of accounting policy for income tax [text block]	8 Accounting policies Income taxes comprise of current, non-current and deferred tax. Income tax is recognized in the Consolidated statements of income except to the extent that it relates to items recognized directly within equity or in other comprehensive income. Current tax is the expected taxes payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. In cases where it is concluded it is not probable that tax authorities will accept a tax treatment, the effect of the uncertainty is reflected in the recognition and measurement of tax assets and liabilities or, alternatively, a provision is made for the amount that is expected to be settled, where this can be reasonably estimated. This assessment relies on estimates and assumptions and may involve a series of judgments about future events. New information may become available that causes the company to change its judgment regarding the adequacy of existing tax assets and liabilities. Such changes to tax assets and liabilities will impact the income tax expense in the period during which such a determination is made. Deferred tax assets and liabilities are recognized, using the consolidated balance sheet method, for the expected tax consequences of temporary differences between the carrying amounts of assets and liabilities and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: (a) the initial recognition of goodwill; or (b) the initial recognition of an asset or liability in a transaction which: (i) is not a business combination, (ii) at the time of transaction, affects neither accounting profit nor taxable profit (tax loss), (iii) at the time of the transaction, does not give rise to equal amounts of taxable and deductible differences; or (c) differences relating to investments in subsidiaries, joint ventures and associates where the reversal of the respective temporary difference can be controlled by the company and it is probable that it will not reverse in the foreseeable future. Deferred taxes are measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity or on different taxable entities, but the company intends to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences to the extent that it is probable that there will be future taxable profits against which they can be utilized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the countries where the deferred tax assets originated and during the periods when the deferred tax assets become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Deferred tax liabilities for withholding taxes are recognized for subsidiaries in situations where the income is to be paid out as dividend in the foreseeable future and for undistributed earnings of unconsolidated companies to the extent that these withholding taxes are not expected to be refundable or deductible. Changes in tax rates and tax laws are reflected in the period when the change was enacted or substantively enacted by the reporting date. Any subsequent adjustment to a tax asset or liability that originated in discontinued operations and for which no specific arrangements were made at the time of divestment, due to a change in the tax base or its measurement, is allocated to discontinued operations (i.e. backwards tracing). Examples are a tax rate change or change in retained assets or liabilities directly relating to the discontinued operation. Any subsequent change to the recognition of deferred tax assets is allocated to the component in which the taxable gain is or will be recognized. The above principles are applied to the extent the ‘discontinued operations’ are sufficiently separable from continuing operations. Consistent with the IAS 12 amendment regarding Pillar Two taxation as issued by the IASB and adopted by the EU, Philips does not recognize and disclose deferred taxes arising from tax laws that implement Pillar Two model rules published by the Organisation for Economic Co-operation and Development. Furthermore, Philips will recognize and disclose the impact (if any) from Pillar Two income taxes on current tax effective from 2024 . Accounting estimates and judgments Deferred tax recoverability Deferred tax assets are recognized to the extent that it is probable that there will be future taxable profits against which these can be utilized. Significant judgment is involved in determining whether such profits are probable. Management determines this on the basis of expected taxable profits arising from the reversal of recognized deferred tax liabilities, appropriate tax planning opportunities to support business goals and on the basis of forecasts. Uncertain tax positions Uncertain tax positions are recognized as liabilities if and to the extent it is probable that additional tax will be due and the amount can be reliably measured. Significant judgment is involved in determining these positions.
Description of accounting policy for earnings per share [text block]	9 Accounting policies The company presents basic and diluted earnings per share (EPS) data for its common shares. Basic EPS is calculated by dividing the Net income (loss) attributable to shareholders by the weighted average number of common shares outstanding (after deduction of treasury shares) during the period. Diluted EPS is determined by adjusting the Net income (loss) attributable to shareholders and the weighted average number of common shares outstanding (after deduction of treasury shares) during the period, for the effects of all dilutive potential common shares, which comprise performance shares, restricted shares and share options granted under share-based compensation plans as well as forward contracts to repurchase shares.
Description of accounting policy for property, plant and equipment [text block]	10 Accounting policies Owned assets The cost of property, plant and equipment comprise all directly attributable costs (including the cost of material and direct labor). Depreciation is generally calculated using the straight-line method over the useful life of the asset. Land and assets under construction are not depreciated. When assets under construction are ready for their intended use, they are transferred to the relevant asset category and depreciation starts. All other property, plant and equipment items are depreciated over their estimated useful lives to their estimated residual values. The estimated useful lives of property, plant and equipment are as follows: Philips Group Useful lives of property, plant and equipment Buildings from 5 to 50 years Machinery and installations from 3 to 20 years Other equipment from 1 to 10 years Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the assets concerned may not be recoverable. An impairment loss is recognized for the amount by which the asset's book value exceeds their recoverable amount. Impairments are reversed if and to the extent that the impairment no longer exists. The recoverable amount is defined as the higher of the asset’s fair value less costs of disposal and its value in use. Gains and losses on the sale of property, plant and equipment are included in other business income. Costs related to repair and maintenance activities are expensed in the period in which they are incurred unless they extend the asset's original lifetime or capacity. Right-of-use assets The company leases various items of real estate, vehicles and other equipment. The company determines whether an arrangement constitutes or contains a lease based on the substance of the arrangement at the lease inception. The arrangement constitutes or contains a lease if fulfillment is dependent on the use of a specific asset and the arrangement conveys a right to use the asset, even if that asset is not explicitly specified in the arrangement. Company as a lessee The company recognizes right-of-use assets and lease liabilities for leases with a term of more than twelve months if the underlying asset is not of low value. Payments for short-term and low-value leases are expensed over the lease term. Extension options are included in the lease term if their exercise is reasonably certain. Right-of-use assets are measured at cost less accumulated depreciation and impairment losses, adjusted for any remeasurements. Right-of-use assets are depreciated using the straight-line method over the shorter of the lease term and the useful life of the underlying assets. Company as a lessor When the company acts as a lessor, it determines at lease inception whether a lease is a finance lease or an operating lease. Leases in which the company does not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating leases. The company recognizes lease payments received under operating leases as income on a straight-line basis over the lease term in the Consolidated statement of income. Accounting estimates and judgments Impairment of owned and right-of-use assets Judgments are required, not only to determine whether there is an indication that an asset may be impaired, but also whether indications exist that impairment losses previously recognized may no longer exist or may have decreased (impairment reversal). After indications of impairment have been identified, estimates and assumptions are used in the determination of the recoverable amount of a fixed asset. These involve estimates of expected future cash flows (based on future growth rates and remaining useful life) and residual value assumptions, as well as discount rates to calculate the present value of the future cash flows. Owned assets Estimates are required to determine the (remaining) useful lives of fixed assets. Useful lives are determined based on an asset's age, the frequency of its use, repair and maintenance policy, technology changes in production and expected restructuring. The company estimates the expected residual value per asset item. The residual value is the higher of the asset's expected sales price (based on recent market transactions of similar sold items) and its material scrap value. Right-of-use assets Judgment is required to determine the lease term. The assessment of whether the company is reasonably certain to exercise extension options impacts the lease term, which could affect the amount of lease liabilities and right-of-use assets recognized.
Description of accounting policy for goodwill [text block]	11 Accounting policies The measurement of goodwill at initial recognition is described in the Acquisitions and divestments note. Goodwill is subsequently measured at cost less accumulated impairment losses. Goodwill is not amortized but is instead tested for impairment annually in the fourth quarter, or more frequently if indicators of potential impairment exist. Internal and external sources of information are considered to assess if there are indicators that an asset or groups of cash-generating units (CGUs) may be impaired. Goodwill is allocated to groups of CGUs and tested for impairment at the business level (one level below segment), as this represents the lowest level at which goodwill is monitored for internal management purposes. An impairment loss is recognized in the Consolidated statements of income whenever and to the extent that the carrying amount of a group of CGUs exceeds the recoverable amount for the group of CGUs, whichever is the greater, its value in use or its fair value less cost of disposal. Value in use is measured as the present value of future cash flows expected to be generated by the asset. Fair value less cost of disposal is measured as the amount obtained from the sale of an asset in an arm’s length transaction, less costs of disposal. Accounting estimates and judgments The cash flow projections used in the value in use calculations for goodwill impairment testing contain various judgments and estimations as described in the ‘key assumptions’ section.
Description of accounting policy for intangible assets other than goodwill [text block]	12 Accounting policies Acquired finite-lived intangible assets are amortized using the straight-line method over their estimated useful life. The useful lives are evaluated annually. Intangible assets are initially capitalized at cost, with the exception of intangible assets acquired as part of a business combination, which are capitalized at their acquisition date fair value. The company expenses all research costs as incurred. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized as an intangible asset if the product or process is technically and commercially feasible, the company has sufficient resources and the intention to complete development and can measure the attributable expenditure reliably. The capitalized development expenditure comprises of all directly attributable costs (including the cost of materials and direct labor). Other development expenditures and expenditures on research activities are recognized in the Consolidated statements of income. Capitalized development expenditure is stated at cost less accumulated amortization and impairment losses. Amortization of capitalized development expenditure is charged to the Consolidated statements of income on a straight-line basis over the estimated useful lives of the intangible assets. The expected useful lives of the intangible assets excluding goodwill are as follows: Philips Group Expected useful lives of intangible assets excluding goodwill in years Brand names 2-20 Customer relationships 2-25 Technology 3-20 Other 1-10 Software 1-10 Product development 3-10 The weighted average expected remaining life of brand names, customer relationships, technology and other intangible assets is 9.3 years as of December 31, 2023 (2022: 9.4 years). Impairment of intangible assets not yet ready for use Intangible assets not yet ready for use are not amortized but are tested for impairment annually and whenever impairment indicators require. In the case of intangible assets not yet ready for use, either internal or external sources of information are considered to assess if there are indicators that an asset or a CGU may be impaired. Impairment of non-financial assets other than goodwill, intangible assets not yet ready for use, inventories and deferred tax assets Non-financial assets other than goodwill, intangible assets not yet ready for use, inventories and deferred tax assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is assessed by a comparison of the carrying amount of an asset with the greater of its value in use and fair value less cost of disposal. Value in use is measured as the present value of future cash flows expected to be generated by the asset. Fair value less cost of disposal is measured as the amount obtained from a sale of an asset in an arm’s length transaction, less costs of disposal. If the carrying amount of an asset is deemed not recoverable, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the recoverable amount. The review for impairment is carried out at the level where cash flows occur that are independent of other cash flows. Impairment losses recognized in prior periods for Intangible assets other than goodwill are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if and to the extent that there has been a change in the estimates used to determine the recoverable amount. The loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Reversals of impairment are recognized in the Consolidated statements of income. Accounting estimates and judgments The cash flow projections used in the value in use calculations for intangible assets excluding goodwill contain various judgments and estimations. For intangible assets excluding goodwill, estimates are required to determine the (remaining) useful lives.
Description of accounting policy for financial assets [text block]	13 Accounting policies Classification and measurement of financial assets The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the company’s business model for managing them. The company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. For the purposes of subsequent measurement, financial assets are classified into four categories: Financial assets at amortized cost (debt instruments). Financial assets at fair value through other comprehensive income (OCI) with recycling of cumulative gains and losses (debt instruments). Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments). Financial assets at fair value through profit or loss (debt instruments and equity instruments). Impairment of financial assets The company recognizes a loss allowance for expected credit losses for trade receivables, contract assets, lease receivables, debt investments carried at amortized cost and fair value through other comprehensive income (FVTOCI). At each balance sheet date, the company assesses whether there is objective evidence that a financial asset or a group of financial assets is impaired and recognizes a loss allowance for expected credit losses for financial assets measured at either amortized costs or at fair value through other comprehensive income. If, at the reporting date, the credit risk on a financial instrument has not increased significantly since initial recognition, the company measures the loss allowance for the financial instrument at an amount equal to 12 months of expected credit losses. If, at the reporting date, the credit risk on a financial instrument has increased significantly since initial recognition, the company measures the loss allowance for the financial instrument at an amount equal to the lifetime-expected credit losses. For all trade receivables, contract assets and lease receivables the company measures the loss allowance at an amount equal to lifetime-expected credit losses. Accounting estimates and judgments The determination of fair value is subject to estimates for investments that are not publicly traded. Refer to Fair value of financial assets and liabilities Financial assets classified at amortized cost and at fair value through OCI are subject to impairment assessment. The calculation of expected credit losses requires the company to apply significant judgment and make estimates and assumptions that involve significant uncertainty at the time they are made. Changes to these estimates and assumptions can result in significant changes to the timing and amount of expected credit losses to be recognized.
Description of accounting policy for other assets [text block]	14 Accounting policies The company recognizes contract assets for revenue earned from installation services because the receipt of consideration is conditional on successful completion of the installation. Upon completion of the installation and acceptance by the customer, the amount recognized as contract assets is reclassified to trade receivables. Other assets are measured at amortized cost minus any impairment losses.
Description of accounting policy for measuring inventories [text block]	15 Accounting policies Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. The costs of conversion of inventories include direct labor and fixed and variable production overheads, considering the stage of completion and the normal capacity of production facilities. Costs of idle facility and abnormal waste are expensed. The cost of inventories is determined using the first-in, first-out (FIFO) method. The write-down of inventories to net realizable value is included in cost of sales. Accounting estimates and judgments Inventory is reduced for the estimated losses due to obsolescence. This reduction is determined for groups of products based on sales in the recent past and/or expected future demand.
Description of accounting policy for trade and other receivables [text block]	16 Accounting policies Receivables are held by the company to collect the related cash flows. These receivables are measured at fair value and subsequently measured at amortized cost minus any impairment losses. Receivables are derecognized when the company has transferred substantially all risks and rewards, which includes transactions in which the company enters into factoring transactions, or if the company does not retain control over the receivables. Accounting estimates Receivables are subject to impairment assessment, which involves estimating expected credit losses. Refer to Other financial assets
Description of accounting policy for issued capital [text block]	17 Accounting policies Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from equity. Where the company repurchases the company’s equity share capital (treasury shares), the consideration paid, including any directly attributable incremental transaction costs (net of income taxes), is deducted from shareholders’ equity until such treasury shares are cancelled or reissued. Where such treasury shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in shareholders’ equity. Call options on own shares are treated as equity instruments. Dividends are recognized as a liability in the period in which they are declared and approved by shareholders. The income tax consequences of dividends are recognized when a liability to pay the dividend is recognized.
Description of accounting policy for borrowings [text block]	18 Accounting policies Debt Debt is initially measured at fair value net of directly attributable transaction costs. Subsequently, debt is measured at amortized cost using the effective interest rate method. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Lease liabilities Lease liabilities are measured at the present value of the lease payments due over the lease term, generally discounted using the incremental borrowing rate. Lease liabilities are subsequently measured at amortized cost using the effective interest method. Lease liabilities are remeasured in case of modifications or reassessments of the lease.
Description of accounting policy for provisions [text block]	19 Accounting policies A provision is a liability of uncertain timing or amount. Provisions are recognized if, as a result of a past event, the company has a present legal or constructive obligation, it is probable that an outflow of economic benefits will be required to settle the obligation and the amount can be estimated reliably. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax discount rate that reflects current market assessments of the time value of money. The increase in the provision due to passage of time (accretion) is recognized as interest expense. Restructuring-related provisions Provisions for severance and termination benefits are recognized for those costs only when the company has a detailed formal plan for the restructuring and has raised a valid expectation with those affected that it will carry out the restructuring by starting to implement that plan or announcing its main features to those affected by it. Before a provision is established, the company recognizes any impairment loss on the assets associated with the restructuring. Accounting estimates and judgments By their nature, the recognition of provisions requires estimates and assumptions regarding the timing and the amount of outflow of resources. The main estimates include: Respironics field-action provision Product warranty provisions Environmental provisions Legal provisions . Contingent consideration provisions
Description of accounting policy for post-employment benefits [text block]	20 Accounting policies Defined contribution plans A defined contribution plan is a post-employment benefit plan for which the company pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an employee benefit expense in the Consolidated statements of income in the periods during which services are rendered by employees. Defined benefit plans A defined benefit plan is a post-employment benefit plan that is not a defined contribution plan. Defined benefit plans define an amount of pension benefit that an employee will receive after retirement. That pension benefit typically depends on several factors such as years of service, age and salary. The net pension asset or liability recognized in the Consolidated balance sheets in respect of defined benefit plans is the fair value of plan assets less the present value of the projected defined benefit obligation at the balance sheet date. The defined benefit obligation is calculated annually by qualified actuaries using the projected unit credit method. Recognized assets are limited to the present value of any reductions in future contributions or any future refunds. The net pension liability is presented as a long-term provision; no distinction is made for the short-term portion. For the company’s major plans, a full discount rate curve of high-quality corporate bonds is used to determine the defined benefit obligation, where available. The curves are based on the Mercer Yield Curve methodology, which uses data of corporate bonds rated AA or equivalent. For the other plans the Mercer Yield Curve/Mercer Methodology has also been used taking into account the cash flows as much as possible in case there is a deep market in corporate bonds. For plans in countries without a deep corporate bond market, the discount rate is based on government bonds and the plan’s maturity. Pension costs in respect of defined benefit plans primarily represent the increase of the actuarial present value of the obligation for post-employment benefits based on employee service during the year and the interest on the net recognized asset or liability in respect of employee service in previous years. Remeasurements of the net defined benefit asset or liability comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (excluding interest). The company recognizes all remeasurements in Other comprehensive income. Past service costs arising from the introduction of a change to the benefit payable under a plan or a significant reduction of the number of employees covered by a plan (curtailment) are recognized in full in the Consolidated statements of income. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. The company recognizes a liability and an expense for bonuses and incentives based on a formula that takes into consideration the profit attributable to the company’s shareholders after certain adjustments. The company’s net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods, such as jubilee entitlements. That benefit is discounted to determine its present value. Remeasurements are recognized in the Consolidated statements of income in the period in which they arise. Further information on other employee benefits can be found in Provisions Accounting estimates and judgments To make the actuarial calculations for the valuation of defined benefit obligations, assumptions are needed for interest rates, healthcare cost increases, future pension increases, life expectancy and employee turnover rates. The actuarial calculations are made by external actuaries based on inputs from observable market data, such as corporate bond returns and yield curves to determine the discount rates to apply, mortality tables to determine life expectancy and inflation rates to determine future salary and pension growth assumptions.
Description of accounting policy for financial liabilities [text block]	21 Accounting policies Accrued liabilities are initially measured at fair value and subsequently at amortized cost and are derecognized when the obligation under the liability is discharged, cancelled or has expired.
Description of accounting policy for other liabilities [text block]	22 Accounting policies Other liabilities are initially measured at fair value and subsequently at amortized cost and are derecognized when the obligation under the liability is discharged, cancelled or has expired. The company recognizes contract liabilities if a payment is received or a payment is due (whichever is earlier) from a customer before the company transfers the related goods or services. Contract liabilities are recognized as revenue when the company performs under the contract (i.e., transfers control of the related goods or services to the customer).
Description of accounting policy for cash flows [text block]	23 Accounting policies Cash and cash equivalents Cash and cash equivalents include all cash balances, certain money market funds and short-term highly liquid investments with an original maturity of three months or less that are readily convertible into known amounts of cash. Bank overdrafts are included in borrowings in current liabilities. Cash flow statements The cash flow statement is prepared using the indirect method. Cash flows related to interest and tax are included in operating activities. Assets and liabilities acquired as part of a business combination are included in investing activities (net of cash acquired). Dividends paid to shareholders are included in financing activities. Dividends received are included in operating activities. Cash flows arising from transactions in a foreign currency are translated into the company’s functional currency using the exchange rate at the date of the cash flow. Cash flows from derivative instruments that are accounted for as cash flow hedges are classified in the same category as the cash flows from the hedged items. Cash flows from other derivative instruments are classified as investing cash flows.
Description of accounting policy for contingent liabilities and contingent assets [text block]	24 Accounting policies Contingent liabilities A contingent liability is a liability of uncertain timing and amount. Contingencies are not recognized in the balance sheet because they are dependent on the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company or because the risk of loss is estimated to be possible but not probable or because the amount cannot be measured reliably. Pursuant to IAS 37, Provisions, Contingent Liabilities and Contingent Assets, certain information is not disclosed for legal proceedings for which the company concludes that disclosure can be expected to seriously prejudice the outcome of the matter. Contingent assets Contingent assets are disclosed if the inflow of economic benefits is probable, but not virtually certain. If the inflow of economic benefits becomes virtually certain, the asset would be considered no longer contingent and its recognition appropriate. Contingent assets are assessed continually and require management to apply judgment, especially to estimate the likelihood of the inflow of economic benefits. Financial guarantees Philips’ policy is to provide guarantees and other letters of support only in writing. Philips does not stand by other forms of support. The company recognizes a liability at the fair value of the obligation at the inception of a financial guarantee contract. The guarantee is subsequently measured at the higher of the best estimate of the obligation or the amount initially recognized less, when appropriate, cumulative amortization. Accounting estimates and judgments Significant judgment is required to determine the likelihood of a potential outflow of resources. In addition, judgment is involved in determining whether the amount of an obligation can be measured with sufficient reliability. Contingencies involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties, governmental actions, tax and environmental remediation.
Description of accounting policy for share-based payment transactions [text block]	26 Accounting policies Philips share-based compensation is an equity-settled plan comprising restricted and performance shares. The restricted shares are subject to a three-year service condition and the performance shares include both market and non-market-based performance conditions, in addition to a three-year service condition. These shares are awarded to the Executive Committee and Senior Management. The grant date fair value of market-based performance shares is determined through a Monte Carlo valuation model. The grant date fair value of non-market-based performance shares and restricted shares is determined as the share price at the grant date as participants receive notional dividends throughout the vesting period. The costs of share-based compensation plans are revised for expected performance (non-market-based performance shares) and forfeiture and are spread evenly over the service period. In 2023, an additional non-recurring retention option grant was issued for certain key employees. This grant has an exercise price that was 15% higher than the share price at grant and will vest in two years and expires ten years after the grant date. The grant date fair value was calculated using the Black-Scholes-Merton option valuation model. Share-based compensation is recognized over the service period as personnel expense in the consolidated statement of income, with a corresponding increase to equity. Accounting estimates and judgments The use of a valuation model to determine market-based performance share fair value requires estimates for the expected volatility of the Philips share price and correlation among input variables. At each reporting date, Philips calculates the expected realization the of non-market-based performance targets and revises the expected share-based compensation expense. The cumulative effect is recorded in the consolidated statement of income with a corresponding adjustment in equity. No expense is recognized for awards that do not ultimately vest because non-market performance and/or service conditions have not been met.
Description of accounting policy for fair value measurement [text block]	28 Accounting policies Fair value hierarchy For financial reporting purposes, financial instruments are categorized into Level 1, 2 or 3, based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are as follows: Level 1 – inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets that the company can access at the measurement date. Level 2 – all significant inputs (other than quoted prices included within Level 1) are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices). Level 3 – one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, for the asset or liability. Transfers between levels of the fair value hierarchy are recognized at the end of the reporting period during which the change has occurred. Offsetting and master netting agreements Financial assets and liabilities are offset and the net amount is reported in the balance sheet when, and only when, the company has currently a legally enforceable right to set-off the amounts and the group intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Accounting estimates and judgments Determining the fair value of financial instruments requires the use of estimates according to the method applied for each type of financial asset of liability. The estimated fair value of financial instruments has been determined by the company using available market information and appropriate valuation methods. The estimates presented are not necessarily indicative of the amounts that will ultimately be realized by the company upon maturity or disposal. The use of different market assumptions and/or estimation methods may have a material effect on the estimated fair value amounts. Specific valuation techniques used to value financial instruments include: Level 1 Instruments included in level 1 are comprised primarily of listed equity investments classified as financial assets carried at fair value through profit or loss or carried at fair value through other comprehensive income. The fair value of financial instruments traded in active markets is based on quoted market prices at the balance sheet date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm’s length basis. Level 2 The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives or convertible bond instruments) is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are based on observable market data, the instrument is included in level 2. The fair value of derivatives is calculated as the present value of the estimated future cash flows based on observable interest yield curves, basis spread and foreign exchange rates. The valuation of convertible bond instruments uses observable market quoted data for the options and present value calculations using observable yield curves for the fair value of the bonds. The fair value of debt is estimated on the basis of the quoted market prices for certain issuances, or on the basis of discounted cash flow analysis using market rates plus Philips’ spread for the particular tenors of the borrowing arrangement. Accrued interest is not included within the carrying amount or estimated fair value of debt. Level 3 If one or more of the significant inputs are not based on observable market data, such as third-party pricing information without adjustments, the instrument is included in level 3. The fair value of contingent consideration is dependent on the terms of the respective acquisition agreement that may require Philips to pay additional consideration to former shareholders if specified future events occur or conditions are met, such as the achievement of certain regulatory milestones or the achievement of certain commercial milestones. The fair value of the contingent consideration provision is generally determined using a probability-weighted and a risk-adjusted approach to estimate the achievement of future regulatory and commercial milestones, respectively. The discount rates used in the risk adjusted approach reflect the inherent risk related to achieving the commercial milestones. Both regulatory and commercial milestones are discounted for the time value of money at risk-free rates. The fair value measurement is based on management’s estimates and assumptions and hence classified as Level 3 in the fair value hierarchy.
Description of accounting policy for derivative financial instruments and hedging [text block]	29 Accounting policies Derivative financial instruments, including hedge accounting The company uses derivative financial instruments principally to manage its foreign currency risks and, to a more limited extent, interest rate and commodity price risks. All derivative financial instruments are accounted for at the trade date and classified as current or non-current assets or liabilities based on the maturity date or the early termination date. The company measures all derivative financial instruments at fair value that is derived from the market prices of the instruments, calculated on the basis of the present value of the estimated future cash flows based on observable interest yield curves, basis spread, credit spreads and foreign exchange rates, or derived from option pricing models, as appropriate. Gains or losses arising from changes in fair value of derivatives are recognized in the Consolidated statements of income, except for derivatives that are highly effective and qualify for cash flow or net investment hedge accounting. Changes in the fair value of foreign exchange forward contracts attributable to forward points and changes in the time value of the option contracts are deferred in the cash flow hedges reserve within equity. The deferred amounts are recognized in the Consolidated statements of income against the related hedged transaction when it occurs. Changes in the fair value of a derivative that is highly effective and that is designated and qualifies as a cash flow hedge are recorded in OCI until the Consolidated statements of income are affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffective, changes in the fair value are recognized in the Consolidated statements of income. The company formally assesses, both at the hedge’s inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. When it is established that a derivative is not highly effective as a hedge or that it has ceased to be a highly effective hedge, the company discontinues hedge accounting prospectively. When hedge accounting is discontinued because it is expected that a forecasted transaction will not occur, the company continues to carry the derivative on the Consolidated balance sheets at its fair value, and gains and losses that were accumulated in OCI are recognized immediately in the same line item as they relate to in the Consolidated statements of income. Foreign currency differences arising upon retranslation of financial instruments designated as a hedge of a net investment in a foreign operation are recognized directly in the currency translation differences reserve through OCI, to the extent that the hedge is effective. To the extent that the hedge is ineffective, such differences are recognized in the Consolidated statements of income. Accounting estimates and judgments Financial assets are subject to impairment assessment, which involves estimating expected credit losses. Refer to Other financial assets

Information by segment and ma_2

Information by segment and main country (Tables)	12 Months Ended
	Dec. 31, 2023
Information by segment and main country [Abstract]
Information by segment and main country - Information on income statements [Text Block]	Philips Group Information on income statements in millions of EUR sales sales including intercompany depreciation and amortization 1 ) Adjusted EBITA 2023 Diagnosis & Treatment 8,818 9,253 (306) 1,026 Connected Care 5,138 5,149 (445) 369 Personal Health 3,602 3,685 (115) 597 Other 612 428 (394) (71) Inter-segment eliminations (346) Philips Group 18,169 18,169 (1,261) 1,921 2022 Diagnosis & Treatment 8,290 8,576 (417) 788 Connected Care 5,268 5,280 (646) 111 Personal Health 3,626 3,684 (132) 538 Other 643 736 (407) (119) Inter-segment eliminations (449) Philips Group 17,827 17,827 (1,602) 1,318 2021 Diagnosis & Treatment 7,825 8,023 (363) 1,028 Connected Care 5,371 5,388 (472) 553 Personal Health 3,429 3,462 (131) 590 Other 530 636 (357) (117) Inter-segment eliminations (353) Philips Group 17,156 17,156 (1,323) 2,054 1 ) Includes impairments (excluding goodwill impairment); for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill
Information by segment and main country - Reconciliation from net income to Adjusted EBITA [Text Block]	Philips Group Reconciliation from net income to Adjusted EBITA In millions of EUR Philips Group Diagnosis & Treatment Connected Care Personal Health Other 2023 Net Income (463) Discontinued operations, net of income taxes 10 Income taxes (73) Investments in associates, net of income taxes 98 Financial expenses 376 Financial income (63) Income from operations (115) 720 (1,199) 552 (188) Amortization and impairment of acquired intangible assets 290 89 178 14 9 Impairment of goodwill 8 8 - EBITA 183 816 (1,020) 567 (179) Restructuring and acquisition-related charges 381 118 115 9 140 Other items: 1,358 92 1,275 22 (32) Respironics litigation provision 575 575 Respironics field-action connected to the proposed consent decree 363 363 Respironics field-action running remediation costs 224 224 Quality remediation actions 175 81 94 Provision for a legal matter 31 31 Investment re-measurement loss 23 23 Gain on divestment of business (35) (35) Remaining items 2 11 (12) (1) 3 Adjusted EBITA 1,921 1,026 369 597 (71) Philips Group Reconciliation from net income to Adjusted EBITA In millions of EUR Philips Group Diagnosis & Treatment Connected Care Personal Health Other 2022 Net Income (1,605) Discontinued operations, net of income taxes (13) Income taxes (113) Investments in associates, net of income taxes 2 Financial expenses 258 Financial income (58) Income from operations (1,529) 538 (2,347) 515 (235) Amortization and impairment of acquired intangible assets 363 115 226 15 8 Impairment of goodwill 1,357 1,357 EBITA 192 652 (764) 531 (227) Restructuring and acquisition-related charges 202 3 125 11 62 Other items: 925 133 750 (4) 46 Respironics field-action connected to the proposed consent decree 250 250 Respironics field-action running remediation costs 210 210 R&D project impairments 134 73 59 3 Portfolio realignment charges 109 109 Provision for public investigations tender irregularities 60 60 Quality remediation actions 59 59 Impairments of assets in S&RC 39 39 Remaining items 63 - 24 (6) 46 Adjusted EBITA 1,318 788 111 538 (119) Philips Group Reconciliation from net income to Adjusted EBITA In millions of EUR Philips Group Diagnosis & Treatment Connected Care Personal Health Other 2021 Net Income 3,323 Discontinued operations, net of income taxes (2,711) Income taxes (103) Investments in associates, net of income taxes 4 Financial expenses 188 Financial income (149) Income from operations 553 948 (716) 576 (255) Amortization and impairment of acquired intangible assets 322 142 158 15 6 Impairment of goodwill 15 2 13 EBITA 890 1,092 (545) 591 (248) Restructuring and acquisition-related charges 95 (30) 130 (1) (5) Other items: 1,069 (35) 968 - 136 Respironics field-action connected to the proposed consent decree 719 719 Respironics field-action running remediation costs 94 94 Quality remediation actions 94 94 Loss on divestment of business 76 76 Remaining items 87 (35) 61 - 61 Adjusted EBITA 2,054 1,028 553 590 (117)
Information by segment and main country - Main countries [Text Block]	Philips Group Main countries in millions of EUR sales 1 ) tangible and intangible assets 2 ) 2023 Netherlands 2,390 1,624 United States 7,178 11,410 China 1,408 234 Japan 941 407 Germany 573 348 Other countries 5,679 1,527 Total main countries 18,169 15,550 2022 Netherlands 2,021 1,746 United States 7,226 12,087 China 1,239 260 Japan 1,011 436 Germany 642 323 Other countries 5,688 1,550 Total main countries 17,827 16,402 2021 Netherlands 1,860 1,934 United States 6,403 12,615 China 1,400 258 Japan 1,068 480 Germany 970 305 France 446 49 India 431 85 United Kingdom 426 567 Other countries 4,150 693 Total main countries 17,156 16,986 1 ) To better align with the Country Activity and Tax reporting, the allocation of country-level sales was revised from country of destination to country of origin. Comparative information in this table has been restated to be consistent with the current-period presentation. 2 ) Consists of Property plant and equipment, Intangible assets excluding goodwill and Goodwill

Discontinued operations and a_2

Discontinued operations and assets classified as held for sale (Tables)	12 Months Ended
	Dec. 31, 2023
Discontinued operations and assets classified as held for sale [Abstract]
Discontinued operations and assets classified as held for sale - Discontinued operations, net of income taxes [Text Block]	Philips Group Discontinued operations, net of income taxes in millions of EUR 2021 2022 2023 Domestic Appliances 2,698 3 (2) Other 13 10 (7) Discontinued operations, net of income taxes 2,711 13 (10)
Discontinued operations and assets classified as held for sale - Results of Domestic Appliances [Text Block]	Philips Group Results of Domestic Appliances in millions of EUR 2021 2022 2023 Sales 1,516 6 - Costs and expenses (1,322) (2) (2) Income from operations 194 4 (2) Result on the sale of discontinued operations 3,241 1 (1) Income before tax 3,435 5 (3) Income tax benefit (expense) 1 ) 6 (2) 1 Income tax related the sale of discontinued operations (743) Results from discontinued operations 2,698 3 (2) 1 ) The income tax of discontinued operations is calculated based on the separate return method, as if Domestic Appliances was filing its own separate tax returns.
Discontinued operations and assets classified as held for sale - Net cash provided by (used for) discontinued operations [Text Block]	Net cash provided by (used for) discontinued operations in millions of EUR 2021 2022 2023 Net cash provided by (used for) operating activities 85 (27) 123 Net cash provided by (used for) investing activities 3,319 15 Net cash provided by (used for) discontinued operations 3,403 (12) 123

Acquisitions and divestments (T

Acquisitions and divestments (Tables)	12 Months Ended
	Dec. 31, 2023
Acquisitions and divestments [Abstract]
Acquisitions and divestments - Opening balance sheet [Text Block]	Opening balance sheet in millions of EUR At acquisition date Vesper Medical Inc, Assets Intangible assets excluding goodwill 84 Deferred tax assets 15 Cash 7 Total Assets 106 Liabilities Accounts payable and other payables (1) Deferred tax liabilities (20) Total Liabilities (21) Total identifiable net assets at fair value 85 Goodwill arising on acquisition 177 Total purchase consideration 262 Of which: Purchase consideration transferred 227 Contingent consideration 34

Interests in entities (Tables)

Interests in entities (Tables)	12 Months Ended
	Dec. 31, 2023
Interests in entities [Abstract]
Interests in entities - Interests in group companies [Text Block]	Philips Group Interests in group companies in alphabetical order by country 2023 Legal entity name Principal country of business Philips (China) Investment Company, Ltd. China Philips Medizin Systeme Böblingen GmbH Germany 1 ) Philips Japan, Ltd. Japan Philips Consumer Lifestyle B.V. Netherlands Philips Medical Systems (Cleveland), Inc. United States ATL International LLC United States Philips North America LLC United States Philips RS North America LLC United States 1 ) Application of Sec. 264 (3) and Sec. 264b HGB (German Commercial Code) for fully consolidated legal entities: Philips GmbH, Hamburg; Philips Medical Systems DMC GmbH, Hamburg; Respironics Deutschland GmbH & Co. KG, München; Philips Medizin Systeme Hofheim-Wallau GmbH, Hamburg; Philips Medizin Systeme Böblingen GmbH, Böblingen; TomTec Imaging Systems GmbH, Unterschleißheim; Forecare GmbH, Ratingen.

Income from operations (Tables)

Income from operations (Tables)	12 Months Ended
	Dec. 31, 2023
Income from operations [Abstract]
Income from operations - Sales and costs by nature [Text Block]	Philips Group Sales and costs by nature in millions of EUR 2021 2022 2023 Sales 17,156 17,827 18,169 Costs of materials used (4,142) (4,320) (4,626) Employee benefit expenses (6,246) (6,952) (6,903) Depreciation and amortization 1 ) (1,323) (1,602) (1,261) Impairment of goodwill (15) (1,357) (8) Shipping and handling (645) (756) (668) Advertising and promotion (752) (739) (700) Lease expenses (19) (39) (51) Other operational costs (3,524) (3,609) (3,535) Other business income (expenses) 63 18 (533) Income from operations 553 (1,529) (115) 1 ) Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill
Income from operations - Sales composition [Text Block]	Philips Group Sales composition in millions of EUR 2021 2022 2023 Goods 11,981 12,139 12,419 Services 4,374 4,878 4,926 Royalties 383 419 434 Total sales from contracts with customers 16,738 17,435 17,779 Sales from other sources 418 391 390 Total sales 17,156 17,827 18,169
Income from operations - Disaggregation of Sales per segment [Text Block]	Philips Group Disaggregation of Sales per segment in millions of EUR 2023 Sales at a Sales Total sales from Sales from Total Diagnosis & Treatment 5,762 2,978 8,742 76 8,818 Connected Care 2,970 1,854 4,824 314 5,138 Personal Health 3,586 16 3,602 3,602 Other 251 361 612 - 612 Philips Group 12,569 5,210 17,779 390 18,169 Philips Group Disaggregation of Sales per segment in millions of EUR 2022 Sales at a Sales Total sales from Sales from Total Diagnosis & Treatment 5,285 2,950 8,234 55 8,290 Connected Care 3,079 1,853 4,932 336 5,268 Personal Health 3,615 11 3,626 3,626 Other 284 357 643 - 643 Philips Group 12,263 5,172 17,435 391 17,827 Philips Group Disaggregation of Sales per segment in millions of EUR 2021 Sales at a Sales Total sales from Sales from Total Diagnosis & Treatment 5,120 2,656 7,776 50 7,825 Connected Care 3,399 1,604 5,002 369 5,371 Personal Health 3,423 6 3,429 3,429 Other 200 330 530 - 530 Philips Group 12,142 4,596 16,738 418 17,156
Income from operations - Disaggregation of Sales per geographic area [Text Block]	Philips Group Disaggregation of Sales per geographic area in millions of EUR 2023 Sales at a Sales Total sales from Sales from Total Western Europe 2,552 1,221 3,770 49 3,819 North America 4,859 2,608 7,470 92 7,562 Other mature geographies 980 398 1,378 248 1,626 Mature geographies 8,392 4,227 12,618 389 13,007 Growth geographies 4,177 984 5,161 1 5,162 Sales 12,569 5,210 17,779 390 18,169 Philips Group Disaggregation of Sales per geographic area in millions of EUR 2022 Sales at a Sales Total sales from Sales from Total Western Europe 2,387 1,183 3,572 31 3,603 North America 4,889 2,612 7,502 86 7,588 Other mature geographies 972 399 1,369 274 1,643 Mature geographies 8,248 4,194 12,443 390 12,833 Growth geographies 4,015 978 4,992 1 4,993 Sales 12,263 5,172 17,435 391 17,827 Philips Group Disaggregation of Sales per geographic area in millions of EUR 2021 Sales at a Sales Total sales from Sales from Total Western Europe 2,537 1,087 3,624 21 3,645 North America 4,427 2,268 6,695 86 6,781 Other mature geographies 1,000 386 1,386 309 1,694 Mature geographies 7,964 3,741 11,705 415 12,120 Growth geographies 4,178 856 5,033 3 5,036 Sales 12,142 4,596 16,738 418 17,156
Income from operations - Employee benefit expenses [Text Block]	Philips Group Employee benefit expenses in millions of EUR 2021 2022 2023 Salaries and wages excluding share-based compensation 5,014 5,594 5,635 Share-based compensation 115 104 97 Post-employment benefit costs 396 439 402 Other social security and similar charges: Required by law 529 590 567 Voluntary 192 225 202 Employee benefit expenses 6,246 6,952 6,903
Income from operations - Employees by category [Text Block]	Philips Group Employees by category in FTEs 2021 2022 2023 Production 38,618 39,742 35,281 Research & development 10,751 11,690 10,833 Other 22,543 23,019 23,001 Employees 71,912 74,451 69,115 Third party workers 4,533 4,086 3,149 Philips Group 76,445 78,538 72,264
Income from operations - Employees by geographical location [Text Block]	Philips Group Employees by geographical location in FTEs 2021 2022 2023 Netherlands 11,142 11,180 9,794 Other countries 65,303 67,357 62,471 Philips Group 76,445 78,538 72,264
Income from operations - Depreciation and amortization [Text Block]	Philips Group Depreciation and amortization 1 ) in millions of EUR 2021 2022 2023 Depreciation of property, plant and equipment 630 711 689 Amortization of software 88 117 98 Amortization of other intangible assets 322 363 290 Amortization of development costs 284 411 184 Depreciation and amortization 1,323 1,602 1,261 1 ) Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill
Income from operations - Audit and audit-related fees [Text Block]	Philips Group Audit and audit-related fees in millions of EUR 2021 2022 2023 EY NL 1 ) EY Network Total EY NL 1 ) EY Network Total EY NL 1 ) EY Network Total Audit fees 10.3 5.4 15.7 9.5 5.6 15.2 9.7 5.1 14.7 consolidated financial statements 10.3 2.7 13.0 9.5 3.1 12.6 9.7 2.6 12.3 statutory financial statements 2.7 2.7 2.5 2.5 2.5 2.5 Audit-related fees 2 ) 0.6 0.3 0.9 0.8 0.2 1.0 0.9 0.2 1.0 divestment sustainability assurance 0.5 0.5 0.6 0.6 0.8 0.8 other 0.1 0.3 0.4 0.1 0.2 0.3 0.1 0.2 0.3 Tax fees - - All other fees Fees 10.9 5.7 16.6 10.3 5.8 16.2 10.6 5.2 15.8 1 ) Ernst & Young Accountants LLP 2 ) Also known as Assurance fees
Income from operations - Other business income (expenses) [Text Block]	Philips Group Other business income (expenses) in millions of EUR 2021 2022 2023 Result on disposal of businesses: income - 4 50 expenses (75) - - Result on disposal of fixed assets: income 24 3 12 expenses (5) (1) (1) Result on other remaining businesses: income 161 121 49 expenses (43) (109) (643) Other business income (expenses) 63 18 (533) Total other business income 186 127 112 Total other business expenses (123) (109) (645)

Financial income and expenses (

Financial income and expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Financial income and expenses [Abstract]
Financial income and expenses - Financial income and expenses [Text Block]	Philips Group Financial income and expenses in millions of EUR 2021 2022 2023 Interest income 18 25 46 Interest income from loans and receivables 7 7 13 Interest income from cash and cash equivalents 11 18 33 Dividend income from financial assets 2 3 2 Net gains from disposal of financial assets - - - Net change in fair value of financial assets through profit or loss 95 9 Other financial income 33 20 15 Financial income 149 58 63 Interest expense (159) (235) (277) Interest expense on debt and borrowings (126) (200) (229) Finance charges under lease contract (25) (25) (27) Interest expense on pensions (8) (10) (21) Provision-related accretion expenses (5) (9) (29) Net foreign exchange gains (losses) - 9 (23) Net change in fair value of financial assets through profit or loss (26) Other financial expenses (24) (24) (21) Financial expenses (188) (258) (376) Financial income and expenses, net (39) (200) (314)

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income taxes [Abstract]
Income taxes - Income tax expense [Text Block]	Philips Group Income tax expense in millions of EUR 2021 2022 2023 Income before taxes 509 (1,731) (526) Investments in associates, net of income taxes (4) (2) (98) Income before taxes and Investment in associates 513 (1,729) (429) Current tax (expense) benefit (298) (97) (201) Deferred tax (expense) benefit 401 210 274 Income tax (expense) benefit of continuing operations 103 113 73
Income taxes - Current income tax expense [Text Block]	Philips Group Current income tax expense in millions of EUR 2021 2022 2023 Current year tax (expense) benefit (291) (111) (211) Prior year tax (expense) benefit (7) 14 10 Current tax (expense) benefit (298) (97) (201)
Income taxes - Deferred income tax expense [Text Block]	Philips Group Deferred income tax expense In millions of EUR 2021 2022 2023 Recognition of previously unrecognized tax loss and credit carryforwards 138 2 72 Unrecognized tax loss and credit carryforwards (10) (13) (41) Changes to recognition of temporary differences (1) (4) (112) Prior year tax (expense) benefit 20 (1) (2) Tax rate changes 10 (18) 4 Origination and reversal of temporary differences, tax losses and tax credits 245 244 353 Deferred tax (expense) benefit 401 210 274
Income taxes - Effective income tax rate [Text Block]	Philips Group Effective income tax rate in % 2021 2022 2023 Weighted average statutory income tax rate in % 22.7 23.6 22.0 Recognition of previously unrecognized tax loss and credit carryforwards (26.9) 0.1 16.8 Unrecognized tax loss and credit carryforwards 1.9 (0.7) (9.6) Changes to recognition of temporary differences 0.3 (0.2) (26.2) Non-taxable income and tax incentives (40.6) 5.8 22.8 Non-deductible expenses 19.3 (22.9) (10.7) Withholding and other taxes 7.2 (1.4) (5.1) Tax rate changes (1.9) (1.0) 0.9 Prior year tax (2.4) 0.7 1.9 Tax expense (benefit) due to change in uncertain tax treatments 4.4 2.8 2.3 Others, net (4.0) (0.2) 1.9 Effective income tax rate (20.0) 6.5 17.0
Income taxes - Deferred tax assets and liabilities [Text Block]	Philips Group Deferred tax assets and liabilities in millions of EUR Balance as of January 1, 2023 recognized in income statement other 1 ) Balance as of December 31, 2023 Assets Liabilities Intangible assets 630 61 (12) 679 826 (147) Property, plant and equipment (2) 18 (103) (88) 44 (132) Inventories 464 (26) (78) 360 363 (2) Other assets 44 20 120 184 233 (48) Pensions and other employee benefits 153 69 (29) 193 204 (11) Other liabilities 483 (56) 69 496 521 (25) Deferred tax assets on tax loss carryforwards 586 188 (44) 730 730 Set-off deferred tax positions (294) 294 Net deferred tax assets 2,358 274 (77) 2,556 2,627 (71) 1 ) Other includes the movements of assets and liabilities recognized in equity and OCI, which includes foreign currency translation differences, acquisitions and divestments. Philips Group Deferred tax assets and liabilities in millions of EUR Balance as of January 1, 2022 recognized in income statement other 1 ) Balance as of December 31, 2022 Assets Liabilities Intangible assets 587 63 (20) 630 783 (152) Property, plant and equipment 29 (33) 2 (2) 49 (52) Inventories 372 75 17 464 473 (8) Other assets 68 (16) (8) 44 98 (55) Pensions and other employee benefits 180 6 (32) 153 175 (22) Other liabilities 499 (34) 17 483 560 (77) Deferred tax assets on tax loss carryforwards 398 149 38 586 586 Set-off deferred tax positions (275) 275 Net deferred tax assets 2,134 210 14 2,358 2,449 (91) 1 ) Other includes the movements of assets and liabilities recognized in equity and OCI, which includes foreign currency translation differences, acquisitions and divestments.
Income taxes - Expiry years of net operating loss and credit carryforwards [Text Block]	Philips Group Expiry years of net operating loss and credit carryforwards in millions of EUR Total Unrecognized Total Unrecognized Within 1 year 4 3 17 15 1 to 2 years 10 5 20 16 2 to 3 years 9 3 7 2 3 to 4 years 13 4 9 5 4 to 5 years 38 3 38 16 Later 812 93 808 81 Unlimited 2,301 920 2,997 1,231 Total 3,187 1,032 3,896 1,366

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings per share [Abstract]
Earnings per share - Earnings per share [Text Block]	Philips Group Earnings per share in millions of EUR unless otherwise stated 1 ) 2021 2022 2023 Income from continuing operations 612 (1,618) (454) Income from continuing operations attributable to shareholders 608 (1,622) (456) Income from continuing operations attributable to non-controlling interests 4 3 2 Income from discontinued operations 2,711 13 (10) Income from discontinued operations attributable to shareholders 2,711 13 (10) Net income 3,323 (1,605) (463) Net income attributable to shareholders 3,319 (1,608) (466) Net income attributable to non-controlling interests 4 3 2 Weighted average number of common shares outstanding (after deduction of treasury shares) during the period 943,606,613 920,950,800 917,440,090 Plus incremental shares from assumed conversions of: Share options 387,125 25,506 Performance shares 2,548,891 1,147,790 2,623,097 Restricted shares 2,376,736 1,986,538 2,574,738 Forward contracts to repurchase shares 70,329 17,611,920 15,511,844 Dilutive potential common shares 2 ) 5,383,080 20,771,753 20,709,680 Diluted weighted average number of shares outstanding (after deduction of treasury shares) during the period 948,989,692 920,950,800 917,440,090 Basic earnings per common share in EUR Income from continuing operations attributable to shareholders 0.64 (1.76) (0.50) Income from discontinued operations attributable to shareholders 2.87 0.01 (0.01) Net income attributable to shareholders 3.52 (1.75) (0.51) Diluted earnings per common share in EUR 2 ) Income from continuing operations attributable to shareholders 0.64 (1.76) (0.50) Income from discontinued operations attributable to shareholders 2.86 0.01 (0.01) Net income attributable to shareholders 3.50 (1.75) (0.51) Dividend distributed per common share in EUR 0.85 0.85 0.85 1 ) Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. 2 ) The dilutive potential common shares are not taken into account in the periods for which there is a loss, as the effect would be antidilutive

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, plant and equipment [Abstract]
Property, plant and equipment - Useful lives of property, plant and equipment [Text Block]	Philips Group Useful lives of property, plant and equipment Buildings from 5 to 50 years Machinery and installations from 3 to 20 years Other equipment from 1 to 10 years
Property, plant and equipment - Property, plant and equipment [Text Block]	Philips Group Property, plant and equipment in millions of EUR 2022 2023 Owned assets 1,718 1,565 Right-of-use assets 919 919 Total 2,638 2,483
Property, plant and equipment - Property, plant and equipment - owned assets [Text Block]	Philips Group Property, plant and equipment - owned assets in millions of EUR Land and Machinery and installations Other Assets under construction Total Balance as of Cost 1,135 1,779 1,454 309 4,676 Accumulated depreciation (621) (1,291) (1,046) (2,958) Book value 514 488 408 309 1,718 Additions 1 115 77 239 433 Assets available for use 20 90 144 (262) (8) Depreciation (56) (196) (167) (420) Impairments (5) (23) (17) - (45) Transfer (to) from AHFS (1) (1) (45) (46) Reclassifications 15 2 (17) (5) (6) Translation differences and other (14) (22) (19) (7) (62) Total change (39) (35) (45) (35) (154) Balance as of Cost 1,114 1,731 1,404 274 4,521 Accumulated depreciation (638) (1,278) (1,041) (2,957) Book value 476 453 363 274 1,565 Philips Group Property, plant and equipment - owned assets in millions of EUR Land and Machinery and installations Other Assets under construction Total Balance as of Cost 1,097 1,585 1,382 208 4,273 Accumulated depreciation (591) (1,074) (967) (2,632) Book value 506 511 415 208 1,641 Additions 1 102 77 314 494 Assets available for use 34 69 111 (220) (6) Depreciation (56) (215) (176) - (447) Impairments (3) (20) (18) (1) (42) Transfer (to) from AHFS (3) - (3) Reclassifications 18 14 (5) 2 29 Translation differences and other 16 26 2 5 50 Total change 8 (23) (8) 100 78 Balance as of Cost 1,135 1,779 1,454 309 4,676 Accumulated depreciation (621) (1,291) (1,046) (2,958) Book value 514 488 408 309 1,718
Property, plant and equipment - Property, plant and equipment - right-of-use assets [Text Block]	Philips Group Property, plant and equipment - right-of-use assets in millions of EUR Land and Other Total Balance as of January 1, 2023 Cost 1,365 206 1,571 Accumulated depreciation (543) (108) (651) Book value 822 98 919 Additions 175 62 236 Assets available for use 2 6 8 Depreciation (150) (51) (201) Impairments (23) - (23) Transfer (to) from AHFS (2) (2) Reclassifications - 4 4 Translation differences and other (18) (5) (23) Total change (16) 15 (1) Balance as of December 31, 2023 Cost 1,425 216 1,641 Accumulated depreciation (619) (104) (722) Book value 806 112 919 Philips Group Property, plant and equipment - right-of-use assets in millions of EUR Land and Machinery and Other Total Balance as of January 1, 2022 Cost 1,332 176 216 1,724 Accumulated depreciation (418) (139) (109) (666) Book value 914 37 107 1,058 Additions 52 - 54 106 Assets available for use 5 1 6 Depreciation (155) (2) (58) (214) Impairments (8) - - (9) Transfer (to) from AHFS 3 3 Reclassifications (19) (13) - (32) Translation differences and other 31 (23) (6) 1 Total change (92) (37) (9) (139) Balance as of December 31, 2022 Cost 1,365 - 206 1,571 Accumulated depreciation (543) (108) (651) Book value 822 - 98 919

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill [Abstract]
Goodwill - Goodwill [Text Block]	Philips Group Goodwill in millions of EUR 2022 2023 Balance as of January 1 Cost 11,793 12,747 Impairments (1,156) (2,509) Book value 10,637 10,238 Acquisitions 1 ) 317 24 Impairments (1,357) (8) Divestments and transfers to assets classified as held for sale 2 ) (8) Translation differences and other 641 (370) Total change (399) (362) Balance as of December 31 Cost 12,747 12,133 Impairments (2,509) (2,256) Book value 10,238 9,876 1 ) Refer to Acquisitions and divestments 2 ) Refer to Discontinued operations and assets classified as held for sale
Goodwill - Goodwill by business [Text Block]	Philips Group Goodwill by business in millions of EUR 2022 2023 Monitoring 1 ) 4,110 3,964 Image-Guided Therapy 3,154 3,044 Precision Diagnosis 1,429 1,363 Sleep & Respiratory Care 731 687 Personal Health 488 483 Enterprise Informatics 327 336 Book value 10,238 9,876 1 ) Monitoring includes the goodwill previously allocated to Hospital Patient Monitoring and Ambulatory Monitoring & Diagnostics as disclosed in the Annual Report 2022.
Goodwill - Key assumptions [Text Block]	Philips Group Key assumptions 2023 compound sales growth rate initial forecast period extrapolation period used to calculate terminal value pre-tax discount rates Monitoring 8.2% 5.5% 2.5% 9.5% Image-Guided Therapy 7.9% 5.2% 2.5% 10.7% Precision Diagnosis 3.8% 3.4% 2.5% 10.4% Sleep & Respiratory Care 9.5% 9.3% 2.5% 10.8% Personal Health 5.0% 4.6% 2.5% 10.3% Enterprise Informatics 5.3% 5.8% 2.5% 9.0% Philips Group Key assumptions 2022 compound sales growth rate initial forecast period extrapolation period used to calculate terminal value pre-tax discount rates Ambulatory Monitoring & Diagnostics 1 ) 15.4% 9.5% 2.5% 8.5% Hospital Patient Monitoring 1 ) 4.8% 3.4% 2.5% 8.5% Image-Guided Therapy 8.7% 5.0% 2.5% 10.6% Sleep & Respiratory Care 10.0% 5.0% 2.5% 9.9% 1 ) Effective April 1, 2023, the Hospital Patient Monitoring and Ambulatory Monitoring & Diagnostics CGUs are included in the group of CGUs that comprise the Monitoring business.

Intangible assets excluding g_2

Intangible assets excluding goodwill (Tables)	12 Months Ended
	Dec. 31, 2023
Intangible assets excluding goodwill [Abstract]
Intangible assets excluding goodwill - Expected useful lives of intangible assets excluding goodwill [Text Block]	Philips Group Expected useful lives of intangible assets excluding goodwill in years Brand names 2-20 Customer relationships 2-25 Technology 3-20 Other 1-10 Software 1-10 Product development 3-10
Intangible assets excluding goodwill - Intangible assets excluding goodwill [Text Block]	Philips Group Intangible assets excluding goodwill in millions of EUR brand names customer relationships technology product development product development construction in progress software other total Balance as of January 1, 2023 Cost 647 2,735 2,947 2,605 648 869 152 10,602 Amortization / impairments (507) (1,665) (1,845) (2,212) (146) (589) (113) (7,077) Book value 140 1,070 1,102 393 502 280 39 3,526 Additions 33 - 214 70 - 317 Assets available for use 157 (157) Acquisitions 40 - - 40 Amortization (20) (137) (131) (169) (97) (1) (556) Impairments - - - (7) (7) (1) - (16) Transfers to assets classified as held for sale (1) (20) (8) (2) (32) Translation differences and other (1) (37) (30) (38) 1 18 - (87) Total change (22) (195) (89) (57) 42 (13) (1) (335) Balance as of December 31, 2023 Cost 629 2,593 2,908 2,432 635 929 139 10,265 Amortization / impairments (511) (1,718) (1,895) (2,096) (91) (662) (101) (7,075) Book Value 118 875 1,013 336 544 267 38 3,190 Philips Group Intangible assets excluding goodwill in millions of EUR brand names customer relationships technology product development product development construction in progress software other total Balance as of January 1, 2022 Cost 644 2,590 2,605 2,701 505 754 146 9,944 Amortization / impairments (481) (1,447) (1,605) (2,102) (91) (467) (101) (6,294) Book value 162 1,143 1,000 599 414 287 44 3,650 Additions (3) - 51 - 257 109 1 416 Assets available for use 118 (118) - - - Acquisitions 1 3 177 - - - 180 Amortization (24) (141) (140) (206) (1) (100) (3) (614) Impairments - (6) (46) (123) (81) (17) (2) (276) Translation differences and other 4 71 59 5 31 1 (2) 169 Total change (22) (74) 102 (206) 88 (7) (6) (125) Balance as of December 31, 2022 Cost 647 2,735 2,947 2,605 648 869 152 10,602 Amortization / impairments (507) (1,665) (1,845) (2,212) (146) (589) (113) (7,077) Book Value 140 1,070 1,102 393 502 280 39 3,526

Other financial assets (Tables)

Other financial assets (Tables)	12 Months Ended
	Dec. 31, 2023
Other financial assets [Abstract]
Other financial assets - Other non-current financial assets [Text Block]	Philips Group Other non-current financial assets in millions of EUR Non-current financial assets at FVTP&L Non-current financial assets at FVTOCI Non-current financial assets at Amortized cost Total Balance as of January 1, 2023 322 284 54 660 Changes: Acquisitions/additions 71 14 20 105 Sales/redemptions/reductions (33) (14) (11) (58) Impairments Value adjustment through OCI - (17) (17) Value adjustment through P&L (39) - (39) Translation differences and other (29) (14) (1) (44) Reclassifications (8) 5 15 12 Balance as of December 31, 2023 284 258 77 619 Philips Group Other non-current financial assets in millions of EUR Non-current financial assets at FVTP&L Non-current financial assets at FVTOCI Non-current financial assets at Amortized cost Total Balance as of January 1, 2022 283 300 47 630 Changes: Acquisitions/additions 114 18 18 150 Sales/redemptions/reductions (75) (3) (8) (86) Impairments (3) (1) (5) Value adjustment through OCI - (35) (35) Value adjustment through P&L 5 - 5 Translation differences and other (2) 5 (1) 2 Reclassifications 1 (2) (1) (2) Balance as of December 31, 2022 322 284 54 660

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
Inventories - Inventories [Text Block]	Philips Group Inventories in millions of EUR 2022 2023 Raw materials and supplies 1,541 1,309 Work in process 648 552 Finished goods 1,860 1,629 Inventories 4,049 3,491

Receivables (Tables)

Receivables (Tables)	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Receivables - Trade accounts receivable, net [Text Block]	Philips Group Trade accounts receivable, net in millions of EUR 2022 2023 Diagnosis & Treatment 1,795 1,688 Connected Care 1,332 1,105 Personal Health 479 576 Other 226 177 Trade accounts receivable, net 3,832 3,546
Receivables - Aging analysis [Text Block]	Philips Group Aging analysis in millions of EUR 2022 2023 Current 3,280 3,132 Overdue 1-30 days 169 117 Overdue 31-180 days 282 234 Overdue more than 180 days 101 63 Trade accounts receivable, net 3,832 3,546
Receivables - Allowance for accounts receivable [Text Block]	Philips Group Allowance for accounts receivable in millions of EUR 2022 2023 Balance as of January 1 190 226 Additions charged to expense 66 27 Deductions from allowance 1 ) (51) (26) Transfer to assets held for sale (1) Other movements 21 (10) Balance as of December 31 226 216 1 ) Write-offs for which an allowance was previously provided.

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Equity - Outstanding number of shares [Text Block]	Philips Group Outstanding number of shares 2021 2022 2023 Balance as of January 1 905,128,293 870,182,445 881,480,527 Dividend distributed 6,345,968 14,174,568 39,334,938 Purchase of treasury shares (45,486,392) (5,080,693) (15,964,445) Delivery of treasury shares 4,194,577 2,204,207 1,552,136 Balance as of December 31 870,182,445 881,480,527 906,403,156
Equity - Transactions related to share-based compensation plans [Text Block]	Philips Group Transactions related to share-based compensation plans 2021 2022 2023 Shares acquired 3,996,576 2,142,445 3,000,000 Average market price EUR 36.15 EUR 31.76 EUR 41.59 Amount paid EUR 144 million EUR 68 million EUR 125 million Shares delivered 4,194,577 2,204,207 1,552,136 Average price (FIFO) EUR 34.14 EUR 35.16 EUR 34.59 Cost of delivered shares EUR 143 million EUR 77 million EUR 54 million Total shares in treasury at year-end 5,726,708 5,664,946 7,112,810 Total cost EUR 201 million EUR 191 million EUR 262 million
Equity - Transactions related to capital reduction [Text Block]	Philips Group Transactions related to capital reduction 2021 2022 2023 Shares acquired 41,489,816 2,938,248 12,964,445 Average market price EUR 36.22 EUR 36.61 EUR 37.25 Amount paid EUR 1,503 million EUR 108 million EUR 483 million Cancellation of treasury shares (shares) 33,500,000 8,758,455 15,134,054 Cancellation of treasury shares (EUR) EUR 1,216 million EUR 299 million EUR 566 million Total shares in treasury at year-end 7,989,816 2,169,609 Total cost EUR 287 million EUR 83 million
Equity - Composition of net debt and group equity [Text Block]	Philips Group Composition of net debt and group equity in millions of EUR unless otherwise stated 2021 2022 2023 Long-term debt 6,473 7,270 7,035 Short-term debt 506 931 654 Total debt 6,980 8,201 7,689 Cash and cash equivalents 2,303 1,172 1,869 Net debt 4,676 7,028 5,820 Shareholders' equity 14,438 13,249 12,028 Non-controlling interests 36 34 33 Group equity 14,475 13,283 12,061 Net debt and group equity ratio 24:76 35:65 33:67
Equity - Adjusted income from continuing operations attributable to shareholders [Text Block]	Philips Group Adjusted income from continuing operations attributable to shareholders 1 ) 2021 2022 2023 Net income 3,323 (1,605) (463) Discontinued operations, net of income taxes (2,711) (13) 10 Income from continuing operations 612 (1,618) (454) Income from continuing operations attributable to non-controlling interests (4) (3) (2) Income from continuing operations attributable to shareholders 1 ) 608 (1,622) (456) Adjustments for: Amortization and impairment of acquired intangible assets 322 363 290 Impairment of goodwill 15 1,357 8 Restructuring costs and acquisition-related charges 95 202 381 Other items: 1,069 925 1,358 Respironics litigation provision 575 Respironics field-action connected to the proposed consent decree 719 250 363 Respironics field-action running remediation cost 94 210 224 Quality remediation actions 94 59 175 R&D project impairments 134 Portfolio realignment charges 109 Impairment of assets in S&RC 39 Provision for public investigations tender irregularities 60 Provision for a legal matter 31 Investment re-measurement loss 23 Loss (gain) on divestment of business 76 (35) Remaining items 87 63 2 Net finance income/expenses (84) (4) 18 Tax impact of adjusted items and tax only adjusting items (527) (376) (450) Adjusted Income from continuing operations attributable to shareholders 1 ) 1,497 845 1,148 1 ) Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt [Abstract]
Debt - Long-term debt [Text Block]	Philips Group Long-term debt in millions of EUR unless otherwise stated 2023 amount outstanding Current portion Non-current portion Between amount due after 5 years average remaining term (in years) average rate of interest USD bonds 1,325 1,325 240 1,085 13.3 6.3% EUR bonds 4,569 4,569 2,335 2,234 5.1 2.0% Forward contracts 396 321 76 76 0.8 1.4% Lease liabilities 1,074 211 864 505 358 3.9 3.1% Bank borrowings 203 1 201 201 1.2 4.2% Other long-term debt - - - - - 7.4 1.2% Long-term debt 7,568 532 7,035 3,357 3,678 6.0 2.9% Philips Group Long-term debt in millions of EUR unless otherwise stated 2022 amount outstanding Current portion Non-current portion Between amount due after 5 years average remaining term (in years) average rate of interest USD bonds 1,378 1,378 250 1,128 14.3 6.3% EUR bonds 4,061 4,061 1,836 2,225 5.7 1.7% Forward contracts 858 606 252 252 1.0 Lease liabilities 1,082 230 852 504 348 3.9 2.4% Bank borrowings 705 2 702 702 1.9 1.7% Other long-term debt 28 4 24 17 6 8.9 2.9% Long-term debt 8,111 842 7,270 3,562 3,706 6.1 2.4%
Debt - Unsecured Bonds [Text Block]	Philips Group Unsecured Bonds in millions of EUR unless otherwise stated effective rate 2022 2023 Unsecured EUR Bonds Due 30/03/2025; 1 3/8% 1.509% 346 346 Due 22/05/2026; 1/2% 0.608% 750 750 Due 05/05/2027; 1 7/8% 2.049% 750 750 Due 02/05/2028; 1 3/8% 1.523% 500 500 Due 05/11/2029; 2 1/8% 2.441% 650 650 Due 30/03/2030; 2% 2.128% 500 500 Due 08/09/2031; 4 2/8% 4.330% 500 Due 05/05/2033; 2 5/8% 2.710% 600 600 Unsecured USD Bonds Due 15/05/2025; 7 3/4% 7.429% 51 49 Due 15/05/2025; 7 1/8% 6.794% 78 75 Due 01/06/2026; 7 1/5% 6.885% 119 114 Due 03/11/2038; 6 7/8% 7.210% 683 657 Due 15/03/2042; 5% 5.273% 470 452 Adjustments 1 ) (57) (47) Unsecured Bonds 5,439 5,894 1 ) Adjustments related to both EUR and USD bonds and concern bond discounts, premium and transaction costs.
Debt - Lease liabilities [Text Block]	Philips Group Lease liabilities in millions of EUR 2022 2023 future minimum lease payments interest present value of minimum lease payments future minimum lease payments interest present value of minimum lease payments Less than one year 251 21 230 239 28 211 Between one and five years 554 49 505 572 67 505 More than five years 376 28 348 388 30 358 Lease liabilities 1,180 98 1,082 1,200 125 1,074
Debt - Short-term debt [Text Block]	Philips Group Short-term debt in millions of EUR 2022 2023 Short-term bank borrowings 89 122 Current portion of long-term debt 842 532 Short-term debt 931 654

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Dec. 31, 2023
Provisions [Abstract]
Provisions - Provisions [Text Block]	Philips Group Provisions in millions of EUR Post-employment Respironics Product Environmental Restructuring- Legal Contingent Other Total Current 366 287 20 134 74 23 112 1,018 Non-current 546 23 57 83 6 14 89 279 1,097 Balance as of December 31, 2022 546 390 344 104 140 89 113 390 2,115 Additions 112 240 313 18 263 644 24 223 1,836 Utilizations (91) (285) (268) (14) (219) (235) (20) (134) (1,266) Releases (10) (20) (2) (67) (10) (7) (45) (159) Accretion 5 23 1 (3) 25 Acquisitions 6 6 Changes in discount rate (6) (6) Translation differences and other - (10) (12) (3) (2) (23) (2) (1) (53) Total change 12 (55) 13 (2) (24) 399 2 39 383 Current 331 293 22 102 477 57 181 1,463 Non-current 558 3 64 80 14 10 58 248 1,035 Balance as of December 31, 2023 558 334 357 102 116 487 115 429 2,498 Philips Group Provisions in millions of EUR Post-employment Respironics Product Environmental Restructuring Legal Contingent Other Total Current 525 207 26 58 39 52 92 998 Non-current 659 52 32 99 8 53 156 257 1,315 Balance as of December 31, 2021 659 577 238 124 66 91 208 349 2,313 Additions 61 250 320 15 154 89 160 1,049 Utilizations (185) (486) (224) (17) (61) (100) (105) (95) (1,274) Releases (1) (2) (18) (3) (35) (59) Accretion 4 - (3) 2 Acquisitions 4 96 99 Changes in discount rate (27) (27) Fair value changes (86) (86) Translation differences and other 12 49 9 7 (1) 7 14 97 Total change (113) (187) 105 (21) 74 (3) (95) 41 (198) Current 366 287 20 134 74 23 112 1,018 Non-current 546 23 57 83 6 14 89 279 1,097 Balance as of December 31, 2022 546 390 344 104 140 89 113 390 2,115
Provisions - Restructuring-related provisions [Text Block]	Philips Group Restructuring-related provisions in millions of EUR December 31, 2022 December 31, 2023 Diagnosis & Treatment 42 36 Connected Care 42 18 Personal Health 10 7 Other 47 56 Philips Group 140 116
Provisions - Other provisions [Text Block]	Philips Group Other provisions in millions of EUR unless otherwise stated 2022 2023 Employee jubilee funds 83 77 Self-insurance 57 63 Non-income taxes / social security 46 51 Rights of return 36 39 Decommissioning costs 33 34 Onerous contracts 38 76 Remaining 97 89 Balance as of December 31 390 429

Post-employment benefits (Table

Post-employment benefits (Tables)	12 Months Ended
	Dec. 31, 2023
Post-employment benefits [Abstract]
Post-employment benefits - Post-employment benefits [Text Block]	Philips Group Post-employment benefits in millions of EUR Germany United States Other Countries Total 2022 2023 2022 2023 2022 2023 2022 2023 Present value of funded DBO (489) (511) (440) (404) (179) (182) (1,108) (1,097) Present value of unfunded DBO (249) (253) (128) (118) (136) (137) (513) (508) Total present value of DBO (738) (764) (568) (522) (315) (319) (1,621) (1,605) Fair value of plan assets 477 481 474 442 171 166 1,122 1,089 Net position (261) (283) (94) (80) (144) (153) (499) (516) Value of reimbursement rights 6 8 6 8
Post-employment benefits - Classification net position [Text Block]	Philips Group Classification net position in millions of EUR Germany United States Other Countries Total 2022 2023 2022 2023 2022 2023 2022 2023 Total asset for plans in a surplus 9 - 34 39 4 2 46 41 Total liability for plans in a deficit (270) (283) (128) (118) (148) (156) (546) (558) Provisions for post-employment benefit plans under AHFS Net position (261) (283) (94) (80) (144) (153) (499) (516)
Post-employment benefits - Pre-tax costs for post-employment benefits [Text Block]	Philips Group Pre-tax costs for post-employment benefits in millions of EUR 2021 2022 2023 Defined benefit plans 36 50 47 - included in income from operations 28 39 25 - included in financial expense 8 10 21 - included in Discontinued operations 1 Defined contribution plans 375 400 376 - included in income from operations 368 400 376 - included in Discontinued operations 7 Post-employment benefits costs 411 449 423
Post-employment benefits - Defined benefit obligations [Text Block]	Philips Group Defined benefit obligations in millions of EUR 2022 2023 Balance as of January 1 1,970 1,621 Service cost 32 32 Interest cost 36 71 Employee contributions 4 3 Actuarial (gains) / losses - demographic assumptions 2 - financial assumptions (366) 48 - experience adjustment 12 2 (Negative) past service cost 16 (9) Settlements - 2 Benefits paid from plan (95) (104) Benefits paid directly by employer (41) (39) Translation differences and other 52 (22) Balance as of December 31 1,621 1,605
Post-employment benefits - Plan assets [Text Block]	Philips Group Plan assets in millions of EUR 2022 2023 Balance as of January 1 1,380 1,122 Interest income on plan assets 26 49 Admin expenses paid (1) (1) Return on plan assets excluding interest income (254) 23 Employee contributions 4 3 Employer contributions 17 14 Settlements Benefits paid from plan (95) (104) Translation differences and other 45 (17) Balance as of December 31 1,122 1,089
Post-employment benefits - Plan assets allocation [Text Block]	Philips Group Plan assets allocation in millions of EUR 2022 2023 Assets quoted in active markets - Debt securities 560 513 - Equity securities - Other 203 182 Assets not quoted in active markets - Debt securities - Equity securities 101 31 - Other 258 363 Total assets 1,122 1,089
Post-employment benefits - Assumptions used for defined benefit obligations [Text Block]	Philips Group Assumptions used for defined benefit obligations in % Germany United States Other Countries Total 2022 2023 2022 2023 2022 2023 2022 2023 Discount rate 4.1% 3.7% 5.2% 5.0% 4.9% 4.9% 4.7% 4.3% Inflation rate 2.0% 2.0% 2.3% 2.3% 2.6% 2.5% 2.2% 2.2% Salary increase 2.8% 2.8% 0.0% 0.0% 3.3% 4.3% 2.9% 3.0%
Post-employment benefits - Sensitivity of key assumptions [Text Block]	Philips Group Sensitivity of key assumptions in millions of EUR 2022 2023 Increase Discount rate (1% movement) (122) (123) Pension increase (1% movement) 57 60 Salary increase (1% movement) 12 12 Longevity 1 ) 32 32 Decrease Discount rate (1% movement) 145 147 Pension increase (1% movement) (49) (52) Salary increase (1% movement) (11) (11) 1 ) The mortality table (i.e. longevity) also impacts the DBO. The above sensitivity table illustrates the impact on the DBO of a further 10% decrease in the assumed rates of mortality for the company’s major plans. A 10% decrease in assumed mortality rates equals improvement of life expectancy by 0.5 - 1 year.

Accrued liabilities (Tables)

Accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Accrued liabilities [Abstract]
Accrued liabilities - Accrued liabilities [Text Block]	Philips Group Accrued liabilities in millions of EUR 2022 2023 Personnel-related costs: - Salaries and wages 490 791 - Accrued holiday entitlements 97 96 - Other personnel-related costs 101 93 Fixed-asset-related costs: - Gas, water, electricity, rent and other 46 43 Communication and IT costs 64 61 Distribution costs 110 99 Sales-related costs: - Commission payable 8 12 - Advertising and marketing-related costs 127 133 - Other sales-related costs 20 20 Material-related costs 132 138 Interest-related accruals 71 76 Other accrued liabilities 361 324 Accrued liabilities 1,626 1,887

Other liabilities (Tables)

Other liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Other liabilities [Abstract]
Other liabilities - Other current liabilities [Text Block]	Philips Group Other current liabilities in millions of EUR 2022 2023 Accrued customer rebates 213 186 Other taxes including social security premiums 115 129 Other liabilities 120 98 Other current liabilities 448 414

Cash flow statement supplemen_2

Cash flow statement supplementary information (Tables)	12 Months Ended
	Dec. 31, 2023
Cash flow statement supplementary information [Abstract]
Cash flow statement supplementary information - Reconciliation of liabilities arising from financing activities [Text Block]	Philips Group Reconciliation of liabilities arising from financing activities in millions of EUR Balance as of Cash flow Currency effects and Other 1 ) Balance as of December 31, 2023 Long term debt 2 ) 8,111 (210) (96) (238) 7,567 EUR bonds 4,061 497 11 4,569 USD bonds 1,378 (53) 1,325 Leases 1,082 (200) (42) 235 1,074 Forward contracts 3 ) 858 (462) 396 Bank borrowings 705 (502) 203 Other long-term debt 28 (5) (1) (22) Short term debt 2 ) 89 29 3 122 Short-term bank borrowings 89 46 (14) 122 Other short-term loans (17) 17 Equity (1,133) (666) 1,143 (656) Dividend payable (4) 4 Forward contracts 3 ) (858) 465 (394) Treasury shares 4 ) (275) (662) 675 (262) Total (848) 1 ) Besides non-cash, other includes interest paid on leases, which is part of cash flows from operating activities 2 ) In this table, current portion of long-term debt is included in long-term debt (and excluded from short-term debt). 3 ) The forward contracts are related to the share buyback program and LTI plans 4 ) Cash flow in 2023 includes withholding tax for share buyback amounting to EUR 55 million. Philips Group Reconciliation of liabilities arising from financing activities in millions of EUR Balance as of Cash flow Currency effects and consolidation changes Other 1 ) Balance as of Long term debt 2 ) 6,933 1,045 107 27 8,111 EUR bonds 3,233 827 4,061 USD bonds 1,313 (20) 85 1,378 Leases 1,220 (260) 17 105 1,082 Forward contracts 3 ) 934 (76) 858 Bank borrowings 203 498 4 705 Other long-term debt 30 (1) 1 (1) 28 Short term debt 2 ) 47 47 (6) 1 89 Short-term bank borrowings 47 47 (6) 1 89 Other short-term loans Equity (1,410) (593) 869 (1,133) Dividend payable (418) 418 Forward contracts 3 ) (934) 76 (858) Treasury shares (476) (174) 375 (275) Total 500 1 ) Besides non-cash, other includes interest paid on finance leases, which is part of cash flows from operating activities 2 ) In this table, current portion of long-term debt is included in long-term debt (and excluded from short-term debt). 3 ) The forward contracts are related to the share buyback program and LTI plans

Related-party transactions (Tab

Related-party transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Related-party transactions [Abstract]
Related-party transactions - Related-party transactions [Text Block]	Philips Group Related-party transactions in millions of EUR 2021 2022 2023 Sales of goods and services 116 111 106 Purchases of goods and services 41 46 42 Receivables from related parties 40 55 18 Payables to related parties 2 2 2

Share-based compensation (Table

Share-based compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-based compensation [Abstract]
Share-based compensation - Performance shares [Text Block]	Philips Group Performance shares 2022 2023 shares weighted average shares weighted average EUR-denominated Outstanding as of January 1 3,097,713 45.28 4,385,837 33.13 Granted 2,323,435 20.55 2,299,280 23.65 Notional dividends 1 ) 155,067 33.91 240,977 27.15 Vested/Issued (434,329) 40.90 (154,987) 44.08 Forfeited (233,556) 38.67 (489,295) 27.05 Adjusted quantity 2 ) (522,493) 40.48 (889,777) 44.27 Outstanding as of December 31 4,385,837 33.13 5,392,035 27.22 USD-denominated Outstanding as of January 1 2,005,000 51.48 2,749,983 36.66 Granted 1,530,585 21.93 1,667,812 25.96 Notional dividends 1 ) 98,883 37.15 152,750 29.78 Vested/Issued (248,848) 45.23 (121,760) 48.33 Forfeited (309,570) 44.04 (596,846) 28.95 Adjusted quantity 2 ) (326,066) 45.26 (590,890) 48.28 Outstanding as of December 31 2,749,983 36.66 3,261,048 29.73 1 ) Dividend declared in 2023 on outstanding shares. 2 ) Adjusted quantity includes the adjustments made to Performance shares outstanding due to updates on the actual TSR, EPS, and SDG.
Share-based compensation - Restricted shares [Text Block]	Philips Group Restricted shares 2022 2023 shares weighted average shares weighted average EUR-denominated Outstanding as of January 1 1,618,488 39.93 2,321,250 30.73 Granted 1,349,003 22.03 1,471,975 16.35 Notional dividends 1 ) 81,500 35.67 135,791 27.98 Vested/Issued (540,930) 35.82 (595,796) 35.07 Forfeited (186,811) 35.06 (337,968) 24.46 Outstanding as of December 31 2,321,250 30.73 2,995,252 23.39 USD-denominated Outstanding as of January 1 1,611,021 46.26 2,345,263 33.87 Granted 1,463,855 23.60 1,284,761 17.72 Notional dividends 1 ) 83,151 39.37 126,498 31.12 Vested/Issued (541,336) 41.48 (679,430) 37.83 Forfeited (271,427) 38.51 (422,899) 26.79 Outstanding as of December 31 2,345,263 33.87 2,654,193 26.04 1 ) Dividend declared in 2023 on outstanding shares.
Share-based compensation - Black-Scholes-Merton option pricing model inputs [Text Block]	Philips Group Black-Scholes-Merton option pricing model inputs EUR-denominated USD-denominated Share price at grant date EUR 18.24 USD 21.12 Exercise price EUR 22.16 USD 24.42 Risk-free interest rate 2.37% 3.5% Expected dividend yield 4.45% 4.45% Expected option life 6 years 6 years Expected share price volatility 30.47% 32.31%
Share-based compensation - Options on EUR-denominated listed share [Text Block]	Philips Group Options on EUR-denominated listed share options weighted average Granted on April 28, 2023 3,831,000 22.16 Forfeited (171,000) 22.16 Outstanding as of December 31, 2023 3,660,000 22.16
Share-based compensation - Options on USD-denominated listed share [Text Block]	Philips Group Options on USD-denominated listed share options weighted average Granted on April 28, 2023 2,179,500 24.42 Forfeited (250,500) 24.42 Outstanding as of December 31, 2023 1,929,000 24.42
Share-based compensation - Outstanding options [Text Block]	Philips Group Outstanding options in millions of EUR unless otherwise stated number of intrinsic value weighted average EUR-denominated 20-25 3,660,000 0 9.3 Outstanding options 3,660,000 0 9.3 USD-denominated 20-25 1,929,000 0 9.3 Outstanding options 1,929,000 0 9.3

Information on remuneration (Ta

Information on remuneration (Tables)	12 Months Ended
	Dec. 31, 2023
Information on remuneration [Abstract]
Information on remuneration - Remuneration costs of the Executive Committee [Text Block]	Philips Group Remuneration costs of the Executive Committee 1 ) in EUR 2021 2022 2023 Base salary/Base compensation 9,598,588 9,528,279 8,729,458 Annual incentive 2 ) 5,250,408 208,370 11,405,130 Performance shares 3 ) 12,610,073 11,242,581 7,272,815 Stock options 13,358 Restricted share rights 3 ) 1,380,644 1,191,529 1,907,511 Pension allowances 4 ) 2,107,953 1,949,204 1,346,937 Pension scheme costs 306,694 288,179 260,554 Other compensation 5 ) 2,104,044 1,216,163 1,900,224 Total 33,358,405 25,624,305 32,835,987 1 ) The Executive Committee consisted of 13 members as per December 31, 2023 (2022: 13 members; 2021: 13 members) 2 ) The annual incentives are related to the performance in the year reported which are paid out in the subsequent year. 3 ) Costs of performance shares and restricted share rights are based on accounting standards (IFRS) and do not reflect the value of performance shares at the vesting/release date 4 ) Pension allowances are gross taxable allowances paid to the Executive Committee members in the Netherlands. These allowances are part of the pension arrangement 5 ) The stated amounts mainly concern (share of) allowances to members of the Executive Committee that can be considered as remuneration. In a situation where such a share of an allowance can be considered as (indirect) remuneration (for example, private use of the company car), then the share is both valued and accounted for here. The method employed by the fiscal authorities is the starting point for the value stated
Information on remuneration - Remuneration costs of individual members of the Board of Management [Text Block]	Philips Group Remuneration costs of individual members of the Board of Management in EUR base compen­sation/salary annual incentive 1 ) perfor­mance shares 2 ) restricted share rights 2 ) pension allowances 3 ) pension scheme costs other compen­sation total costs 2023 R. Jakobs 1,200,000 2,004,480 968,922 267,798 31,891 109,256 4,582,347 A. Bhattacharya 810,000 1,075,939 793,429 197,133 31,891 94,516 3,002,907 M.J. van Ginneken 630,000 846,922 614,840 125,298 31,891 53,446 2,302,397 2,640,000 3,927,341 2,377,191 590,228 95,673 257,218 9,887,650 2022 R. Jakobs 4 ) 256,438 112,737 57,973 6,012 11,507 444,667 F.A. van Houten 4 ) 1,041,849 208,370 2,930,068 444,051 22,121 42,533 4,688,992 A. Bhattacharya 806,250 763,140 237,250 28,133 61,308 1,896,081 M.J. van Ginneken 626,250 585,490 141,622 28,133 35,343 1,416,837 2,730,788 208,370 4,391,434 880,896 84,398 150,691 8,446,577 2021 F.A. van Houten 1,325,000 850,915 2,626,295 565,403 27,462 57,224 5,452,299 A. Bhattacharya 790,000 360,103 1,172,533 233,857 27,462 68,908 2,652,864 M.J. van Ginneken 605,000 317,192 886,035 150,755 27,462 42,610 2,029,054 2,720,000 1,528,211 4,684,863 950,014 82,387 168,742 10,134,217 1 ) The annual incentives are related to the performance in the year reported which are paid out in the subsequent year. 2 ) Costs of performance shares and restricted share rights are based on accounting standards (IFRS) and do not reflect the value of performance shares at the vesting/release date 3 ) The stated amounts mainly concern (share of) allowances to members of the Board of Management that can be considered as remuneration. In a situation where such a share of an allowance can be considered as (indirect) remuneration (for example, private use of the company car), then the share is both valued and accounted for here. The method employed by the fiscal authorities is the starting point for the value stated. 4 ) As per October 15, 2022, Roy Jakobs was appointed as CEO of the company. The table includes actual costs incurred in respect of the remuneration received by Mr Van Houten and Mr Jakobs, respectively, as CEO.
Information on remuneration - Accumulated annual pension entitlements and pension-related costs [Text Block]	Philips Group Accumulated annual pension entitlements and pension-related costs in EUR unless otherwise stated age at December 31, 2023 accumulated annual pension as of December 31, 2023 total pension related costs R. Jakobs 49 56,383 299,689 A. Bhattacharya 62 40,324 229,024 M.J. van Ginneken 50 53,769 157,189 Pension costs 685,901
Information on remuneration - Remuneration of the Supervisory Board [Text Block]	Philips Group Remuneration of the Supervisory Board in EUR membership committees other compensation 1 ) total 2023 F. Sijbesma 155,000 35,000 16,345 206,345 P.A.M. Stoffels 115,000 35,000 22,269 172,269 D.E.I. Pyott 100,000 35,000 19,769 154,769 A.M. Harrison 100,000 14,000 19,769 133,769 M.E. Doherty 100,000 27,000 27,269 154,269 P. Löscher 100,000 32,000 17,269 149,269 I. Nooyi 100,000 14,000 17,269 131,269 S.K. Chua 100,000 18,000 22,269 140,269 H. Verhagen 100,000 14,000 7,269 121,269 S. Poonen 100,000 18,000 19,769 137,769 1,070,000 242,000 189,266 1,501,266 2022 F. Sijbesma 155,000 35,000 16,345 206,345 P.A.M. Stoffels 115,000 35,000 27,269 177,269 N. Dhawan 35,616 6,411 5,808 47,836 D.E.I. Pyott 100,000 35,000 17,269 152,269 A.M. Harrison 100,000 14,000 12,269 126,269 M.E. Doherty 100,000 27,000 24,769 151,769 P. Löscher 100,000 32,000 24,769 156,769 I. Nooyi 100,000 14,000 17,269 131,269 S.K. Chua 100,000 18,000 22,269 140,269 H. Verhagen 100,000 14,000 7,269.0 121,269 S. Poonen 100,000 18,000 17,269 135,269 1,105,616 248,411 192,574 1,546,602 2021 J. van der Veer 53,507 12,082 3,916 69,505 C.A. Poon 39,699 16,915 783 57,397 N. Dhawan 100,000 18,000 2,269 120,269 O. Gadiesh 34,521 4,833 783 40,137 D.E.I. Pyott 100,000 36,370 2,269 138,639 P.A.M. Stoffels 109,863 27,808 4,769 142,440 A.M. Harrison 100,000 14,000 2,269 116,269 M.E. Doherty 100,000 27,000 4,769 131,769 P. Löscher 100,000 32,000 4,769 136,769 F. Sijbesma 141,301 27,808 8,237 177,346 I. Nooyi 100,000 14,000 2,269 116,269 S.K. Chua 65,753 11,836 1,492 79,081 1,044,644 242,652 38,595 1,325,891 1 ) The amounts mentioned under other compensation relate to the fee for intercontinental travel, inter-European travel, the entitlement of EUR 2,000 under the Philips product arrangement and the annual fixed net expense allowance.
Information on remuneration - Shares held by Board members [Text Block]	Philips Group Shares held by Board members 1 ) 2 ) in number of shares December 31, 2022 December 31, 2023 R. Jakobs 109,422 126,809 A. Bhattacharya 169,517 177,088 M.J. van Ginneken 123,914 129,447 P. Stoffels 17,000 17,759 S. Poonen 3,000 3,133 I. Nooyi 3,100 3,238 D. Pyott 19,000 19,848 S.K. Chua 2,000 2,089 F. Sijbesma 12,500 25,000 M. Harrison 1,500 1,567 P. Löscher 20,732 21,658 1 ) Reference date for board membership is December 31, 2023. 2 ) The total shares held by the members of the Board of Management is less than 1% of the company's issued share capital.

Fair value of financial asset_2

Fair value of financial assets and liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Fair value of financial assets and liabilities [Abstract]
Fair value of financial assets and liabilities - Fair value of financial assets and liabilities [Text Block]	Philips Group Fair value of financial assets and liabilities in millions of EUR carrying amount estimated fair value 1 ) Level 1 Level 2 Level 3 December 31, 2023 Financial assets Carried at fair value: Debt instruments 226 226 226 Equity instruments 2 2 2 Other financial assets 56 56 34 22 Financial assets carried at FVTP&L 284 284 34 250 Debt instruments 27 27 26 Equity instruments 231 231 14 217 Current financial assets 3 3 3 Receivables - current 32 32 32 Financial assets carried at FVTOCI 293 293 14 26 253 Derivative financial instruments 48 48 48 Financial assets carried at fair value 624 624 14 108 503 Carried at (amortized) cost: Cash and cash equivalents 1,869 Loans and receivables: Current loans receivables - Other non-current loans and receivables 77 Receivables - current 3,701 Receivables - non-current 193 Financial assets carried at (amortized) cost 5,840 Total financial assets 6,465 Financial liabilities Carried at fair value: Contingent consideration (115) (115) (115) Financial liabilities carried at FVTP&L (115) (115) (115) Derivative financial instruments (43) (43) (43) Financial liabilities carried at fair value (158) (158) (43) (115) Carried at (amortized) cost: Accounts payable (1,917) Interest accrual (76) Debt (Corporate bonds and leases) (6,969) (6,798) (5,724) (1,074) Debt (excluding corporate bonds and leases) (721) Financial liabilities carried at (amortized) cost (9,682) Total financial liabilities (9,840) 1 ) For Cash and cash equivalents, Loans and receivables, Accounts payable, interest accrual and Debt (excluding corporate bonds and leases), the carrying amounts approximate fair value because of the nature of these instruments (including maturity and interest conditions) and therefore fair value information is not included in the table above. Philips Group Fair value of financial assets and liabilities in millions of EUR carrying amount estimated fair value 1 ) Level 1 Level 2 Level 3 December 31, 2022 Financial assets Carried at fair value: Debt instruments 232 232 232 Equity instruments 4 4 1 2 Other financial assets 86 86 35 51 Financial assets carried at FVTP&L 322 322 1 35 285 Debt instruments 25 25 25 Equity instruments 259 259 30 229 Current financial assets 9 9 9 Receivables - current 26 26 26 Financial assets carried at FVTOCI 319 319 30 25 264 Derivative financial instruments 127 127 127 Financial assets carried at fair value 768 768 32 187 549 Carried at (amortized) cost: Cash and cash equivalents 1,172 Loans and receivables: Current loans receivables 2 Other non-current loans and receivables 54 Receivables - current 4,088 Receivables - non-current 279 Financial assets carried at (amortized) cost 5,596 Total financial assets 6,364 Financial liabilities Carried at fair value: Contingent consideration (113) (113) (113) Financial liabilities carried at FVTP&L (113) (113) (113) Derivative financial instruments (211) (211) (211) Financial liabilities carried at fair value (324) (324) (211) (113) Carried at (amortized) cost: Accounts payable (1,968) Interest accrual (71) Debt (Corporate bonds and leases) (6,520) (6,083) (5,001) (1,082) Debt (excluding corporate bonds and leases) (1,680) Financial liabilities carried at (amortized) cost (10,240) Total financial liabilities (10,564) 1 ) For Cash and cash equivalents, Loans and receivables, Accounts payable, interest accrual and Debt (excluding corporate bonds and leases), the carrying amounts approximate fair value because of the nature of these instruments (including maturity and interest conditions) and therefore fair value information is not included in the table above.
Fair value of financial assets and liabilities - Reconciliation of Level 3 fair value measurements [Text Block]	Philips Group Reconciliation of Level 3 fair value measurements in millions of EUR Financial assets Financial liabilities Balance as of January 1, 2023 549 113 Acquisitions 6 Purchase 85 Sales (56) Utilizations (20) Recognized in profit and loss: other business income 16 financial income and expenses 1 ) (43) 1 Recognized in other comprehensive income 2 ) (40) (2) Receivables held to collect and sell 6 Reclassification 1 Balance as of December 31, 2023 503 115 1 ) Refer to Financial income and expenses 2 ) Includes translation differences Philips Group Reconciliation of Level 3 fair value measurements in millions of EUR Financial assets Financial liabilities Balance as of January 1, 2022 523 208 Acquisitions 96 Purchase 131 Sales (76) Utilizations (105) Recognized in profit and loss: other business income (85) financial income and expenses 7 (8) Recognized in other comprehensive income 1 ) 8 Receivables held to collect and sell (41) Reclassification from associates 5 Balance as of December 31, 2022 549 113 1 ) Includes translation differences
Fair value of financial assets and liabilities - Financial assets subject to offsetting, enforceable master netting arrangements or similar agreements [Text Block]	Philips Group Financial assets subject to offsetting, enforceable master netting arrangements or similar agreements in millions of EUR 2022 2023 Derivatives Gross amounts of recognized financial assets 127 48 Gross amounts of recognized financial liabilities offset in the balance sheet Net amounts of financial assets presented in the balance sheet 127 48 Related amounts not offset in the balance sheet Financial instruments (54) (34) Net amount 73 13
Fair value of financial assets and liabilities - Financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements [Text Block]	Philips Group Financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in millions of EUR 2022 2023 Derivatives Gross amounts of recognized financial liabilities (211) (43) Gross amounts of recognized financial assets offset in the balance sheet Net amounts of financial liabilities presented in the balance sheet (211) (43) Related amounts not offset in the balance sheet Financial instruments 54 34 Net amount (157) (9)

Details of treasury and other_2

Details of treasury and other financial risks (Tables)	12 Months Ended
	Dec. 31, 2023
Details of treasury and other financial risks [Abstract]
Details of treasury and other financial risks - Contractual cash obligations [Text Block]	Philips Group Contractual cash obligations 1 ) 2 ) in millions of EUR payments due by period total less than 1 year 1-3 years 3-5 years after 5 years Long-term debt 7,615 533 1,934 1,431 3,717 Short-term debt 122 122 Interest on debt 1,704 180 328 285 911 Derivative liabilities 39 38 1 Purchase obligations 3 ) 668 355 286 27 Trade and other payables 1,917 1,917 Contractual cash obligations 12,065 3,145 2,549 1,716 4,655 1 ) Amounts in this table are undiscounted 2 ) This table excludes post-employment benefit plan contribution commitments and income tax liabilities in respect of tax risks because it is not possible to make a reasonably reliable estimate of the actual period of cash settlement. 3 ) Purchase obligations are agreements to purchase goods or services that are enforceable and legally binding for the Group. They specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions and the approximate timing of the transaction. They do not include open purchase orders or other commitments which do not specify all significant terms.
Details of treasury and other financial risks - Remaining minimum payments under sale-and-leaseback arrangements [Text Block]	Philips Group Remaining minimum payments under sale-and-leaseback arrangements in millions of EUR 2024 43 2025 30 2026 21 2027 12 2028 5 Thereafter 26
Details of treasury and other financial risks - Estimated transaction exposure and related hedges [Text Block]	Philips Group Estimated transaction exposure and related hedges in millions of EUR Sales/Receivables Purchases/Payable exposure hedges exposure hedges Balance as of December 31, 2023 Exposure currency USD 1,793 (1,449) (888) 805 JPY 547 (319) (14) 14 GBP 312 (196) (12) 12 CNY 439 (304) (98) 95 CAD 249 (161) (1) 1 PLN 91 (103) AUD 226 (137) CHF 103 (63) (1) 1 CZK 63 (70) SEK 33 (18) (3) 3 EUR 233 (232) (114) 113 Others 198 (134) (216) 130 Total 2023 4,287 (3,185) (1,346) 1,173 Total 2022 3,779 (2,920) (1,468) 1,326
Details of treasury and other financial risks - Estimated impact of 10% increase of value of the EUR on the fair value of hedges [Text Block]	Philips Group Estimated impact of 10% increase of value of the EUR on the fair value of hedges in millions of EUR 2022 2023 USD 68 64 JPY 15 15 GBP 16 16 CHF 4 5 PLN 2 1 RUB -
Details of treasury and other financial risks - Net debt and interest rate sensitivity [Text Block]	Philips Group Net debt 1 ) in millions of EUR 2022 2023 Impact 1% interest increase on the fair value of the fixed-rate long-term debt 2 ) 3 ) (274) (283) Impact 1% interest decrease on the fair value of the fixed-rate long-term debt 2 ) 3 ) 274 284 Impact 1% interest increase on the annualized net interest expense 4 ) 4 15 1 ) The definition of this non-IFRS measure and a reconciliation to the IFRS measure is included in Equity 2 ) The sensitivity analysis conducted shows that if long-term interest rates were to increase/decrease instantaneously by 1% from their level of December 31, 2023, with all other variables (including foreign exchange rates) held constant. 3 ) Fixed-rate long-term debt is excluding forward contracts. 4 ) The impact is based on the outstanding net floating-rate position as of December 31, 2023.
Details of treasury and other financial risks - Credit risk with number of counterparties [Text Block]	Philips Group Credit risk with number of counterparties for deposits above EUR 10 million 10-100 million 100-500 million 500 million and above AAA rated bank counterparties 4 AA- rated bank counterparties 1 A+ rated bank counterparties 2 3 A rated bank counterparties 2 1 A- rated bank counterparties 1 6 8

Information by segment and ma_3

Information by segment and main country - Text Details (Detail)	12 Months Ended
	Dec. 31, 2023
Information by segment and main country [Abstract]
Share of sales for single customer	10%

Information by segment and ma_4

Information by segment and main country - Information on income statements (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Information by segment and main country [Line Items]
Revenue	€ 18,169		€ 17,827		€ 17,156
Sales including intercompany	18,169		17,827		17,156
Depreciation and amortisation expense	1,261	[1]	1,602	[2]	1,323	[1]
Adjusted EBITA	1,921		1,318		2,054
Diagnosis & Treatment [Member]
Information by segment and main country [Line Items]
Revenue	8,818		8,290		7,825
Sales including intercompany	9,253		8,576		8,023
Depreciation and amortisation expense	306		417		363
Adjusted EBITA	1,026		788		1,028
Connected Care [Member]
Information by segment and main country [Line Items]
Revenue	5,138		5,268		5,371
Sales including intercompany	5,149		5,280		5,388
Depreciation and amortisation expense	445		646		472
Adjusted EBITA	369		111		553
Personal Health [Member]
Information by segment and main country [Line Items]
Revenue	3,602		3,626		3,429
Sales including intercompany	3,685		3,684		3,462
Depreciation and amortisation expense	115		132		131
Adjusted EBITA	597		538		590
Other [Member]
Information by segment and main country [Line Items]
Revenue	612		643		530
Sales including intercompany	428		736		636
Depreciation and amortisation expense	394		407		357
Adjusted EBITA	(71)		(119)		(117)
Intersector Eliminations [member]
Information by segment and main country [Line Items]
Sales including intercompany	€ (346)		€ (449)		€ (353)
[1] Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill

Information by segment and ma_5

Information by segment and main country - Reconciliation from net income to Adjusted EBITA (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Information by segment and main country [Line Items]
Profit (loss)		€ (463)	[1]	€ (1,605)	[2]	€ 3,323	[2]
Profit (loss) from discontinued operations		(10)	[2]	13	[2]	2,711	[1]
Tax expense (income)		(73)		(113)		(103)
Share of profit (loss) of associates and joint ventures accounted for using equity method		(98)		(2)		(4)
Finance costs		376		258		188
Finance income		63		58		149
Profit (loss) from operating activities		(115)		(1,529)		553
Amortization of acquired intangible assets	[2]	290		363		322
Impairment loss recognised in profit or loss, goodwill	[2]	8		1,357		15
Earnings before interest, taxes and amortization		183		192		890
Restructuring and acquisition-related charges	[2]	381		202		95
Other items	[2]	1,358		925		1,069
Adjusted EBITA		1,921		1,318		2,054
Respironics litigation provision [Member]
Information by segment and main country [Line Items]
Other items	[2]	575
Respironics field-action connected to the anticipated consent decree [Member]
Information by segment and main country [Line Items]
Other items	[2]	363		250		719
Respironics field-action running remediation costs [Member]
Information by segment and main country [Line Items]
Other items	[2]	224		210		94
Quality remediation actions [Member]
Information by segment and main country [Line Items]
Other items	[2]	175		59		94
Provision for a legal matter [Member]
Information by segment and main country [Line Items]
Other items	[2]	31
Investment re-measurement loss [Member]
Information by segment and main country [Line Items]
Other items	[2]	23
Gain on divestment of business [Member]
Information by segment and main country [Line Items]
Other items	[2]	(35)
Remaining items [Member]
Information by segment and main country [Line Items]
Other items	[2]	2		63		87
R&D project impairments [Member]
Information by segment and main country [Line Items]
Other items	[2]			134
Portfolio realignment charges [Member]
Information by segment and main country [Line Items]
Other items	[2]			109
Provision for public investigations tender irregularities [Member]
Information by segment and main country [Line Items]
Other items	[2]			60
Impairment of assets in S&RC [Member]
Information by segment and main country [Line Items]
Other items	[2]			39
Loss on divestment of business [Member]
Information by segment and main country [Line Items]
Other items	[2]					76
Diagnosis & Treatment [Member]
Information by segment and main country [Line Items]
Profit (loss) from operating activities		720		538		948
Amortization of acquired intangible assets		89		115		142
Impairment loss recognised in profit or loss, goodwill		8				2
Earnings before interest, taxes and amortization		816		652		1,092
Restructuring and acquisition-related charges		118		3		(30)
Other items		92		133		(35)
Adjusted EBITA		1,026		788		1,028
Diagnosis & Treatment [Member] | Quality remediation actions [Member]
Information by segment and main country [Line Items]
Other items		81
Diagnosis & Treatment [Member] | Remaining items [Member]
Information by segment and main country [Line Items]
Other items		11		0		(35)
Diagnosis & Treatment [Member] | R&D project impairments [Member]
Information by segment and main country [Line Items]
Other items				73
Diagnosis & Treatment [Member] | Provision for public investigations tender irregularities [Member]
Information by segment and main country [Line Items]
Other items				60
Connected Care [Member]
Information by segment and main country [Line Items]
Profit (loss) from operating activities		(1,199)		(2,347)		(716)
Amortization of acquired intangible assets		178		226		158
Impairment loss recognised in profit or loss, goodwill		0		1,357		13
Earnings before interest, taxes and amortization		(1,020)		(764)		(545)
Restructuring and acquisition-related charges		115		125		130
Other items		1,275		750		968
Adjusted EBITA		369		111		553
Connected Care [Member] | Respironics litigation provision [Member]
Information by segment and main country [Line Items]
Other items		575
Connected Care [Member] | Respironics field-action connected to the anticipated consent decree [Member]
Information by segment and main country [Line Items]
Other items		363		250		719
Connected Care [Member] | Respironics field-action running remediation costs [Member]
Information by segment and main country [Line Items]
Other items		224		210		94
Connected Care [Member] | Quality remediation actions [Member]
Information by segment and main country [Line Items]
Other items		94		59		94
Connected Care [Member] | Provision for a legal matter [Member]
Information by segment and main country [Line Items]
Other items		31
Connected Care [Member] | Remaining items [Member]
Information by segment and main country [Line Items]
Other items		(12)		24		61
Connected Care [Member] | R&D project impairments [Member]
Information by segment and main country [Line Items]
Other items				59
Connected Care [Member] | Portfolio realignment charges [Member]
Information by segment and main country [Line Items]
Other items				109
Connected Care [Member] | Impairment of assets in S&RC [Member]
Information by segment and main country [Line Items]
Other items				39
Personal Health [Member]
Information by segment and main country [Line Items]
Profit (loss) from operating activities		552		515		576
Amortization of acquired intangible assets		14		15		15
Earnings before interest, taxes and amortization		567		531		591
Restructuring and acquisition-related charges		9		11		(1)
Other items		22		(4)		0
Adjusted EBITA		597		538		590
Personal Health [Member] | Investment re-measurement loss [Member]
Information by segment and main country [Line Items]
Other items		23
Personal Health [Member] | Remaining items [Member]
Information by segment and main country [Line Items]
Other items		(1)		(6)		0
Personal Health [Member] | R&D project impairments [Member]
Information by segment and main country [Line Items]
Other items				3
Other [Member]
Information by segment and main country [Line Items]
Profit (loss) from operating activities		(188)		(235)		(255)
Amortization of acquired intangible assets		9		8		6
Earnings before interest, taxes and amortization		(179)		(227)		(248)
Restructuring and acquisition-related charges		140		62		(5)
Other items		(32)		46		136
Adjusted EBITA		(71)		(119)		(117)
Other [Member] | Gain on divestment of business [Member]
Information by segment and main country [Line Items]
Other items		(35)
Other [Member] | Remaining items [Member]
Information by segment and main country [Line Items]
Other items		€ 3		€ 46		61
Other [Member] | Loss on divestment of business [Member]
Information by segment and main country [Line Items]
Other items						€ 76
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Information by segment and ma_6

Information by segment and main country - Main countries (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Information by segment and main country [Line Items]
Revenue	€ 18,169	€ 17,827	€ 17,156
Netherlands [Member]
Information by segment and main country [Line Items]
Revenue	2,390	2,021	1,860
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	1,624	1,746	1,934
United States of America [Member]
Information by segment and main country [Line Items]
Revenue	7,178	7,226	6,403
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	11,410	12,087	12,615
China [Member]
Information by segment and main country [Line Items]
Revenue	1,408	1,239	1,400
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	234	260	258
Japan [Member]
Information by segment and main country [Line Items]
Revenue	941	1,011	1,068
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	407	436	480
Germany [Member]
Information by segment and main country [Line Items]
Revenue	573	642	970
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	348	323	305
Other countries [Member]
Information by segment and main country [Line Items]
Revenue	5,679	5,688	4,150
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	1,527	1,550	693
Foreign countries [member]
Information by segment and main country [Line Items]
Revenue	18,169	17,827	17,156
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	€ 15,550	€ 16,402	16,986
France [Member]
Information by segment and main country [Line Items]
Revenue			446
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts			49
India [Member]
Information by segment and main country [Line Items]
Revenue			431
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts			85
United Kingdom of Great Britain and Northern Ireland [Member]
Information by segment and main country [Line Items]
Revenue			426
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts			€ 567

Discontinued operations and a_3

Discontinued operations and assets classified as held for sale - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Discontinued operations and assets classified as held for sale [Line Items]
Profit (loss) from discontinued operations	€ (10)	[1]	€ 13	[1]	€ 2,711	[2]
Increase (decrease) in cash and cash equivalents, discontinued operations	123		(12)		3,403
Cash flows from (used in) investing activities, discontinued operations			15		3,319
Domestic Appliances [Member]
Discontinued operations and assets classified as held for sale [Line Items]
Separation expenses, continuing operations					64
Result on the sale of discontinued operations, before tax	(1)		1		3,241
Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations					4,041
Assets, liabilities directly associated with assets held for sale					715
Transaction cost					16
Reclassification adjustments on exchange differences on translation, before tax in discontinued operations					69
Tax expense (income) relating to gain (loss) on discontinuance					743
Result on the sale of discontinued operations net of tax					€ 2,499
Brand license agreement					15 years
Profit (loss) from discontinued operations	(2)		3		€ 2,698
Cash flows from (used in) investing activities, discontinued operations					3,319
Domestic Appliances [Member] | Goods or services transferred over time [member]
Discontinued operations and assets classified as held for sale [Line Items]
Licence fee income					700
Domestic Appliances [Member] | Closing adjustments [Member]
Discontinued operations and assets classified as held for sale [Line Items]
Assets, liabilities directly associated with assets held for sale					191
Domestic Appliances [Member] | Disposal groups classified as held for sale [member]
Discontinued operations and assets classified as held for sale [Line Items]
Assets classified as held for sale					3,850
Other operations [Member]
Discontinued operations and assets classified as held for sale [Line Items]
Profit (loss) from discontinued operations	€ (7)		€ 10		€ 13
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Discontinued operations and a_4

Discontinued operations and assets classified as held for sale - Discontinued operations, net of income taxes (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Discontinued operations and assets classified as held for sale [Line Items]
Profit (loss) from discontinued operations	€ (10)	[1]	€ 13	[1]	€ 2,711	[2]
Domestic Appliances [Member]
Discontinued operations and assets classified as held for sale [Line Items]
Profit (loss) from discontinued operations	(2)		3		2,698
Other operations [Member]
Discontinued operations and assets classified as held for sale [Line Items]
Profit (loss) from discontinued operations	(7)		10		13
Discontinued operations [member]
Discontinued operations and assets classified as held for sale [Line Items]
Profit (loss) from discontinued operations	€ (10)		€ 13		€ 2,711
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Discontinued operations and a_5

Discontinued operations and assets classified as held for sale - Results of Domestic Appliances (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Discontinued operations and assets classified as held for sale [Line Items]
Revenue		€ 18,169		€ 17,827		€ 17,156
Profit (loss) from operating activities		(115)		(1,529)		553
Tax expense (income) relating to profit (loss) from ordinary activities of discontinued operations		9		18		737
Profit (loss) from discontinued operations		(10)	[1]	13	[1]	2,711	[2]
Domestic Appliances [Member]
Discontinued operations and assets classified as held for sale [Line Items]
Revenue		0		6		1,516
Discontinued Operations, Expenses		2		2		1,322
Profit (loss) from operating activities		(2)		4		194
Result on the sale of discontinued operations, before tax		(1)		1		3,241
Profit Loss Discontinued Operations, Before Tax		(3)		5		3,435
Tax expense (income) relating to profit (loss) from ordinary activities of discontinued operations	[3]	(1)		2		(6)
Tax expense (income) relating to gain (loss) on discontinuance						743
Profit (loss) from discontinued operations		€ (2)		€ 3		€ 2,698
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. The income tax of discontinued operations is calculated based on the separate return method, as if Domestic Appliances was filing its own separate tax returns.

Discontinued operations and a_6

Discontinued operations and assets classified as held for sale - Net cash provided by (used for) discontinued operations (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Discontinued operations and assets classified as held for sale [Abstract]
Cash flows from (used in) operating activities, discontinued operations	€ 123	€ (27)	€ 85
Cash flows from (used in) investing activities, discontinued operations		15	3,319
Increase (decrease) in cash and cash equivalents, discontinued operations	€ 123	€ (12)	€ 3,403

Acquisitions and divestments -

Acquisitions and divestments - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended			24 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2023
Acquisitions and divestments [Line Items]
Contingent consideration recognised as of acquisition date	€ 96			€ 96
Goodwill recognised as of acquisition date	307			307
Identifiable intangible assets recognised as of acquisition date	179			179
Deferred tax assets recognised as of acquisition date	20			20
Deferred tax liabilities recognised as of acquisition date	43			43
Aggregated net cash consideration for divestments	80
Gains on disposal of businesses	50	€ 4	€ 0
Aggregated net cash outflow for acquisitions				359
DiA Imaging Analysis [Member]
Acquisitions and divestments [Line Items]
Cash transferred	53			53
Contingent consideration recognised as of acquisition date	6			6
Goodwill recognised as of acquisition date	24			24
Identifiable intangible assets recognised as of acquisition date	40			40
Deferred tax assets recognised as of acquisition date	5			5
Deferred tax liabilities recognised as of acquisition date	2			2
Aggregated individually immaterial business combinations [member]
Acquisitions and divestments [Line Items]
Aggregated net cash outflow for acquisitions				139
Remaining two acquisitions [Member]
Acquisitions and divestments [Line Items]
Contingent consideration recognised as of acquisition date	61			61
Goodwill recognised as of acquisition date	130			130
Identifiable intangible assets recognised as of acquisition date	95			95
Deferred tax liabilities recognised as of acquisition date	23			23
Vesper Medical [Member]
Acquisitions and divestments [Line Items]
Cash transferred	227			227
Goodwill recognised as of acquisition date	177			177
Identifiable intangible assets recognised as of acquisition date	84			84
Deferred tax assets recognised as of acquisition date	15			15
Deferred tax liabilities recognised as of acquisition date	(20)			(20)
Discount rate applied to cash flow projections		12%
Vesper Medical [Member] | Business combinations [member]
Acquisitions and divestments [Line Items]
Discount rate applied to cash flow projections		12%
Vesper Medical [Member] | At fair value [member]
Acquisitions and divestments [Line Items]
Contingent consideration recognised as of acquisition date	€ 34			€ 34
Vesper Medical [Member] | Carrying amount [member]
Acquisitions and divestments [Line Items]
Contingent consideration recognised as of acquisition date		€ 44

Acquisitions and divestments _2

Acquisitions and divestments - Opening balance sheet (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Acquisitions and divestments [Line Items]
Identifiable intangible assets recognised as of acquisition date	€ 179
Deferred tax assets recognised as of acquisition date	20
Assets	29,406	€ 30,688
Deferred tax liabilities recognised as of acquisition date	43
Goodwill recognised as of acquisition date	307
Contingent consideration recognised as of acquisition date	96
Vesper Medical [Member]
Acquisitions and divestments [Line Items]
Identifiable intangible assets recognised as of acquisition date	84
Deferred tax assets recognised as of acquisition date	15
Cash and cash equivalents recognised as of acquisition date	7
Assets	106
Trade and other payables recognised as of acquisition date	(1)
Deferred tax liabilities recognised as of acquisition date	(20)
Liabilities	(21)
Identifiable assets acquired (liabilities assumed)	85
Goodwill recognised as of acquisition date	177
Consideration transferred, acquisition-date fair value	262
Cash transferred	227
Vesper Medical [Member] | At fair value [member]
Acquisitions and divestments [Line Items]
Contingent consideration recognised as of acquisition date	€ 34

Interests in entities - Text De

Interests in entities - Text Details (Detail) € in Millions	12 Months Ended
	Dec. 31, 2023 EUR (€)		Dec. 31, 2022 EUR (€)		Dec. 31, 2021 EUR (€)
Interests in entities [Line Items]
Presumed significant influence, voting rights	50%
Number of consolidated subsidiaries not wholly owned	4		4
Revenue	€ 18,169		€ 17,827		€ 17,156
Profit (loss)	(463)	[1]	(1,605)	[2]	€ 3,323	[2]
Net cash outflow for acquisitions	3
Gain (loss) recognized as a result of remeasuring to fair value equity interest in associate upon loss of significant influence	23
Share of profit (loss) of associates accounted for using equity method	51
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	33
Currency translation differences			1,866
Philips Medical Capital LLC [Member]
Interests in entities [Line Items]
Stake in unconsolidated structured entity	27		29
Associates [member]
Interests in entities [Line Items]
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	58
Currency translation differences	(21)		(22)
Subsidiaries with material non-controlling interests [member]
Interests in entities [Line Items]
Revenue	492		472
Profit (loss)	€ 27		€ 28
Consolidated structured entities [member]
Interests in entities [Line Items]
Materiality threshold on group sales, income from operations or net income	5%
Bottom of range [member]
Interests in entities [Line Items]
Presumed significant influence, voting rights	20%
Top of range [member]
Interests in entities [Line Items]
Presumed significant influence, voting rights	50%
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Interests in entities - Interes

Interests in entities - Interests in group companies (Detail)	12 Months Ended
	Dec. 31, 2023
Philips (China) Investment Company Ltd [Member]
Interests in entities [Line Items]
Name of subsidiary	Philips (China) Investment Company, Ltd.
Principal place of business of subsidiary	China
Philips Medizin Systeme Boblingen GmbH [Member]
Interests in entities [Line Items]
Name of subsidiary	Philips Medizin Systeme Böblingen GmbH
Principal place of business of subsidiary	Germany	[1]
Philips Japan, Ltd. [member]
Interests in entities [Line Items]
Name of subsidiary	Philips Japan, Ltd.
Principal place of business of subsidiary	Japan
Philips Consumer Lifestyle BV [Member]
Interests in entities [Line Items]
Name of subsidiary	Philips Consumer Lifestyle B.V.
Principal place of business of subsidiary	Netherlands
Philips Medical Systems (Cleveland), Inc. [Member]
Interests in entities [Line Items]
Name of subsidiary	Philips Medical Systems (Cleveland), Inc.
Principal place of business of subsidiary	United States
ATL International LLC [Member]
Interests in entities [Line Items]
Name of subsidiary	ATL International LLC
Principal place of business of subsidiary	United States
Philips North America LLC [Member]
Interests in entities [Line Items]
Name of subsidiary	Philips North America LLC
Principal place of business of subsidiary	United States
Philips RS North America LLC [Member]
Interests in entities [Line Items]
Name of subsidiary	Philips RS North America LLC
Principal place of business of subsidiary	United States
[1] Application of Sec. 264 (3) and Sec. 264b HGB (German Commercial Code) for fully consolidated legal entities: Philips GmbH, Hamburg; Philips Medical Systems DMC GmbH, Hamburg; Respironics Deutschland GmbH & Co. KG, München; Philips Medizin Systeme Hofheim-Wallau GmbH, Hamburg; Philips Medizin Systeme Böblingen GmbH, Böblingen; TomTec Imaging Systems GmbH, Unterschleißheim; Forecare GmbH, Ratingen.

Income from operations - Text D

Income from operations - Text Details (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income from operations [Line Items]
Refunds provision		€ 174
Income from subleasing right-of-use assets		234	€ 258	€ 293
Transaction price allocated to remaining performance obligations		€ 15,571
Percentage of remaining performance obligations within 1 year		47%
Royalty income		€ 434	419	383
Impairment loss recognised in profit or loss, goodwill	[1]	8	1,357	15
Income from government grants		95	103	104
Other items	[1]	1,358	925	1,069
Respironics litigation provision [Member]
Income from operations [Line Items]
Other items	[1]	575
Investment re-measurement loss [Member]
Income from operations [Line Items]
Other items	[1]	23
Sleep & Respiratory Care [Member]
Income from operations [Line Items]
Impairment loss recognised in profit or loss, goodwill			(1,331)
Precision Diagnosis Solutions [Member]
Income from operations [Line Items]
Impairment loss recognised in profit or loss, goodwill			27
Goods or services transferred over time [member]
Income from operations [Line Items]
Royalty income		€ 283	€ 292	€ 220
Not later than one year [member]
Income from operations [Line Items]
Explanation of when entity expects to recognise transaction price allocated to remaining performance obligations as revenue		1 year
Later than one year [member]
Income from operations [Line Items]
Explanation of when entity expects to recognise transaction price allocated to remaining performance obligations as revenue		1 year
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Income from operations - Sales

Income from operations - Sales and costs by nature (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Income from operations [Abstract]
Revenue		€ 18,169		€ 17,827		€ 17,156
Raw materials and consumables used		4,626		4,320		4,142
Employee benefits expense		6,903		6,952		6,246
Depreciation and amortisation expense		1,261	[1]	1,602	[2]	1,323	[1]
Impairment loss recognised in profit or loss, goodwill	[3]	8		1,357		15
Transportation expense		668		756		645
Advertising expense		700		739		752
Lease expenses, net		51		39		19
Other operational costs		3,535		3,609		3,524
Other gains (losses)		(533)		18		63
Profit (loss) from operating activities		€ (115)		€ (1,529)		€ 553
[1] Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Income from operations - Sale_2

Income from operations - Sales composition (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income from operations [Abstract]
Revenue from sale of goods	€ 12,419	€ 12,139	€ 11,981
Revenue from rendering of services	4,926	4,878	4,374
Royalty income	434	419	383
Revenue from contracts with customers	17,779	17,435	16,738
Revenue From Other Sources	390	391	418
Revenue	€ 18,169	€ 17,827	€ 17,156

Income from operations - Disagg

Income from operations - Disaggregation of Sales per segment (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income from operations [Line Items]
Revenue from contracts with customers	€ 17,779	€ 17,435	€ 16,738
Revenue From Other Sources	390	391	418
Revenue	18,169	17,827	17,156
Diagnosis & Treatment [Member]
Income from operations [Line Items]
Revenue from contracts with customers	8,742	8,234	7,776
Revenue From Other Sources	76	55	50
Revenue	8,818	8,290	7,825
Connected Care [Member]
Income from operations [Line Items]
Revenue from contracts with customers	4,824	4,932	5,002
Revenue From Other Sources	314	336	369
Revenue	5,138	5,268	5,371
Personal Health [Member]
Income from operations [Line Items]
Revenue from contracts with customers	3,602	3,626	3,429
Revenue	3,602	3,626	3,429
Other [Member]
Income from operations [Line Items]
Revenue from contracts with customers	612	643	530
Revenue From Other Sources	0	0	0
Revenue	612	643	530
Goods or services transferred at point in time [member]
Income from operations [Line Items]
Revenue from contracts with customers	12,569	12,263	12,142
Goods or services transferred at point in time [member] | Diagnosis & Treatment [Member]
Income from operations [Line Items]
Revenue from contracts with customers	5,762	5,285	5,120
Goods or services transferred at point in time [member] | Connected Care [Member]
Income from operations [Line Items]
Revenue from contracts with customers	2,970	3,079	3,399
Goods or services transferred at point in time [member] | Personal Health [Member]
Income from operations [Line Items]
Revenue from contracts with customers	3,586	3,615	3,423
Goods or services transferred at point in time [member] | Other [Member]
Income from operations [Line Items]
Revenue from contracts with customers	251	284	200
Goods or services transferred over time [member]
Income from operations [Line Items]
Revenue from contracts with customers	5,210	5,172	4,596
Goods or services transferred over time [member] | Diagnosis & Treatment [Member]
Income from operations [Line Items]
Revenue from contracts with customers	2,978	2,950	2,656
Goods or services transferred over time [member] | Connected Care [Member]
Income from operations [Line Items]
Revenue from contracts with customers	1,854	1,853	1,604
Goods or services transferred over time [member] | Personal Health [Member]
Income from operations [Line Items]
Revenue from contracts with customers	16	11	6
Goods or services transferred over time [member] | Other [Member]
Income from operations [Line Items]
Revenue from contracts with customers	€ 361	€ 357	€ 330

Income from operations - Disa_2

Income from operations - Disaggregation of Sales per geographic area (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income from operations [Line Items]
Revenue from contracts with customers	€ 17,779	€ 17,435	€ 16,738
Revenue From Other Sources	390	391	418
Revenue	18,169	17,827	17,156
Western Europe [member]
Income from operations [Line Items]
Revenue from contracts with customers	3,770	3,572	3,624
Revenue From Other Sources	49	31	21
Revenue	3,819	3,603	3,645
North America [member]
Income from operations [Line Items]
Revenue from contracts with customers	7,470	7,502	6,695
Revenue From Other Sources	92	86	86
Revenue	7,562	7,588	6,781
Other Mature Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	1,378	1,369	1,386
Revenue From Other Sources	248	274	309
Revenue	1,626	1,643	1,694
Total Mature Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	12,618	12,443	11,705
Revenue From Other Sources	389	390	415
Revenue	13,007	12,833	12,120
Growth Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	5,161	4,992	5,033
Revenue From Other Sources	1	1	3
Revenue	5,162	4,993	5,036
Goods or services transferred at point in time [member]
Income from operations [Line Items]
Revenue from contracts with customers	12,569	12,263	12,142
Goods or services transferred at point in time [member] | Western Europe [member]
Income from operations [Line Items]
Revenue from contracts with customers	2,552	2,387	2,537
Goods or services transferred at point in time [member] | North America [member]
Income from operations [Line Items]
Revenue from contracts with customers	4,859	4,889	4,427
Goods or services transferred at point in time [member] | Other Mature Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	980	972	1,000
Goods or services transferred at point in time [member] | Total Mature Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	8,392	8,248	7,964
Goods or services transferred at point in time [member] | Growth Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	4,177	4,015	4,178
Goods or services transferred over time [member]
Income from operations [Line Items]
Revenue from contracts with customers	5,210	5,172	4,596
Goods or services transferred over time [member] | Western Europe [member]
Income from operations [Line Items]
Revenue from contracts with customers	1,221	1,183	1,087
Goods or services transferred over time [member] | North America [member]
Income from operations [Line Items]
Revenue from contracts with customers	2,608	2,612	2,268
Goods or services transferred over time [member] | Other Mature Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	398	399	386
Goods or services transferred over time [member] | Total Mature Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	4,227	4,194	3,741
Goods or services transferred over time [member] | Growth Geographies [member]
Income from operations [Line Items]
Revenue from contracts with customers	€ 984	€ 978	€ 856

Income from operations - Employ

Income from operations - Employee benefit expenses (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income from operations [Line Items]
Wages and salaries	€ 5,635	€ 5,594	€ 5,014
Share-based compensation costs	97	104	115
Post-employment benefits costs	402	439	396
Social security contributions	567	590	529
Voluntary social security contributions	202	225	192
Employee benefits expense	€ 6,903	€ 6,952	€ 6,246

Income from operations - Empl_2

Income from operations - Employees by category (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Production [Member]
Income from operations [Line Items]
Average number of employees	35,281	39,742	38,618
Research & development [Member]
Income from operations [Line Items]
Average number of employees	10,833	11,690	10,751
Other [Member]
Income from operations [Line Items]
Average number of employees	23,001	23,019	22,543
Employees [Member]
Income from operations [Line Items]
Average number of employees	69,115	74,451	71,912
Third party workers [Member]
Income from operations [Line Items]
Average number of employees	3,149	4,086	4,533
Aggregate continuing and discontinued operations [member]
Income from operations [Line Items]
Average number of employees	72,264	78,538	76,445

Income from operations - Empl_3

Income from operations - Employees by geographical location (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Aggregate continuing and discontinued operations [member]
Income from operations [Line Items]
Average number of employees	72,264	78,538	76,445
Country of domicile [member]
Income from operations [Line Items]
Average number of employees	9,794	11,180	11,142
Foreign countries [member]
Income from operations [Line Items]
Average number of employees	62,471	67,357	65,303

Income from operations - Deprec

Income from operations - Depreciation and amortization (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Income from operations [Line Items]
Depreciation and amortisation expense		€ 1,261	[1]	€ 1,602	[2]	€ 1,323	[1]
Property, plant and equipment [member]
Income from operations [Line Items]
Depreciation expense	[2]	689		711		630
Computer software [member]
Income from operations [Line Items]
Amortisation expense	[2]	98		117		88
Other intangible assets [member]
Income from operations [Line Items]
Amortisation expense	[2]	290		363		322
Capitalised development expenditure [member]
Income from operations [Line Items]
Amortisation expense	[2]	€ 184		€ 411		€ 284
[1] Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill Includes impairments; for impairment values please refer to Property, plant and equipment Intangible assets excluding goodwill

Income from operations - Audit

Income from operations - Audit and audit-related fees (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income from operations [Line Items]
Auditor's remuneration for audit services		€ 14.7	€ 15.2	€ 15.7
Audit-related fees	[1]	1	1	0.9
Auditor's remuneration for tax services		0
Auditor's remuneration		15.8	16.2	16.6
EY NL [Member]
Income from operations [Line Items]
Auditor's remuneration for audit services		9.7	9.5	10.3
Audit-related fees	[1]	0.9	0.8	0.6
Auditor's remuneration		10.6	10.3	10.9
EY Network [Member]
Income from operations [Line Items]
Auditor's remuneration for audit services		5.1	5.6	5.4
Audit-related fees	[1]	0.2	0.2	0.3
Auditor's remuneration for tax services		0
Auditor's remuneration		5.2	5.8	5.7
Consolidated financial statements [Member]
Income from operations [Line Items]
Auditor's remuneration for audit services		12.3	12.6	13
Consolidated financial statements [Member] | EY NL [Member]
Income from operations [Line Items]
Auditor's remuneration for audit services		9.7	9.5	10.3
Consolidated financial statements [Member] | EY Network [Member]
Income from operations [Line Items]
Auditor's remuneration for audit services		2.6	3.1	2.7
Statutory financial statement [Member]
Income from operations [Line Items]
Auditor's remuneration for audit services		2.5	2.5	2.7
Statutory financial statement [Member] | EY Network [Member]
Income from operations [Line Items]
Auditor's remuneration for audit services		2.5	2.5	2.7
Sustainability assurance [Member]
Income from operations [Line Items]
Audit-related fees		0.8	0.6	0.5
Sustainability assurance [Member] | EY NL [Member]
Income from operations [Line Items]
Audit-related fees		0.8	0.6	0.5
Other services [Member]
Income from operations [Line Items]
Audit-related fees		0.3	0.3	0.4
Other services [Member] | EY NL [Member]
Income from operations [Line Items]
Audit-related fees		0.1	0.1	0.1
Other services [Member] | EY Network [Member]
Income from operations [Line Items]
Audit-related fees		€ 0.2	€ 0.2	€ 0.3
[1] Also known as Assurance fees

Income from operations - Other

Income from operations - Other business income (expenses) (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income from operations [Abstract]
Gains on disposal of businesses	€ 50	€ 4	€ 0
Losses on disposal of businesses	0	0	75
Gains on disposals of non-current assets	12	3	24
Losses on disposals of non-current assets	1	1	5
Gains on other remaining businesses	49	121	161
Losses on other remaining businesses	643	109	43
Other gains (losses)	(533)	18	63
Other income	112	127	186
Other expense, by function	€ 645	€ 109	€ 123

Financial income and expenses -

Financial income and expenses - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Financial income and expenses [Abstract]
Increase (decrease) in financial income expense	€ 114	€ 161
Increase (decrease) in net interest expense	€ 21	€ 69

Financial income and expenses_2

Financial income and expenses - Financial income and expenses (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financial income and expenses [Abstract]
Interest income	€ 46	€ 25	€ 18
Interest income on loans and receivables	13	7	7
Interest income on cash and cash equivalents	33	18	11
Dividend Income From Financial Assets	2	3	2
Net Gains From Disposal Of Financial Assets	0	0	0
Gains (losses) on financial assets at fair value through profit or loss	(26)	9	95
Other finance income (cost)	15	20	33
Finance income	63	58	149
Interest expense	277	235	159
Interest expense on borrowings	229	200	126
Interest expense on lease liabilities	27	25	25
Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)	(21)	(10)	(8)
Provision-related accretion and interest	29	9	5
Net foreign exchange loss	23	(9)	0
Other finance cost	21	24	24
Finance costs	376	258	188
Finance income (cost)	€ (314)	€ (200)	€ (39)

Income taxes - Text Details (De

Income taxes - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income taxes [Line Items]
Tax expense (income)	€ (73)	€ (113)	€ (103)
Tax expense (income) relating to profit (loss) from ordinary activities of discontinued operations	€ 9	€ 18	€ 737
Applicable tax rate	25.80%	25.80%	25%
Global minimum corporate income tax rate	15%
Pillar Two - Consolidated revenue threshold	€ 750
Pillar Two – Sensitivity analysis result	16.40%
Pillar Two – Sensitivity analysis gap	0.60%
Average effective tax rate	17%	6.50%	(20.00%)
Net deferred tax assets	€ 2,556	€ 2,358
Deferred tax assets	2,627	2,449
Deferred tax liabilities	71	91
Deferred tax asset when utilisation is dependent on future taxable profits in excess of profits from reversal of taxable temporary differences and entity has suffered loss in jurisdiction to which deferred tax asset relates	1,676	1,453
Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised	444	355
Deductible temporary differences for which no deferred tax asset is recognised	125	45
Other tax liability	€ 390	€ 435

Income taxes - Income tax expen

Income taxes - Income tax expense (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income taxes [Line Items]
Profit (loss) before tax	€ (526)	€ (1,731)	€ 509
Share of profit (loss) of associates and joint ventures accounted for using equity method	(98)	(2)	(4)
Income before taxes continuing operations	(429)	(1,729)	513
Current tax expense (income) and adjustments for current tax of prior periods	201	97	298
Deferred tax expense (income) recognised in profit or loss	274	210	401
Tax expense (income)	€ (73)	€ (113)	€ (103)

Income taxes - Current income t

Income taxes - Current income tax expense (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income taxes [Abstract]
Current tax expense (income)	€ 211	€ 111	€ 291
Adjustments for current tax of prior periods	(10)	(14)	7
Current tax expense (income) and adjustments for current tax of prior periods	€ 201	€ 97	€ 298

Income taxes - Deferred income

Income taxes - Deferred income tax expense (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income taxes [Abstract]
Changes to Recognition of Tax Loss and Credit Carry Forwards	€ 72	€ 2	€ 138
Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense	(41)	(13)	(10)
Changes to Recognition of Temporary Differences	(112)	(4)	(1)
Adjustments for deferred tax of prior periods	(2)	(1)	20
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes	4	(18)	10
Deferred tax expense (income) relating to origination and reversal of temporary differences	353	244	245
Deferred tax expense (income) recognised in profit or loss	€ 274	€ 210	€ 401

Income taxes - Effective income

Income taxes - Effective income tax rate (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income taxes [Abstract]
Weighted average statutory income tax rate	22%	23.60%	22.70%
Recognition of previously unrecognized tax loss and credit carryforwards rate	16.80%	0.10%	(26.90%)
Unrecognized tax loss and credit carryforwards rate	(9.60%)	(0.70%)	1.90%
Changes to Recognition of Temporary Differences Rate	(26.20%)	(0.20%)	0.30%
Tax rate effect of revenues exempt from taxation	22.80%	5.80%	(40.60%)
Tax rate effect of expense not deductible in determining taxable profit (tax loss)	(10.70%)	(22.90%)	19.30%
Withholding and other taxes	(5.10%)	(1.40%)	7.20%
Tax rate effect from change in tax rate	0.90%	(1.00%)	(1.90%)
Tax rate effect of adjustments for current tax of prior periods	1.90%	0.70%	(2.40%)
Tax expenses (benefit) due to other tax liabilities	2.30%	2.80%	4.40%
Other tax rate effects for reconciliation between accounting profit and tax expense (income)	1.90%	(0.20%)	(4.00%)
Average effective tax rate	17%	6.50%	(20.00%)

Income taxes - Deferred tax ass

Income taxes - Deferred tax assets and liabilities (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income taxes [Line Items]
Deferred tax expense (income) recognised in profit or loss	€ 274	€ 210	€ 401
Net deferred tax assets	2,556	2,358
Intangible assets and goodwill [member]
Income taxes [Line Items]
Deferred tax liability (asset)	(679)	(630)	(587)
Deferred tax expense (income) recognised in profit or loss	61	63
Other changes in deferred tax assets and liabilities	(12)	(20)
Net deferred tax assets	826	783
Net deferred tax liabilities	147	152
Property, plant and equipment [member]
Income taxes [Line Items]
Deferred tax liability (asset)	88	2	(29)
Deferred tax expense (income) recognised in profit or loss	18	(33)
Other changes in deferred tax assets and liabilities	(103)	2
Net deferred tax assets	44	49
Net deferred tax liabilities	132	52
Inventories [Member]
Income taxes [Line Items]
Deferred tax liability (asset)	(360)	(464)	(372)
Deferred tax expense (income) recognised in profit or loss	(26)	75
Other changes in deferred tax assets and liabilities	(78)	17
Net deferred tax assets	363	473
Net deferred tax liabilities	2	8
Other assets [member]
Income taxes [Line Items]
Deferred tax liability (asset)	(184)	(44)	(68)
Deferred tax expense (income) recognised in profit or loss	20	(16)
Other changes in deferred tax assets and liabilities	120	(8)
Net deferred tax assets	233	98
Net deferred tax liabilities	48	55
Pensions and other employee benefits [Member]
Income taxes [Line Items]
Deferred tax liability (asset)	(193)	(153)	(180)
Deferred tax expense (income) recognised in profit or loss	69	6
Other changes in deferred tax assets and liabilities	(29)	(32)
Net deferred tax assets	204	175
Net deferred tax liabilities	11	22
Other liabilities [Member]
Income taxes [Line Items]
Deferred tax liability (asset)	(496)	(483)	(499)
Deferred tax expense (income) recognised in profit or loss	(56)	(34)
Other changes in deferred tax assets and liabilities	69	17
Net deferred tax assets	521	560
Net deferred tax liabilities	25	77
Deferred tax assets on taxLoss carryforwards [Member]
Income taxes [Line Items]
Deferred tax liability (asset)	(730)	(586)	(398)
Deferred tax expense (income) recognised in profit or loss	188	149
Other changes in deferred tax assets and liabilities	(44)	38
Net deferred tax assets	730	586
Set-off deffered tax positions [Member]
Income taxes [Line Items]
Net deferred tax assets	(294)	(275)
Net deferred tax liabilities	(294)	(275)
Net deferred tax assets [Member]
Income taxes [Line Items]
Deferred tax liability (asset)	(2,556)	(2,358)	€ (2,134)
Deferred tax expense (income) recognised in profit or loss	274	210
Other changes in deferred tax assets and liabilities	(77)	14
Net deferred tax assets	2,627	2,449
Net deferred tax liabilities	€ 71	€ 91

Income taxes - Expiry years of

Income taxes - Expiry years of net operating loss and credit carryforwards (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Income taxes [Line Items]
Net operating loss carryforwards	€ 3,896	€ 3,187
Net operating loss and tax credit carryforwards for which no deferred tax asset has been recognized	1,366	1,032
Not later than one year [member]
Income taxes [Line Items]
Net operating loss carryforwards	17	4
Net operating loss and tax credit carryforwards for which no deferred tax asset has been recognized	15	3
Later than one year and not later than two years [member]
Income taxes [Line Items]
Net operating loss carryforwards	20	10
Net operating loss and tax credit carryforwards for which no deferred tax asset has been recognized	16	5
Later than two years and not later than three years [member]
Income taxes [Line Items]
Net operating loss carryforwards	7	9
Net operating loss and tax credit carryforwards for which no deferred tax asset has been recognized	2	3
Later than three years and not later than four years [member]
Income taxes [Line Items]
Net operating loss carryforwards	9	13
Net operating loss and tax credit carryforwards for which no deferred tax asset has been recognized	5	4
Later than four years and not later than five years [member]
Income taxes [Line Items]
Net operating loss carryforwards	38	38
Net operating loss and tax credit carryforwards for which no deferred tax asset has been recognized	16	3
Later than five years [member]
Income taxes [Line Items]
Net operating loss carryforwards	808	812
Net operating loss and tax credit carryforwards for which no deferred tax asset has been recognized	81	93
Unlimited [Member]
Income taxes [Line Items]
Net operating loss carryforwards	2,997	2,301
Net operating loss and tax credit carryforwards for which no deferred tax asset has been recognized	€ 1,231	€ 920

Earnings per share - Text Detai

Earnings per share - Text Details (Detail) - € / shares		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [Abstract]
Dividends paid, ordinary shares per share	[1]	€ 0.85	€ 0.85	€ 0.85
Number of shares issued		39,334,938	14,174,568	6,345,968
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Earnings per share - Earnings p

Earnings per share - Earnings per share (Detail) - EUR (€) € / shares in Units, € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Earnings per share [Abstract]
Profit (loss) from continuing operations		€ (454)	[1]	€ (1,618)	[2]	€ 612	[2]
Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share	[1]	(456)		(1,622)		608
Profit (loss) from continuing operations attributable to non-controlling interests	[1]	2		3		4
Profit (loss) from discontinued operations		(10)	[2]	13	[2]	2,711	[1]
Income from discontinued operations attributable to owners of parent	[1]	(10)		13		2,711
Profit (loss)		(463)	[1]	(1,605)	[2]	3,323	[2]
Profit (loss), attributable to owners of parent	[1]	(466)		(1,608)		3,319
Profit (loss), attributable to non-controlling interests	[1]	€ 2		€ 3		€ 4
Weighted average number of ordinary shares used in calculating basic earnings per share	[1]	917,440,090		920,950,800		943,606,613
Incremental shares from assumed conversions of options	[1]			25,506		387,125
Incremental shares from assumed conversions of performance shares	[1]	2,623,097		1,147,790		2,548,891
Incremental shares from assumed conversions of restricted share rights	[1]	2,574,738		1,986,538		2,376,736
Incremental shares from assumed conversions of forward contracts	[1]	15,511,844		17,611,920		70,329
Dilutive potential common shares	[1],[3]	20,709,680		20,771,753		5,383,080
Diluted weighted average number of shares (after deduction of treasury shares) during the year	[1]	917,440,090		920,950,800		948,989,692
Basic earnings (loss) per share from continuing operations attributable to shareholders	[1]	€ (0.5)		€ (1.76)		€ 0.64
Basic earnings (loss) per share from discontinued operations	[1]	(0.01)		0.01		2.87
Basic earnings (loss) per share	[1],[4]	(0.51)		(1.75)		3.52
Diluted earnings (loss) per share from continuing operations attributable to shareholders	[1],[3]	(0.5)		(1.76)		0.64
Diluted earnings (loss) per share from discontinued operations	[1],[3]	(0.01)		0.01		2.86
Diluted earnings (loss) per share	[1],[3],[4]	(0.51)		(1.75)		3.5
Dividends paid, ordinary shares per share	[1]	€ 0.85		€ 0.85		€ 0.85
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. The dilutive potential common shares are not taken into account in the periods for which there is a loss, as the effect would be antidilutive Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Property, plant and equipment -

Property, plant and equipment - Useful lives of property, plant and equipment (Detail)	12 Months Ended
	Dec. 31, 2023
Buildings [member] | Bottom of range [member]
Property, plant and equipment [Line Items]
Useful life measured as period of time, property, plant and equipment	5 years
Buildings [member] | Top of range [member]
Property, plant and equipment [Line Items]
Useful life measured as period of time, property, plant and equipment	50 years
Machinery [member] | Bottom of range [member]
Property, plant and equipment [Line Items]
Useful life measured as period of time, property, plant and equipment	3 years
Machinery [member] | Top of range [member]
Property, plant and equipment [Line Items]
Useful life measured as period of time, property, plant and equipment	20 years
Other property, plant and equipment [member] | Bottom of range [member]
Property, plant and equipment [Line Items]
Useful life measured as period of time, property, plant and equipment	1 year
Other property, plant and equipment [member] | Top of range [member]
Property, plant and equipment [Line Items]
Useful life measured as period of time, property, plant and equipment	10 years

Property, plant and equipment_2

Property, plant and equipment - Property, plant and equipment (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, plant and equipment [Line Items]
Property, plant and equipment	€ 2,483	€ 2,638
Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment	1,565	1,718
Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment	€ 919	€ 919	€ 1,058

Property, plant and equipment_3

Property, plant and equipment - Property, plant and equipment - owned assets (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	€ 2,638
Assets available for use		€ 0
Reclassifications	12	(2)
Property, plant and equipment at end of period	2,483	2,638
Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	1,718
Additions other than through business combinations, property, plant and equipment	433	494
Assets available for use	(8)	(6)
Depreciation, property, plant and equipment	420	447
Impairment loss recognised in profit or loss, property, plant and equipment	45	42
Decrease through classified as held for sale, property, plant and equipment	46	3
Reclassifications	(6)	29
Increase (decrease) through net exchange differences, property, plant and equipment	(62)	50
Increase (decrease) in property, plant and equipment	(154)	78
Property, plant and equipment at end of period	1,565	1,718
Owned [member] | IFRS 16 [Member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	1,718	1,641
Property, plant and equipment at end of period	1,565	1,718
Gross carrying amount [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	4,676	4,273
Property, plant and equipment at end of period	4,521	4,676
Accumulated depreciation, amortisation and impairment [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	(2,958)	(2,632)
Property, plant and equipment at end of period	(2,957)	(2,958)
Land and buildings [member] | Owned [member]
Property, plant and equipment [Line Items]
Additions other than through business combinations, property, plant and equipment	1	1
Assets available for use	20	34
Depreciation, property, plant and equipment	56	56
Impairment loss recognised in profit or loss, property, plant and equipment	5	3
Decrease through classified as held for sale, property, plant and equipment	1	3
Reclassifications	15	18
Increase (decrease) through net exchange differences, property, plant and equipment	(14)	16
Increase (decrease) in property, plant and equipment	(39)	8
Land and buildings [member] | Owned [member] | IFRS 16 [Member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	514	506
Property, plant and equipment at end of period	476	514
Land and buildings [member] | Gross carrying amount [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	1,135	1,097
Property, plant and equipment at end of period	1,114	1,135
Land and buildings [member] | Accumulated depreciation, amortisation and impairment [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	(621)	(591)
Property, plant and equipment at end of period	(638)	(621)
Machinery [member] | Owned [member]
Property, plant and equipment [Line Items]
Additions other than through business combinations, property, plant and equipment	115	102
Assets available for use	90	69
Depreciation, property, plant and equipment	196	215
Impairment loss recognised in profit or loss, property, plant and equipment	23	20
Decrease through classified as held for sale, property, plant and equipment	1
Reclassifications	2	14
Increase (decrease) through net exchange differences, property, plant and equipment	(22)	26
Increase (decrease) in property, plant and equipment	(35)	(23)
Machinery [member] | Owned [member] | IFRS 16 [Member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	488	511
Property, plant and equipment at end of period	453	488
Machinery [member] | Gross carrying amount [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	1,779	1,585
Property, plant and equipment at end of period	1,731	1,779
Machinery [member] | Accumulated depreciation, amortisation and impairment [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	(1,291)	(1,074)
Property, plant and equipment at end of period	(1,278)	(1,291)
Other equipment [Member] | Owned [member]
Property, plant and equipment [Line Items]
Additions other than through business combinations, property, plant and equipment	77	77
Assets available for use	144	111
Depreciation, property, plant and equipment	167	176
Impairment loss recognised in profit or loss, property, plant and equipment	17	18
Decrease through classified as held for sale, property, plant and equipment	45	0
Reclassifications	(17)	(5)
Increase (decrease) through net exchange differences, property, plant and equipment	(19)	2
Increase (decrease) in property, plant and equipment	(45)	(8)
Other equipment [Member] | Owned [member] | IFRS 16 [Member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	408	415
Property, plant and equipment at end of period	363	408
Other equipment [Member] | Gross carrying amount [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	1,454	1,382
Property, plant and equipment at end of period	1,404	1,454
Other equipment [Member] | Accumulated depreciation, amortisation and impairment [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	(1,046)	(967)
Property, plant and equipment at end of period	(1,041)	(1,046)
Construction in progress [member] | Owned [member]
Property, plant and equipment [Line Items]
Additions other than through business combinations, property, plant and equipment	239	314
Assets available for use	(262)	(220)
Depreciation, property, plant and equipment		0
Impairment loss recognised in profit or loss, property, plant and equipment	0	1
Reclassifications	(5)	2
Increase (decrease) through net exchange differences, property, plant and equipment	(7)	5
Increase (decrease) in property, plant and equipment	(35)	100
Construction in progress [member] | Owned [member] | IFRS 16 [Member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	309	208
Property, plant and equipment at end of period	274	309
Construction in progress [member] | Gross carrying amount [member] | Owned [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	309	208
Property, plant and equipment at end of period	€ 274	€ 309

Property, plant and equipment_4

Property, plant and equipment - Property, plant and equipment - right-of-use assets (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	€ 2,638
Assets available for use		€ 0
Reclassifications	12	(2)
Property, plant and equipment at end of period	2,483	2,638
Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	919	1,058
Additions other than through business combinations, property, plant and equipment	236	106
Assets available for use	8	6
Depreciation, property, plant and equipment	201	214
Impairment loss recognised in profit or loss, property, plant and equipment	23	9
Decrease through classified as held for sale, property, plant and equipment	2	(3)
Reclassifications	4	(32)
Increase (decrease) through net exchange differences, property, plant and equipment	(23)	1
Increase (decrease) in property, plant and equipment	(1)	(139)
Property, plant and equipment at end of period	919	919
Gross carrying amount [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	1,571	1,724
Property, plant and equipment at end of period	1,641	1,571
Accumulated depreciation, amortisation and impairment [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	(651)	(666)
Property, plant and equipment at end of period	(722)	(651)
Land and buildings [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	822	914
Additions other than through business combinations, property, plant and equipment	175	52
Assets available for use	2	5
Depreciation, property, plant and equipment	150	155
Impairment loss recognised in profit or loss, property, plant and equipment	23	8
Decrease through classified as held for sale, property, plant and equipment	2	(3)
Reclassifications	0	(19)
Increase (decrease) through net exchange differences, property, plant and equipment	(18)	31
Increase (decrease) in property, plant and equipment	(16)	(92)
Property, plant and equipment at end of period	806	822
Land and buildings [member] | Gross carrying amount [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	1,365	1,332
Property, plant and equipment at end of period	1,425	1,365
Land and buildings [member] | Accumulated depreciation, amortisation and impairment [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	(543)	(418)
Property, plant and equipment at end of period	(619)	(543)
Other equipment [Member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	98	107
Additions other than through business combinations, property, plant and equipment	62	54
Assets available for use	6	1
Depreciation, property, plant and equipment	51	58
Impairment loss recognised in profit or loss, property, plant and equipment	0	0
Reclassifications	4	0
Increase (decrease) through net exchange differences, property, plant and equipment	(5)	(6)
Increase (decrease) in property, plant and equipment	15	(9)
Property, plant and equipment at end of period	112	98
Other equipment [Member] | Gross carrying amount [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	206	216
Property, plant and equipment at end of period	216	206
Other equipment [Member] | Accumulated depreciation, amortisation and impairment [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	(108)	(109)
Property, plant and equipment at end of period	(104)	(108)
Machinery [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	0	37
Additions other than through business combinations, property, plant and equipment		0
Depreciation, property, plant and equipment		2
Impairment loss recognised in profit or loss, property, plant and equipment		0
Reclassifications		(13)
Increase (decrease) through net exchange differences, property, plant and equipment		(23)
Increase (decrease) in property, plant and equipment		(37)
Property, plant and equipment at end of period		0
Machinery [member] | Gross carrying amount [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period	€ 0	176
Property, plant and equipment at end of period		0
Machinery [member] | Accumulated depreciation, amortisation and impairment [member] | Right-of-use assets [member]
Property, plant and equipment [Line Items]
Property, plant and equipment at beginning of period		€ (139)

Goodwill - Text Details (Detail

Goodwill - Text Details (Detail) € in Millions		12 Months Ended
		Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Goodwill [Line Items]
Impairment loss recognised in profit or loss, goodwill	[1]	€ 8	€ 1,357	€ 15
Amount by which unit's recoverable amount exceeds its carrying amount		€ 326
Precision Diagnosis business group [Member]
Goodwill [Line Items]
Impairment loss recognised in profit or loss, goodwill			€ 27
Sleep & Respiratory Care [Member]
Goodwill [Line Items]
Initial forecast period		0.095	0.10
Growth rate used to extrapolate cash flow projections		9.30%	5%
Impairment loss recognised in profit or loss, goodwill			€ (1,331)
Sensitivity pre-tax discount rate		190
Sensitivity compound long-term sales growth		690
Sensitivity terminal value		27%
Goodwill [member]
Goodwill [Line Items]
Initial forecast period		4
Impairment loss recognised in profit or loss, goodwill		€ 8	€ 1,357
Decrease through classified as held for sale, intangible assets and goodwill	[2]	8
Goodwill [member] | Precision Diagnosis business group [Member]
Goodwill [Line Items]
Decrease through classified as held for sale, intangible assets and goodwill		€ 16
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Refer to Discontinued operations and assets classified as held for sale

Goodwill - Goodwill (Detail)

Goodwill - Goodwill (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Line Items]
Impairment loss recognised in profit or loss, goodwill	[1]	€ 8	€ 1,357	€ 15
Goodwill [member]
Goodwill [Line Items]
Intangible assets and goodwill at beginning of period		10,238	10,637
Intangible assets and goodwill		9,876	10,238	10,637
Acquisitions through business combinations, intangible assets and goodwill	[2]	24	317
Impairment loss recognised in profit or loss, goodwill		8	1,357
Decrease through classified as held for sale, intangible assets and goodwill	[3]	8
Increase (decrease) through net exchange differences, intangible assets and goodwill		(370)	641
Increase (decrease) in goodwill		(362)	(399)
Intangible assets and goodwill at end of period		9,876	10,238	10,637
Gross carrying amount [member] | Goodwill [member]
Goodwill [Line Items]
Intangible assets and goodwill at beginning of period		12,747	11,793
Intangible assets and goodwill		12,133	12,747	11,793
Intangible assets and goodwill at end of period		12,133	12,747	11,793
Accumulated impairment [member] | Goodwill [member]
Goodwill [Line Items]
Intangible assets and goodwill at beginning of period		2,509	1,156
Intangible assets and goodwill		2,256	2,509	1,156
Intangible assets and goodwill at end of period		€ 2,256	€ 2,509	€ 1,156
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Refer to Acquisitions and divestments Refer to Discontinued operations and assets classified as held for sale

Goodwill - Goodwill by business

Goodwill - Goodwill by business (Detail) - EUR (€) € in Millions		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Line Items]
Goodwill		€ 9,876	€ 10,238
Goodwill [member]
Goodwill [Line Items]
Intangible assets and goodwill		9,876	10,238	€ 10,637
Monitoring [Member]
Goodwill [Line Items]
Goodwill	[1]	3,964	4,110
Image-Guided Therapy [Member]
Goodwill [Line Items]
Goodwill		3,044	3,154
Precision Diagnosis [Member]
Goodwill [Line Items]
Goodwill		1,363	1,429
Sleep & Respiratory Care [Member]
Goodwill [Line Items]
Goodwill		687	731
Personal Health [Member]
Goodwill [Line Items]
Goodwill		483	488
Enterprise Informatics [Member]
Goodwill [Line Items]
Goodwill		336	327
Cash-generating units [member] | Goodwill [member]
Goodwill [Line Items]
Intangible assets and goodwill		€ 9,876	€ 10,238
[1] Monitoring includes the goodwill previously allocated to Hospital Patient Monitoring and Ambulatory Monitoring & Diagnostics as disclosed in the Annual Report 2022.

Goodwill - Key assumptions (Det

Goodwill - Key assumptions (Detail)		Dec. 31, 2023	Dec. 31, 2022
Goodwill [member]
Goodwill [Line Items]
Initial forecast period		4
Monitoring [Member]
Goodwill [Line Items]
Initial forecast period		0.082
Growth rate used to extrapolate cash flow projections		5.50%
Used to calculate terminal value		2.50%
Monitoring [Member] | Goodwill [member]
Goodwill [Line Items]
Discount rate applied to cash flow projections		9.50%
Image-Guided Therapy [Member]
Goodwill [Line Items]
Initial forecast period		0.079	0.087
Growth rate used to extrapolate cash flow projections		5.20%	5%
Used to calculate terminal value		2.50%	2.50%
Discount rate applied to cash flow projections		10.70%
Image-Guided Therapy [Member] | Goodwill [member]
Goodwill [Line Items]
Discount rate applied to cash flow projections			10.60%
Precision Diagnosis [Member]
Goodwill [Line Items]
Initial forecast period		0.038
Growth rate used to extrapolate cash flow projections		3.40%
Used to calculate terminal value		2.50%
Discount rate applied to cash flow projections		10.40%
Sleep & Respiratory Care [Member]
Goodwill [Line Items]
Initial forecast period		0.095	0.10
Growth rate used to extrapolate cash flow projections		9.30%	5%
Used to calculate terminal value		2.50%	2.50%
Discount rate applied to cash flow projections		10.80%	9.90%
Personal Health [Member]
Goodwill [Line Items]
Initial forecast period		0.05
Growth rate used to extrapolate cash flow projections		4.60%
Used to calculate terminal value		2.50%
Discount rate applied to cash flow projections		10.30%
Enterprise Informatics [Member]
Goodwill [Line Items]
Initial forecast period		0.053
Growth rate used to extrapolate cash flow projections		5.80%
Used to calculate terminal value		2.50%
Discount rate applied to cash flow projections		9%
Ambulatory Monitoring & Diagnostics [Member]
Goodwill [Line Items]
Initial forecast period	[1]		0.154
Growth rate used to extrapolate cash flow projections	[1]		9.50%
Used to calculate terminal value	[1]		2.50%
Discount rate applied to cash flow projections	[1]		8.50%
Hospital Patient Monitoring [Member]
Goodwill [Line Items]
Initial forecast period	[1]		0.048
Growth rate used to extrapolate cash flow projections	[1]		3.40%
Used to calculate terminal value	[1]		2.50%
Discount rate applied to cash flow projections	[1]		8.50%
[1] Effective April 1, 2023, the Hospital Patient Monitoring and Ambulatory Monitoring & Diagnostics CGUs are included in the group of CGUs that comprise the Monitoring business.

Intangible assets excluding g_3

Intangible assets excluding goodwill - Text Details (Detail) € in Millions	12 Months Ended
	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Intangible assets excluding goodwill [Line Items]
Acquisitions through business combinations, intangible assets other than goodwill	€ 40	€ 180
Impairment loss recognised in profit or loss, intangible assets other than goodwill	16	276
Intangible assets other than goodwill	€ 3,190	€ 3,526	€ 3,650
Brand names, customer relationships, technology and other intangible assets [Member]
Intangible assets excluding goodwill [Line Items]
Weighted average expected remaining life	9.3	9.4
Customer-related intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Acquisitions through business combinations, intangible assets other than goodwill		€ 3
Impairment loss recognised in profit or loss, intangible assets other than goodwill	€ 0	6
Intangible assets other than goodwill	875	1,070	1,143
Customer-related intangible assets [member] | Image Guided Therapy business group [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	€ 261	€ 291
Remaining amortisation period of intangible assets material to entity	14 years	15 years
Customer-related intangible assets [member] | BioTelemetry [Member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	€ 327	€ 385
Remaining amortisation period of intangible assets material to entity	13 years	14 years
Technology-based intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Acquisitions through business combinations, intangible assets other than goodwill	€ 40	€ 177
Impairment loss recognised in profit or loss, intangible assets other than goodwill	0	46
Intangible assets other than goodwill	1,013	1,102	€ 1,000
Technology-based intangible assets [member] | Image Guided Therapy business group [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	€ 175	€ 203
Remaining amortisation period of intangible assets material to entity	9 years	10 years
Technology-based intangible assets [member] | BioTelemetry [Member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	€ 123	€ 150
Remaining amortisation period of intangible assets material to entity	9 years	10 years

Intangible assets excluding g_4

Intangible assets excluding goodwill - Expected useful lives of intangible assets excluding goodwill (Detail)	12 Months Ended
	Dec. 31, 2023
Brand names [member] | Bottom of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	2 years
Brand names [member] | Top of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	20 years
Customer-related intangible assets [member] | Bottom of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	2 years
Customer-related intangible assets [member] | Top of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	25 years
Technology-based intangible assets [member] | Bottom of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	3 years
Technology-based intangible assets [member] | Top of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	20 years
Other intangible assets [member] | Bottom of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	1 year
Other intangible assets [member] | Top of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	10 years
Computer software [member] | Bottom of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	1 year
Computer software [member] | Top of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	10 years
Product development [Member] | Bottom of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	3 years
Product development [Member] | Top of range [member]
Intangible assets excluding goodwill [Line Items]
Useful life measured as period of time, intangible assets other than goodwill	10 years

Intangible assets excluding g_5

Intangible assets excluding goodwill - Intangible assets excluding goodwill (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	€ 3,190	€ 3,526
Intangible assets other than goodwill at beginning of period	3,526	3,650
Additions other than through business combinations, intangible assets other than goodwill	317	416
Assets available for use		0
Acquisitions through business combinations, intangible assets other than goodwill	40	180
Amortisation, intangible assets other than goodwill	556	614
Impairment loss recognised in profit or loss, intangible assets other than goodwill	16	276
Decrease through classified as held for sale, intangible assets other than goodwill	32
Increase (decrease) through net exchange differences, intangible assets other than goodwill	(87)	169
Increase (decrease) in intangible assets other than goodwill	(335)	(125)
Intangible assets other than goodwill at end of period	3,190	3,526
Brand names [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	118	140
Intangible assets other than goodwill at beginning of period	140	162
Additions other than through business combinations, intangible assets other than goodwill		(3)
Acquisitions through business combinations, intangible assets other than goodwill		1
Amortisation, intangible assets other than goodwill	20	24
Impairment loss recognised in profit or loss, intangible assets other than goodwill	0	0
Decrease through classified as held for sale, intangible assets other than goodwill	1
Increase (decrease) through net exchange differences, intangible assets other than goodwill	(1)	4
Increase (decrease) in intangible assets other than goodwill	(22)	(22)
Intangible assets other than goodwill at end of period	118	140
Customer-related intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	875	1,070
Intangible assets other than goodwill at beginning of period	1,070	1,143
Additions other than through business combinations, intangible assets other than goodwill		0
Acquisitions through business combinations, intangible assets other than goodwill		3
Amortisation, intangible assets other than goodwill	137	141
Impairment loss recognised in profit or loss, intangible assets other than goodwill	0	6
Decrease through classified as held for sale, intangible assets other than goodwill	20
Increase (decrease) through net exchange differences, intangible assets other than goodwill	(37)	71
Increase (decrease) in intangible assets other than goodwill	(195)	(74)
Intangible assets other than goodwill at end of period	875	1,070
Technology-based intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	1,013	1,102
Intangible assets other than goodwill at beginning of period	1,102	1,000
Additions other than through business combinations, intangible assets other than goodwill	33	51
Acquisitions through business combinations, intangible assets other than goodwill	40	177
Amortisation, intangible assets other than goodwill	131	140
Impairment loss recognised in profit or loss, intangible assets other than goodwill	0	46
Increase (decrease) through net exchange differences, intangible assets other than goodwill	(30)	59
Increase (decrease) in intangible assets other than goodwill	(89)	102
Intangible assets other than goodwill at end of period	1,013	1,102
Product development [Member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	336	393
Intangible assets other than goodwill at beginning of period	393	599
Additions other than through business combinations, intangible assets other than goodwill	0	0
Assets available for use	157	118
Acquisitions through business combinations, intangible assets other than goodwill	0	0
Amortisation, intangible assets other than goodwill	169	206
Impairment loss recognised in profit or loss, intangible assets other than goodwill	7	123
Increase (decrease) through net exchange differences, intangible assets other than goodwill	(38)	5
Increase (decrease) in intangible assets other than goodwill	(57)	(206)
Intangible assets other than goodwill at end of period	336	393
Product development construction in progress [Member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	544	502
Intangible assets other than goodwill at beginning of period	502	414
Additions other than through business combinations, intangible assets other than goodwill	214	257
Assets available for use	(157)	(118)
Amortisation, intangible assets other than goodwill		1
Impairment loss recognised in profit or loss, intangible assets other than goodwill	7	81
Decrease through classified as held for sale, intangible assets other than goodwill	8
Increase (decrease) through net exchange differences, intangible assets other than goodwill	1	31
Increase (decrease) in intangible assets other than goodwill	42	88
Intangible assets other than goodwill at end of period	544	502
Computer software [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	267	280
Intangible assets other than goodwill at beginning of period	280	287
Additions other than through business combinations, intangible assets other than goodwill	70	109
Assets available for use		0
Acquisitions through business combinations, intangible assets other than goodwill	0	0
Amortisation, intangible assets other than goodwill	97	100
Impairment loss recognised in profit or loss, intangible assets other than goodwill	1	17
Decrease through classified as held for sale, intangible assets other than goodwill	2
Increase (decrease) through net exchange differences, intangible assets other than goodwill	18	1
Increase (decrease) in intangible assets other than goodwill	(13)	(7)
Intangible assets other than goodwill at end of period	267	280
Other intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	38	39
Intangible assets other than goodwill at beginning of period	39	44
Additions other than through business combinations, intangible assets other than goodwill	0	1
Assets available for use		0
Acquisitions through business combinations, intangible assets other than goodwill		0
Amortisation, intangible assets other than goodwill	1	3
Impairment loss recognised in profit or loss, intangible assets other than goodwill	0	2
Increase (decrease) through net exchange differences, intangible assets other than goodwill	0	(2)
Increase (decrease) in intangible assets other than goodwill	(1)	(6)
Intangible assets other than goodwill at end of period	38	39
Gross carrying amount [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	10,265	10,602
Intangible assets other than goodwill at beginning of period	10,602	9,944
Intangible assets other than goodwill at end of period	10,265	10,602
Gross carrying amount [member] | Brand names [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	629	647
Intangible assets other than goodwill at beginning of period	647	644
Intangible assets other than goodwill at end of period	629	647
Gross carrying amount [member] | Customer-related intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	2,593	2,735
Intangible assets other than goodwill at beginning of period	2,735	2,590
Intangible assets other than goodwill at end of period	2,593	2,735
Gross carrying amount [member] | Technology-based intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	2,908	2,947
Intangible assets other than goodwill at beginning of period	2,947	2,605
Intangible assets other than goodwill at end of period	2,908	2,947
Gross carrying amount [member] | Product development [Member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	2,432	2,605
Intangible assets other than goodwill at beginning of period	2,605	2,701
Intangible assets other than goodwill at end of period	2,432	2,605
Gross carrying amount [member] | Product development construction in progress [Member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	635	648
Intangible assets other than goodwill at beginning of period	648	505
Intangible assets other than goodwill at end of period	635	648
Gross carrying amount [member] | Computer software [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	929	869
Intangible assets other than goodwill at beginning of period	869	754
Intangible assets other than goodwill at end of period	929	869
Gross carrying amount [member] | Other intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	139	152
Intangible assets other than goodwill at beginning of period	152	146
Intangible assets other than goodwill at end of period	139	152
Accumulated depreciation, amortisation and impairment [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	(7,075)	(7,077)
Intangible assets other than goodwill at beginning of period	(7,077)	(6,294)
Intangible assets other than goodwill at end of period	(7,075)	(7,077)
Accumulated depreciation, amortisation and impairment [member] | Brand names [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	(511)	(507)
Intangible assets other than goodwill at beginning of period	(507)	(481)
Intangible assets other than goodwill at end of period	(511)	(507)
Accumulated depreciation, amortisation and impairment [member] | Customer-related intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	(1,718)	(1,665)
Intangible assets other than goodwill at beginning of period	(1,665)	(1,447)
Intangible assets other than goodwill at end of period	(1,718)	(1,665)
Accumulated depreciation, amortisation and impairment [member] | Technology-based intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	(1,895)	(1,845)
Intangible assets other than goodwill at beginning of period	(1,845)	(1,605)
Intangible assets other than goodwill at end of period	(1,895)	(1,845)
Accumulated depreciation, amortisation and impairment [member] | Product development [Member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	(2,096)	(2,212)
Intangible assets other than goodwill at beginning of period	(2,212)	(2,102)
Intangible assets other than goodwill at end of period	(2,096)	(2,212)
Accumulated depreciation, amortisation and impairment [member] | Product development construction in progress [Member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	(91)	(146)
Intangible assets other than goodwill at beginning of period	(146)	(91)
Intangible assets other than goodwill at end of period	(91)	(146)
Accumulated depreciation, amortisation and impairment [member] | Computer software [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	(662)	(589)
Intangible assets other than goodwill at beginning of period	(589)	(467)
Intangible assets other than goodwill at end of period	(662)	(589)
Accumulated depreciation, amortisation and impairment [member] | Other intangible assets [member]
Intangible assets excluding goodwill [Line Items]
Intangible assets other than goodwill	(101)	(113)
Intangible assets other than goodwill at beginning of period	(113)	(101)
Intangible assets other than goodwill at end of period	€ (101)	€ (113)

Other financial assets - Text D

Other financial assets - Text Details (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other financial assets [Line Items]
Other current financial assets	€ 3	€ 11	€ 2
Non-current investments in equity instruments designated at fair value through other comprehensive income	€ 231	€ 259
12-month expected credit losses [member]
Other financial assets [Line Items]
Expected credit loss rate	1,200%

Other financial assets - Other

Other financial assets - Other non-current financial assets (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other financial assets [Line Items]
Non-current financial assets at fair value through profit or loss	€ 284	€ 322	€ 283
Non-current financial assets measured at fair value through other comprehensive income	258	284	300
Non-current financial assets at amortised cost	77	54	47
Other non-current financial assets	619	660	€ 630
Acquisitions	105	150
Sales redemptions	58	86
Value adjustment through OCI	(17)	(35)
Value adjustment through P&L	(39)	5
Translation Differences And Other	(44)	2
Reclassifications	12	(2)
Financial assets impaired [member]
Other financial assets [Line Items]
Impairment loss on financial assets		(5)
Financial assets at fair value through profit or loss, category [member]
Other financial assets [Line Items]
Acquisitions	71	114
Sales redemptions	33	75
Value adjustment through OCI	0	0
Value adjustment through P&L	(39)	5
Translation Differences And Other	(29)	(2)
Reclassifications	(8)	1
Financial assets at fair value through profit or loss, category [member] | Financial assets impaired [member]
Other financial assets [Line Items]
Impairment loss on financial assets		(3)
Financial assets at fair value through other comprehensive income, category [member]
Other financial assets [Line Items]
Acquisitions	14	18
Sales redemptions	14	3
Value adjustment through OCI	(17)	(35)
Translation Differences And Other	(14)	5
Reclassifications	5	(2)
Financial assets at amortised cost, category [member]
Other financial assets [Line Items]
Acquisitions	20	18
Sales redemptions	11	8
Value adjustment through P&L	0	0
Translation Differences And Other	(1)	(1)
Reclassifications	€ 15	(1)
Financial assets at amortised cost, category [member] | Financial assets impaired [member]
Other financial assets [Line Items]
Impairment loss on financial assets		€ (1)

Other assets - Text Details (De

Other assets - Text Details (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Other assets [Line Items]
Current contract assets	€ 297	€ 292
Non-current assets [member]
Other assets [Line Items]
Non-current prepaid expenses	93	98
Current assets [Member]
Other assets [Line Items]
Other current assets	500	490
Accrued income including contract assets	6	24
Current prepaid expenses	€ 197	€ 174

Inventories - Text Details (Det

Inventories - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Inventories [Line Items]
Inventory write-down	€ 339	€ 215
Respironics consent decree [Member]
Inventories [Line Items]
Inventory write-down	€ 82

Inventories - Inventories (Deta

Inventories - Inventories (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Inventories [Abstract]
Current raw materials and current production supplies	€ 1,309	€ 1,541
Current work in progress	552	648
Current finished goods	1,629	1,860
Current inventories	€ 3,491	€ 4,049

Receivables - Text Details (Det

Receivables - Text Details (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Receivables [Line Items]
Signify indemnification	€ 4	€ 26
Advance income tax payment	12	126
Non-current interest receivable	3
Trade and other current receivables	3,733	4,115
Current trade receivables	3,546	3,832
Other current receivables	170	228
Allowance for non-current customer finance receivables	8	7
Financial assets individually assessed for credit losses [member]
Receivables [Line Items]
Allowance account for credit losses of financial assets	210	222
Diagnosis & Treatment [Member]
Receivables [Line Items]
Loans and advances to customers	102	69
Current trade receivables	1,688	1,795
Other US [Member]
Receivables [Line Items]
Insurance receivables	33	30
Associates [member]
Receivables [Line Items]
Other current receivables	€ 18	€ 55

Receivables - Trade accounts re

Receivables - Trade accounts receivable, net (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Receivables [Line Items]
Current trade receivables	€ 3,546	€ 3,832
Diagnosis & Treatment [Member]
Receivables [Line Items]
Current trade receivables	1,688	1,795
Connected Care [Member]
Receivables [Line Items]
Current trade receivables	1,105	1,332
Personal Health [Member]
Receivables [Line Items]
Current trade receivables	576	479
Other Segments [member]
Receivables [Line Items]
Current trade receivables	€ 177	€ 226

Receivables - Aging analysis (D

Receivables - Aging analysis (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Receivables [Line Items]
Current trade receivables	€ 3,546	€ 3,832
Current [member]
Receivables [Line Items]
Current trade receivables	3,132	3,280
Not later than one month [member]
Receivables [Line Items]
Current trade receivables	117	169
Later than one month and not later than six months [member]
Receivables [Line Items]
Current trade receivables	234	282
Later than six months [member]
Receivables [Line Items]
Current trade receivables	€ 63	€ 101

Receivables - Allowance for acc

Receivables - Allowance for accounts receivable (Detail) - Doubtful accounts receivable [Member] - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Receivables [Line Items]
Allowance account for credit losses of financial assets at beginning of period		€ 226	€ 190
Additional allowance recognised in profit or loss, allowance account for credit losses of financial assets		27	66
Utilisation, allowance account for credit losses of financial assets	[1]	(26)	(51)
Increase (decrease) through other changes, allowance account for credit losses of financial assets		(10)	21
Allowance account for credit losses of financial assets at end of period		216	€ 226
Assets and liabilities classified as held for sale [member]
Receivables [Line Items]
Increase (decrease) through other changes, allowance account for credit losses of financial assets		€ (1)
[1] Write-offs for which an allowance was previously provided.

Equity - Text Details (Detail)

Equity - Text Details (Detail) - EUR (€) € / shares in Units, € in Millions		1 Months Ended	3 Months Ended	12 Months Ended
		Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 14, 2023	Oct. 31, 2022	Oct. 26, 2022	Jun. 13, 2022	Nov. 23, 2021	Sep. 30, 2021	Jul. 26, 2021	Dec. 31, 2020
Equity [Line Items]
Number of shares authorised			2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000
Withholding and other taxes				(5.10%)	(1.40%)	7.20%
Other tax liability				€ 390	€ 435
Notional amount					€ 500
Number of shares purchased through forward contracts			2,000,000	7,100,000	3,200,000	2,000,000			1,750,000					5,000,000
Forward price for unsettled (open) forward contracts			€ 44.85	€ 19.43	€ 19.75	€ 44.85								€ 34.85
Increase (Decrease) retained earnings connected to long-term incentive				€ 125	€ 57
Purchase of treasury shares				€ 0	24	€ 757
Reduction of treasury shares				15,100,000
Cancellation of treasury shares				€ 566
Borrowings			€ 6,980	€ 7,689	€ 8,201	€ 6,980		€ 1,000
Dividends paid, ordinary shares per share	[1]			€ 0.85	€ 0.85	€ 0.85
Dividends paid, ordinary shares				€ 749	€ 741	€ 773
Number of shares issued			6,345,968	39,334,938	14,174,568	6,345,968
Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share					€ 0.85
Percentage of shareholders electing share dividend					45%	38%
Settlement of cash dividend					€ 411	€ 482
Shareholder equity subject to limitations				€ 2,435	3,054
Shareholder Equity Subject To Limitations Ordinary Shares				183	178
Legal reserves required by Dutch law				990	1,010
Equity			€ 14,475	12,061	13,283	€ 14,475								€ 11,901
Currency translation differences					1,866
Purchase forward contracts [Member]
Equity [Line Items]
Notional amount				224	211		€ 138			€ 63	€ 90			174
Purchase forward contracts capital reduction [Member]
Equity [Line Items]
Notional amount				€ 167	€ 648
Share buyback program [Member]
Equity [Line Items]
Borrowings													€ 1,500
Euro [Member]
Equity [Line Items]
Number of options outstanding					55,750
Ordinary shares [member]
Equity [Line Items]
Number of shares authorised			2,000,000,000	2,000,000,000	2,000,000,000	2,000,000,000
Number of shares issued and fully paid			883,898,969	913,515,966	889,315,082	883,898,969
Par value per share				€ 0.2
Treasury shares [member]
Equity [Line Items]
Purchase of treasury shares					€ 24	€ 758
Cancellation of treasury shares				€ 566	299	1,228
Equity			€ (476)	(262)	€ (275)	€ (476)								€ (199)
Treasury shares [member] | Euro [Member]
Equity [Line Items]
Cash outflow for share purchase transactions related to employee option and share plans and reduction of share capital				€ 662
Capital reduction [Member]
Equity [Line Items]
Withholding and other taxes				6,600,000,000%
Other tax liability				€ 11
Number of shares purchased through forward contracts				4,400,000	17,400,000
Share repurchase LTI [Member]
Equity [Line Items]
Number of treasury shares				7,100,000	3,300,000
Increase (Decrease) retained earnings connected to long-term incentive				€ 35
Share repurchase LTI [Member] | Performance share plans [Member]
Equity [Line Items]
Number of shares purchased through forward contracts				11,100,000
Share repurchase LTI 2022 [Member]
Equity [Line Items]
Number of treasury shares				4,300,000	3,200,000
Share repurchase LTI 2021 [Member]
Equity [Line Items]
Number of treasury shares			2,000,000			2,000,000
Increase (Decrease) retained earnings connected to long-term incentive				€ 90
Share repurchase LTI 2021 [Member] | Performance share plans [Member]
Equity [Line Items]
Number of shares purchased through forward contracts					7,000,000
Share repurchase LTI 2020 [Member]
Equity [Line Items]
Number of treasury shares														6,000,000
Share repurchase program [member]
Equity [Line Items]
Number of treasury shares				15,100,000	2,200,000
Notional amount			€ 781	€ 481	€ 83	€ 781
Purchase of treasury shares						1,500
Purchase of treasury shares, number of		800,000	21,000,000
Forward share repurchase contracts [Member]
Equity [Line Items]
Number of treasury shares												20,000,000
Notional amount												€ 731
Forward price for unsettled (open) forward contracts												€ 37.36
Share repurchase program – Capital reduction [Member]
Equity [Line Items]
Notional amount				483
Reserve of exchange differences on translation [member]
Equity [Line Items]
Equity			€ 1,117	1,263	1,866	1,117								€ (58)
Reserve of cash flow hedges [member]
Equity [Line Items]
Equity			(25)	6	(2)	(25)								23
Reserve of gains and losses on financial assets measured at fair value through other comprehensive income [member]
Equity [Line Items]
Equity			€ (344)	€ (390)	€ (376)	€ (344)								€ (305)
Dividend distribution [Member] | Bottom of range [member]
Equity [Line Items]
Dividend payout ratio				40%
Dividend distribution [Member] | Top of range [member]
Equity [Line Items]
Dividend payout ratio				50%
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Equity - Outstanding number of

Equity - Outstanding number of shares (Detail) - Ordinary shares [member] - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Line Items]
Number of shares outstanding at beginning of period	881,480,527	870,182,445	905,128,293
Dividend distributed	39,334,938	14,174,568	6,345,968
Purchase of treasury shares, number of	(15,964,445)	(5,080,693)	(45,486,392)
Re-issuance of treasury shares, number of	1,552,136	2,204,207	4,194,577
Number of shares outstanding at end of period	906,403,156	881,480,527	870,182,445

Equity - Transactions related t

Equity - Transactions related to share-based compensation plans (Detail) - EUR (€) € / shares in Units, € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Line Items]
Purchase of treasury shares	€ 0	€ 24	€ 757
Treasury shares for share-based payments [Member]
Equity [Line Items]
Shares acquired	3,000,000	2,142,445	3,996,576
Average market price	€ 41.59	€ 31.76	€ 36.15
Purchase of treasury shares	€ 125	€ 68	€ 144
Shares delivered	1,552,136	2,204,207	4,194,577
Average price (FIFO)	€ 34.59	€ 35.16	€ 34.14
Cost of delivered shares	€ 54	€ 77	€ 143
Shares in treasury, at the end of the period	7,112,810	5,664,946	5,726,708
Cost of treasury shares for employee options	€ 262	€ 191	€ 201

Equity - Transactions related_2

Equity - Transactions related to capital reduction (Detail) - EUR (€) € / shares in Units, € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Line Items]
Purchase of treasury shares	€ 0	€ 24	€ 757
Reduction of treasury shares	15,100,000
Cancellation of treasury shares	€ 566
Treasury shares transactions [Member]
Equity [Line Items]
Shares acquired	12,964,445	2,938,248	41,489,816
Average market price	€ 37.25	€ 36.61	€ 36.22
Purchase of treasury shares	€ 483	€ 108	€ 1,503
Reduction of treasury shares	15,134,054	8,758,455	33,500,000
Cancellation of treasury shares	€ 566	€ 299	€ 1,216
Shares in treasury, at the end of the period		2,169,609	7,989,816
Total cost		€ 83	€ 287

Equity - Composition of net deb

Equity - Composition of net debt and group equity (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Oct. 31, 2022	Dec. 31, 2020
Equity [Abstract]
Non-current portion of non-current borrowings	€ 7,035	€ 7,270	€ 6,473
Current borrowings and current portion of non-current borrowings	654	931	506
Borrowings	7,689	8,201	6,980	€ 1,000
Cash and cash equivalents	1,869	1,172	2,303		€ 3,226
Net debt	5,820	7,028	4,676
Equity attributable to owners of parent	12,028	13,249	14,438
Non-controlling interests	33	34	36
Equity	€ 12,061	€ 13,283	€ 14,475		€ 11,901
Net debt and group equity ratio	33:67	35:65	24:76

Equity - Adjusted income from c

Equity - Adjusted income from continuing operations attributable to shareholders (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Equity [Line Items]
Profit (loss)		€ (463)	[1]	€ (1,605)	[2]	€ 3,323	[2]
Profit (loss) from discontinued operations		(10)	[2]	13	[2]	2,711	[1]
Profit (loss) from continuing operations		(454)	[1]	(1,618)	[2]	612	[2]
Income from continuing operations attributable to non-controlling interests	[2]	(2)		(3)		(4)
Income from continuing operations attributable to owners of parent	[2]	(456)		(1,622)		608
Amortization of acquired intangible assets	[2]	290		363		322
Impairment loss recognised in profit or loss, goodwill	[2]	8		1,357		15
Restructuring and acquisition-related charges	[2]	381		202		95
Other items	[2]	1,358		925		1,069
Net finance expenses	[2]	18		(4)		(84)
Tax impact of adjusted items	[2]	(450)		(376)		(527)
Adjusted Income from continuing operations attributable to shareholders	[2]	1,148		845		1,497
Respironics litigation provision [Member]
Equity [Line Items]
Other items	[2]	575
Respironics field-action connected to the anticipated consent decree [Member]
Equity [Line Items]
Other items	[2]	363		250		719
Respironics field-action running remediation costs [Member]
Equity [Line Items]
Other items	[2]	224		210		94
Quality remediation actions [Member]
Equity [Line Items]
Other items	[2]	175		59		94
R&D project impairments [Member]
Equity [Line Items]
Other items	[2]			134
Portfolio realignment charges [Member]
Equity [Line Items]
Other items	[2]			109
Impairment of assets in S&RC [Member]
Equity [Line Items]
Other items	[2]			39
Provision for public investigations tender irregularities [Member]
Equity [Line Items]
Other items	[2]			60
Provision for a legal matter [Member]
Equity [Line Items]
Other items	[2]	31
Investment re-measurement loss [Member]
Equity [Line Items]
Other items	[2]	23
Loss on divestment of business [Member]
Equity [Line Items]
Other items	[2]					76
Gain on divestment of business [Member]
Equity [Line Items]
Other items	[2]	(35)
Remaining items [Member]
Equity [Line Items]
Other items	[2]	€ 2		€ 63		€ 87
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022. Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.

Debt - Text Details (Detail)

Debt - Text Details (Detail) € in Millions, $ in Billions	12 Months Ended
	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2023 USD ($)	Aug. 31, 2023 EUR (€)	Jun. 14, 2023 EUR (€)	Oct. 31, 2022 EUR (€)	Sep. 30, 2022 EUR (€)	Jun. 13, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Nov. 23, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Sep. 03, 2020 EUR (€)	Mar. 09, 2020 EUR (€)
Debt [Line Items]
Notional amount		€ 500
Euro Medium-Term Note program	€ 3,300	2,000		€ 500								€ 10,000	€ 10,000
Change of Control Triggering Event, potentially required purchase price related to principal amount	101%		101%
Increase (Decrease) retained earnings connected to long-term incentive	€ 125	57
Borrowings	€ 7,689	€ 8,201				€ 1,000			€ 6,980
Weighted average [member]
Debt [Line Items]
Borrowings, interest rate	2.90%	2.40%	2.90%
Share repurchase program [member]
Debt [Line Items]
Notional amount	€ 481	€ 83							€ 781
Commercial Paper Programme [Member]
Debt [Line Items]
Notional amount			$ 2.5			€ 101	€ 200
Committed revolving credit facility [Member]
Debt [Line Items]
Undrawn borrowing facilities	1,000
Purchase forward contracts [Member]
Debt [Line Items]
Notional amount	224	€ 211			€ 138			€ 63		€ 90	€ 174
Purchase forward contracts [Member] | Not later than one year [member]
Debt [Line Items]
Notional amount	61
Purchase forward contracts [Member] | Later than one year and not later than two years [member]
Debt [Line Items]
Notional amount	€ 77
Bank borrowings [Member] | Weighted average [member]
Debt [Line Items]
Borrowings, interest rate	8.60%	5.70%	8.60%

Debt - Long-term debt (Detail)

Debt - Long-term debt (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt [Line Items]
Long-term debt including current portion of long-term debt	€ 7,568	€ 8,111
Non-current portion of non-current borrowings	€ 7,035	7,270	€ 6,473
Borrowings, maturity	6.0
Current portion of non-current borrowings	€ 532	842
Forward contract [member]
Debt [Line Items]
Long-term debt including current portion of long-term debt	396	858
Non-current portion of non-current borrowings	76	252
Current portion of non-current borrowings	321	606
Lease liabilities [member]
Debt [Line Items]
Long-term debt including current portion of long-term debt	1,074	1,082
Non-current portion of non-current borrowings	864	852
Current portion of non-current borrowings	211	230
Bank borrowings [Member]
Debt [Line Items]
Long-term debt including current portion of long-term debt	203	705
Non-current portion of non-current borrowings	201	702
Current portion of non-current borrowings	1	2
Other long-term debt [Member]
Debt [Line Items]
Long-term debt including current portion of long-term debt	0	28
Non-current portion of non-current borrowings	0	24
Current portion of non-current borrowings	0	4
US Dollar [Member] | Bonds [Member]
Debt [Line Items]
Long-term debt including current portion of long-term debt	1,325	1,378
Euro [Member] | Bonds [Member]
Debt [Line Items]
Long-term debt including current portion of long-term debt	€ 4,569	€ 4,061
Weighted average [member]
Debt [Line Items]
Borrowings, maturity	6.0	6.1
Borrowings, interest rate	2.90%	2.40%
Weighted average [member] | Forward contract [member]
Debt [Line Items]
Borrowings, maturity	0.8	1.0
Borrowings, interest rate	1.40%
Weighted average [member] | Lease liabilities [member]
Debt [Line Items]
Borrowings, maturity	3.9	3.9
Borrowings, interest rate	3.10%	2.40%
Weighted average [member] | Bank borrowings [Member]
Debt [Line Items]
Borrowings, maturity	1.2	1.9
Borrowings, interest rate	4.20%	1.70%
Weighted average [member] | Other long-term debt [Member]
Debt [Line Items]
Borrowings, maturity	7.4	8.9
Borrowings, interest rate	1.20%	2.90%
Weighted average [member] | US Dollar [Member] | Bonds [Member]
Debt [Line Items]
Borrowings, maturity	13.3	14.3
Borrowings, interest rate	6.30%	6.30%
Weighted average [member] | Euro [Member] | Bonds [Member]
Debt [Line Items]
Borrowings, maturity	5.1	5.7
Borrowings, interest rate	2%	1.70%
Later than one year [member] | US Dollar [Member] | Bonds [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	€ 1,325	€ 1,378
Later than one year [member] | Euro [Member] | Bonds [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	4,569	4,061
Later than one year and not later than five years [member]
Debt [Line Items]
Non-current portion of non-current borrowings	3,357	3,562
Later than one year and not later than five years [member] | Forward contract [member]
Debt [Line Items]
Non-current portion of non-current borrowings	76	252
Later than one year and not later than five years [member] | Lease liabilities [member]
Debt [Line Items]
Long-term debt including current portion of long-term debt	505	505
Non-current portion of non-current borrowings	505	504
Later than one year and not later than five years [member] | Bank borrowings [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	201	702
Later than one year and not later than five years [member] | Other long-term debt [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	0	17
Later than one year and not later than five years [member] | US Dollar [Member] | Bonds [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	240	250
Later than one year and not later than five years [member] | Euro [Member] | Bonds [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	2,335	1,836
Later than five years [member]
Debt [Line Items]
Non-current portion of non-current borrowings	3,678	3,706
Later than five years [member] | Lease liabilities [member]
Debt [Line Items]
Long-term debt including current portion of long-term debt	358	348
Non-current portion of non-current borrowings	358	348
Later than five years [member] | Other long-term debt [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	0	6
Later than five years [member] | US Dollar [Member] | Bonds [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	1,085	1,128
Later than five years [member] | Euro [Member] | Bonds [Member]
Debt [Line Items]
Non-current portion of non-current borrowings	€ 2,234	€ 2,225

Debt - Unsecured Bonds (Detail)

Debt - Unsecured Bonds (Detail) - EUR (€)		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt [Line Items]
Non-current portion of non-current borrowings		€ 7,035,000,000	€ 7,270,000,000	€ 6,473,000,000
Unsecured bonds [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		5,894	5,439
Euro [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 30/03/2025 1 3/8% [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		346	346
Euro [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 22/05/2026 1/2 percent [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		750	750
Euro [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 05/05/2027 1 7/8% [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		750	750
Euro [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 05/02/2028 1 3/8 Percent [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		500	500
Euro [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 05/11/2029 2 1/8% [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		650	650
Euro [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 30/03/2030 2% [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		500	500
Euro [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds due 08/09/2031 4 2.8% [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		500
Euro [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 05/05/2033 2 5/8% [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		€ 600	600
Euro [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured EUR Bonds Due 30/03/2025 1 3/8% [Member]
Debt [Line Items]
Borrowings, interest rate		1.509%
Euro [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured EUR Bonds Due 22/05/2026 1/2 percent [Member]
Debt [Line Items]
Borrowings, interest rate		0.608%
Euro [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured EUR Bonds Due 05/05/2027 1 7/8% [Member]
Debt [Line Items]
Borrowings, interest rate		2.049%
Euro [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured EUR Bonds Due 05/11/2029 2 1/8% [Member]
Debt [Line Items]
Borrowings, interest rate		4.33%
Euro [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured EUR Bonds Due 30/03/2030 2% [Member]
Debt [Line Items]
Borrowings, interest rate		2.128%
Euro [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured EUR Bonds Due 05/05/2033 2 5/8% [Member]
Debt [Line Items]
Borrowings, interest rate		2.71%
Euro [Member] | Effective interest rate [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 05/02/2028 1 3/8 Percent [Member]
Debt [Line Items]
Borrowings, interest rate		1.523%
Euro [Member] | Effective interest rate [Member] | Unsecured bonds [Member] | Unsecured EUR Bonds Due 05/11/2029 2 1/8% [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		€ 0.02441
US Dollar [Member] | Unsecured bonds [Member]
Debt [Line Items]
Unsecured bonds adjustments	[1]	(47)	(57)
US Dollar [Member] | Unsecured bonds [Member] | Unsecured USD Bonds Due 05/15/2025 7 3/4 Percent [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		49	51
US Dollar [Member] | Unsecured bonds [Member] | Unsecured USD Bonds Due 05/15/2025 7 1/8 Percent [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		75	78
US Dollar [Member] | Unsecured bonds [Member] | Unsecured USD Bonds Due 06/01/2026 7 1/5 Percent [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		114	119
US Dollar [Member] | Unsecured bonds [Member] | Unsecured USD Bonds Due 11/03/2038 6 7/8 Percent [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		657	683
US Dollar [Member] | Unsecured bonds [Member] | Unsecured USD Bonds Due 03/15/2042 5 Percent [Member]
Debt [Line Items]
Non-current portion of non-current borrowings		€ 452	€ 470
US Dollar [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured USD Bonds Due 05/15/2025 7 3/4 Percent [Member]
Debt [Line Items]
Borrowings, interest rate		7.429%
US Dollar [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured USD Bonds Due 05/15/2025 7 1/8 Percent [Member]
Debt [Line Items]
Borrowings, interest rate		6.794%
US Dollar [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured USD Bonds Due 06/01/2026 7 1/5 Percent [Member]
Debt [Line Items]
Borrowings, interest rate		6.885%
US Dollar [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured USD Bonds Due 11/03/2038 6 7/8 Percent [Member]
Debt [Line Items]
Borrowings, interest rate		7.21%
US Dollar [Member] | Effective interest rate [Member] | Long-term borrowings [member] | Unsecured USD Bonds Due 03/15/2042 5 Percent [Member]
Debt [Line Items]
Borrowings, interest rate		5.273%
[1] Adjustments related to both EUR and USD bonds and concern bond discounts, premium and transaction costs.

Debt - Lease liabilities (Detai

Debt - Lease liabilities (Detail) - EUR (€) € in Millions		Dec. 31, 2023	Dec. 31, 2022
Debt [Line Items]
Gross lease liabilities		€ 1,200	€ 1,180
Current interest payable	[1],[2]	1,704
Long-term debt including current portion of long-term debt		7,568	8,111
Interest payable		76	71
Lease liabilities [member]
Debt [Line Items]
Long-term debt including current portion of long-term debt		1,074	1,082
Interest payable		125	98
Not later than one year [member]
Debt [Line Items]
Gross lease liabilities		239	251
Current interest payable	[1],[2]	180
Not later than one year [member] | Lease liabilities [member]
Debt [Line Items]
Current interest payable		28	21
Long-term debt including current portion of long-term debt		211	230
Later than one year and not later than five years [member]
Debt [Line Items]
Gross lease liabilities		572	554
Later than one year and not later than five years [member] | Lease liabilities [member]
Debt [Line Items]
Long-term debt including current portion of long-term debt		505	505
Non-current interest payable		67	49
Later than five years [member]
Debt [Line Items]
Gross lease liabilities		388	376
Current interest payable	[1],[2]	911
Later than five years [member] | Lease liabilities [member]
Debt [Line Items]
Long-term debt including current portion of long-term debt		358	348
Non-current interest payable		€ 30	€ 28
[1] Amounts in this table are undiscounted This table excludes post-employment benefit plan contribution commitments and income tax liabilities in respect of tax risks because it is not possible to make a reasonably reliable estimate of the actual period of cash settlement.

Debt - Short-term debt (Detail)

Debt - Short-term debt (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt [Abstract]
Short-term bank borrowings	€ 122	€ 89
Current portion of non-current borrowings	532	842
Current borrowings and current portion of non-current borrowings	€ 654	€ 931	€ 506

Provisions - Text Details (Deta

Provisions - Text Details (Detail) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 EUR (€)
Provisions [Line Items]
Number of replaced and repaired devices	5,600,000
Remediation costs	€ 224		€ 210
Charges in connection with the proposed Respironics consent decree	363
Additional provisions, other provisions	1,836		1,049
Inventory write-down	339		215
Provision used, other provisions	€ 1,266		€ 1,274
Number of employees reduced	6,000		4,000
Restructuring provision	€ 140		€ 80
Estimated financial effect of contingent liabilities			60
Settlement related to alleged tender irregularities	58
Fund in relation to the economic loss class action settlement | $		$ 155
Contingent Consideration	115		113
Acquisitions through business combinations, other provisions	6		99
Currency in which supplementary information is displayed [member]
Provisions [Line Items]
Fund in relation to the economic loss class action settlement	€ 141
Not later than five years [Member]
Provisions [Line Items]
Provision utilization period	five years	five years
Warranty provision [member]
Provisions [Line Items]
Additional provisions, other provisions	€ 313		320
Provision used, other provisions	268		224
Warranty provision [member] | Diagnosis & Treatment [Member]
Provisions [Line Items]
Additional provisions, other provisions	81
Other environment related provision [member]
Provisions [Line Items]
Additional provisions, other provisions	18		15
Provision used, other provisions	14		17
Other environment related provision [member] | Later than one year and not later than five years [member]
Provisions [Line Items]
Provision used, other provisions	€ 63
Other environment related provision long term [member] | Bottom of range [member]
Provisions [Line Items]
Provision utilization period	one	one
Other environment related provision long term [member] | Top of range [member]
Provisions [Line Items]
Provision utilization period	five	five
Other environment related provision remainder [member]
Provisions [Line Items]
Provision utilization period	five	five
Legal proceedings provision [member]
Provisions [Line Items]
Additional provisions, other provisions	€ 644		89
Provision used, other provisions	235		100
Acquisitions through business combinations, other provisions			4
Legal proceedings provision [member] | Respironics litigation provision [Member]
Provisions [Line Items]
Additional provisions, other provisions	€ 575
Legal proceedings provision [member] | Not later than three years [member]
Provisions [Line Items]
Provision utilization period	three	three
Provisions for contingent considerations [Member]
Provisions [Line Items]
Additional provisions, other provisions	€ 24
Provision used, other provisions	20		105
Acquisitions through business combinations, other provisions	6		96
Provisions for contingent considerations [Member] | Intact Vascular [Member]
Provisions [Line Items]
Contingent Consideration	€ 20
Provisions for contingent considerations [Member] | Not later than three years [member]
Provisions [Line Items]
Provision utilization period	three	three
Contingent Consideration	€ 28
Provisions for contingent considerations [Member] | Later than five years [member]
Provisions [Line Items]
Provision utilization period	four	four
Respironics field action [Member]
Provisions [Line Items]
Additional provisions, other provisions	€ 240		250
Provision used, other provisions	€ 285		€ (486)
Respironics field action [Member] | Ten percentage point increase [Member]
Provisions [Line Items]
Sensitivity analysis effect of change in main assumption	10	10
Respironics field action [Member] | Ten percentage point increase [Member] | Refund portion [Member]
Provisions [Line Items]
Sensitivity analysis effect of change in main assumption	19,000,000	19,000,000
Respironics consent decree [Member]
Provisions [Line Items]
Inventory write-down	€ 82
Onerous contracts provision	31
Impairment loss recognised in profit or loss, property, plant and equipment	€ 6

Provisions - Provisions (Detail

Provisions - Provisions (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Provisions [Line Items]
Current provisions	€ 1,463	€ 1,018	€ 998
Non-current provisions	1,035	1,097	1,315
Provisions	2,498	2,115	2,313
Additional provisions, other provisions	1,836	1,049
Provision used, other provisions	1,266	1,274
Unused provision reversed, other provisions	159	59
Increase through adjustments arising from passage of time, other provisions	25	2
Acquisitions through business combinations, other provisions	6	99
Increase (decrease) through change in discount rate, other provisions	(6)	(27)
Increase (decrease) through net exchange differences, other provisions	(53)	97
Increase (decrease) in other provisions	383	(198)
Change in Fair value on contingent consideration		(86)
Respironics field action [Member]
Provisions [Line Items]
Current provisions	331	366	525
Non-current provisions	3	23	52
Provisions	334	390	577
Additional provisions, other provisions	240	250
Provision used, other provisions	285	(486)
Increase (decrease) through net exchange differences, other provisions	(10)	49
Increase (decrease) in other provisions	(55)	(187)
Warranty provision [member]
Provisions [Line Items]
Current provisions	293	287	207
Non-current provisions	64	57	32
Provisions	357	344	238
Additional provisions, other provisions	313	320
Provision used, other provisions	268	224
Unused provision reversed, other provisions	20
Increase (decrease) through net exchange differences, other provisions	(12)	9
Increase (decrease) in other provisions	13	105
Other environment related provision [member]
Provisions [Line Items]
Current provisions	22	20	26
Non-current provisions	80	83	99
Provisions	102	104	124
Additional provisions, other provisions	18	15
Provision used, other provisions	14	17
Unused provision reversed, other provisions	2	2
Increase through adjustments arising from passage of time, other provisions	5	4
Increase (decrease) through change in discount rate, other provisions	(6)	(27)
Increase (decrease) through net exchange differences, other provisions	(3)	7
Increase (decrease) in other provisions	(2)	(21)
Restructuring provision [member]
Provisions [Line Items]
Current provisions	102	134	58
Non-current provisions	14	6	8
Provisions	116	140	66
Additional provisions, other provisions	263	154
Provision used, other provisions	219	61
Unused provision reversed, other provisions	67	18
Increase (decrease) through transfers and other changes, other provisions	(2)	(1)
Increase (decrease) in other provisions	(24)	74
Legal proceedings provision [member]
Provisions [Line Items]
Current provisions	477	74	39
Non-current provisions	10	14	53
Provisions	487	89	91
Additional provisions, other provisions	644	89
Provision used, other provisions	235	100
Unused provision reversed, other provisions	10	3
Increase through adjustments arising from passage of time, other provisions	23	0
Acquisitions through business combinations, other provisions		4
Increase (decrease) through net exchange differences, other provisions	(23)	7
Increase (decrease) in other provisions	399	(3)
Provisions for contingent considerations [Member]
Provisions [Line Items]
Current provisions	57	23	52
Non-current provisions	58	89	156
Provisions	115	113	208
Additional provisions, other provisions	24
Provision used, other provisions	20	105
Unused provision reversed, other provisions	7
Increase through adjustments arising from passage of time, other provisions	1
Acquisitions through business combinations, other provisions	6	96
Increase (decrease) through net exchange differences, other provisions	(2)
Increase (decrease) in other provisions	2	(95)
Change in Fair value on contingent consideration		(86)
Miscellaneous other provisions [member]
Provisions [Line Items]
Current provisions	181	112	92
Non-current provisions	248	279	257
Provisions	429	390	349
Additional provisions, other provisions	223	160
Provision used, other provisions	134	95
Unused provision reversed, other provisions	45	35
Increase through adjustments arising from passage of time, other provisions	(3)	(3)
Increase (decrease) through net exchange differences, other provisions	(1)	14
Increase (decrease) in other provisions	39	41
Post-employement benefit [Member]
Provisions [Line Items]
Non-current provisions	558	546	659
Provisions	558	546	€ 659
Additional provisions, other provisions	112	61
Provision used, other provisions	91	185
Unused provision reversed, other provisions	10	1
Increase (decrease) through net exchange differences, other provisions	0	12
Increase (decrease) in other provisions	€ 12	€ (113)

Provisions - Restructuring-rela

Provisions - Restructuring-related provisions (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Provisions [Line Items]
Provisions	€ 2,498	€ 2,115	€ 2,313
Restructuring provision [member]
Provisions [Line Items]
Provisions	116	140	€ 66
Restructuring provision [member] | Diagnosis & Treatment [Member]
Provisions [Line Items]
Provisions	36	42
Restructuring provision [member] | Connected Care [Member]
Provisions [Line Items]
Provisions	18	42
Restructuring provision [member] | Personal Health [Member]
Provisions [Line Items]
Provisions	7	10
Restructuring provision [member] | Other [Member]
Provisions [Line Items]
Provisions	€ 56	€ 47

Provisions - Other provisions (

Provisions - Other provisions (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Provisions [Line Items]
Other provisions	€ 89	€ 97
Provisions	2,498	2,115	€ 2,313
Provisions for employee jubilee funds [Member]
Provisions [Line Items]
Other provisions	77	83
Self-insurance provisions [Member]
Provisions [Line Items]
Other provisions	63	57
Provision for taxes other than income tax [member]
Provisions [Line Items]
Other provisions	51	46
Provisions for rights of return [Member]
Provisions [Line Items]
Other provisions	39	36
Provision for decommissioning, restoration and rehabilitation costs [member]
Provisions [Line Items]
Other provisions	34	33
Onerous contracts provision [member]
Provisions [Line Items]
Other provisions	76	38
Miscellaneous other provisions [member]
Provisions [Line Items]
Provisions	€ 429	€ 390	€ 349

Post-employment benefits - Text

Post-employment benefits - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Post-employment benefits [Line Items]
Percentage of unquoted assets		36%	32%
Actuarial assumption of mortality rates		0.10
Description of methods and assumptions used in preparing sensitivity analysis for actuarial assumptions		1%
Weighted average duration of defined benefit obligation		10 years	8 years
Employer contributions	€ 434
Current service cost, defined benefit plans	30
Interest expense (income), defined benefit plans	21
Wholly or partly funded defined benefit plans [member]
Post-employment benefits [Line Items]
Employer contributions	17
Unfunded defined-benefit plans [Member]
Post-employment benefits [Line Items]
Employer contributions	42
Defined contribution plans [Member]
Post-employment benefits [Line Items]
Employer contributions	375
Bottom of range [member]
Post-employment benefits [Line Items]
Increase in actuarial assumption of life expectancy after retirement		6 months
Top of range [member]
Post-employment benefits [Line Items]
Increase in actuarial assumption of life expectancy after retirement		1 year
Germany [Member]
Post-employment benefits [Line Items]
Actuarial assumption of mortality rates		0.93
Weighted average duration of defined benefit obligation		11 years
Employer contributions	8
Germany [Member] | Unfunded defined-benefit plans [Member]
Post-employment benefits [Line Items]
Employer contributions	20
Germany [Member] | Bottom of range [member]
Post-employment benefits [Line Items]
Age		60
Germany [Member] | Top of range [member]
Post-employment benefits [Line Items]
Age		85
United States of America [Member]
Post-employment benefits [Line Items]
Weighted average duration of defined benefit obligation		8 years
Employer contributions	0
United States of America [Member] | Unfunded defined-benefit plans [Member]
Post-employment benefits [Line Items]
Employer contributions	10
United States of America [Member] | Defined contribution plans [Member]
Post-employment benefits [Line Items]
Employer contributions	136
Other countries [Member]
Post-employment benefits [Line Items]
Weighted average duration of defined benefit obligation		10 years
Employer contributions	9
Other countries [Member] | Unfunded defined-benefit plans [Member]
Post-employment benefits [Line Items]
Employer contributions	12
Other countries [Member] | Defined contribution plans [Member]
Post-employment benefits [Line Items]
Employer contributions	65
Netherlands [Member] | Defined contribution plans [Member]
Post-employment benefits [Line Items]
Employer contributions	€ 174

Post-employment benefits - Post

Post-employment benefits - Post-employment benefits (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Post-employment benefits [Line Items]
Present value of funded obligations	€ 1,097	€ 1,108
Present value of unfunded obligations	508	513
Net defined benefit liability (asset)	516	499
Value of reimbursement rights	8	6
Post-employement benefit [Member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	516	499
Present value of defined benefit obligation [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	1,605	1,621	€ 1,970
Plan assets [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	1,089	1,122	€ 1,380
Germany [Member]
Post-employment benefits [Line Items]
Present value of funded obligations	511	489
Present value of unfunded obligations	253	249
Net defined benefit liability (asset)	283	261
Germany [Member] | Present value of defined benefit obligation [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	764	738
Germany [Member] | Plan assets [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	481	477
United States of America [Member]
Post-employment benefits [Line Items]
Present value of funded obligations	(404)	440
Present value of unfunded obligations	118	128
Net defined benefit liability (asset)	80	94
United States of America [Member] | Post-employement benefit [Member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	80
United States of America [Member] | Present value of defined benefit obligation [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	522	568
United States of America [Member] | Plan assets [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	442	474
Other countries [Member]
Post-employment benefits [Line Items]
Present value of funded obligations	(182)	179
Present value of unfunded obligations	137	136
Net defined benefit liability (asset)	153	144
Value of reimbursement rights	8	6
Other countries [Member] | Present value of defined benefit obligation [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	319	315
Other countries [Member] | Plan assets [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	€ 166	€ 171

Post-employment benefits - Clas

Post-employment benefits - Classification net position (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Post-employment benefits [Line Items]
Other non-current assets	€ 41	€ 46
Non-current provisions for employee benefits	(558)	(546)
Net defined benefit liability (asset)	516	499
Germany [Member]
Post-employment benefits [Line Items]
Other non-current assets	0	9
Non-current provisions for employee benefits	(283)	(270)
Net defined benefit liability (asset)	283	261
United States of America [Member]
Post-employment benefits [Line Items]
Other non-current assets	39	34
Non-current provisions for employee benefits	(118)	(128)
Net defined benefit liability (asset)	80	94
Other countries [Member]
Post-employment benefits [Line Items]
Other non-current assets	2	4
Non-current provisions for employee benefits	(156)	(148)
Net defined benefit liability (asset)	€ 153	€ 144

Post-employment benefits - Pre-

Post-employment benefits - Pre-tax costs for post-employment benefits (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Post-employment benefits [Line Items]
Post-employment benefit expense in profit or loss, defined benefit plans	€ 47	€ 50	€ 36
Post-employment benefit expense, defined contribution plans	376	400	375
Post-employment benefits costs, pre-tax	423	449	411
Included in income from operations [Member]
Post-employment benefits [Line Items]
Post-employment benefit expense in profit or loss, defined benefit plans	25	39	28
Post-employment benefit expense, defined contribution plans	376	400	368
Included in financial expense [Member]
Post-employment benefits [Line Items]
Post-employment benefit expense in profit or loss, defined benefit plans	€ 21	€ 10	8
Included in discontinued operations [Member]
Post-employment benefits [Line Items]
Post-employment benefit expense in profit or loss, defined benefit plans			1
Post-employment benefit expense, defined contribution plans			€ 7

Post-employment benefits - Defi

Post-employment benefits - Defined benefit obligations (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Post-employment benefits [Line Items]
Net defined benefit liability (asset) at beginning of period	€ 499
Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)	(21)	€ (10)	€ (8)
Net defined benefit liability (asset) at end of period	516	499
Present value of defined benefit obligation [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset) at beginning of period	1,621	1,970
Increase in net defined benefit liability (asset) resulting from current service cost	32	32
Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)	71	36
Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan by plan participants	3	4
Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions		2
Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions	48	(366)
Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments	2	12
Increase (decrease) in net defined benefit liability (asset) resulting from past service cost	(9)	16
Decrease (increase) in net defined benefit liability (asset) resulting from gains (losses) arising from settlements	2	0
Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan	(104)	(95)
Benefits paid directly by employer	(39)	(41)
Increase (decrease) in net defined benefit liability (asset) resulting from changes in foreign exchange rates, net defined benefit liability (asset)	(22)	52
Net defined benefit liability (asset) at end of period	€ 1,605	€ 1,621	€ 1,970

Post-employment benefits - Plan

Post-employment benefits - Plan assets (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Post-employment benefits [Line Items]
Net defined benefit liability (asset) at beginning of period	€ 499
Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)	(21)	€ (10)	€ (8)
Net defined benefit liability (asset) at end of period	516	499
Plan assets [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset) at beginning of period	1,122	1,380
Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)	49	26
Increase in net defined benefit liability (asset) resulting from current service cost	1	1
Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense	23	(254)
Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan by plan participants	3	4
Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer	14	17
Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan	104	95
Increase (decrease) in net defined benefit liability (asset) resulting from changes in foreign exchange rates, net defined benefit liability (asset)	(17)	45
Net defined benefit liability (asset) at end of period	€ 1,089	€ 1,122	€ 1,380

Post-employment benefits - Pl_2

Post-employment benefits - Plan assets allocation (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	€ 516	€ 499
Plan assets [member]
Post-employment benefits [Line Items]
Net defined benefit liability (asset)	1,089	1,122	€ 1,380
Plan assets [member] | Assets quoted in active market [Member]
Post-employment benefits [Line Items]
Debt instruments, amount contributed to fair value of plan assets	513	560
Other assets, amount contributed to fair value of plan assets	182	203
Equity instruments, amount contributed to fair value of plan assets	31
Plan assets [member] | Assets not quoted in active market [Member]
Post-employment benefits [Line Items]
Other assets, amount contributed to fair value of plan assets	€ 363	258
Equity instruments, amount contributed to fair value of plan assets		€ 101

Post-employment benefits - Assu

Post-employment benefits - Assumptions used for defined benefit obligations (Detail)	Dec. 31, 2023	Dec. 31, 2022
Post-employment benefits [Line Items]
Actuarial assumption of discount rates	4.30%	4.70%
Actuarial assumption of expected rates of inflation	2.20%	2.20%
Actuarial assumption of expected rates of salary increases	3%	2.90%
Germany [Member]
Post-employment benefits [Line Items]
Actuarial assumption of discount rates	3.70%	4.10%
Actuarial assumption of expected rates of inflation	2%	2%
Actuarial assumption of expected rates of salary increases	2.80%	2.80%
United States of America [Member]
Post-employment benefits [Line Items]
Actuarial assumption of discount rates	5%	5.20%
Actuarial assumption of expected rates of inflation	2.30%	2.30%
Actuarial assumption of expected rates of salary increases	0%	0%
Other countries [Member]
Post-employment benefits [Line Items]
Actuarial assumption of discount rates	4.90%	4.90%
Actuarial assumption of expected rates of inflation	2.50%	2.60%
Actuarial assumption of expected rates of salary increases	4.30%	3.30%

Post-employment benefits - Sens

Post-employment benefits - Sensitivity of key assumptions (Detail) - EUR (€) € in Millions		Dec. 31, 2023	Dec. 31, 2022
Actuarial assumption of discount rates [member]
Post-employment benefits [Line Items]
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption		€ (123)	€ (122)
Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption		147	145
Actuarial assumption of expected rates of inflation [member]
Post-employment benefits [Line Items]
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption		60	57
Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption		(52)	(49)
Actuarial assumption of expected rates of salary increases [member]
Post-employment benefits [Line Items]
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption		12	12
Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption		(11)	(11)
Actuarial assumption of life expectancy after retirement [member]
Post-employment benefits [Line Items]
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	[1]	€ 32	€ 32
[1] The mortality table (i.e. longevity) also impacts the DBO. The above sensitivity table illustrates the impact on the DBO of a further 10% decrease in the assumed rates of mortality for the company’s major plans. A 10% decrease in assumed mortality rates equals improvement of life expectancy by 0.5 - 1 year.

Accrued liabilities - Accrued l

Accrued liabilities - Accrued liabilities (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Accrued liabilities [Line Items]
Accruals	€ 1,887	€ 1,626
Salaries and wages [Member]
Accrued liabilities [Line Items]
Accruals	791	490
Holiday entitlements [Member]
Accrued liabilities [Line Items]
Accruals	96	97
Other personnel-related costs [Member]
Accrued liabilities [Line Items]
Accruals	93	101
Gas, water, electricity, rent and other [Member]
Accrued liabilities [Line Items]
Accruals	43	46
Communication and IT costs [Member]
Accrued liabilities [Line Items]
Accruals	61	64
Distribution costs [Member]
Accrued liabilities [Line Items]
Accruals	99	110
Commission payable [Member]
Accrued liabilities [Line Items]
Accruals	12	8
Advertising and marketing-related costs [Member]
Accrued liabilities [Line Items]
Accruals	133	127
Other sales-related costs [Member]
Accrued liabilities [Line Items]
Accruals	20	20
Material-related costs [Member]
Accrued liabilities [Line Items]
Accruals	138	132
Interest-related accruals [Member]
Accrued liabilities [Line Items]
Accruals	76	71
Other accrued liabilities [Member]
Accrued liabilities [Line Items]
Accruals	€ 324	€ 361

Other liabilities - Text Detail

Other liabilities - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Other liabilities [Abstract]
Other non-current non-financial liabilities	€ 54	€ 60
Non-current contract liabilities	469	515
Current contract liabilities	1,809	1,696
Increase (Decrease) in current contract liabilities through operational activities	€ 113
Revenue that was included in contract liability balance at beginning of period		€ 1,696

Other liabilities - Other curre

Other liabilities - Other current liabilities (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Other liabilities [Abstract]
Accrued customer rebates that cannot be offset with accounts receivables for those customers	€ 186	€ 213
Other taxes including social security premiums	129	115
Other current liabilities	98	120
Other current non-financial liabilities	€ 414	€ 448

Cash flow statement supplemen_3

Cash flow statement supplementary information - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flow statement supplementary information [Line Items]
Interest related to uncertain tax positions	€ 2
Payments of lease liabilities, classified as financing activities	271	€ 316	€ 308
Interest paid, classified as operating activities	250	205	151
Purchase of financial instruments, classified as investing activities	46	72	48
Net cash outflow from non-current financial assets	44	38	0
Lease liabilities [member]
Cash flow statement supplementary information [Line Items]
Interest paid, classified as operating activities	€ 27	€ 25	€ 25

Cash flow statement supplemen_4

Cash flow statement supplementary information - Reconciliation of liabilities arising from financing activities (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities				€ (1,133)		€ (1,410)
Increase (decrease) through financing cash flows, liabilities arising from financing activities		€ (848)		500
Increase (decrease) through other changes, liabilities arising from financing activities	[1]			1
Long-term borrowings including current portion of long-term borrowings [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		7,567	[2]	8,111	[1]	6,933	[1]
Increase (decrease) through financing cash flows, liabilities arising from financing activities		(210)	[2]	1,045	[1]
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities		(96)	[2]	107	[1]
Increase (decrease) through other changes, liabilities arising from financing activities		(238)	[2]	27	[1]
EUR Bond [member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		4,569		4,061
USD Bond [member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		1,325		1,378
Lease liabilities [member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		1,074		1,082		1,220
Increase (decrease) through financing cash flows, liabilities arising from financing activities		(200)		(260)
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities		(42)		17
Increase (decrease) through other changes, liabilities arising from financing activities		235		105
Lease liabilities [member] | IFRS 16 [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities				1,082
Forward contracts long term [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		396	[3]	858	[4]	934	[4]
Increase (decrease) through other changes, liabilities arising from financing activities		(462)	[3]	(76)	[4]
Bank borrowings [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		203		705		203
Increase (decrease) through financing cash flows, liabilities arising from financing activities		(502)		498
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities				4
Other long-term debt [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities				28		30
Increase (decrease) through financing cash flows, liabilities arising from financing activities		(5)		(1)
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities		(1)		1
Increase (decrease) through other changes, liabilities arising from financing activities		(22)		(1)
Short-term borrowings [member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		122	[2]	89	[2]	47	[1]
Increase (decrease) through financing cash flows, liabilities arising from financing activities		29	[2]	47	[1]
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities		3	[2]	(6)	[1]
Increase (decrease) through other changes, liabilities arising from financing activities				1
Short-term bank borrowings [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		122		89		47
Increase (decrease) through financing cash flows, liabilities arising from financing activities		46		47
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities		(14)		(6)
Other short-term loans [Member]
Cash flow statement supplementary information [Line Items]
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities		17
Equity [member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		(656)		(1,133)
Increase (decrease) through financing cash flows, liabilities arising from financing activities		(666)		(593)
Increase (decrease) through other changes, liabilities arising from financing activities		1,143		869
Dividend payable [Member]
Cash flow statement supplementary information [Line Items]
Increase (decrease) through financing cash flows, liabilities arising from financing activities		(4)		(418)
Increase (decrease) through other changes, liabilities arising from financing activities		4		418
Forward contracts equity [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		(394)	[3]	(858)	[3]	(934)	[4]
Increase (decrease) through other changes, liabilities arising from financing activities		465	[3]	76	[4]
Treasury shares [member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities		(262)	[5]	(275)	[5]	(476)
Increase (decrease) through financing cash flows, liabilities arising from financing activities		(662)	[5]	(174)
Increase (decrease) through other changes, liabilities arising from financing activities		675	[5]	375
Euro [Member] | Bonds [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities				4,061		3,233
Increase (decrease) through financing cash flows, liabilities arising from financing activities		497		827
Increase (decrease) through other changes, liabilities arising from financing activities		11
Euro [Member] | Other short-term loans [Member]
Cash flow statement supplementary information [Line Items]
Increase (decrease) through financing cash flows, liabilities arising from financing activities		(17)
US Dollar [Member] | Bonds [Member]
Cash flow statement supplementary information [Line Items]
Liabilities arising from financing activities				1,378		€ 1,313
Increase (decrease) through financing cash flows, liabilities arising from financing activities				(20)
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities		€ (53)		€ 85
[1] In this table, current portion of long-term debt is included in long-term debt (and excluded from short-term debt). In this table, current portion of long-term debt is included in long-term debt (and excluded from short-term debt). The forward contracts are related to the share buyback program and LTI plans The forward contracts are related to the share buyback program and LTI plans Cash flow in 2023 includes withholding tax for share buyback amounting to EUR 55 million.

Contingencies - Text Details (D

Contingencies - Text Details (Detail) € in Millions	12 Months Ended
	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)
Contingencies [Line Items]
Fair value of guarantees recognized on the balance sheet
Increase (decrease) of off-balance-sheet business and credit-related guarantees provided on behalf of third parties and associates	(2)
Off-balance-sheet business and credit-related guarantees provided on behalf of third parties and associates		€ 2
Estimated financial effect of contingent liabilities		€ 60
Number of personal injury complaints		600
Additional provisions, other provisions	€ 1,836	€ 1,049
Number of individuals entered private tolling agreement		60,000
Number of individuals joined census registry	57,000
Other contingent liabilities [member]
Contingencies [Line Items]
Estimated financial effect of contingent liabilities	€ 300
Legal proceedings provision [member]
Contingencies [Line Items]
Additional provisions, other provisions	644	€ 89
Legal proceedings provision [member] | Respironics litigation provision [Member]
Contingencies [Line Items]
Additional provisions, other provisions	€ 575

Related-party transactions - Te

Related-party transactions - Text Details (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related-party transactions [Line Items]
Presumed significant influence, voting rights	50%
Revenue from sale of goods, related party transactions	€ 106	€ 111	€ 116
Non-recourse third-party receivables sold from PMC	117	117	162
PMC [Member]
Related-party transactions [Line Items]
Revenue from sale of goods, related party transactions	€ 87	€ 101	€ 106
PMC [Member] | Philips North America LLC [Member]
Related-party transactions [Line Items]
Proportion of ownership interest in associate	40%
De Lage Landen Financial Services, Inc. (DLL) [Member]
Related-party transactions [Line Items]
Proportion of ownership interest in associate	60%
Exor N.V [Member]
Related-party transactions [Line Items]
Minority stake	15%
Bottom of range [member]
Related-party transactions [Line Items]
Presumed significant influence, voting rights	20%

Related-party transactions - Re

Related-party transactions - Related-party transactions (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related-party transactions [Abstract]
Revenue from sale of goods, related party transactions	€ 106	€ 111	€ 116
Purchases of goods, related party transactions	42	46	41
Amounts receivable, related party transactions	18	55	40
Amounts payable, related party transactions	€ 2	€ 2	€ 2

Share-based compensation - Text

Share-based compensation - Text Details (Detail)	12 Months Ended
	Dec. 31, 2023 EUR (€) € / shares	Dec. 31, 2022 EUR (€) € / shares	Dec. 31, 2021 EUR (€)	Dec. 31, 2020	Dec. 31, 2023 $ / shares	Apr. 28, 2023 EUR (€)	Apr. 28, 2023 USD ($)	Dec. 31, 2022 $ / shares
Share-based compensation [Line Items]
Share-based compensation costs	€ 97,000,000	€ 104,000,000	€ 115,000,000
Employee stock purchase plan	9,000,000
Increase (decrease) through share-based payment transactions, equity	€ 88,000,000	€ 95,000,000	€ 110,000,000
Comparison group for performance shares		20	20	20
Description of vesting requirements for share-based payment arrangement	40%
Risk free interest rate, share options granted	2.55%
Expected volatility, share options granted		36%
Cost recognition period (weighted average)	1.3
Euro [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement	3,660,000				3,660,000
Weighted average exercise price of share options outstanding in share-based payment arrangement | € / shares	€ 22.16
Weighted average remaining contractual life of outstanding share options	9 years 3 months 18 days
US Dollar [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement	1,929,000				1,929,000
Weighted average exercise price of share options outstanding in share-based payment arrangement | $ / shares					$ 24.42
Weighted average remaining contractual life of outstanding share options	9 years 3 months 18 days
Top of range [member]
Share-based compensation [Line Items]
Description of vesting requirements for share-based payment arrangement	50%
Bottom of range [member]
Share-based compensation [Line Items]
Description of vesting requirements for share-based payment arrangement	10%
Retention option plan [Member]
Share-based compensation [Line Items]
Option price premium	15%
Unrecognized compensation costs related to non-vested shares	€ 11,000,000
Vesting period	2				2
Total contractual life	10				10
Retention option plan [Member] | Euro [Member]
Share-based compensation [Line Items]
Risk free interest rate, share options granted	2.37%
Expected volatility, share options granted	30.47%
Number of share options outstanding in share-based payment arrangement	3,660,000				3,660,000
Weighted average fair value at measurement date, share options granted						€ 2.61
Retention option plan [Member] | US Dollar [Member]
Share-based compensation [Line Items]
Expected volatility, share options granted	32.31%
Number of share options outstanding in share-based payment arrangement	1,929,000				1,929,000
Weighted average fair value at measurement date, share options granted | $							$ 3.89
Weighted average remaining contractual life of outstanding share options	9 years 3 months 18 days
Performance share plans [Member]
Share-based compensation [Line Items]
Unrecognized compensation costs related to non-vested shares	€ 102,000,000	€ 103,000,000	€ 110,000,000
Cost recognition period (weighted average)	1.98
Restricted shares [Member]
Share-based compensation [Line Items]
Unrecognized compensation costs related to non-vested shares	€ 63,000,000	€ 72,000,000	66,000,000
Cost recognition period (weighted average)	1.8
Cliff-vesting period	3				3
Accelerate options [Member] | Euro [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement		55,000						55,000
Weighted average exercise price of share options outstanding in share-based payment arrangement | € / shares		€ 22.43
Option plans [Member] | Euro [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement		750						750
Weighted average exercise price of share options outstanding in share-based payment arrangement | € / shares		€ 22.43
Proceeds from exercise of options		€ 7,000,000	10,000,000
Tax deductions realized as a result of option exercises		€ 700,000	€ 1,000,000
Option plans [Member] | US Dollar [Member]
Share-based compensation [Line Items]
Risk free interest rate, share options granted	3.50%
Number of share options outstanding in share-based payment arrangement		1,950						1,950
Weighted average exercise price of share options outstanding in share-based payment arrangement | $ / shares								$ 30.27

Share-based compensation - Perf

Share-based compensation - Performance shares (Detail)		12 Months Ended
		Dec. 31, 2023 € / shares shares	Dec. 31, 2023 $ / shares € / shares shares	Dec. 31, 2022 € / shares shares	Dec. 31, 2022 $ / shares € / shares shares	Dec. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Dec. 31, 2021 € / shares	Dec. 31, 2021 $ / shares
Euro [Member]
Share-based compensation [Line Items]
Number of other equity instruments outstanding in share-based payment arrangement				2,321,250	2,321,250		2,321,250	1,618,488	1,618,488
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement		€ 22.16
Euro [Member] | Performance share plans [Member]
Share-based compensation [Line Items]
Number of other equity instruments outstanding in share-based payment arrangement		5,392,035	5,392,035	4,385,837	4,385,837	5,392,035	4,385,837	3,097,713	3,097,713
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement		€ 27.22	€ 27.22	€ 33.13	€ 33.13			€ 45.28
Number of other equity instruments granted in share-based payment arrangement		2,299,280	2,299,280	2,323,435	2,323,435
Weighted average exercise price of other equity instruments granted in share-based payment arrangement		€ 23.65		€ 20.55
Notional Dividends	[1]	240,977	240,977	155,067	155,067
Weighted Average Exercise Price Notional Dividends	[1]	€ 27.15		€ 33.91
Number of other equity instruments exercised or vested in share-based payment arrangement		(154,987)	(154,987)	(434,329)	(434,329)
Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement		€ 44.08		€ 40.9
Number of other equity instruments forfeited in share-based payment arrangement		(489,295)	(489,295)	(233,556)	(233,556)
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement		€ 27.05		€ 38.67
Number of other equity instruments adjusted quantity | shares	[2]	(889,777)	(889,777)	(522,493)	(522,493)
Weighted average exercise price of other equity instruments adjusted quantity	[2]	€ 44.27		€ 40.48
US Dollar [Member]
Share-based compensation [Line Items]
Number of other equity instruments outstanding in share-based payment arrangement				2,345,263	2,345,263		2,345,263	1,611,021	1,611,021
US Dollar [Member] | Performance share plans [Member]
Share-based compensation [Line Items]
Number of other equity instruments outstanding in share-based payment arrangement		3,261,048	3,261,048	2,749,983	2,749,983	3,261,048	2,749,983	2,005,000	2,005,000
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement | $ / shares						$ 29.73	$ 36.66		$ 51.48
Number of other equity instruments granted in share-based payment arrangement		1,667,812	1,667,812	1,530,585	1,530,585
Weighted average exercise price of other equity instruments granted in share-based payment arrangement | $ / shares			€ 25.96		€ 21.93
Notional Dividends	[1]	152,750	152,750	98,883	98,883
Weighted Average Exercise Price Notional Dividends | $ / shares	[1]		€ 29.78		€ 37.15
Number of other equity instruments exercised or vested in share-based payment arrangement		(121,760)	(121,760)	(248,848)	(248,848)
Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement | $ / shares			€ 48.33		€ 45.23
Number of other equity instruments forfeited in share-based payment arrangement		(596,846)	(596,846)	(309,570)	(309,570)
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement | $ / shares			€ 28.95		€ 44.04
Number of other equity instruments adjusted quantity | shares	[2]	(590,890)	(590,890)	(326,066)	(326,066)
Weighted average exercise price of other equity instruments adjusted quantity | $ / shares	[2]		€ 48.28		€ 45.26
[1] Dividend declared in 2023 on outstanding shares. Adjusted quantity includes the adjustments made to Performance shares outstanding due to updates on the actual TSR, EPS, and SDG.

Share-based compensation - Rest

Share-based compensation - Restricted shares (Detail)	12 Months Ended
	Dec. 31, 2023 € / shares		Dec. 31, 2023 $ / shares € / shares		Dec. 31, 2022 € / shares		Dec. 31, 2022 $ / shares € / shares		Dec. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Dec. 31, 2021 € / shares	Dec. 31, 2021 $ / shares
Euro [Member]
Share-based compensation [Line Items]
Number of other equity instruments outstanding in share-based payment arrangement					2,321,250		2,321,250			2,321,250	1,618,488	1,618,488
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement	€ 22.16
US Dollar [Member]
Share-based compensation [Line Items]
Number of other equity instruments outstanding in share-based payment arrangement					2,345,263		2,345,263			2,345,263	1,611,021	1,611,021
Restricted shares [Member] | Euro [Member]
Share-based compensation [Line Items]
Number of other equity instruments outstanding in share-based payment arrangement	2,995,252		2,995,252		2,321,250		2,321,250		2,995,252	2,321,250
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement	€ 23.39		€ 23.39		€ 30.73		€ 30.73				€ 39.93
Number of other equity instruments granted in share-based payment arrangement	1,471,975		1,471,975		1,349,003		1,349,003
Weighted average exercise price of other equity instruments granted in share-based payment arrangement	€ 16.35				€ 22.03
Notional Dividends	135,791	[1]	135,791	[1]	81,500	[1]	81,500	[1]
Weighted Average Exercise Price Notional Dividends	€ 27.98	[1]			€ 35.67	[1]
Number of other equity instruments exercised or vested in share-based payment arrangement	(595,796)		(595,796)		(540,930)		(540,930)
Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement	€ 35.07				€ 35.82
Number of other equity instruments forfeited in share-based payment arrangement	(337,968)		(337,968)		(186,811)		(186,811)
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement	€ 24.46				€ 35.06
Restricted shares [Member] | US Dollar [Member]
Share-based compensation [Line Items]
Number of other equity instruments outstanding in share-based payment arrangement	2,654,193		2,654,193		2,345,263		2,345,263		2,654,193	2,345,263
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement | $ / shares									$ 26.04	$ 33.87		$ 46.26
Number of other equity instruments granted in share-based payment arrangement	1,284,761		1,284,761		1,463,855		1,463,855
Weighted average exercise price of other equity instruments granted in share-based payment arrangement | $ / shares			€ 17.72				€ 23.6
Notional Dividends	126,498	[1]	126,498	[1]	83,151	[1]	83,151	[1]
Weighted Average Exercise Price Notional Dividends | $ / shares			€ 31.12	[1]			€ 39.37	[1]
Number of other equity instruments exercised or vested in share-based payment arrangement	(679,430)		(679,430)		(541,336)		(541,336)
Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement | $ / shares			€ 37.83				€ 41.48
Number of other equity instruments forfeited in share-based payment arrangement	(422,899)		(422,899)		(271,427)		(271,427)
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement | $ / shares			€ 26.79				€ 38.51
[1] Dividend declared in 2023 on outstanding shares.

Share-based compensation - Blac

Share-based compensation - Black-Scholes-Merton option pricing model inputs (Detail)	12 Months Ended
	Dec. 31, 2023 € / shares	Dec. 31, 2023 $ / shares	Dec. 31, 2022
Share-based compensation [Line Items]
Risk free interest rate, share options granted	2.55%	2.55%
Expected volatility, share options granted			36%
Euro [Member]
Share-based compensation [Line Items]
Weighted average share price, share options granted	€ 22.16
Euro [Member] | Retention option plan [Member]
Share-based compensation [Line Items]
Weighted average share price, share options granted	18.24
Exercise price, share options granted	€ 22.16
Risk free interest rate, share options granted	2.37%	2.37%
Expected dividend as percentage, share options granted	4.45%	4.45%
Option life, share options granted	6	6
Expected volatility, share options granted	30.47%	30.47%
US Dollar [Member] | Retention option plan [Member]
Share-based compensation [Line Items]
Weighted average share price, share options granted | $ / shares		$ 21.12
Exercise price, share options granted | $ / shares		$ 24.42
Expected dividend as percentage, share options granted	4.45%	4.45%
Option life, share options granted	6	6
Expected volatility, share options granted	32.31%	32.31%
US Dollar [Member] | Option plans [Member]
Share-based compensation [Line Items]
Risk free interest rate, share options granted	3.50%	3.50%

Share-based compensation - Opti

Share-based compensation - Options on EUR-denominated listed share (Detail)	12 Months Ended
	Dec. 31, 2023 € / shares
Share-based compensation [Line Items]
Number of share options granted in share-based payment arrangement	3,831,000
Euro [Member]
Share-based compensation [Line Items]
Weighted average share price, share options granted	€ 22.16
Number of share options forfeited in share-based payment arrangement	(171,000)
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement	€ 22.16
Number of share options outstanding in share-based payment arrangement	3,660,000
Weighted average exercise price of share options outstanding in share-based payment arrangement	€ 22.16

Share-based compensation - Op_2

Share-based compensation - Options on USD-denominated listed share (Detail)	12 Months Ended
	Dec. 31, 2023 $ / shares
Share-based compensation [Line Items]
Number of share options granted in share-based payment arrangement	3,831,000
US Dollar [Member]
Share-based compensation [Line Items]
Number of share options granted in share-based payment arrangement	2,179,500
Weighted average exercise price of share options granted in share-based payment arrangement	$ 24.42
Number of share options forfeited in share-based payment arrangement	(250,500)
Weighted average exercise price of share options forfeited in share-based payment arrangement	$ 24.42
Number of share options outstanding in share-based payment arrangement	1,929,000
Weighted average exercise price of share options outstanding in share-based payment arrangement	$ 24.42

Share-based compensation - Outs

Share-based compensation - Outstanding options (Detail)	12 Months Ended
	Dec. 31, 2023 EUR (€)	Dec. 31, 2022
Euro [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement	3,660,000
Weighted average remaining contractual life of outstanding share options	9 years 3 months 18 days
Euro [Member] | Retention option plan [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement	3,660,000
Euro [Member] | Option plans [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement		750
Intrinsic value of liabilities from share-based payment transactions for which counterparty's right to cash or other assets vested	€ 0
Euro [Member] | Price range five [Member] | Retention option plan [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement	3,660,000
Weighted average remaining contractual life of outstanding share options	9 years 3 months 18 days
Euro [Member] | Price range one [Member] | Retention option plan [Member]
Share-based compensation [Line Items]
Intrinsic value of liabilities from share-based payment transactions for which counterparty's right to cash or other assets vested	€ 0
US Dollar [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement	1,929,000
Weighted average remaining contractual life of outstanding share options	9 years 3 months 18 days
US Dollar [Member] | Retention option plan [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement	1,929,000
Intrinsic value of liabilities from share-based payment transactions for which counterparty's right to cash or other assets vested	€ 0
Weighted average remaining contractual life of outstanding share options	9 years 3 months 18 days
US Dollar [Member] | Option plans [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement		1,950
US Dollar [Member] | Price range five [Member] | Retention option plan [Member]
Share-based compensation [Line Items]
Number of share options outstanding in share-based payment arrangement	1,929,000
Weighted average remaining contractual life of outstanding share options	9 years 3 months 18 days
US Dollar [Member] | Price range one [Member] | Retention option plan [Member]
Share-based compensation [Line Items]
Intrinsic value of liabilities from share-based payment transactions for which counterparty's right to cash or other assets vested	€ 0

Information on remuneration - T

Information on remuneration - Text Details (Detail)		12 Months Ended
		Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Executive committee [Member]
Information on remuneration [Line Items]
Number of members throughout the period		16
Key management personnel compensation	[1]	€ 32,835,987	€ 25,624,305	€ 33,358,405
Number of members		13	13	13
Number of share options outstanding in share-based payment arrangement		0	0	184,900
Board of management [Member]
Information on remuneration [Line Items]
Key management personnel compensation		€ 9,900,000	€ 8,400,000	€ 10,300,000
Percentage of shares held by board of management				1%
Supervisory board [Member]
Information on remuneration [Line Items]
Key management personnel compensation		€ 1,501,266	€ 1,546,602	€ 1,325,891
Other compensation, product arrangement entitlement				€ 2,000
[1] The Executive Committee consisted of 13 members as per December 31, 2023 (2022: 13 members; 2021: 13 members)

Information on remuneration - R

Information on remuneration - Remuneration costs of the Executive Committee (Detail) - Executive committee [Member] - EUR (€)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Information on remuneration [Line Items]
Key management personnel compensation	[1]	€ 32,835,987	€ 25,624,305	€ 33,358,405
Base salary [Member]
Information on remuneration [Line Items]
Key management personnel compensation	[1]	8,729,458	9,528,279	9,598,588
Annual incentive [Member]
Information on remuneration [Line Items]
Key management personnel compensation	[1],[2]	11,405,130	208,370	5,250,408
Performance share plans [Member]
Information on remuneration [Line Items]
Key management personnel compensation	[1],[3]	7,272,815	11,242,581	12,610,073
Stock options [Member]
Information on remuneration [Line Items]
Key management personnel compensation	[1]	13,358
Restricted shares [Member]
Information on remuneration [Line Items]
Key management personnel compensation	[1],[3]	1,907,511	1,191,529	1,380,644
Pension allowances [Member]
Information on remuneration [Line Items]
Key management personnel compensation	[1],[4]	1,346,937	1,949,204	2,107,953
Pension scheme costs [Member]
Information on remuneration [Line Items]
Key management personnel compensation	[1]	260,554	288,179	306,694
Other compensation [Member]
Information on remuneration [Line Items]
Key management personnel compensation	[1],[5]	€ 1,900,224	€ 1,216,163	€ 2,104,044
[1] The Executive Committee consisted of 13 members as per December 31, 2023 (2022: 13 members; 2021: 13 members) The annual incentives are related to the performance in the year reported which are paid out in the subsequent year. Costs of performance shares and restricted share rights are based on accounting standards (IFRS) and do not reflect the value of performance shares at the vesting/release date Pension allowances are gross taxable allowances paid to the Executive Committee members in the Netherlands. These allowances are part of the pension arrangement The stated amounts mainly concern (share of) allowances to members of the Executive Committee that can be considered as remuneration. In a situation where such a share of an allowance can be considered as (indirect) remuneration (for example, private use of the company car), then the share is both valued and accounted for here. The method employed by the fiscal authorities is the starting point for the value stated

Information on remuneration -_2

Information on remuneration - Remuneration costs of individual members of the Board of Management (Detail) - Board of management [Member] - EUR (€)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022		Dec. 31, 2021
Information on remuneration [Line Items]
Key management personnel compensation	€ 9,900,000	€ 8,400,000		€ 10,300,000
Base salary [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits	2,640,000	2,730,788		2,720,000
Key management personnel compensation other	257,218	150,691		168,742
Key management personnel compensation	9,887,650	8,446,577		10,134,217
Base salary [Member] | R. Jakobs [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits	1,200,000	256,438	[1]
Key management personnel compensation other	109,256	11,507	[1]
Key management personnel compensation	4,582,347	444,667	[1]
Base salary [Member] | A. Bhattacharya [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits	810,000	806,250		790,000
Key management personnel compensation other	94,516	61,308		68,908
Key management personnel compensation	3,002,907	1,896,081		2,652,864
Base salary [Member] | M.J. van Ginneken [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits	630,000	626,250		605,000
Key management personnel compensation other	53,446	35,343		42,610
Key management personnel compensation	2,302,397	1,416,837		2,029,054
Base salary [Member] | F.A. van Houten [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits		1,041,849	[1]	1,325,000
Key management personnel compensation other		42,533	[1]	57,224
Key management personnel compensation		4,688,992	[1]	5,452,299
Annual incentive [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits	3,927,341	208,370		1,528,211
Annual incentive [Member] | R. Jakobs [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits	2,004,480
Annual incentive [Member] | A. Bhattacharya [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits	1,075,939			360,103
Annual incentive [Member] | M.J. van Ginneken [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits	846,922			317,192
Annual incentive [Member] | F.A. van Houten [Member]
Information on remuneration [Line Items]
Key management personnel compensation, short-term employee benefits		208,370	[1]	850,915
Performance share plans [Member]
Information on remuneration [Line Items]
Key management personnel compensation, share-based payment	2,377,191	4,391,434		4,684,863
Performance share plans [Member] | R. Jakobs [Member]
Information on remuneration [Line Items]
Key management personnel compensation, share-based payment	968,922	112,737	[1]
Performance share plans [Member] | A. Bhattacharya [Member]
Information on remuneration [Line Items]
Key management personnel compensation, share-based payment	793,429	763,140		1,172,533
Performance share plans [Member] | M.J. van Ginneken [Member]
Information on remuneration [Line Items]
Key management personnel compensation, share-based payment	614,840	585,490		886,035
Performance share plans [Member] | F.A. van Houten [Member]
Information on remuneration [Line Items]
Key management personnel compensation, share-based payment		2,930,068	[1]	2,626,295
Pension allowances [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits	590,228	880,896		950,014
Pension allowances [Member] | R. Jakobs [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits	267,798	57,973	[1]
Pension allowances [Member] | A. Bhattacharya [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits	197,133	237,250		233,857
Pension allowances [Member] | M.J. van Ginneken [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits	125,298	141,622		150,755
Pension allowances [Member] | F.A. van Houten [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits		444,051	[1]	565,403
Pension scheme costs [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits	95,673	84,398		82,387
Pension scheme costs [Member] | R. Jakobs [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits	31,891	6,012	[1]
Pension scheme costs [Member] | A. Bhattacharya [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits	31,891	28,133		27,462
Pension scheme costs [Member] | M.J. van Ginneken [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits	€ 31,891	28,133		27,462
Pension scheme costs [Member] | F.A. van Houten [Member]
Information on remuneration [Line Items]
Key management personnel compensation, post-employment benefits		€ 22,121	[1]	€ 27,462
[1] As per October 15, 2022, Roy Jakobs was appointed as CEO of the company. The table includes actual costs incurred in respect of the remuneration received by Mr Van Houten and Mr Jakobs, respectively, as CEO.

Information on remuneration - A

Information on remuneration - Accumulated annual pension entitlements and pension-related costs (Detail) - Board of management [Member]	Dec. 31, 2023 EUR (€)
Information on remuneration [Line Items]
Pension-related costs	€ 685,901
R. Jakobs [Member]
Information on remuneration [Line Items]
Age	49
Accumulated annual pension	€ 56,383
Pension-related costs	€ 299,689
A. Bhattacharya [Member]
Information on remuneration [Line Items]
Age	62
Accumulated annual pension	€ 40,324
Pension-related costs	€ 229,024
M.J. van Ginneken [Member]
Information on remuneration [Line Items]
Age	50
Accumulated annual pension	€ 53,769
Pension-related costs	€ 157,189

Information on remuneration -_3

Information on remuneration - Remuneration of the Supervisory Board (Detail) - Supervisory board [Member] - EUR (€)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Information on remuneration [Line Items]
Key management personnel compensation	€ 1,501,266	€ 1,546,602	€ 1,325,891
F. Sijbesma [Member]
Information on remuneration [Line Items]
Key management personnel compensation	206,345		177,346
P.A.M. Stoffels [Member]
Information on remuneration [Line Items]
Key management personnel compensation	172,269	177,269	142,440
D.E.I. Pyott [Member]
Information on remuneration [Line Items]
Key management personnel compensation	154,769	152,269	138,639
A.M. Harrison [Member]
Information on remuneration [Line Items]
Key management personnel compensation	133,769	126,269	116,269
M.E. Doherty [member]
Information on remuneration [Line Items]
Key management personnel compensation	154,269	151,769	131,769
P. Löscher [Member]
Information on remuneration [Line Items]
Key management personnel compensation	149,269	156,769	136,769
I. Nooyi [Member]
Information on remuneration [Line Items]
Key management personnel compensation	131,269	131,269	116,269
S.K. Chua [Member]
Information on remuneration [Line Items]
Key management personnel compensation	140,269	140,269	79,081
H. Verhagen [Member]
Information on remuneration [Line Items]
Key management personnel compensation	121,269	121,269
S. Poonen [Member]
Information on remuneration [Line Items]
Key management personnel compensation	137,769	135,269
J. van der Veer [Member]
Information on remuneration [Line Items]
Key management personnel compensation		206,345	69,505
C.A. Poon [Member]
Information on remuneration [Line Items]
Key management personnel compensation			57,397
N. Dhawan [Member]
Information on remuneration [Line Items]
Key management personnel compensation		47,836	120,269
O. Gadiesh [Member]
Information on remuneration [Line Items]
Key management personnel compensation			40,137
Membership [Member]
Information on remuneration [Line Items]
Key management personnel compensation	1,070,000	1,105,616	1,044,644
Membership [Member] | F. Sijbesma [Member]
Information on remuneration [Line Items]
Key management personnel compensation	155,000	155,000	141,301
Membership [Member] | P.A.M. Stoffels [Member]
Information on remuneration [Line Items]
Key management personnel compensation	115,000	115,000	109,863
Membership [Member] | D.E.I. Pyott [Member]
Information on remuneration [Line Items]
Key management personnel compensation	100,000	100,000	100,000
Membership [Member] | A.M. Harrison [Member]
Information on remuneration [Line Items]
Key management personnel compensation	100,000	100,000	100,000
Membership [Member] | M.E. Doherty [member]
Information on remuneration [Line Items]
Key management personnel compensation	100,000	100,000	100,000
Membership [Member] | P. Löscher [Member]
Information on remuneration [Line Items]
Key management personnel compensation	100,000	100,000	100,000
Membership [Member] | I. Nooyi [Member]
Information on remuneration [Line Items]
Key management personnel compensation	100,000	100,000	100,000
Membership [Member] | S.K. Chua [Member]
Information on remuneration [Line Items]
Key management personnel compensation	100,000	100,000	65,753
Membership [Member] | H. Verhagen [Member]
Information on remuneration [Line Items]
Key management personnel compensation	100,000	100,000
Membership [Member] | S. Poonen [Member]
Information on remuneration [Line Items]
Key management personnel compensation	100,000	100,000
Membership [Member] | J. van der Veer [Member]
Information on remuneration [Line Items]
Key management personnel compensation			53,507
Membership [Member] | C.A. Poon [Member]
Information on remuneration [Line Items]
Key management personnel compensation			39,699
Membership [Member] | N. Dhawan [Member]
Information on remuneration [Line Items]
Key management personnel compensation		35,616	100,000
Membership [Member] | O. Gadiesh [Member]
Information on remuneration [Line Items]
Key management personnel compensation			34,521
Committees [Member]
Information on remuneration [Line Items]
Key management personnel compensation	242,000	248,411	242,652
Committees [Member] | F. Sijbesma [Member]
Information on remuneration [Line Items]
Key management personnel compensation	35,000	35,000	27,808
Committees [Member] | P.A.M. Stoffels [Member]
Information on remuneration [Line Items]
Key management personnel compensation	35,000		27,808
Committees [Member] | D.E.I. Pyott [Member]
Information on remuneration [Line Items]
Key management personnel compensation	35,000	35,000	36,370
Committees [Member] | A.M. Harrison [Member]
Information on remuneration [Line Items]
Key management personnel compensation	14,000	14,000	14,000
Committees [Member] | M.E. Doherty [member]
Information on remuneration [Line Items]
Key management personnel compensation	27,000	27,000	27,000
Committees [Member] | P. Löscher [Member]
Information on remuneration [Line Items]
Key management personnel compensation	32,000	32,000	32,000
Committees [Member] | I. Nooyi [Member]
Information on remuneration [Line Items]
Key management personnel compensation	14,000	14,000	14,000
Committees [Member] | S.K. Chua [Member]
Information on remuneration [Line Items]
Key management personnel compensation	18,000	18,000	11,836
Committees [Member] | H. Verhagen [Member]
Information on remuneration [Line Items]
Key management personnel compensation	14,000	14,000
Committees [Member] | S. Poonen [Member]
Information on remuneration [Line Items]
Key management personnel compensation	18,000	18,000
Committees [Member] | J. van der Veer [Member]
Information on remuneration [Line Items]
Key management personnel compensation			12,082
Committees [Member] | C.A. Poon [Member]
Information on remuneration [Line Items]
Key management personnel compensation		35,000	16,915
Committees [Member] | N. Dhawan [Member]
Information on remuneration [Line Items]
Key management personnel compensation		6,411	18,000
Committees [Member] | O. Gadiesh [Member]
Information on remuneration [Line Items]
Key management personnel compensation			4,833
Other compensation [Member]
Information on remuneration [Line Items]
Key management personnel compensation	189,266	192,574	38,595
Other compensation [Member] | F. Sijbesma [Member]
Information on remuneration [Line Items]
Key management personnel compensation	16,345	16,345	8,237
Other compensation [Member] | P.A.M. Stoffels [Member]
Information on remuneration [Line Items]
Key management personnel compensation	22,269	27,269	4,769
Other compensation [Member] | D.E.I. Pyott [Member]
Information on remuneration [Line Items]
Key management personnel compensation	19,769	17,269	2,269
Other compensation [Member] | A.M. Harrison [Member]
Information on remuneration [Line Items]
Key management personnel compensation	19,769	12,269	2,269
Other compensation [Member] | M.E. Doherty [member]
Information on remuneration [Line Items]
Key management personnel compensation	27,269	24,769	4,769
Other compensation [Member] | P. Löscher [Member]
Information on remuneration [Line Items]
Key management personnel compensation	17,269	24,769	4,769
Other compensation [Member] | I. Nooyi [Member]
Information on remuneration [Line Items]
Key management personnel compensation	17,269	17,269	2,269
Other compensation [Member] | S.K. Chua [Member]
Information on remuneration [Line Items]
Key management personnel compensation	22,269	22,269	1,492
Other compensation [Member] | H. Verhagen [Member]
Information on remuneration [Line Items]
Key management personnel compensation	7,269	7,269
Other compensation [Member] | S. Poonen [Member]
Information on remuneration [Line Items]
Key management personnel compensation	€ 19,769	17,269
Other compensation [Member] | J. van der Veer [Member]
Information on remuneration [Line Items]
Key management personnel compensation			3,916
Other compensation [Member] | C.A. Poon [Member]
Information on remuneration [Line Items]
Key management personnel compensation			783
Other compensation [Member] | N. Dhawan [Member]
Information on remuneration [Line Items]
Key management personnel compensation		€ 5,808	2,269
Other compensation [Member] | O. Gadiesh [Member]
Information on remuneration [Line Items]
Key management personnel compensation			€ 783

Information on remuneration - S

Information on remuneration - Shares held by Board members (Detail) - Board of management [Member] - shares		Dec. 31, 2023	Dec. 31, 2022
R. Jakobs [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	126,809	109,422
A. Bhattacharya [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	177,088	169,517
M.J. van Ginneken [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	129,447	123,914
P.A.M. Stoffels [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	17,759	17,000
S. Poonen [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	3,133	3,000
I. Nooyi [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	3,238	3,100
D.E.I. Pyott [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	19,848	19,000
S.K. Chua [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	2,089	2,000
F. Sijbesma [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	25,000	12,500
A.M. Harrison [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	1,567	1,500
P. Löscher [Member]
Information on remuneration [Line Items]
Shares held	[1],[2]	21,658	20,732
[1] Reference date for board membership is December 31, 2023. The total shares held by the members of the Board of Management is less than 1% of the company's issued share capital.

Fair value of financial asset_3

Fair value of financial assets and liabilities - Fair value of financial assets and liabilities (Detail) - EUR (€) € in Millions	Dec. 31, 2023		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	€ 284		€ 322
Financial assets at fair value through other comprehensive income	293		319
Derivative financial assets	48		127
Cash and cash equivalents	1,869		1,172	€ 2,303	€ 3,226
Trade and other current receivables	3,733		4,115
Trade and other non-current receivables	193		279
Contingent Consideration	115		113
Financial Liabilities Carried At FV through P&L	115		113
Derivative financial liabilities	43		211
Financial liabilities, at fair value	158		324
Trade and other current payables	1,917	[1],[2]	1,968
Interest payable	76		71
Debt (Corporate bond and finance lease)	6,969		6,520
Debt (Bank loans, overdrafts etc.)	721		1,680
Financial liabilities at amortised cost	9,682		10,240
Financial liabilities	9,840		10,564
Financial assets at amortised cost, category [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets, at fair value	624		768
Cash and cash equivalents	1,869		1,172
Current loans and receivables	0		2
Non-current loans and receivables	77		54
Trade and other current receivables	3,701		4,088
Trade and other non-current receivables	193		279
Financial assets at amortised cost	5,840		5,596
Financial assets	6,465		6,364
Trade receivables [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets measured at fair value through other comprehensive income	32		26
At fair value [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	284		322
Financial assets at fair value through other comprehensive income	293		319
Derivative financial assets	48		127
Financial assets, at fair value	624		768
Contingent Consideration	115		113
Financial Liabilities Carried At FV through P&L	115		113
Derivative financial liabilities	43		211
Financial liabilities, at fair value	158		324
Debt (Corporate bond and finance lease)	6,798		6,083
At fair value [member] | Trade receivables [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets measured at fair value through other comprehensive income	32		26
Debt securities [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	226		232
Financial assets measured at fair value through other comprehensive income	27		25
Debt securities [member] | At fair value [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	226		232
Financial assets measured at fair value through other comprehensive income	27		25
Other equity securities [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	2		4
Other equity securities [member] | At fair value [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	2		4
Financial assets measured at fair value through other comprehensive income	231		259
Other equity securities [member] | Carrying amount [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets measured at fair value through other comprehensive income	231		259
Other Financial Assets [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	56		86
Other Financial Assets [member] | At fair value [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	56		86
Current assets [Member]
Fair value of financial assets and liabilities [Line Items]
Financial assets measured at fair value through other comprehensive income	3		9
Current assets [Member] | At fair value [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets measured at fair value through other comprehensive income	3		9
Level 3 of fair value hierarchy [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	250		285	523
Financial assets at fair value through other comprehensive income	253		264
Financial assets, at fair value	503		549
Contingent Consideration	115		113
Financial Liabilities Carried At FV through P&L	115		113
Financial liabilities, at fair value	115		113
Financial liabilities	115		113	€ 208
Level 3 of fair value hierarchy [member] | Trade receivables [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets measured at fair value through other comprehensive income	32		26
Level 3 of fair value hierarchy [member] | Fair value model [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets measured at fair value through other comprehensive income	3		9
Level 3 of fair value hierarchy [member] | Debt securities [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	226		232
Level 3 of fair value hierarchy [member] | Other equity securities [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	2		2
Financial assets measured at fair value through other comprehensive income	217		229
Level 3 of fair value hierarchy [member] | Other Financial Assets [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	22		51
Level 2 of fair value hierarchy [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	34		35
Financial assets at fair value through other comprehensive income	26		25
Derivative financial assets	48		127
Financial assets, at fair value	108		187
Derivative financial liabilities	43		211
Financial liabilities, at fair value	43		211
Debt (Corporate bond and finance lease)	1,074		1,082
Level 2 of fair value hierarchy [member] | Debt securities [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets measured at fair value through other comprehensive income	26		25
Level 2 of fair value hierarchy [member] | Other Financial Assets [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss	34		35
Level 1 of fair value hierarchy [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss			1
Financial assets at fair value through other comprehensive income	14		30
Financial assets, at fair value	14		32
Debt (Corporate bond and finance lease)	5,724		5,001
Level 1 of fair value hierarchy [member] | Other equity securities [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets at fair value through profit or loss			1
Financial assets measured at fair value through other comprehensive income	€ 14		€ 30
[1] Amounts in this table are undiscounted This table excludes post-employment benefit plan contribution commitments and income tax liabilities in respect of tax risks because it is not possible to make a reasonably reliable estimate of the actual period of cash settlement.

Fair value of financial asset_4

Fair value of financial assets and liabilities - Reconciliation of Level 3 fair value measurements (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Fair value of financial assets and liabilities [Line Items]
Financial liabilities		€ 9,840		€ 10,564
Reclassifications		12		(2)
Financial assets at fair value through profit or loss		284		322
Level 3 of fair value hierarchy [member]
Fair value of financial assets and liabilities [Line Items]
Financial liabilities		115		113		€ 208
Assumed in a Business Combination		6
Utilizations		(20)		105
Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities		16		(85)
Financial income and expenses		1	[1]	(8)
Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, liabilities		(2)	[2]	8	[3]
Reclassifications		1
Financial assets at fair value through profit or loss		250		285		€ 523
Financial liabilities recognised as of acquisition date				96
Level 3 of fair value hierarchy [member] | Financial assets, class [member]
Fair value of financial assets and liabilities [Line Items]
Financial assets		503		549
Purchases, fair value measurement, assets		85		131
Sales, fair value measurement, assets		56		76
Financial income and expenses		(43)	[1]	7
Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, assets	[2]	(40)
Receivables Held To Collect And Sell		€ 6		(41)
Reclassifications				€ 5
[1] Refer to Financial income and expenses Includes translation differences Includes translation differences

Fair value of financial asset_5

Fair value of financial assets and liabilities - Financial assets subject to offsetting, enforceable master netting arrangements or similar agreements (Detail) - Derivatives [member] - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Fair value of financial assets and liabilities [Line Items]
Gross financial assets subject to offsetting, enforceable master netting arrangements or similar agreements	€ 48	€ 127
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position	48	127
Financial instruments subject to enforceable master netting arrangement or similar agreement not set off against financial assets	34	54
Net financial assets subject to offsetting, enforceable master netting arrangements or similar agreements	€ 13	€ 73

Fair value of financial asset_6

Fair value of financial assets and liabilities - Financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements (Detail) - Derivatives [member] - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Fair value of financial assets and liabilities [Line Items]
Gross financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements	€ 43	€ 211
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements in statement of financial position	43	211
Financial instruments subject to enforceable master netting arrangement or similar agreement not set off against financial liabilities	34	54
Net financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements	€ 9	€ 157

Details of treasury and other_3

Details of treasury and other financial risks - Text Details (Detail) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2023 USD ($)	Aug. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Oct. 31, 2022 EUR (€)	Dec. 31, 2020 EUR (€)	Sep. 03, 2020 EUR (€)	Mar. 09, 2020 EUR (€)
Details of treasury and other financial risks [Line Items]
Cash and cash equivalents	€ 1,869	€ 1,172	€ 2,303					€ 3,226
Short-term deposits, classified as cash equivalents	1,399	482
Notional amount		500
Euro Medium-Term Note program	3,300	2,000			€ 500				€ 10,000	€ 10,000
Other non-current financial assets	619	660	630
Contractual capital commitments	153	127
Accounts payable known to have been sold onwards under supplier finance arrangements	114	151
Committed future leases not yet commenced	128
Minimum payments under sale-and-leaseback arrangements	55	72
Discounted unguaranteed residual value of assets subject to finance lease	0	€ 0.6
Hedge tenor of net anticipated exposure		15 months
Net anticipated exposures hedge layer size		20%
Net anticipated exposures hedge maximum		80%
Equity	12,061	€ 13,283	€ 14,475					11,901
Net fair value of transactional hedges	(10)
Increase in the value of the EUR against all currencies		10%	10%
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	(116)
Impact on income statement following a change in the value of transactional hedges due to 10% increase in the value of the EUR against all currencies	40
Impact on equity following a change in the value of transactional hedges due to 10% increase in the value of the EUR against all currencies	77
Other comprehensive income, before tax, exchange differences on translation of foreign operations	579
Change in currency translation reserve following 10% decrease USD against EUR	1,146
Change in currency translation reserve following 10% increase USD against EUR	1,400
External bond funding for a nominal value designated as net investment hedges		€ 1,490		$ 1,474
External bond funding book value designated as net investment hedges	(1,325)	1,378
Gain (loss) on hedge ineffectiveness recognised in profit or loss	2		€ 1.1
Change in the value of derivatives following a 10% increase in the value of the EUR against all currencies	52	192
Cross-currency interest rate swaps nominal value | $						$ 500
Fair value liability of cross-currency interest rate swaps designated as net investment hedges		147
Net fair value of financing derivatives		147
Borrowings	7,689	8,201	6,980				€ 1,000
Non-current portion of non-current borrowings	7,035	7,270	6,473
Current borrowings and current portion of non-current borrowings	€ 654	€ 931	506
Ratio of fixed-rate long-term debt to total outstanding debt	89%	80%		89%		80%
Borrowings, maturity	6.0
Instantaneous increase or decrease in long-term interest rates	1%
Threshold of cash and short term deposits with A- credit rating	€ 10
Captive retained per claim for general, product and professional liability claims	25
Captive retained per claim for general, product and professional liability claims, aggregate	50
Captive retained per claim for cyber claims, aggregate	15
Bottom of range [member]
Details of treasury and other financial risks [Line Items]
Policy deductibles per occurrence	0
Top of range [member]
Details of treasury and other financial risks [Line Items]
Policy deductibles per occurrence	10
United States of America [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure	13,300
Netherlands [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure	1,400
China [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure	1,300
Other countries [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure		€ 500
Germany [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure	786
United Kingdom of Great Britain and Northern Ireland [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure	731
Japan [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure	614
Singapore [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure	202
Israel [Member]
Details of treasury and other financial risks [Line Items]
Country risk exposure	214
US Dollar [Member]
Details of treasury and other financial risks [Line Items]
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	(64)	(68)
Change in the value of derivatives following a 10% increase in the value of the EUR against all currencies		€ 191
Change in the value of derivatives following a 10% increase in the value of a currency against EUR	11
Reserve of exchange differences on translation [member]
Details of treasury and other financial risks [Line Items]
Description of methods and assumptions used in preparing sensitivity analysis		10%
Cash flow hedges [member]
Details of treasury and other financial risks [Line Items]
Gain (loss) on hedge ineffectiveness		€ 1
Reserve of cash flow hedges [member]
Details of treasury and other financial risks [Line Items]
Equity	6	(2)	€ (25)					€ 23
Change in value of forward elements of forward contracts and time value of options[Member]
Details of treasury and other financial risks [Line Items]
Equity	19
Level 1 of fair value hierarchy [member]
Details of treasury and other financial risks [Line Items]
Financial assets, at fair value	14	32
Level 1 of fair value hierarchy [member] | Equity investments [member]
Details of treasury and other financial risks [Line Items]
Other non-current financial assets	14
Financial assets, at fair value	14	€ 32
Level 2 and 3 of fair value hierarchy [member] | Equity investments [member]
Details of treasury and other financial risks [Line Items]
Financial assets measured at fair value through other comprehensive income	219
Committed revolving credit facility [Member]
Details of treasury and other financial risks [Line Items]
Undrawn borrowing facilities	€ 1,000
Royal Philips NV [Member]
Details of treasury and other financial risks [Line Items]
Notional amount | $				$ 2,500

Details of treasury and other_4

Details of treasury and other financial risks - Contractual cash obligations (Detail) - EUR (€) € in Millions		Dec. 31, 2023		Dec. 31, 2022
Details of treasury and other financial risks [Line Items]
Long-term debt including current portion of long-term debt and excluding finance lease obligations	[1],[2]	€ 7,615
Short-term debt	[1],[2]	122
Current interest payable	[1],[2]	1,704
Derivative liabilities	[1],[2]	39
Purchase obligations	[1],[2],[3]	668
Trade and other current payables		1,917	[1],[2]	€ 1,968
Contractual cash obligations	[1],[2]	12,065
Not later than one year [member]
Details of treasury and other financial risks [Line Items]
Long-term debt including current portion of long-term debt and excluding finance lease obligations	[1],[2]	533
Short-term debt	[1],[2]	122
Current interest payable	[1],[2]	180
Derivative liabilities	[1],[2]	38
Purchase obligations	[1],[2],[3]	355
Trade and other current payables	[1],[2]	1,917
Contractual cash obligations	[1],[2]	3,145
Later than one year and not later than three years [member]
Details of treasury and other financial risks [Line Items]
Long-term debt including current portion of long-term debt and excluding finance lease obligations	[1],[2]	1,934
Current interest payable	[1],[2]	328
Derivative liabilities	[1],[2]	1
Purchase obligations	[1],[2],[3]	286
Contractual cash obligations	[1],[2]	2,549
Later than three years and not later than five years [member]
Details of treasury and other financial risks [Line Items]
Long-term debt including current portion of long-term debt and excluding finance lease obligations	[1],[2]	1,431
Current interest payable	[1],[2]	285
Contractual cash obligations	[1],[2]	1,716
Later than five years [member]
Details of treasury and other financial risks [Line Items]
Long-term debt including current portion of long-term debt and excluding finance lease obligations	[1],[2]	3,717
Current interest payable	[1],[2]	911
Purchase obligations	[1],[2],[3]	27
Contractual cash obligations	[1],[2]	€ 4,655
[1] Amounts in this table are undiscounted This table excludes post-employment benefit plan contribution commitments and income tax liabilities in respect of tax risks because it is not possible to make a reasonably reliable estimate of the actual period of cash settlement. Purchase obligations are agreements to purchase goods or services that are enforceable and legally binding for the Group. They specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions and the approximate timing of the transaction. They do not include open purchase orders or other commitments which do not specify all significant terms.

Details of treasury and other_5

Details of treasury and other financial risks - Remaining minimum payments under sale-and-leaseback arrangements (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Details of treasury and other financial risks [Line Items]
Minimum payments under sale-and-leaseback arrangements	€ 55	€ 72
Not later than one year [member]
Details of treasury and other financial risks [Line Items]
Minimum payments under sale-and-leaseback arrangements	43
Later than one year and not later than two years [member]
Details of treasury and other financial risks [Line Items]
Minimum payments under sale-and-leaseback arrangements	30
Later than two years and not later than three years [member]
Details of treasury and other financial risks [Line Items]
Minimum payments under sale-and-leaseback arrangements	21
Later than three years and not later than four years [member]
Details of treasury and other financial risks [Line Items]
Minimum payments under sale-and-leaseback arrangements	12
Later than four years and not later than five years [member]
Details of treasury and other financial risks [Line Items]
Minimum payments under sale-and-leaseback arrangements	5
Later than five years [member]
Details of treasury and other financial risks [Line Items]
Minimum payments under sale-and-leaseback arrangements	€ 26

Details of treasury and other_6

Details of treasury and other financial risks - Estimated transaction exposure and related hedges (Detail) - EUR (€) € in Millions	Dec. 31, 2023	Dec. 31, 2022
Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	€ 4,287	€ 3,779
Hedge of transaction exposure	3,185	2,920
Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	1,346	1,468
Hedge of transaction exposure		€ 1,326
Payables cash flow [Member] | Cash flow hedges [member]
Details of treasury and other financial risks [Line Items]
Hedge of transaction exposure	1,173
US Dollar [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	1,793
Hedge of transaction exposure	(1,449)
US Dollar [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	888
Hedge of transaction exposure	805
Yen [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	547
Hedge of transaction exposure	319
Yen [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	14
Hedge of transaction exposure	14
Pound Sterling [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	312
Hedge of transaction exposure	196
Pound Sterling [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	12
Hedge of transaction exposure	12
Yuan Renminbi [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	439
Hedge of transaction exposure	304
Yuan Renminbi [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	98
Hedge of transaction exposure	95
Canadian Dollar [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	249
Hedge of transaction exposure	161
Canadian Dollar [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	(1)
Hedge of transaction exposure	1
Zloty [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	91
Hedge of transaction exposure	103
Australian Dollar [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	226
Hedge of transaction exposure	137
Swiss Franc [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	103
Hedge of transaction exposure	63
Swiss Franc [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	1
Hedge of transaction exposure	1
Czech Koruna [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	63
Hedge of transaction exposure	70
Swedish Krona [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	33
Hedge of transaction exposure	18
Swedish Krona [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	(3)
Hedge of transaction exposure	3
Euro [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	233
Euro [Member] | Receivables cash flow [Member] | Cash flow hedges [member]
Details of treasury and other financial risks [Line Items]
Hedge of transaction exposure	232
Euro [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	(114)
Hedge of transaction exposure	113
Others [Member] | Receivables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	198
Hedge of transaction exposure	134
Others [Member] | Payables cash flow [Member]
Details of treasury and other financial risks [Line Items]
Transaction exposure	216
Hedge of transaction exposure	€ 130

Details of treasury and other_7

Details of treasury and other financial risks - Estimated impact of 10% increase of value of the EUR on the fair value of hedges (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Details of treasury and other financial risks [Line Items]
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	€ (116)
US Dollar [Member]
Details of treasury and other financial risks [Line Items]
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	(64)	€ (68)
Yen [Member]
Details of treasury and other financial risks [Line Items]
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	(15)	(15)
Pound Sterling [Member]
Details of treasury and other financial risks [Line Items]
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	(16)	(16)
Swiss Franc [Member]
Details of treasury and other financial risks [Line Items]
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	(5)	(4)
Zloty [Member]
Details of treasury and other financial risks [Line Items]
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	(1)	€ (2)
RUB [member]
Details of treasury and other financial risks [Line Items]
Change in the value of transactional hedges following a 10% increase in the value of a currency against EUR	€ 0

Details of treasury and other_8

Details of treasury and other financial risks - Net debt and interest rate sensitivity (Detail) - Interest rate risk [member] - EUR (€) € in Millions		Dec. 31, 2023	Dec. 31, 2022
Details of treasury and other financial risks [Line Items]
Increase in the value of the fixed rate long term debt excluding forward contracts driven by 1% interest decrease	[1],[2],[3]	€ (283)	€ (274)
Decrease in the value of the fixed rate long term debt excluding forward contracts driven by 1% interest increase	[1],[2],[3]	284	274
Annualized net interest expense driven by 1% interest increase	[2],[4]	€ 15	€ 4
[1] Fixed-rate long-term debt is excluding forward contracts. The definition of this non-IFRS measure and a reconciliation to the IFRS measure is included in Equity The sensitivity analysis conducted shows that if long-term interest rates were to increase/decrease instantaneously by 1% from their level of December 31, 2023, with all other variables (including foreign exchange rates) held constant. The impact is based on the outstanding net floating-rate position as of December 31, 2023.

Details of treasury and other_9

Details of treasury and other financial risks - Credit risk with number of counterparties (Detail)	Dec. 31, 2023
Range 100-500 million [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	8
Range 100-500 million [Member] | AAA rated [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	4
Range 100-500 million [Member] | A+ rated [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	3
Range 100-500 million [Member] | A rated [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	1
Range 10-100 million [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	6
Range 10-100 million [Member] | AA- Rated [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	1
Range 10-100 million [Member] | A+ rated [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	2
Range 10-100 million [Member] | A rated [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	2
Range 10-100 million [Member] | A- rated [Member]
Details of treasury and other financial risks [Line Items]
Counterparties	1

Subsequent events - Text Detail

Subsequent events - Text Details (Detail) - EUR (€) € in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsequent events [Line Items]
Other items	[1]	€ 1,358	€ 925	€ 1,069
Respironics field-action connected to the anticipated consent decree [Member]
Subsequent events [Line Items]
Other items	[1]	€ 363	€ 250	€ 719
[1] Shareholders in this table refers to shareholders of Koninklijke Philips N.V. Per share calculations have been adjusted retrospectively for all periods presented to reflect the issuance of shares for the share dividend in respect of 2022.